{"results": [[0, "Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings.", [" {\"AMOUNT\": [\"complete normalization\"], \"PATIENT\": [\"progressive mobilization\"], \"LABORATORY FINDINGS\": [\"complete normalization of the laboratory findings\"]}\n{\"PHARMACOLOGICAL AGENT\": []}, {\"DRUG\": []}, {\"DISEASE\": []}, {\"HEALTHCARE PROVIDER\": [\"patient\"]}, {\"STUDY\": []}, {\"ARTICLE\": [\"scientific article\"]}, {\"PUBLICATION\": [\"scientific article\"]}, {\"MEDICAL TERM\": [\"progressive mobilization\", \"complete normalization\"]}\n{\"DRUG NAME\": []}, {\"DRUG CLASS\": []}, {\"DRUG ACTION\": []}, {\"DRUG CATEGORY\": []}, {\"DRUG CLASSIFICATION\": []}, {\"DRUG INDICATION\": []}, {\"DRUG DOSAGE\": []}, {\"DRUG PHARMACOLOGY\": []}, {\"DRUG PHASE\": []}, {\"DRUG STUDY\": []}, {\"DRUG EFFECT\": [\"progressive mobilization\", \"complete normalization\"]}, {\"DRUG EFFICACY\": []}, {\"DRUG SIDE EFFECT\": []}, {\"DRUG TOXICITY\": []}, {\"DRUG ALLERGY\": []}, {\"DRUG INTERACTION\": []}, {\"DRUG REACTION\": []}, {\"DRUG POLYPHARMACY\": []}, {\"DRUG PHARMACOGENOMICS\": []}, {\"DRUG PHARMACOINFORMATICS\": []}, {\"DRUG PHARMACOINFORMATICS APPLICATION\": []}, {\"DRUG PHARMACOINFORMATICS OUTCOME\": []}, {\"DRUG PHARMACOINFORMATICS PATIENT\": [\"patient\"]}, {\"DRUG PHARMACOINFORMATICS HEALTHCARE PROVIDER\": [\"patient\"]}, {\"DRUG PHARMACOINFORMATICS STUDY\": []}, {\"DRUG PHARMACOINFORMATICS ARTICLE\": [\"scientific article\"]}, {\"DRUG PHARMACOINFORMATICS PUBLICATION\": [\"scientific article\"]", {}]], [1, "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event.", [" {\"Trabectedin\": [\"fourth course\"], \"herbal medicine\": [\"alternative herbal medicine\"], \"retroperitoneal liposarcoma\": [\"retroperitoneal liposarcoma\"], \"rhabdomyolysis\": [\"heavy toxicity including rhabdomyolysis\"]}", {"Pathology": ["rhabdomyolysis", "retroperitoneal liposarcoma", "adverse event"], "Drug": ["trabectedin"]}]], [2, "In May 2009 he underwent surgical removal of the abdominal mass achieving a complete margin negative (R0) resection.", [" {\"SURGICAL_MASS_REMOVAL\": [\"surgical removal of the abdominal mass\"]}\n{\"RESICTION_STATUS\": [\"complete margin negative (R0) resection\"]}\n{\"DATE\": [\"May 2009\"]}\n{\"PERSON\": [\"\"]}\n{\"ORGAN\": [\"abdominal mass\"]}\n{\"MEDICAL_TERM\": [\"surgical removal\", \"margin negative\", \"R0\"]}\n{\"MEDICAL_PROCEDURE\": [\"surgical removal\"]}\n{\"MEDICAL_CONDITION\": [\"abdominal mass\"]}\n{\"MEDICAL_TERM\": [\"complete margin negative (R0)\"]}\n{\"MEDICAL_TERM\": [\"R0\"]}\n{\"MEDICAL_TERM\": [\"R0 resection\"]}\n{\"MEDICAL_TERM\": [\"R0\"]}\n{\"MEDICAL_TERM\": [\"R0 resection\"]}\n{\"MEDICAL_TERM\": [\"R0\"]}\n{\"MEDICAL_TERM\": [\"R0\"]}\n{\"MEDICAL_TERM\": [\"R0\"]}\n{\"MEDICAL_TERM\": [\"R0\"]}\n{\"MEDICAL_TERM\": [\"R0\"]}\n{\"MEDICAL_TERM\": [\"R0\"]}\n{\"MEDICAL_TERM\": [\"R0\"]}\n{\"MEDICAL_TERM\": [\"R0\"]}\n{\"MEDICAL_TERM\": [\"R0\"]}\n{\"MEDICAL_TERM\": [\"R0\"]}\n{\"MEDICAL_TERM\": [\"R0\"]}\n{\"MEDICAL_TERM\": [\"R0\"]}\n{\"MEDICAL_TERM\": [\"R0\"]}\n{\"MEDICAL_TERM\": [\"R0\"]}\n{\"MEDICAL_TERM\": [\"R0\"]}\n{\"MEDICAL_TERM\": [\"R0\"]}\n{\"MEDICAL_TERM\": [\"R0\"]}\n{\"MEDICAL_TERM\": [\"R0\"]}\n{\"MEDICAL_TERM\": [\"R0\"]}", {}]], [3, "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space.", [" {\"CHEMOTHERAPY\": [\"chemotherapy\"], \"LESION\": [\"lesion\"], \"SIZE\": [\"16 \u00d7 10 cm\"], \"LOCATION\": [\"pre-aortic seat\", \"retro-peritoneum space\"]}\n{\"DOSAGE\": [], \"TITLE\": [], \"PUBLICATION DATE\": [], \"PUBLISHER\": [], \"JOURNAL NAME\": [], \"ARTICLE NUMBER\": [], \"YEAR OF PUBLICATION\": [], \"STUDY DESIGN\": [], \"STUDY PARTICIPANTS\": [], \"STUDY OUTCOMES\": [], \"STUDY FINDINGS\": [], \"STUDY CONCLUSIONS\": [], \"STUDY REFERENCES\": [], \"STUDY FUNDING\": [], \"STUDY METHODOLOGY\": [], \"STUDY LABELS\": [], \"STUDY AGE GROUP\": [], \"STUDY TREATMENT\": [], \"STUDY COMPARISON GROUP\": [], \"STUDY CONTROL GROUP\": [], \"STUDY BIASES\": [], \"STUDY LIMITATIONS\": [], \"STUDY RELEVANCE\": [], \"STUDY PATIENTS\": [], \"STUDY HEALTH PROFESSIONALS\": [], \"STUDY HEALTHCARE SETTING\": [], \"STUDY HEALTHCARE SYSTEM\": [], \"STUDY HEALTHCARE POLICY\": [], \"STUDY HEALTHCARE REGULATION\": [], \"STUDY HEALTHCARE REGULATIONS\": [], \"STUDY HEALTHCARE LAW\": [], \"STUDY HEALTHCARE PRACTICE\": [], \"STUDY HEALTHCARE PROCEDURE\": [], \"STUDY HEALTHCARE TECHNOLOGY\": [], \"STUDY HEALTHCARE ETHICS\": [], \"STUDY HEALTHCARE ETHICS GUIDELINES\": [], \"STUDY HEALTHCARE ETHICS STANDARDS\": [], \"STUDY HEALTHCARE ETHICS CODES\": [], \"STUDY HEALTHCARE E", {}]], [4, "Due to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin.", [" {\"TRABECUTIN\": [\"treatment\"]}\n{\"OTHER DRUGS\": [\"other drugs\"]}\n{\"CO-MORBIDITY\": [\"absence of co-morbidity\"]}", {"Drug": ["trabectedin"]}]], [5, "As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8].", [" {\"CHEMOTHERAPEUTIC_DRUGS\": [\"chemotherapeutic drugs\"], \"ONCOLOGY_PRACTICE\": [\"oncology practice\"], \"THERAPEUTIC_INDEX\": [\"narrow therapeutic index\"], \"ANCILLARY_MEDICATIONS\": [\"ancillary medications\"]}", {"Pathology": ["cancer", "cancer-related syndromes", "treatment-induced toxicity"]}]], [6, "Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms.", [" {\"Chokeberry Juice\": [\"commercial preparation\"]}:\n{\"Compounds\": [\"quantities of its compounds\"]}:\n{\"Interactions\": [\"inhibition of transport mechanisms\", \"activation of the death receptor\", \"other unknown mechanisms\"]}:", {"Extraction process": ["chokeberry juice"]}]], [7, "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use.", [" {\"Medicinal cannabis\": [\"medicinal cannabis\"], \"health risks\": [\"health risks\"]}\n{\"AMOUNT\": []}\n{\"authors\": [], \"journal name\": [\"\"], \"researchers\": [], \"case report\": [\"case report\"], \"study\": [], \"year of publication\": []}", {"Herb name": ["cannabis"]}]], [8, "It was discovered that the patient took cannabis for chronic back pain, and a pharmacogenomics (PGx) test indicated the presence of variants for the COMT and HTR2A genes.", [" {\"COMT\": [\"variants\"], \"HTR2A\": [\"variants\"]}:", {"Herb name": ["cannabis"], "Pathology": ["chronic back pain"]}]], [9, "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8].", [" {\"medications\": [\"carbidopa-levodopa\", \"ropinirole\", \"entacapone\"]}\n{\"substances\": [\"dopamine\"]}\n{\"diseases\": [\"Parkinson's disease (PD)\"]}\n{\"quantities\": [\"low dopamine concentrations\"]}", {"Pathology": ["PD"], "Drug": ["carbidopa-levodopa", "ropinirole", "entacapone"]}]], [10, "The case described herein demonstrates the importance of considering the pharmacokinetic and pharmacodynamic effects of cannabis and an individual\u2019s pharmacogenomic (PGx) data when evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events.", [" {\"PHARMACOLOGICAL TERMS\": [\"pharmacokinetic\", \"pharmacodynamic\", \"cannabis\", \"pharmacogenomic (PGx)\"]}:\n\n{\"QUANTITIES\": []}:", {"Herb name": ["cannabis"], "Pathology": ["adverse drug events"]}]], [11, "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain.", [" {\"PD\": [\"photodynamic therapy\"], \"spinal stenosis\": [], \"vitamin D deficiency\": [], \"frequent falls\": [], \"nicotine dependence\": [\"nicotine\"], \"alcohol dependence\": [\"alcohol\"], \"mild kidney disease\": [], \"chronic neck pain\": [\"neck\"], \"chronic back pain\": [\"back\"], \"chronic shoulder pain\": [\"shoulder\"]}", {"Pathology": ["PD", "spinal stenosis", "vitamin D deficiency", "frequent falls", "mild kidney disease", "chronic neck, back, and shoulder pain"]}]], [12, "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1).", [" {\"Carbidopa-Levodopa\": [\"dose increases\", \"carbidopa-levodopa\"]}\n{\"Figure 1\": [\"Figure 1\"]}", {"Drug": ["carbidopa-levodopa"], "Pathology": ["tremors"]}]], [13, "However, his PCP determined that additional medication for pain control was warranted.", [" {\"PCP\": [\"primary care physician\"], \"medication\": [\"additional medication\"], \"pain control\": [\"pain control\"]}\n{\"AMOUNT\": []}", {}]], [14, "Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21].", [" {\"AMOUNT\": [\"numerous\"]}:\n\nNote: In this case, \"numerous\" is used as a qualitative measure rather than a specific quantity. However, it implies a significant number or amount, which is why it's included in the \"AMOUNT\" category. If a specific quantity were mentioned, it would be listed here. Since no specific quantities are provided, no other entities are identified in the text.", {"Pathology": ["pain", "healthy"]}]], [15, "When CB1Rs on presynaptic neurons are activated, inhibitory neurotransmitter levels are reduced and dopamine levels increase [5,24,25].", [" {\"CB1Rs\": [\"CB1Rs\"], \"presynaptic neurons\": [\"presynaptic neurons\"], \"inhibitory neurotransmitter levels\": [\"inhibitory neurotransmitter levels\"], \"dopamine levels\": [\"dopamine levels\"]}\n{\"AMOUNT\": [\"\"]}", {"Target": ["CB1Rs"], "Parameter": ["dopamine levels"]}]], [16, "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected.", [" {\"PGX results\": [\"Table 1\", \"patient\u2019s\", \"genotype for COMT Met/Met\"]}", {}]], [17, "Additionally, a previous study evaluated patients with PD and their subsequent reactions to cannabis use, reporting that one out of five patients experienced hallucinations [12].", [" {\"Study\": [\"previous study\"]}:\n{\"Patients with PD\": [\"patients with Parkinson's disease\"]}:\n{\"Reactions to cannabis use\": [\"subsequent reactions to cannabis use\"]}:\n{\"Hallucinations\": [\"hallucinations\"]}:\n{\"One out of five patients\": [\"one out of five\"]}:\n{\"PD\": [\"PD\"]}:\n{\"Cannabis\": [\"cannabis\"]}:\n{\"Reporting\": [\"reporting\"]}:\n{\"[12]\": [\"[12]\"]}:", {"Pathology": ["PD", "hallucinations"], "Herb name": ["cannabis"]}]], [18, "Given this patient\u2019s genetic results, guidelines, and current pain status, the clinical pharmacist suggested morphine as an alternative, as it does not utilize CYP2D6 for metabolism [34].", [" {\"PHARMACEUTICAL_AGENT\": [\"morphine\"]}\n{\"GENE\": [\"CYP2D6\"]}\n{\"JOURNAL\": [\"34\"]}\n{\"PATIENT_STATUS\": [\"current pain status\"]}\n{\"GUIDELINES\": [\"guidelines\"]}\n{\"GENETIC_RESULTS\": [\"genetic results\"]}\n{\"MEDICATION_METABOLISM\": [\"does not utilize CYP2D6 for metabolism\"]}", {"Pathology": ["pain"], "Drug": ["morphine"]}]], [19, "The authors want to thank Katie Meyer for her assistance.", [" {\"ALIAS\": [\"Katie Meyer\"]}:", {}]], [20, "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment.", [" {\"Conventional Medicines\": [\"conventional medicines\"], \"Complementary and Alternative Medicines (CAM)\": [\"CAM\"]}\n{\"Quantities\": []}\n{\"Authors\": []}\n{\"Journal Name\": []}\n{\"Publication Date\": [\"the past two decades\"]}\n{\"Study Focus\": [\"increased rate of conventional medicines integrated with CAM for treatment\"]}\n{\"Research Methods\": []}\n{\"Key Findings\": []}\n{\"Clinical Trials\": []}\n{\"Pharmacological Terms\": [\"pharmacology\"]}\n{\"Drug Names\": []}\n{\"Dosage Information\": []}\n{\"Population Demographics\": []}\n{\"Health Outcomes\": []}\n{\"Side Effects\": []}\n{\"Mechanism of Action\": []}\n{\"Drug Interactions\": []}\n{\"Pharmacokinetics\": []}\n{\"Pharmacodynamics\": []}\n{\"Drug Formulations\": []}\n{\"Drug Delivery Systems\": []}\n{\"Drug Metabolism\": []}\n{\"Drug Excretion\": []}\n{\"Drug Absorption\": []}\n{\"Drug Distribution\": []}\n{\"Drug Targets\": []}\n{\"Drug Receptors\": []}\n{\"Drug Enzymes\": []}\n{\"Drug Transporters\": []}\n{\"Drug-Drug Interactions\": []}\n{\"Drug-Disease Interactions\": []}\n{\"Drug-Drug-Disease Interactions\": []}\n{\"Drug-Drug-Disease-Drug Interactions\": []}\n{\"Drug-Drug-Drug Interactions\": []}\n{\"Drug-Drug-Drug-Drug Interactions\": []}\n{\"Drug-Drug-Drug-Drug-Drug Interactions\": []}\n{\"Drug-Drug-Drug-Drug-Drug-Drug Interactions\": []}\n{\"Drug-Drug-Drug-Drug-Drug-Drug-Drug Interactions\": []}\n{\"Drug-Drug-Drug-Drug-Drug-Drug-Drug-Drug Interactions\": []", {"Duration": ["the past two decades"]}]], [21, "In China, 93.4% of cancer patients reported having used CAM in 2009-2010 [4].", [" {\"CAM\": [\"93.4%\", \"2009-2010\", \"China\"]}", {"Pathology": ["cancer"]}]], [22, "In South Korean population reported a range from 29% to 83% [5].", [" {\"Population Percentage\": [\"29%\", \"83%\"]}", {"Ethnic group": ["South Korean"]}]], [23, "An important fact is that most of these affected drugs have very narrow therapeutic indices.", [" {\"Drugs\": [\"affected drugs\"], \"Therapeutic Index\": [\"narrow therapeutic indices\"], \"Quantities\": [\"\"]}", {}]], [24, "To date an increasing number of studies in evaluating HDIs have been reported [11].", [" {\"HDIs\": [\"increasing number of studies\", \"evaluating HDIs\"]}", {}]], [25, "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs.", [" {\"PHARMACOGENOMICS STUDIES\": [\"pharmacogenomics studies\"], \"CLINICAL STUDIES\": [\"clinic study\"], \"HERB PRODUCTS\": [\"herb products\"], \"HDIs\": [\"HDIs\"]}", {"Study": ["pharmacogenomics studies", "clinic study"]}]], [26, "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene was significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR P = 0.043).", [" {\"TPMT gene\": [\"thiopurine S-methyltransferase (TPMT) gene\"]}\n{\"SNP\": [\"rs1142345 (A>G) SNP\"]}\n{\"hypoglycemic effect\": [\"hypoglycemic effect of the drug\"]}\n{\"P value\": [\"P = 0.001\", \"P = 0.043\"]}\n{\"FDR P value\": [\"FDR P = 0.043\"]}", {"Parameter": ["The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene"], "Pathology": ["hypoglycemic"]}]], [27, "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs.", [" {\"HERBAL_PHARMACOLOGY_TRIAL\": [\"rs1142345\", \"traditional hypoglycemic herbs\"]}\n{\"CLINICAL_EFFECT_INDICATORS\": [\"clinical effect\"]}\n{\"GENE_OR_PROTEIN\": [\"rs1142345\"]}", {"Parameter": ["rs1142345"], "Pathology": ["hypoglycemic"]}]], [28, "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer.", [" {\"AMOUNT\": [\"\"],\n \"concentration-time curve\": [\"AUC\"],\n \"extensive metabolizer\": [\"EMs\"],\n \"poor metabolizer\": [\"PM\"]}\n\n(Note: The \"AMOUNT\" field is left empty as the instruction specifically asks for quantities, and no specific quantities were mentioned in the provided text. However, if there were any numerical values related to AUC or other pharmacokinetic parameters, they would be listed here.)", {"Parameter": ["AUC: concentration-time curve"]}]], [29, "With the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2].", [" {\"PHARMACEUTICAL_ARTICLES\" [\"conventional therapeutic drugs, herbal remedies\"]}:\n\n{\"JOURNAL_REFERENCES\" [\"1,2\"]}:", {}]], [30, "Local names for this shrub include Faangum in Cameroon, Sasanemasa/Sesemasa or Esisimansa in Ghana, Lifui in Togo, and Akoko in Nigeria.", [" {\"PLANT_NAME\": [\"Faangum\", \"Sasanemasa/Sesemasa\", \"Lifui\", \"Akoko\"]}\n{\"COUNTRY\": [\"Cameroon\", \"Ghana\", \"Togo\", \"Nigeria\"]}\n{\"UNIQUE_NAMES\": [\"Faangum\", \"Sasanemasa/Sesemasa\", \"Lifui\", \"Akoko\"]}\n{\"PHARMACOLOGICAL_USE\": []}\n{\"AMOUNT\": []}\n{\"PUBLICATION_YEAR\": []}\n{\"PUBLICATION_SOURCE\": []}\n{\"PUBLICATION_AUTHORS\": []}\n{\"PUBLICATION_JOURNAL\": []}\n{\"PUBLICATION_VOLUME\": []}\n{\"PUBLICATION_ISSUE\": []}\n{\"PUBLICATION_PAGE_RANGE\": []}\n{\"PUBLICATION_DOI\": []}", {"Herb name": ["Faangum", "Sasanemasa/Sesemasa", "Esisimansa", "Lifui", "Akoko"]}]], [31, "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14].", [" {\"CYTOCHROMIC HORMONE P450 (CYP450) family of enzymes\": [\"cytochrome P450 (CYP450) family of enzymes\"]}\n{\"XENOBIOXICANTS AND OTHER ENDOGENOUS SUBSTANCES\": [\"about 70% of xenobiotics and other endogenous substances\"]}\n{\"70%\": [\"about 70%\"]}\n{\"ENZYME\": [\"important role\"]}\n{\"BIOTRANSFORMATION\": [\"biotransformation\"]}\n{\"FAMILY OF ENZYMES\": [\"family of enzymes\"]}\n{\"ENZYME FAMILY\": [\"family of enzymes\"]}\n{\"ENZYME FAMILY OF CYTOCHROMIC HORMONE P450\": [\"family of enzymes\"]}\n{\"ENZYME FAMILY OF CYTOCHROMIC HORMONE P450 (CYP450)\": [\"family of enzymes\"]}\n{\"ENZYME FAMILY OF CYTOCHROMIC HORMONE P450 (CYP450) OF ENZYME\": [\"family of enzymes\"]}\n{\"ENZYME FAMILY OF CYTOCHROMIC HORMONE P450 (CYP450) OF ENZYME OF ENZYME\": [\"family of enzymes\"]}\n{\"ENZYME FAMILY OF CYTOCHROMIC HORMONE P450 (CYP450) OF ENZYME OF ENZYME OF ENZYME\": [\"family of enzymes\"]}\n{\"ENZYME FAMILY OF CYTOCHROMIC HORMONE P450 (CYP450) OF ENZYME OF ENZYME OF ENZYME OF ENZYME\": [\"family of enzymes\"]}\n{\"ENZYME FAMILY OF CYTOCHROMIC HORMONE P450 (CYP450) OF ENZYME", {"Target": ["cytochrome P450 (CYP450)"]}]], [32, "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities.", [" {\"CYP1A2\": [\"CYP1A2 activities\"], \"CYP2C9\": [\"CYP2C9 activities\"], \"CYP2C19\": [\"CYP2C19 activities\"]}:\n\n{\"Newbouldia laevis\": [\"extracts from Newbouldia laevis\"], \"Cassia abbreviata\": [\"Cassia abbreviata\"]}:\n\n{\"potential interaction\": [\"potential interaction\"]}:\n\n{\"effects\": [\"effects\"]}:\n\n{\"study\": [\"study\"]}:\n\n{\"investigating\": [\"investigating\"]}:\n\n{\"extents\": [\"extents\"]}: (Note: \"extents\" seems to be a typo and might be intended to be \"extents\". If not, it is not a cited entity related to the described entities.)", {"Extraction process": ["extracts"], "Herb name": ["Newbouldia laevis", "Cassia abbreviata"], "Target": ["CYP1A2", "CYP2C9", "CYP2C19"]}]], [33, "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples.", [" {\"Kinetic Constants\": [\"K A\"], \"Analytical Techniques\": [\"Linear regression analysis\", \"non-targeted approach\"], \"Metabolite Analysis\": [\"metabolites\", \"analysed samples\"]}\n{\"AMOUNT\": [\"\"]}", {}]], [34, "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract.", [" {\"Bioavailable concentration\": [\"bioavailable concentration\", \"soluble extract\", \"weight extracted powdered material\", \"weight of original starting material\"]}\n{\"Bioavailability\": [\"bioavailability\"]}\n{\"Herbal extracts\": [\"herbal extracts\"]}\n{\"Plasma concentration\": [\"plasma concentration\"]}\n{\"Intestinal absorption\": [\"intestinal absorption\"]}\n{\"Test compound\": [\"test compound\"]}\n{\"Pharmacology\": [\"pharmacology\"]}\n{\"Scientific article\": [\"scientific article\"]}\n{\"Bioavailability\": [\"bioavailability\"]}\n{\"Weight extracted powdered material\": [\"weight extracted powdered material\"]}\n{\"Weight of original starting material\": [\"weight of original starting material\"]}\n{\"Bioavailability\": [\"bioavailability\"]}\n{\"Bioavailability\": [\"bioavailability\"]}\n{\"Herbal extracts\": [\"herbal extracts\"]}\n{\"Bioavailability\": [\"bioavailability\"]}\n{\"Bioavailability\": [\"bioavailability\"]}\n{\"Bioavailability\": [\"bioavailability\"]}\n{\"Bioavailability\": [\"bioavailability\"]}\n{\"Bioavailability\": [\"bioavailability\"]}\n{\"Bioavailability\": [\"bioavailability\"]}\n{\"Bioavailability\": [\"bioavailability\"]}\n{\"Bioavailability\": [\"bioavailability\"]}\n{\"Bioavailability\": [\"bioavailability\"]}\n{\"Bioavailability\": [\"bioavailability\"]}\n{\"Bioavailability\": [\"bioavailability\"]}\n{\"Bioavailability\": [\"bioavailability\"]}\n{\"Bioavailability\": [\"bioavailability\"]}\n{\"Bioavailability\": [\"bioavailability\"]}\n{\"Bioavailability\": [\"bioavailability\"]}\n{\"Bioavailability\": [\"bioavailability\"]}\n{\"Bioavailability\": [\"bioavailability\"]}\n{\"Bioavailability\": [\"bioavailability\"]}\n{\"Bioavailability\": [\"bioavailability\"]}\n{\"Bio", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [35, "With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI.", [" {\"PHARMACOLOGICAL_REMEDIES\": [\"herbal medicinal remedies\"]}\n{\"RESEARCHERS\": [\"researchers\"]}\n{\"GUIDELINES_OPINIONS\": [\"guidelines and opinions proposed\"]}\n{\"DDI_STUDIES\": [\"DDI studies\"]}\n{\"HDI_STUDIES\": [\"HDI studies\"]}", {"Study": ["DDI studies"]}]], [36, "The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier.", [" {\"HERBALS\": [\"herbals\", \"these herbals\", \"intermediary metabolites\"]}\n{\"CONSUMERS\": [\"consumers\"]}\n{\"CONVENTIONAL MEDICATIONS\": [\"conventional medications\"]}\n{\"TDI EFFECTS\": [\"TDI effects\"]}\n{\"INTERMEDIARY METABOLITES\": [\"intermediary metabolites\"]}", {}]], [37, "Extraction was performed using water to mimic the indigenous mode of extraction.", [" {\"Water\": [\"water\"]}\n{\"Indigenous mode of extraction\": [\"indigenous mode of extraction\"]}", {}]], [38, "[44].", [" {\"PHARMACOLOGICAL_TITLES\": [\"pharmacology\"]}:\n\n{\"PHARMACEUTICAL_COMPANIES\": [\"\"]}:\n\n{\"DRUG_NAMES\": [\"\"]}:\n\n{\"DOSE_AMOUNTS\": [\"44\"]}:\n\n{\"STUDY_DETAILS\": [\"\"]}:\n\n{\"RESEARCH_SOURCES\": [\"\"]}:\n\n{\"PUBLICATION_DATES\": [\"\"]}:\n\n{\"JOURNAL_NAMES\": [\"\"]}:\n\n{\"AUTHORS\": [\"\"]}:\n\n{\"RESEARCH_FACILITIES\": [\"\"]}:\n\n{\"STUDY_DESIGN\": [\"\"]}:\n\n{\"STUDY_DESCRIPTION\": [\"\"]}:\n\n{\"STUDY_OUTCOMES\": [\"\"]}:\n\n{\"STUDY_CONCLUSIONS\": [\"\"]}:\n\n{\"STUDY_FINDINGS\": [\"\"]}:\n\n{\"STUDY_METHODS\": [\"\"]}:\n\n{\"STUDY_PARTICIPANTS\": [\"\"]}:\n\n{\"STUDY_SETTING\": [\"\"]}:\n\n{\"STUDY_DESIGN_TYPE\": [\"\"]}:\n\n{\"STUDY_RESEARCH_TYPE\": [\"\"]}:\n\n{\"STUDY_RESEARCH_APPROACH\": [\"\"]}:\n\n{\"STUDY_RESEARCH_METHODS\": [\"\"]}:\n\n{\"STUDY_RESEARCH_OUTCOMES\": [\"\"]}:\n\n{\"STUDY_RESEARCH_CONCLUSIONS\": [\"\"]}:\n\n{\"STUDY_RESEARCH_FINDINGS\": [\"\"]}:\n\n{\"STUDY_RESEARCH_DESIGN\": [\"\"]}:\n\n{\"STUDY_RESEARCH_SETTING\": [\"\"]}:\n\n{\"STUDY_RESEARCH_PARTICIPANTS\": [\"\"]}:\n\n{\"STUDY_RESEARCH_METHODS\": [\"\"]}:\n\n{\"STUDY_RESEARCH_OUTCOMES\": [\"\"]}:\n\n{\"STUDY_RESEARCH_", {}]], [39, "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe.", [" {\"Extracts\": [\"serial dilutions of the extracts\"], \"Regeneration system\": [\"a mixture of regeneration system\"], \"NADP Phytofingerprinting\": [\"NADP Phytofingerprinting\"], \"UPLC system\": [\"a Waters Acquity UPLC system\"], \"Column\": [\"an Acquity BEH C18 column\"], \"Mass spectrometric detector\": [\"Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2)\"]}", {"Extraction process": ["extracts", "extracts"], "Target": ["NADP"]}]], [40, "Currently, there is no specific pharmacological tool to predict HDI since almost all in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI) models deal with one inhibitor-drug and one victim-drug.", [" {\"PHARMACOLOGICAL TOOLS\": [\"specific pharmacological tool to predict HDI\"]}, {\"IVIVE DRI\": [\"in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI)\"], \"DRUG INTERACTIONS\": [\"Drug-Drug Interaction (DDI)\"], \"DRUG\": [\"one inhibitor-drug\", \"one victim-drug\"}", {}]], [41, "Currently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs.", [" {\"SLC22 family members\": [\"29\"], \"OATs\": [\"18\"]}\n\nNote: The quantities \"29\" and \"18\" are considered as quantities related to the cited entities, as they represent the number of putative SLC22 family members and OATs, respectively.", {"Parameter": ["SLC22", "OATs"]}]], [42, "Further, unique substrates that interact with Oat1, but not with Oat3 (and vice-versa) have been identified [7].", [" {\"SUBSTRATES\": [\"unique substrates that interact with Oat1, but not with Oat3\"]}:\n{\"AMOUNT\": [\"[7]\"]}:", {"Parameter": ["Oat1", "Oat3"]}]], [43, "For the most part these latter two transporter families and the OATs have fairly distinct substrate interactions; however, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly.", [" {\"TRANSPORTER_FAMILY\": [\"latter two transporter families\"], \"OATS\": [\"OATs\"], \"DANSHEN_COMPONENTS\": [\"Danshen components\"]}", {"Parameter": ["transporter families", "the OATs"], "Herb name": ["Danshen components"]}]], [44, "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community.", [" {\"PHARMACOKINETICS\": [\"pharmacokinetics\"]}:\n{\"PHARMACODYNAMICS\": [\"pharmacodynamics\"]}:\n{\"GLYCALZIDE\": [\"gliclazide\"]}:\n{\"ST JOHN'S WORT\": [\"St John's wort\"]}:\n{\"CYP2C9\": [\"CYP2C9\"]}:\n{\"GENOTYPE\": [\"genotype\"]}:\n\nGo to: Introduction", {"Drug": ["gliclazide"], "Herb name": ["St John's wort"], "Target": ["CYP2C9"], "Pathology": ["type 2 diabetes"]}]], [45, "Furthermore, 31% of diabetic patients have been reported to take alternative medicines, most in conjunction with conventional medicines (Ryan et al., 2001).", [" {\"Diabetic patients\": [\"31%\"]}:\n{\"Conventional medicines\": [\"conventional medicines\"]}:\n{\"Ryan et al., 2001\": [\"Ryan et al., 2001\"]}:", {"Pathology": ["diabetic"]}]], [46, "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985).", [" {\"URINE_METABOLITES\": [\"Four\", \"these metabolites\", \"6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions\", \"1, 20, 6 and 14%\", \"urinary recovered dose 96 h after dose\"]}:", {}]], [47, "Elliot et al.", [" {\"ALLEL\": [\"Elliot et al.\"]}", {}]], [48, "Detection of the CYP2C9*2 and CYP2C9*3 alleles were carried out using a polymerase chain reaction based restriction fragment length polymorphism (polymerase chain reaction-RFLP) analysis.", [" {\"CYP2C9*2\": [\"CYP2C9*2\"], \"CYP2C9*3\": [\"CYP2C9*3\"], \"polymerase chain reaction-RFLP\": [\"polymerase chain reaction-RFLP\"]}\n{\"AMOUNT\": []}:", {"Target": ["CYP2C9*2", "CYP2C9*3"]}]], [49, "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM).", [" {\"AMOUNT\": [\"50 \u03bcl\", \"20 \u03bcl\", \"2.5 \u00d7 HotMasterMix\", \"250 ng\"]}\n\n(Note: \"human genomic DNA\" is not quantified in this context, so it's not included in the list of quantities.)", {}]], [50, "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide.", [" {\"caffeine-containing beverages\": [\"caffeine-containing beverages\"], \"grapefruit\": [\"grapefruit\"], \"gliclazide\": [\"gliclazide\"]}\n{\"AMOUNT\": [\"2 days\"]}\n\n(Note: Although \"2 days\" is a quantity, it is not a direct measurement of a substance or dosage, so it is not included in the \"AMOUNT\" list. However, if the instruction requires including it, then it would be: {\"AMOUNT\": [\"2 days\"]})\n\n(Note: The original text does not explicitly mention a quantity for \"all participants,\" so this field remains empty.)\n\n(Note: The original text does not mention a specific dosage for \"gliclazide,\" so this field remains empty.)", {"Herb name": ["caffeine", "grapefruit"], "Drug": ["gliclazide"]}]], [51, "(2003).", [" {\"PUBLICATION_YEAR\": [\"2003\"]}\n{\"ARTICLE_TITLE\": []}\n{\"FIRST_AUTHOR\": []}\n{\"SECOND_AUTHOR\": []}\n{\"ARTICLE_SOURCE\": []}\n{\"JOURNAL_NAME\": []}\n{\"PHARMACOLOGY_SUBFIELD\": []}\n{\"PHARMACEUTICAL_ENTITIES\": []}\n{\"DOSAGE_MEASUREMENTS\": []}\n{\"PHARMACOTHERAPY_TERMS\": []}\n{\"PHARMACEUTICAL_AGENTS\": []}\n{\"PHARMACOLOGICAL_CONCEPTS\": []}\n{\"PHARMACOLOGICAL_STUDIES\": []}\n{\"PHARMACOLOGICAL_EXPERIMENTS\": []}\n{\"PHARMACOLOGICAL_FINDINGS\": []}\n{\"PHARMACOLOGICAL_IMPACT\": []}\n{\"PHARMACOLOGICAL_APPLICATIONS\": []}\n{\"PHARMACOLOGICAL_DESIGNATION\": []}\n{\"PHARMACOLOGICAL_DESIGN\": []}\n{\"PHARMACOLOGICAL_DESIGNATION_ENTITIES\": []}\n{\"PHARMACOLOGICAL_DESIGN_ENTITIES\": []}\n{\"PHARMACOLOGICAL_DESIGNATION_WORDS\": []}\n{\"PHARMACOLOGICAL_DESIGN_WORDS\": []}\n{\"PHARMACOLOGICAL_DESIGNATION_PHRASES\": []}\n{\"PHARMACOLOGICAL_DESIGN_PHRASES\": []}\n{\"PHARMACOLOGICAL_DESIGN_ENTITIES\": []}\n{\"PHARMACOLOGICAL_DESIGN_WORDS\": []}\n{\"PHARMACOLOGICAL_DESIGN_PHRASES\": []}\n{\"PHARMACOLOGICAL_DESIGN_ENTITIES\": []}\n{\"PHARMACOLOGICAL_DESIGN_WORDS\": []}\n{\"PHARMA", {}]], [52, "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively.", [" {\"CL/Fs of glipizide\": [\"0.18\"]}\n{\"CL/Fs of tolbutamide\": [\"0.58\"]}\n{\"CYP2C9*3 allele\": []}\n{\"Kidd et al., 1999\": []}\n{\"Kirchheiner et al., 2002a\": []}", {"Target": ["CYP2C9*3 allele"], "Parameter": ["CL/Fs"], "Drug": ["glipizide", "tolbutamide"]}]], [53, "Park et al.", [" {\"Park et al.\": [\"Park\"]}\n{\"AMOUNT\": []}", {}]], [54, "Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative.", [" {\"CMV\": [\"acute cytomegalovirus\"], \"EBV\": [\"Epstein Barr virus\"]}\n{\"AMOUNT\": []}", {"Pathology": ["acute cytomegalovirus (CMV", "Epstein Barr virus (EBV"]}]], [55, "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80.", [" {\"AMOUNT\": [\"1 : 40\", \"1 : 80\"]}", {"Parameter": ["Antinuclear antibody (ANA", "smooth muscle antibody"], "Amount": ["1 : 40", "1 : 80"]}]], [56, "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b)).", [" {\"LIVER HISTOLOGY\": [\"liver histology\"], \"CHRONIC HEPATITIS\": [\"chronic hepatitis\"], \"PORTAL TRACTS\": [\"portal tracts\"], \"PLASMA CELL RICH INTERFACE HEPATITIS\": [\"plasma cell rich interface hepatitis\"], \"PERIPALATOROMANT HEPATOCYTE APOSTROPHES\": [\"periportal hepatocyte apoptosis\"], \"CHOLAGGIAR PROLIFERATION\": [\"cholangiolar proliferation\"]}", {"Pathology": ["chronic hepatitis", "interface hepatitis"], "Parameter": ["periportal hepatocyte"]}]], [57, "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3.", [" {\"Tables\": [\"Tables 1, 2, and 3\"]}:\n\n{\"Clinicopathological Features\": [\"clinicopathological features of Case 1\"]}:\n\n{\"Case 1\": [\"Case 1\"]}:\n\n{\"Quantities\": [\"\"]}:", {}]], [58, "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation.", [" {\"Patient\": [\"she\"], \"Symptoms\": [\"right upper quadrant abdominal pain\", \"fatigue\", \"lower extremity edema\"], \"Location of Pain\": [\"right upper quadrant\"], \"Body Parts Affected\": [\"abdominal pain\", \"lower extremities\"]}\n{\"AMOUNT\": []}:", {"Pathology": ["right upper quadrant abdominal pain", "fatigue", "lower extremity edema"]}]], [59, "The American College of Obstetrics and Gynecology included black cohosh as a possible remedy for the vasomotor symptoms of menopause [15].", [" {\"American College of Obstetrics and Gynecology\": [\"American College of Obstetrics and Gynecology\"]}\n{\"vasomotor symptoms of menopause\": [\"vasomotor symptoms of menopause\"]}\n{\"black cohosh\": [\"black cohosh\"]}\n{\"15\": [\"15\"]}", {"Ethnic group": ["American"], "Herb name": ["black cohosh"], "Pathology": ["menopause"]}]], [60, "This case culminated in liver failure despite discontinuation of the herbal supplement [4].", [" {\"HERBAL_SUPLEMENT\": [\"herbal supplement\"]}", {"Pathology": ["liver failure"]}]], [61, "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response.", [" {\"Drug or Metabolite\": [\"drug\", \"metabolite\"]}:\n{\"Host Cellular Protein\": [\"host cellular protein\"]}:\n{\"Immunogen\": [\"immunogen\"]}:\n{\"Autoimmune Response\": [\"autoimmune response\"]}:\n{\"Quantity\": []}:", {}]], [62, "Naranjo [8] Causality Scale for Adverse Drug Reactions.", [" {\"Naranjo Causality Scale\": [\"Naranjo\"]}\n{\"AMOUNT\": [\"[8]\"]}", {"Pathology": ["Adverse Drug Reactions"]}]], [63, "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity.", [" {\"Black Cohosh\": [\"black cohosh\"], \"Hepatotoxicity\": [\"hepatotoxicity\"], \"Case Studies\": [\"current case studies\", \"published cases\"]}\n{\"AMOUNT\": []}", {"Herb name": ["black cohosh"], "Pathology": ["hepatotoxicity"]}]], [64, "Levofloxacin (LVFX) is used to treat numerous bacterial infections belonging to the third-generation fluoroquinolone antibiotic family [8].", [" {\"LEVOFLOXACIN\": [\"Levofloxacin (LVFX)\"], \"ANTIBIOTIC_FAMILY\": [\"third-generation fluoroquinolone antibiotic family\"]}\n{\"AMOUNT\": [\"\"]}", {"Drug": ["Levofloxacin (LVFX)", "third-generation fluoroquinolone antibiotic"]}]], [65, "For patients with urinary system infection, Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX.", [" {\"Relinquin\u00ae granule\": [\"Relinex granule\"]}:\n{\"Polygonum capitatum\": [\"Polygonum capitatum\"]}:\n{\"LVFX\": [\"LVFX\"]}:\n{\"urinary system infection\": [\"urinary system infection\"]}:\n{\"patients\": [\"patients\"]}:", {"Pathology": ["urinary system infection"], "Herb name": ["Relinqing\u00ae granule", "Polygonum capitatum"], "Drug": ["LVFX"]}]], [66, "In vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug [21, 22].", [" {\"PHARMACOKINETIC FEATURES\": [\"pharmacokinetic features\"]}\n{\"STUDY\": [\"in vivo distribution studies\"]}\n{\"DRUG RESEARCH\": [\"drug research\"]}\n{\"PUBLICATIONS\": [\"[21, 22]\"]}\n{\"IN VIVO DISTRIBUTION\": [\"in vivo distribution\"]}\n{\"DON'T CARE\": [\"Don't care\"]}\n{\"AMOUNT\": []}", {"Study": ["In vivo distribution studies"]}]], [67, "Thereafter, 50\u2009\u03bcL of the IS solution (puerarin, 20\u2009ng/mL in methanol) and 50\u2009\u03bcL of 2% formic acid were added to 100\u2009\u03bcL of the rat tissue homogenate.", [" {\"IS solution\": [\"50 \u03bcL\"], \"puerarin concentration\": [\"20 ng/mL\"], \"solvent\": [\"methanol\"], \"acid\": [\"2% formic acid\"], \"rat tissue\": [\"rat tissue homogenate\"]}", {"Herb name": ["puerarin"]}]], [68, "Group one was administered 42\u2009mg\u00b7kg Data are presented as mean\u2009\u00b1\u2009standard deviation (SD).", [" {\"AMOUNT\": [\"42 mg/kg\"]}", {}]], [69, "Based on our findings, the developed method is acceptable and accurate for analyzing LVFX in complex matrices.", [" {\"LVFX\": [\"LVFX\"]}\n{\"complex matrices\": [\"complex matrices\"]}\n{\"developed method\": [\"developed method\"]}\n{\"pharmacology\": [\"pharmacology\"]}\n{\"scientific article\": [\"scientific article\"]}\n{\"quantities\": [\"\"]}", {"Drug": ["LVFX"]}]], [70, "The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of \u00b115%.", [" {\"AMOUNT\": [\"\u00b115%\"]}\n\n{\"ENTITY\": [\"calibration curve\"]}", {}]], [71, "Polygonum capitatum may inhibit the entrance of LVFX into blood, thereby directly affecting its distribution rate in the tissue.", [" {\"Polygonum capitatum\": [\"Polygonum capitatum\"]}\n{\"LVFX\": [\"LVFX\"]}", {"Herb name": ["Polygonum capitatum"], "Drug": ["LVFX"]}]], [72, "At present, our current studies at the pharmacokinetic level may not be able to explain this problem strongly.", [" {\"PHARMACOKINETIC_LEVEL\": [\"current studies\", \"pharmacokinetic level\"]}:\n{\"AMOUNT\": [\"\"]}", {}]], [73, "However, drug interactions can be divided into pharmacokinetic interactions and pharmacodynamic interactions.", [" {\"PHARMACOLOGY_SUBFIELD\": [\"pharmacokinetic interactions\", \"pharmacodynamic interactions\"]}\n{\"DRUG_INTERACTIONS\": [\"drug interactions\"]}\n{\"DRUG_TYPES\": [\"pharmacokinetic\", \"pharmacodynamic\"]}\n{\"DRUG_ACTIONS\": [\"interactions\"]}\n{\"DRUG_MECHANISMS\": [\"pharmacokinetic\", \"pharmacodynamic\"]}\n{\"DRUG_CLASSES\": [\"\"]}\n{\"DRUG_CONCENTRATION\": [\"\"]}\n{\"DRUG_DOSAGE\": [\"\"]}\n{\"DRUG_FREQUENCY\": [\"\"]}\n{\"DRUG_DURATION\": [\"\"]}\n{\"DRUG_SIDE_EFFECTS\": [\"\"]}\n{\"DRUG_MECHANISMS_OF_ACTION\": [\"\"]}\n{\"DRUG_REACTIONS\": [\"\"]}\n{\"DRUG_INTERACTION_TYPES\": [\"pharmacokinetic\", \"pharmacodynamic\"]}\n{\"DRUG_INTERACTION_EFFECTS\": [\"\"]}\n{\"DRUG_INTERACTION_OUTCOMES\": [\"\"]}\n{\"DRUG_INTERACTION_METHODS\": [\"\"]}\n{\"DRUG_INTERACTION_STUDIES\": [\"\"]}\n{\"DRUG_INTERACTION_RESEARCH\": [\"\"]}\n{\"DRUG_INTERACTION_RESEARCH_TOPICS\": [\"\"]}\n{\"DRUG_INTERACTION_RESEARCH_METHODS\": [\"\"]}\n{\"DRUG_INTERACTION_RESEARCH_OUTCOMES\": [\"\"]}\n{\"DRUG_INTERACTION_RESEARCH_SOURCES\": [\"\"]}\n{\"DRUG_INTERACTION_RESEARCH_ARTICLES\": [\"\"]}\n{\"DRUG_INTERACTION_RESEARCH_JOURNALS\": [\"\"]}\n{\"DRUG_INTERACTION_RESEARCH_PAPERS\": [\"\"]}\n{\"DRUG_INTERACTION_RESEARCH_PATIENTS\": [\"\"]}\n{\"DRUG_INTERACTION_RESEARCH_CLINICS", {}]], [74, "KY[2017]073).", [" {\"KY\": [\"2017\", \"073\"]}:", {}]], [75, "People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy.", [" {\"Diabetes\": [\"people with diabetes\"], \"Combination Therapy\": [\"this combination\"], \"Monitoring\": [\"closely monitored\"]}\n{\"Dose\": [\"\"]}\n{\"Efficacy\": [\"reduced efficacy\"]}\n{\"Pharmacology\": [\"\"]}\n{\"Signs\": [\"possible signs\"]}", {"Pathology": ["diabetes"]}]], [76, "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013).", [" {\"KF\": [\"anticancer\", \"antioxidant\", \"anti-osteoporosis\", \"anti-inflammatory\"]}\n{\"Nadia et al., 2012\": [], \"Fathilah et al., 2013\": []}\n{\"AMOUNT\": []}", {"Herb name": ["the extract and constituents of KF"], "Pathology": ["anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties"]}]], [77, "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA).", [" {\"PHARMACEUTICAL_SUPPLIERS\": [\"GIBCO BRL\", \"Invitrogen Corp.\", \"Grand Island, NY, USA\"]}:\n{\"PHARMACEUTICAL_SUPPLIERS_PRODUCTS\": [\"Dulbecco\u2019s Modified Eagle Medium (DMEM)\", \"Minimal Essential Medium (MEM)\", \"HEPES\", \"Trypsin EDTA\", \"Penicillin-streptomycin\", \"Sodium Pyruvate\"]}:\n{\"PHARMACEUTICAL_SUPPLIERS_LOCATIONS\": [\"Grand Island, NY, USA\"]}:", {"Extraction process": ["Hanks balanced salt solution (HBSS)", "HEPES", "Trypsin EDTA", "Sodium Pyruvate"], "Drug": ["Penicillin-streptomycin"]}]], [78, "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates.", [" {\"PARAMETERS\": [\"10% FBS\", \"1% non-essential amino acids\", \"1%\", \"200 \u03bcL\"]}:", {"Drug": ["digoxin"], "Amount": ["10%", "1%", "1%", "200 \u03bcL"], "Extraction process": ["FBS"], "Herb name": ["non-essential amino acids"]}]], [79, "The two major classes of compounds isolated from the roots of KF are alkyl phenols and triterpene glycosides (saponins) as reported earlier (Ali and Khan, 2011).", [" {\"alkyl phenols\": [\"compounds\"], \"triterpene glycosides (saponins)\": [\"triterpene glycosides\", \"saponins\"], \"KF\": [\"Kaferaf (Kafiristan)\"]}\n{\"AMOUNT\": []}", {"Herb part": ["the roots"], "Herb name": ["KF", "alkyl phenols and triterpene glycosides (saponins)"]}]], [80, "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006).", [" {\"PHARMACOLOGICAL_PRODUCTS\": [\"L. pumlia extract\", \"calcein-AM\", \"digoxin\"]}:\n\n{\"STUDY_REFERENCES\": [\"Rautio et al., 2006\"]}:\n\n{\"QUANTITIES\": [\"not applicable\"]}:\n\n{\"PHARMACOLOGICAL_CONSTITUENTS\": [\"P-gp\"]}:\n\n{\"INHIBITION_METHODS\": [\"inhibition of P-gp\"]}:", {"Target": ["P-gp"], "Herb name": ["the extract of L. pumila and the constituents", "calcein-AM"], "Drug": ["digoxin"]}]], [81, "*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett\u2019s multiple comparison tests.", [" {\"P-values\": [\"P < 0.05\", \"**P < 0.01\", \"***P < 0.001\"]}:\n\n{\"One way ANOVA\": [\"One way ANOVA\"], \"Dunnett\u2019s multiple comparison tests\": [\"Dunnett\u2019s multiple comparison tests\"]}\n{\"Statistical tests\": [\"One way ANOVA\", \"Dunnett\u2019s multiple comparison tests\"]}:\n\n{\"Quantities\": [\"\"]}", {}]], [82, "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin.", [" {\"CYTOPHYRAM OXEN\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"], \"DRUGS\": [\"hypoglycemic drugs\", \"thiazolidinediones (TZDs)\", \"sulfonylureas\", \"hypocholesterolemic drugs\", \"atorvastatin\"]}\n\n{\"AMOUNT\": []}", {"Target": ["Cytochrome P450 enzymes", "CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["hypoglycemic drugs", "thiazolidinediones (TZDs)", "sulfonylureas", "hypocholesterolemic drugs", "atorvastatin"]}]], [83, "The anti-diabetic [9,10], anti-obesity [11], and cardio-protective effects [12,13,14] of rooibos extracts are of specific relevance given the global increase in the prevalence of diabetes and obesity [15,16,17].", [" {\"anti-diabetic\": [\"9,10\"], \"anti-obesity\": [\"11\"], \"cardio-protective effects\": [\"12,13,14\"], \"diabetes\": [\"15,16,17\"], \"obesity\": [\"15,16,17\"]}", {"Herb name": ["rooibos"], "Extraction process": ["extracts"], "Pathology": ["diabetes", "obesity"]}]], [84, "Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes [31].", [" {\"CYP2C8\": [\"CYP2C8\"], \"CYP2C9\": [\"CYP2C9\"], \"CYP3A4\": [\"CYP3A4\"]}\n{\"AMOUNT\": [\"\"]}", {"Herb name": ["Flavonoids"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [85, "Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4.", [" {\"CYP2C8\": [\"CYP2C8\"], \"CYP2C9\": [\"CYP2C9\"], \"CYP3A4\": [\"CYP3A4\"]}", {"Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [86, "The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a\u2013c).", [" {\"Methanol\": [\"methanol\"], \"Acetonitrile\": [\"acetonitrile\"], \"DMSO\": [\"DMSO\"], \"Supplementary Materials\": [\"Supplementary Materials\"], \"Figure S1a\": [\"Figure S1a\"], \"Figure S1b\": [\"Figure S1b\"], \"Figure S1c\": [\"Figure S1c\"]}", {}]], [87, "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c).", [" {\"CYP2C8\": [\"CYP2C8\"], \"CYP2C9\": [\"CYP2C9\"], \"CYP3A4\": [\"CYP3A4\"], \"GRT\": [\"GRT\"], \"FRE\": [\"FRE\"], \"reaction rate\": [\"reaction rate\"], \"30 min\": [\"30 min\"]}\n{\"AMOUNT\": [\"over 30 min\"]}", {"Extraction process": ["GRT", "FRE"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [88, "GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC CYP2C9 plays a role in the oxidation of xenobiotic and endogenous compounds and is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism [52,53].", [" {\"CYP3A4\": [\"CYP3A4 activity\"], \"FRE\": [\"FRE\"], \"CYP2C9\": [\"CYP2C9 metabolism\"]}\n{\"AMPUTATION\" [\"15%\u201320%\"]}\n{\"PHASE\": [\"phase I metabolism\"]}\n{\"DRUGS\": [\"drugs undergoing phase I metabolism\"]}", {"Extraction process": ["GRT", "FRE"], "Herb name": ["polyphenols", "ASP"], "Target": ["CYP3A4", "CYP2C9"]}]], [89, "Stock solutions (10 mg/mL) were prepared by diluting the extracts and compounds in distilled water.", [" {\"AMOUNT\": [\"10 mg/mL\"]}", {}]], [90, "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor).", [" {\"QUERCETIN\": [\"positive CYP2C8 inhibitor\"], \"SULFAPHENAZOLE\": [\"positive CYP2C9 inhibitor\"], \"KETOCONAZOLE\": [\"positive CYP3A4 inhibitor\"]}", {"Herb name": ["quercetin"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["sulfaphenazole", "ketoconazole"]}]], [91, "Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs.", [" {\"ROOIBOS EXTRACTS\": [\"nutraceuticals containing rooibos extracts\"], \"DRUGS METHODIST\": [\"drugs metabolized by CYP2C8 and CYP3A4\"], \"PHARMACODYNAMICS\": [\"pharmacodynamics\"], \"DRUG SAFETY\": [\"safety of these drugs\"]}", {"Study": ["in vitro study"], "Herb name": ["rooibos"], "Extraction process": ["extracts"], "Target": ["CYP2C8", "CYP3A4"]}]], [92, "All authors reviewed the manuscript.", [" {\"AUTHORS\": [\"All authors\"]}:\n\n{\"MANUSCRIPT\": [\"manuscript\"]}:", {}]], [93, "Echinacea was well tolerated, and all participants completed the study.", [" {\"Echinacea\": [\"Echinacea\"]}\n{\"participants\": [\"all participants\"]}\n{\"study\": [\"the study\"]}\n{\"quantities\": []}\n{\"AMOUNT\": []}", {"Herb name": ["Echinacea"]}]], [94, "2).", [" {\"PHARMACOLOGICAL_CONCEPTS\" [\"pharmacology\", \"drug\", \"medication\", \"pharmacokinetics\", \"pharmacodynamics\", \"dose\", \"concentration\", \"therapeutic window\", \"bioavailability\", \"absorption\", \"distribution\", \"metabolism\", \"excretion\"]}:\n\n{\"RESEARCHERS\" []}:\n\n{\"RESEARCH_ENTITIES\" []}:\n\n{\"STUDIES\" []}:\n\n{\"JOURNALS\" []}:\n\n{\"PUBLICATION_YEARS\" []}:\n\n{\"PUBLICATION_MONTHS\" []}:\n\n{\"PUBLICATION_YEARS\" []}:\n\n{\"PUBLICATION_MONTHS\" []}:\n\n{\"PUBLICATION_TITLES\" []}:\n\n{\"PUBLICATION_AUTHORS\" []}:\n\n{\"PUBLICATION_JOURNALS\" []}:\n\n{\"PUBLICATION_DOI\" []}:\n\n{\"PUBLICATION_URLS\" []}:\n\n{\"PHARMACEUTICAL_COMPANIES\" []}:\n\n{\"DRUG_NAMES\" []}:\n\n{\"DRUG_ACTIONS\" []}:\n\n{\"DRUG_INTERACTIONS\" []}:\n\n{\"DRUG_TOXICITY\" []}:\n\n{\"DRUG_DOSAGES\" []}:\n\n{\"DRUG_CONCENTRATIONS\" []}:\n\n{\"DRUG_EXCRETION_METHODS\" []}:\n\n{\"DRUG_METABOLISM_PATHWAYS\" []}:\n\n{\"DRUG_PHARMACOTHERAPY_APPLICATIONS\" []}:\n\n{\"DRUG_CLINICAL_TRIALS\" []}:\n\n{\"DRUG_CLINICAL_STAGES\" []}:\n\n{\"DRUG_CLINICAL_OUTCOMES\" []}:\n\n{\"DRUG_CLINICAL_STATISTICS\" []}:\n\n{\"DRUG_CLINICAL_STATISTICS_VALUES\" []}:\n\n{\"DRUG_CLINICAL_STATISTICS_UNITS", {}]], [95, "This result was statistically not significant.", [" {\"PHARMACOLOGICAL TITLES\": [\"pharmacology\"], \"DRUG NAMES\": [], \"PHARMACEUTICAL AGENTS\": [], \"RESEARCHERS\": [], \"FACILITIES\": [], \"JOURNALS\": [], \"ARTICLES\": [\"scientific article\"], \"STATISTICAL MEASURES\": [\"statistically not significant\"]}\n{\"AMOUNT\": []}", {}]], [96, "The commercially available E. purpurea extract did not significantly alter the pharmacokinetics of docetaxel.", [" {\"E. purpurea extract\": [\"commercially available\", \"E. purpurea extract\"]}\n{\"docetaxel\": [\"pharmacokinetics\", \"docetaxel\"]}", {"Herb name": ["E. purpurea"], "Drug": ["docetaxel"]}]], [97, "Of these components, caffeic acid derivatives and the more bioavailable alkylamides are found in ethanolic liquid extracts for medicinal use [8].", [" {\"caffeic acid derivatives\": [\"caffeic acid derivatives\"], \"alkylamides\": [\"alkylamides\"], \"ethanolic liquid extracts\": [\"ethanolic liquid extracts\"], \"medicinal use\": [\"medicinal use\"], \"ethanolic liquid extracts for medicinal use\": [\"ethanolic liquid extracts for medicinal use\"], \"ethanol\": [\"ethanol\"]}", {"Herb name": ["caffeic acid derivatives", "alkylamides"], "Extraction process": ["ethanolic liquid extracts"]}]], [98, "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)].", [" {\"E. purpurea\": [\"E. purpurea supplementation\"], \"docetaxel\": [\"docetaxel\"], \"National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)\": [\"NCI CTCAE, version 3.0\"]}", {"Herb name": ["E. purpurea"], "Pathology": ["toxicities", "Cancer", "Adverse Events"], "Drug": ["docetaxel"]}]], [99, "Subsequently, plasma was separated and stored at \u221220\u00b0C until analysis.", [" {\"PLASMA\": [\"plasma\"], \"TEMPERATURE\": [\"\u221220\u00b0C\"], \"STORAGE_METHOD\": [\"separated\", \"stored\"], \"ANALYSIS_TIME\": [\"until analysis\"]}\n{\"AMOUNT\": [\"\"]} (No specific quantities were mentioned in the text.)", {}]], [100, "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax).", [" {\"AUC0\u2013\u221e\": [\"area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)\"], \"elimination half-life (t1/2)\": [\"elimination half-life (t1/2)\"], \"maximum plasma concentration (Cmax)\": [\"maximum plasma concentration (Cmax)\"]}", {"Drug": ["docetaxel"], "Parameter": ["area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)", "elimination half-life (t1/2)", "maximum plasma concentration (Cmax)"]}]], [101, "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea).", [" {\"AUC0\u2013\u221e\": [\"values of AUC0\u2013\u221e of docetaxel in cycle 1 (before E. purpurea)\"], \"t1/2\": [\"values of t1/2 of docetaxel in cycle 1 (before E. purpurea)\"], \"Cmax\": [\"values of Cmax of docetaxel in cycle 1 (before E. purpurea)\"], \"docetaxel\": [\"docetaxel in cycle 1 (before E. purpurea)\"], \"cycle 1\": [\"cycle 1 (before E. purpurea)\"], \"cycle 2\": [\"cycle 2 (after E. purpurea)\"], \"E. purpurea\": [\"E. purpurea\"]}", {"Parameter": ["AUC0\u2013\u221e", "t1/2", "Cmax"], "Drug": ["docetaxel"], "Herb name": ["E. purpurea", "E. purpurea"]}]], [102, "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3.", [" {\"DOCETAXEL\": [\"docetaxel\"]}", {"Drug": ["docetaxel"], "Parameter": ["AUC0\u2013\u221e"]}]], [103, "Compared with the clinical studies in which significant induction of CYP3A4 by E. purpurea was found using midazolam as a CYP3A4 probe [11, 12], our study differed in formulation, dose and dosing regimen, which may explain the divergent outcome.", [" {\"CYP3A4 probe\": [\"midazolam\"], \"clinical studies\": [\"significant induction of CYP3A4 by E. purpurea\"], \"E. purpurea\": [\"E. purpurea\"], \"study\": [\"our study\"]}\n{\"Dose\": [\"dose\"], \"dosing regimen\": [\"dosing regimen\"]}\n{\"[11, 12]\": [\"[11, 12]\"}", {"Study": ["clinical studies"], "Target": ["CYP3A4", "CYP3A4"], "Herb name": ["E. purpurea"], "Drug": ["midazolam"]}]], [104, "Our commercial product was only labelled to contain 95% aerial parts and 5% roots of E. purpurea, and no information was provided about the total amount of extract used.", [" {\"Extract of E. purpurea\": [\"95% aerial parts and 5% roots\", \"total amount of extract used\"]}\n{\"E. purpurea\": [\"95% aerial parts and 5% roots\", \"total amount of extract used\"]}\n{\"Aerial parts\": [\"95% aerial parts\"]}\n{\"Roots\": [\"5% roots\"]}\n{\"Commercial product\": [\"Our commercial product\"]}\n{\"Label\": [\"labelled to contain\"]}\n{\"Information\": [\"no information was provided about\"]}", {"Herb part": ["aerial parts", "roots"], "Herb name": ["E. purpurea"]}]], [105, "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified.", [" {\"DTAI\": [\"DTAI\"], \"alkylamides\": [\"alkylamides\"], \"midazolam studies\": [\"midazolam studies\"]}\n{\"AMOUNT\": []}", {"Herb name": ["DTAI", "alkylamides"], "Drug": ["midazolam"]}]], [106, "For example, alkylamide content is known to vary considerably across different parts of E. purpurea plants [20], and DTAI are more abundant in roots than in leaves.", [" {\"E. purpurea\": [\"E. purpurea plants\"], \"alkylamide content\": [\"alkylamide content\"], \"DTAI\": [\"DTAI\"]}\n{\"AMOUNT\": [\"vary considerably\", \"more abundant\"]}\n{\"PARTS\": [\"different parts\", \"roots\", \"leaves\"} }\n{\"SOURCES\": [\"[20]\"]}", {"Herb name": ["alkylamide", "E. purpurea", "DTAI"], "Herb part": ["roots", "leaves"]}]], [107, "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23].", [" {\"LS180 cells\": [\"LS180 cells\"], \"CYP3A4\": [\"CYP3A4\"], \"alkylamides\": [\"alkylamides\"], \"E. purpurea\": [\"E. purpurea\"], \"gene reporter assay\": [\"gene reporter assay\"], \"compounds\": [\"compounds\"]}\n{\"AMOUNT\": []}", {"Target": ["CYP3A4", "CYP3A4"], "Herb name": ["alkylamides", "E. purpurea"]}]], [108, "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel.", [" {\"E. purpurea\": [\"E. purpurea product\"], \"docetaxel\": [\"docetaxel\"], \"dexamethasone\": [\"dexamethasone\"], \"pharmacokinetics\": [\"pharmacokinetics of docetaxel\"]}", {"Herb name": ["E. purpurea", "E. purpurea"], "Drug": ["docetaxel", "dexamethasone", "docetaxel"]}]], [109, "For example, the potent P-gp inhibitors R101933 [27, 28] and zosuquidar [29] did not significantly alter plasma levels of docetaxel in cancer patients.", [" {\"P-gp inhibitors\": [\"R101933\", \"zosuquidar\"], \"quantities\": [\"27, 28\", \"29\"]}\n{\"docetaxel\": [\"plasma levels\"]}", {"Target": ["P-gp"], "Drug": ["zosuquidar", "docetaxel"], "Pathology": ["cancer"]}]], [110, "Considering the risk of tumour progression, randomization was not in the interest of patients with advanced cancer.", [" {\"Risk of tumour progression\": [\"risk of tumour progression\"], \"advanced cancer\": [\"advanced cancer\"]}\n{\"AMOUNT\": []}", {"Pathology": ["tumour", "advanced cancer"]}]], [111, "Thus, the risk of CYP3A4-mediated interactions may be product dependent.", [" {\"CYP3A4\": [\"CYP3A4-mediated interactions\"]}\n{\"Product\": [\"product dependent\"]}", {"Target": ["CYP3A4"]}]], [112, "Previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1.", [" {\"ABCB1\": [\"p-glycoprotein\"]}\n{\"green tea\": [\"in vitro studies\"]}", {"Herb name": ["green tea"], "Target": ["p-glycoprotein (p-gp) encoded by ABCB1"]}]], [113, "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes.", [" {\"PLASMA_QUANTITY\": [\"100 \u00b5L plasma\"]}:\n\n{\"ETHYL_GALLACTE_CONCENTRATION\": [\"1 \u00b5g/mL\"]}:\n\n{\"ETHYL_ACETATE_AMOUNT\": [\"1 mL\"]}:\n\n{\"ASCORBIC_ACID_EDTA_RATIO\": [\"10:1 (v/v)\"]}:\n\n{\"VORTEXING_DURATION\": [\"15 minutes\"]}:\n\n{\"CENTRIFUGATION_SPEED\": [\"4,500 rpm\"]}:\n\n{\"CENTRIFUGATION_DURATION\": [\"20 minutes\"]):", {}]], [114, "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively.", [" {\"M/Z values\": [\"443.10\", \"123.00\", \"307.20\", \"151.00\", \"291.20\", \"139.00\", \"199.00\", \"127.03\"]}:", {"Herb name": ["ECG", "EGC", "EC"]}]], [115, "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC.", [" {\"CALIBRATION_CURVE_RANGE_EC\": [\"0.1\u201350 ng/mL\"]}:\n{\"CALIBRATION_CURVE_RANGE_EGCG\": [\"1\u2013500 ng/mL\"]}:\n{\"CALIBRATION_CURVE_RANGE_ECG\": [\"1\u2013500 ng/mL\"]}:\n{\"CALIBRATION_CURVE_RANGE_EGC\": [\"1\u2013500 ng/mL\"]}:", {"Herb name": ["EC", "EGCG", "ECG", "EGC"]}]], [116, "DNA was isolated from the 200 \u00b5L of whole blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA).", [" {\"DNA\": [\"DNA\"], \"whole blood samples\": [\"whole blood samples\"], \"QIAamp DNA Blood Mini Kit\": [\"QIAamp DNA Blood Mini Kit\"], \"Qiagen\": [\"Qiagen\"]}\n{\"AMOUNT\": [\"200 \u00b5L\"]}", {}]], [117, "The identification of genotyping was performed for 4 single-nucleotide polymorphisms (SNPs) in ABCB1, namely C3435T (rs1045642), C1236T (rs1128503), G2677A (rs2032582), and G2677T (rs2032582).", [" {\"SNPs\": [\"C3435T (rs1045642)\", \"C1236T (rs1128503)\", \"G2677A (rs2032582)\", \"G2677T (rs2032582)\"]}", {}]], [118, "Sixteen subjects reported 27 adverse events.", [" {\"SUBJECTS\": [\"Sixteen\"]}:\n{\"AMOUNT\": [\"27\"]}:\n\nNote: The entity \"adverse events\" is not quantified in the text, so it is not included in the \"AMOUNT\" list.", {"Cohort": ["Sixteen subjects"], "Pathology": ["adverse events"]}]], [119, "All the adverse events were mild in intensity and resolved without any treatment.", [" {\"PHARMACOLOGICAL_TREATMENT_NAME\": [\"adverse events\"]}:\n{\"DOSAGE\": [\"mild in intensity\"]}:\n{\"TREATMENT_RESOLUTION\": [\"resolved without any treatment\"]}:", {"Pathology": ["adverse events"]}]], [120, "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3.", [" {\"digoxin\": [\"single administration\", \"concomitant administration\", \"systemic exposure\", \"AUC\", \"concentration\u2013time profiles\", \"pharmacokinetics parameters\"]}\n\n{\"GTC\": [\"concomitant administration\"]}\n\n{\"EC\": [\"concentration\u2013time profiles\"]}\n\n{\"EGC\": [\"concentration\u2013time profiles\"]}\n\n{\"ECG\": [\"concentration\u2013time profiles\"]}\n\n{\"EGCG\": [\"concentration\u2013time profiles\"]}\n\n{\"Table 3\": [\"pharmacokinetics parameters\"]}\n\n{\"Figure 4\": [\"concentration\u2013time profiles\"]}", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "EC", "EGC", "ECG", "EGCG"], "Parameter": ["AUC"]}]], [121, "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin.", [" {\"ABCB1 genotype\": [],\n \"digoxin\": [\"pharmacokinetic alteration\", \"AUC\", \"digoxin alone treatment\", \"pharmacokinetics of digoxin\"],\n \"GTC\": [\"GTC\", \"pharmacokinetic alteration\", \"pharmacokinetics of digoxin\"]}", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "GTC"], "Parameter": ["AUC"]}]], [122, "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study.", [" {\"GTC\": [\"GTC\"]}\n{\"digoxin\": [\"digoxin\"]}\n{\"systemic exposure\": [\"systemic exposure\"]}", {"Herb name": ["GTC"], "Drug": ["digoxin"]}]], [123, "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables.", [" {\"AMOUNT\": [\"mean \u00b1 SD\", \"ratios\"], \"SUBJECT\": [\"baseline characteristics\"], \"STUDY\": [\"start of the study\"]}", {"Herb name": ["catechin"], "Parameter": ["AUC", "AUC"]}]], [124, "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group.", [" {\"Methotrexate\": [\"methotrexate\"]}\n{\"Biliary excretion\": [\"biliary excretion\"]}\n{\"Urinary excretion\": [\"urinary excretion\"]}\n{\"RGE repeated administration group\": [\"RGE repeated administration group\"]}\n{\"Control group\": [\"control group\"]}\n{\"AMOUNT\": [\"\"]}", {"Parameter": ["Biliary excretion", "urinary excretion"], "Drug": ["methotrexate"], "Herb name": ["RGE"], "Frequency": ["repeated administration"]}]], [125, "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored.", [" {\"RGE\": [\"RGE\"], \"rats\": [\"rats\"], \"plasma concentrations\": [\"plasma concentrations\"], \"ginsenosides\": [\"ginsenosides\"]}\n{\"Dose\": [\"single or multiple doses\"], \"duration\": [\"1 or 2 weeks\"]}\n{\"RGE\": [\"RGE\"]}\n{\"Rat\": [\"rats\"]}\n{\"Plasma concentrations\": [\"plasma concentrations\"]}\n{\"Ginsenosides\": [\"ginsenosides\"]}\n{\"AMOUNT\": [\"\"]}\n{\"Quantity\": [\"single or multiple doses\", \"1 or 2 weeks\", \"1 or 2 weeks\"]}", {"Herb name": ["RGE", "ginsenosides"], "Duration": ["for 1 or 2 weeks"]}]], [126, "Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats.", [" {\"RGE\": [\"RGE\"], \"Mrp2 substrate drug\": [\"Mrp2 substrate drug\"], \"rats\": [\"rats\"]}\n\n(Note: The quantities \"List of quantities found in text\" are not applicable in this context as the provided text does not contain numerical values.)", {"Herb name": ["RGE"], "Target": ["Mrp2"]}]], [127, "However, other ginsenosides, such as Rg3, Re, and Rh1, were not detected in rat plasma despite their high content in RGE (Table 1 and Table 2).", [" {\"Ginsenosides\": [\"Rg3\", \"Re\", \"Rh1\"]}:\n{\"Rat plasma\": [\"rat plasma\"]}:\n{\"Table 1\": [\"Table 1\"]}:\n{\"Table 2\": [\"Table 2\"]}:", {"Herb name": ["ginsenosides", "Rg3", "Re", "Rh1", "RGE"]}]], [128, "Nuclear receptors, such as farnesoid X receptor (FXR, also known as bile acid receptor) and pregnane X receptor (PXR), are known as major regulators of the expression of Bsep and P-gp, respectively [35].", [" {\"Farnesoid X receptor (FXR)\": [],\n \"bile acid receptor\": [],\n \"Pregane X receptor (PXR)\": [],\n \"major regulators\": [],\n \"expression of Bsep\": [],\n \"expression of P-gp\": []}", {"Target": ["farnesoid X receptor (FXR, also known as bile acid receptor)", "pregnane X receptor (PXR)", "Bsep", "P-gp"]}]], [129, "In particular, the beneficial effects of red ginseng products for reducing the symptoms of rheumatoid arthritis have been proven in animals and humans [24,25,26,27,36].", [" {\"Rheumatoid arthritis\": [\"symptoms of rheumatoid arthritis\"], \"red ginseng products\": [\"red ginseng products\"], \"quantities\": [\"\"]}", {"Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [130, "Therefore, the use of MTX and red ginseng alone or in combination is highly plausible for treatment of rheumatoid arthritis.", [" {\"MTX\": [\"MTX\"], \"red ginseng\": [\"red ginseng\"]}\n{\"AMOUNT\": [\"\"]}", {"Drug": ["MTX"], "Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [131, "Therefore, in conclusion, this study showed that the herb\u2013drug interactions between red ginseng and MTX occurred via Mrp2 regulation changes in rats, but clinical significance thereof should be determined with follow-up studies.", [" {\"Red Ginseng\": [\"red ginseng\"], \"MTX\": [\"MTX\"], \"Mrp2\": [\"Mrp2\"], \"rats\": [\"rats\"]}", {"Herb name": ["red ginseng"], "Drug": ["MTX"], "Target": ["Mrp2"]}]], [132, "The concentration of total RNA was determined by Nano Vue Plus (GE healthcare Korea, Seoul, Korea).", [" {\"GE healthcare Korea\": [\"GE healthcare Korea\"]}\n{\"Nano Vue Plus\": [\"Nano Vue Plus\"]}\n{\"total RNA\": [\"total RNA\"]}\n{\"concentration\": [\"concentration\"]}", {}]], [133, "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer.", [" {\"AMOUNT\": [\"100 mg\"]}\n\n(Note: Although \"equal volume\" is mentioned, it is not a specific quantity and therefore not included in the list of quantities.)", {}]], [134, "Pharmacokinetic studies started 2 h after the last RGE treatment.", [" {\"TIME_FRAME\": [\"2 h\"]}:", {"Herb name": ["RGE"]}]], [135, "Sample Availability: Red ginseng extract are available from the authors.", [" {\"Red ginseng extract\": [\"Red ginseng extract\"]}\n{\"AMOUNT\": [\"available\"]}", {"Herb name": ["Red ginseng extract"]}]], [136, "Conceptualization, M.-K.C.", [" {\"AMOUNT\": [], \"Conceptualization\": [\"M.-K.C.\"} }\n\n(Note: In the provided text, there are no specific quantities mentioned, hence the \"AMOUNT\" list is empty.)", {}]], [137, "Contents of ginsenosides in RGE.", [" {\"Ginsenosides\": [\"Contents of ginsenosides in RGE\"]}:\n\n{\"Quantity\": [\"\"]}:", {"Herb name": ["ginsenosides", "RGE"]}]], [138, "2016; Bautista et\u00a0al.", [" {\"PUBLICATION_YEAR\": [\"2016\"]}:\n{\"AUTHORS\": [\"Bautista et al.\"]}", {}]], [139, "2014; Dybro et\u00a0al.", [" {\"Dybro et al.\": [\"Dybro et al.\"], \"2014\": [\"2014\"]}\n{\"Pharmacology\": [\"pharmacology\"]}", {}]], [140, "However, it is unknown whether there is an interaction between AC and DST.", [" {\"AC\": [\"AC\"], \"DST\": [\"DST\"]}", {"Drug": ["AC"], "Herb name": ["DST"]}]], [141, "; 3.5\u2009\u03bcm) at room temperature.", [" {\"Drug Concentration\": [\"3.5 \u03bcm\"]}:", {}]], [142, "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis.", [" {\"Supernatant\": [\"10 minutes\"]}:\n{\"Frozen\": [\"\u221240 \u00b0C\"]}:\n{\"Centrifuging\": [\"3500 rpm\"]}:\n{\"Duration\": [\"10 minutes\"]}:\n{\"Temperature\": [\"\u221240 \u00b0C\"]}:\n{\"Analysis\": []}:\n{\"Supernatant\": [\"the supernatant\"]}:\n{\"Sample\": [\"the supernatant\"]}:\n{\"Centrifuge\": [\"centrifuging\"]}:\n{\"Supernatant\": [\"the supernatant obtained\"]}:\n{\"Sample\": [\"the supernatant obtained\"]}:\n{\"Supernatant\": [\"the supernatant\"]}:\n{\"Sample\": [\"the supernatant\"]}:\n{\"Supernatant\": [\"the supernatant\"]}:\n{\"Sample\": [\"the supernatant\"]}:\n{\"Supernatant\": [\"the supernatant\"]}:\n{\"Sample\": [\"the supernatant\"]}:\n{\"Supernatant\": [\"the supernatant\"]}:\n{\"Sample\": [\"the supernatant\"]}:\n{\"Supernatant\": [\"the supernatant\"]}:\n{\"Sample\": [\"the supernatant\"]}:\n{\"Supernatant\": [\"the supernatant\"]}:\n{\"Sample\": [\"the supernatant\"]}:\n{\"Supernatant\": [\"the supernatant\"]}:\n{\"Sample\": [\"the supernatant\"]}:\n{\"Supernatant\": [\"the supernatant\"]}:\n{\"Sample\": [\"the supernatant\"]}:\n{\"Supernatant\": [\"the supernatant\"]}:\n{\"Sample\": [\"the supernatant\"]}:\n{\"Supernatant\": [\"the supernatant\"]}:\n{\"Sample\": [\"the supernatant\"]}:\n{\"Supernatant\": [\"the supernatant\"]}:\n{\"Sample\": [\"the supernatant\"]}:\n{\"Supernatant\": [\"the supernatant\"]}:\n{\"Sample\": [\"the supernatant\"]}:\n{\"Supernatant\": [\"the supernatant\"]}:\n{\"Sample\": [\"the supernatant\"]}:\n{\"Supernatant\": [\"the supernatant\"]}:\n{\"Sample\": [\"the supernatant\"]}:\n{\"Supernatant\": [\"the supernatant\"]}:\n{\"Sample\": [\"the supernatant\"]}:\n{\"Supernatant\": [\"the supernatant\"]}:\n{\"Sample\":", {}]], [143, "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC.", [" {\"AMOUNT\": [\"maximum plasma concentration\"], \"ORGANISM\": [\"Rat liver microsomes\"], \"PRODUCT\": [\"AC\"]}\n\nNote: The entities \"C\" and \"microsomes\" are not explicitly mentioned as quantities, but they are related to the context of the study and could be inferred as part of the experimental setup. However, they are not directly listed as quantities in the text provided. If the context implies they are quantities, it would be a subjective interpretation and not explicitly stated in the text. Therefore, they are not included in the \"AMOUNT\" list.", {"Drug": ["AC"]}]], [144, "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD.", [" {\"Half-life (t)\": [\"half-life\"], \"Experimental values\": [\"experimental values\"], \"Mean\": [\"mean\"], \"SD\": [\"SD\"]}", {}]], [145, "The highest recovery was obtained using acetonitrile as a protein precipitant.", [" {\"PROTEIN PRECIPITANT\": [\"acetonitrile\"]}\n{\"AMOUNT\": [\"\"]}", {}]], [146, "In the present study, the selectivity was examined using independent plasma samples from six different rats.", [" {\"PLATFORM_RATS\": [\"six different rats\"]}\n{\"AMOUNT\": [\"individual plasma samples\"]}", {}]], [147, "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL.", [" {\"AMOUNT\": [\"1\", \"500\", \"ng/mL\"]}", {"Drug": ["AC"]}]], [148, "These data indicated that the accuracy and precision of the method were satisfactory.", [" {\"METHODS\": [\"method\"], \"PHARMACOLOGY\": [\"pharmacology\"], \"ACCURACY\": [\"accuracy\"], \"PRECISION\": [\"precision\"]}\n{\"AMOUNT\": []}", {}]], [149, "Its effective plasma drug concentration is close to the toxic concentration, and large individual differences in the effects of the drug have been observed.", [" {\"PLASMA_Drug_Concentration\": [\"effective plasma drug concentration\"], \"TOXIC_CONCENTRATION\": [\"toxic concentration\"], \"DRUG_NAME\": [\"\"]}", {}]], [150, "The results of existing studies are controversial and further in-depth studies are required.", [" {\"STUDY_TITLES\": [\"results of existing studies\"], \"RESEARCHERS\": [], \"ORGANIZATIONS\": [], \"PUBLICATIONS\": [], \"PHARMACOLOGY_TERMS\": [\"pharmacology\"], \"QUANTITIES\": []}\n\n{\"AMOUNT\": []}", {}]], [151, "Most of these reports and studies are on combinations with Western drugs.", [" {\"PHARMACOLOGICAL_STUDIES\": [\"reports and studies\"]}:\n{\"DRUG_COMPANIES\": []}:\n{\"DRUG_NAMES\": [\"Western drugs\"]}:\n{\"DRUG_TYPES\": [\"Western drugs\"]}:\n{\"DRUG_ACTIONS\": []}:\n{\"DRUG_CLASSES\": [\"Western drugs\"]}:\n{\"DRUG_CONCENTRATIONS\": []}:\n{\"DRUG_DOSAGES\": []}:\n{\"DRUG_MECHANISMS\": []}:\n{\"DRUG_REACTIONS\": []}:\n{\"DRUG_TARGETS\": []}:\n{\"DRUG_TOXICITY\": []}:\n{\"DRUG_INTERACTIONS\": [\"combinations\"]}:\n{\"DRUG_COMPOSITION\": []}:\n{\"DRUG_FORMULATIONS\": []}:\n{\"DRUG_CLINICAL_TRIALS\": [\"reports and studies\"]}:\n{\"DRUG_CLINICAL_STAGES\": []}:\n{\"DRUG_CLINICAL_OUTCOMES\": []}:\n{\"DRUG_CLINICAL_MEASURES\": []}:\n{\"DRUG_CLINICAL_ENDPOINTS\": []}:\n{\"DRUG_CLINICAL_STATISTICS\": []}:\n{\"DRUG_CLINICAL_STATISTICS_METHODS\": []}:\n{\"DRUG_CLINICAL_STATISTICS_RESULTS\": []}:\n{\"DRUG_CLINICAL_STATISTICS_ANALYSIS\": []}:\n{\"DRUG_CLINICAL_STATISTICS_INTERPRETATION\": []}:\n{\"DRUG_CLINICAL_STATISTICS_CONCLUSION\": []}:\n{\"DRUG_CLINICAL_TRIAL_PHASES\": []}:\n{\"DRUG_CLINICAL_TRIAL_PARTICIPANTS\": []}:\n{\"DRUG_CLINICAL_TRIAL_ENROLLMENT\": []}:\n{\"DRUG_CLINICAL_TRIAL_DESIGN\": []}:\n{\"DRUG_CLINICAL_TRI", {}]], [152, "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results.", [" {\"Digoxin substances\": [\"endogenous digoxin substances\"]}\n{\"Neonates\": [\"neonates\"]}\n{\"Patients with renal dysfunction\": [\"patients with renal dysfunction\"]}\n{\"Digoxin plasma concentration monitoring\": [\"digoxin plasma concentration monitoring\"]}\n{\"Elevated\": [\"elevated\"]}\n{\"False-positive\": [\"false-positive\"]}", {"Drug": ["digoxin", "digoxin"], "Pathology": ["patients", "renal dysfunction"]}]], [153, "Based on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows: A.", [" {\"TCM formulations\": [\"TCM formulations\"], \"digoxin\": [\"digoxin\"]}\n{\"AMOUNT\": []}", {"Drug": ["digoxin"]}]], [154, "In vivo, digoxin was administered intravenously to control rats and citronellal pretreated experimental rats, and in vitro, the transcellular transport of   Single TCM: Single TCM formulations that are capable of inhibiting or downregulating P-gP include Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong), Vernonia amygdalina (Biantaobanjiuju), Tapinanthus sessilifolius, Carica papaya (Mugua) and Ginkgo biloba L. (Yinxing).", [" {\"PHARMACOLOGICAL_COMPOUNDS\": [\"digoxin\", \"citronellal\", \"Conioselinum anthriscoides\", \"Chuanxiong\", \"Vernonia amygdalina\", \"Tapinanthus sessilifolius\", \"Carica papaya\", \"Ginkgo biloba\"}\n\n{\"TREATMENT_METHODS\": [\"intravenously\", \"in vitro\"]}\n\n{\"LIVES_STAGES\": [\"in vivo\"]}\n\n{\"RAT_MODELS\": [\"rats\"]}\n\n{\"EXPERIMENTAL_TREATMENTS\": [\"transcellular transport\"]}\n\n{\"THERAPEUTIC_PRODUCTS\": [\"TCM\", \"Single TCM\", \"P-gP\"]}\n\n{\"TREATMENT_OUTCOMES\": [\"inhibiting\", \"downregulating\"]}\n\n{\"PLANT_SPECIES\": [\"Conioselinum anthriscoides\", \"Vernonia amygdalina\", \"Tapinanthus sessilifolius\", \"Carica papaya\", \"Ginkgo biloba\"]}", {"Drug": ["digoxin"], "Herb name": ["citronellal", "Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong)", "Vernonia amygdalina (Biantaobanjiuju)", "Tapinanthus sessilifolius", "Carica papaya (Mugua)", "Ginkgo biloba L. (Yinxing)"], "Target": ["P-gP"]}]], [155, "Experiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection.", [" {\"Digoxin\": [\"digoxin\"], \"Quantities\": [\"AUC\"]}\n{\"Gavage\": [\"gavage\"], \"Intravenous injection\": [\"intravenous injection\"]}", {"Parameter": ["AUC"], "Drug": ["digoxin"]}]], [156, "Li Xin et al.", [" {\"LIXIN_ET_AL\": [\"Li Xin et al.\"]}\n{\"AMOUNT\": []}\n{\"PHARMACOLOGY_TOPIC\": [\"pharmacology\"]}\n{\"PUBLICATION_TYPE\": [\"scientific article\"]}\n{\"RESEARCHER_GROUP\": [\"Li Xin et al.\"]}\n{\"RESEARCH_TYPE\": [\"cited entities\"]}\n{\"PUBLICATION_SOURCE\": []}\n{\"PUBLICATION_FORMAT\": [\"parsing\"]}\n{\"PUBLICATION_CITATION\": [\"this is a\"]}\n{\"PUBLICATION_AUTHORS\": [\"Li Xin et al.\"]}\n{\"PUBLICATION_ARTICLE_TOPIC\": [\"pharmacology\"]}\n{\"PUBLICATION_ARTICLE_TYPE\": [\"scientific article\"]}\n{\"PUBLICATION_ARTICLE_PUBLISHER\": []}\n{\"PUBLICATION_ARTICLE_YEAR\": []}\n{\"PUBLICATION_ARTICLE_JOURNAL\": []}\n{\"PUBLICATION_ARTICLE_DOI\": []}\n{\"PUBLICATION_ARTICLE_ABSTRACT\": []}\n{\"PUBLICATION_ARTICLE_KEYWORDS\": [\"pharmacology\"]}\n{\"PUBLICATION_ARTICLE_METHODOLOGY\": []}\n{\"PUBLICATION_ARTICLE_FINDINGS\": []}\n{\"PUBLICATION_ARTICLE_CONCLUSIONS\": []}\n{\"PUBLICATION_ARTICLE_REFERENCES\": [\"cited entities\"]}\n{\"PUBLICATION_ARTICLE_CITED_WORKS\": [\"Li Xin et al.\"]}\n{\"PUBLICATION_ARTICLE_CITED_AUTHORS\": [\"Li Xin et al.\"]}\n{\"PUBLICATION_ARTICLE_CITED_WORK_YEAR\": []}\n{\"PUBLICATION_ARTICLE_CITED_WORK_JOURNAL\": []}\n{\"PUBLICATION_ARTICLE_CITED_WORK_DOI\": []}\n{\"PUBLICATION_ARTICLE_CITED_WORK_ABSTRACT\": []}\n", {}]], [157, "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021).", [" {\"QRS interval duration\": [\"duration of QRS interval prolongation\"], \"ventricular precontraction\": [\"ventricular precontraction\"], \"ventricular tachycardia\": [\"ventricular tachycardia\"], \"ventricular fibrillation\": [\"ventricular fibrillation\"], \"C. pinnatifida Bunge (Shanzha) extract\": [\"C. pinnatifida Bunge (Shanzha) extract\"], \"digoxin-induced arrhythmias\": [\"digoxin-induced arrhythmias\"], \"flavonoid glycoside\": [\"flavonoid glycoside\"], \"flavane polymers\": [\"flavane polymers\"]}", {"Pathology": ["ventricular precontraction, ventricular tachycardia,", "ventricular fibrillation", "arrhythmia", "arrhythmias", "ventricular arrhythmias", "arrhythmias"], "Herb name": ["C. pinnatifida Bunge (Shanzha)", "C. pinnatifida Bunge (Shanzha)", "flavonoid glycoside", "flavane polymers", "C. pinnatifida Bunge (Shanzha)"], "Drug": ["digoxin", "digoxin", "digoxin"], "Parameter": ["blood pressure", "heart rhythm"]}]], [158, "When the bias of medicine is greater than that of food, it will inevitably affect the balance of qi, blood, yin and yang of the human body (Jia et al., 2021).", [" {\"JIA et AL, 2021\": [\"Jia et al., 2021\"]}\n{\"quantities\": []}\n\nNote: The provided text does not contain explicit numerical quantities, hence the \"quantities\" field is left empty.", {}]], [159, "Although a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations.", [" {\"Digoxin\": [\"digoxin\"]}\n{\"Traditional Chinese Medicine (TCM) formulations\": [\"TCM formulations\"]}\n{\"clinical application\": [\"clinical application\"]}\n{\"research\": [\"research\"]}\n{\"quantities\": [\"\"]}", {"Drug": ["digoxin"]}]], [160, "The composition of TCM formulations is complex.", [" {\"TCM Formulations\": [\"TCM formulations\"]}\n{\"Quantities\": [\"\"]}", {}]], [161, "Therefore, the interactions between TCM formulations and digoxin are difficult to elucidate, and they are easily ignored by physicians.", [" {\"TCM formulations\": [], \"digoxin\": [\"digoxin\"]}", {}]], [162, "Many view these medicines as benign because they are of natural origin; however, because their constituents may be metabolized through the same enzymatic pathways as pharmaceutical agents, there is a potential for herb-drug interactions.", [" {\"PHARMACOLOGICAL AGENTS\": [\"pharmaceutical agents\"]}\n{\"HERBS\": [\"medicines\"]}\n{\"ENZYMES\": [\"enzymatic pathways\"]}\n{\"HERB-DRUG INTERACTIONS\": [\"herb-drug interactions\"]}\n{\"QUANTITIES\": [\"\"]}", {}]], [163, "The most important class of enzymes involved in human drug metabolism is cytochrome P450 (P450), which occurs as a superfamily of related monooxygenase forms responsible for oxidative metabolism of xenobiotics and endogenous compounds (Nebert et al., 2013).", [" {\"CYTOCHROM_P450\": [\"cytochrome P450\"]}\n{\"OXIDATIVE_METABOLISM\": [\"oxidative metabolism\"]}\n{\"XENOBIO_INHIBITORS\": [\"xenobiotics\"]}\n{\"ENDGENOUS_COMPOUNDS\": [\"endogenous compounds\"]}\n{\"NEBERT_ALT_2013\": [\"Nebert et al., 2013\"]}\n{\"MONOOXYGENASE_FORMS\": [\"monooxygenase forms\"]}\n{\"DRUG_METABOLISM\": [\"drug metabolism\"]}", {"Parameter": ["cytochrome P450 (P450)", "monooxygenase forms"]}]], [164, "Metabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug (Lin and Lu, 1998; Bohnert et al., 2016).", [" {\"DRUGS\": [\"Metabolic drug interactions\", \"perpetrator drug\", \"victim drug\"]}:\n\n{\"YEARS\": [\"1998\", \"2016\"]}:\n\n{\"AUTHORS\": [\"Lin and Lu\", \"Bohnert et al.\"]}:\n\n{\"QUANTITIES\": [\"two or more\"]}:", {}]], [165, "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline.", [" {\"PHARMACOLOGICAL TRIALS\": [\"NCT03929250\", \"NCT03937908\"]}:\n\n{\"DRUG-METABOLISING ENZYMES\": []}:\n\n{\"CAW EXTRACT\": [\"type of extract\"]}:\n\n{\"BOTANICAL DRUG\": [\"CAW\"]}:\n\n{\"COGNITIVE DECLINE\": []}:", {"Herb name": ["CAW", "CAW"], "Study": ["preclinical studies", "phase II clinical trials"], "Pathology": ["cognitive decline"]}]], [166, "Hepatocytes cultured in this format are responsive to nuclear receptor agonists and maintain important transporter function necessary for proper drug disposition (Yang et al., 2016).", [" {\"Yang et al.\": [\"2016\"]}:\n\n{\"hepatocytes\": [\"\"]}:\n\n{\"nuclear receptor agonists\": [\"\"]}:\n\n{\"transporter function\": [\"\"]}:\n\n{\"drug disposition\": [\"\"]):", {"Parameter": ["nuclear receptor"]}]], [167, "C. asiatica Plant Material and Preparation of CAW-R61J.", [" {\"C. asiatica\": [\"C. asiatica\"]}", {"Herb name": ["C. asiatica Plant"]}]], [168, "Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2).", [" {\"AMOUNT\": [\"21.4%\", \"23.9%\"]}:\n{\"ORGANIZATION\": [\"Oregon Health & Science University (OHSU, Portland, OR)\"}:", {"Amount": ["21.4%", "23.9%"], "Herb name": ["dried CA for CAW-R61F", "dried CA for CAW-R61H"]}]], [169, "DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO.", [" {\"DOSING_SOLUTION_COMPOUND\": [\"DMSO\"]}:\n{\"DOSING_SOLUTION_CONCENTRATION\": [\"0.1% (v/v)\"]}:", {"Parameter": ["DMSO", "DMSO"], "Herb name": ["CAW-R61J"], "Amount": ["0.1% (v/v)", "0.1%"]}]], [170, "Plates were thawed at ambient temperature.", [" {\"PHARMACEUTICAL_PREPARATIONS\": [\"plates\"]}\n{\"QUANTITIES\": [\"thawed\"]}\n{\"CONDITIONS\": [\"ambient temperature\"]}\n{\"TIME_POINTS\": [\"thawed\"]}\n{\"UNITS\": [\"\"]} (No specific units were mentioned in the text)\n{\"STUDY_DESIGN\": [\"\"]} (No specific study design was mentioned in the text)\n{\"RESEARCH_SOURCE\": [\"\"]} (No specific research source was mentioned in the text)\n{\"STUDY_PARTICIPANTS\": [\"\"]} (No specific study participants were mentioned in the text)\n{\"OUTCOMES\": [\"\"]} (No specific outcomes were mentioned in the text)\n{\"METHODOLOGY\": [\"thawed at ambient temperature\"]} (Thawing method can be considered part of the methodology)\n{\"STUDY_SETTING\": [\"\"]} (No specific study setting was mentioned in the text)", {}]], [171, "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH.", [" {\"P450 enzyme\": [\"P450 enzyme activity\", \"P450 enzyme\"]}:\n{\"CAW-R61J\": [\"CAW-R61J\"]}:\n{\"IC50 values\": [\"shift in IC50 values\"]}:\n{\"30-minute preincubations\": [\"30-minute preincubations\"]}:\n{\"NADPH\": [\"NADPH\"]}:", {"Parameter": ["Potential TDI of P450 enzyme activity", "IC50", "NADPH"], "Herb name": ["CAW-R61J"], "Duration": ["30-minute"]}]], [172, "Unless otherwise specified, all results were expressed as the means \u00b1 S.D.", [" {\"PHARMACOLOGICAL_CONCEPTS\" [\"pharmacology\", \"drug\", \"dosage\", \"pharmacokinetics\", \"pharmacodynamics\", \"mean \u00b1 S.D.\", \"quantities\"]}:\n\n{\"RESEARCH_ENTITIES\" [\"scientific article\"]:\n\n{\"RESEARCH_METHODOLOGY\" [\"pharmacological study\"]:\n\n{\"RESEARCH_SOURCES\" [\"\"]}:\n\n{\"RESEARCH_PARTICIPANTS\" [\"\"]}:\n\n{\"RESEARCH_SETTINGS\" [\"\"]}:\n\n{\"RESEARCH_DEVICES\" [\"\"]}:\n\n{\"RESEARCH_STUDIES\" [\"\"]}:\n\n{\"RESEARCH_DATES\" [\"\"]}:\n\n{\"RESEARCH_STATISTICAL_METHODS\" [\"mean \u00b1 S.D.\"]}:\n\n{\"RESEARCH_MEASUREMENTS\" [\"quantities\"]}:\n\n{\"RESEARCH_FINDINGS\" [\"\"]}:\n\n{\"RESEARCH_CONCLUSIONS\" [\"\"]}:\n\n{\"RESEARCH_FUTURE_WORK\" [\"\"]}:\n\n{\"RESEARCH_FUNDING_SOURCES\" [\"\"]}:\n\n{\"RESEARCH_PUBLICATION_DETAILS\" [\"scientific article\"]:\n\n{\"RESEARCH_PUBLICATION_DATES\" [\"\"]}:\n\n{\"RESEARCH_PUBLICATION_JOURNALS\" [\"\"]}:\n\n{\"RESEARCH_PUBLICATION_AUTHORS\" [\"\"]}:\n\n{\"RESEARCH_PUBLICATION_TITLES\" [\"\"]}:\n\n{\"RESEARCH_PUBLICATION_ABSTRACTS\" [\"\"]}:\n\n{\"RESEARCH_PUBLICATION_KEYWORDS\" [\"pharmacology\"]:\n\n{\"RESEARCH_PUBLICATION_METHODOLOGY\" [\"pharmacological study\"]:\n\n{\"RESEARCH_PUBLICATION_DESIGN\" [\"\"]}:\n\n{\"RESEARCH_PUBLICATION_PART", {}]], [173, "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq.", [" {\"IC50\": [\"values\"], \"concentration-response\": [\"curves\"], \"percentage control value\": [\"value\"], \"four-parameter sigmoid model\": [\"model\"], \"eq.\": [\"equation\"]}\n{\"AMOUNT\": [\"\"]}\n(Note: Since no specific quantities were mentioned in the text, the \"AMOUNT\" field is left empty.)", {"Parameter": ["the IC50 values", "the concentration-response (percentage control value)"]}]], [174, "2 above (substituting logEC50 for logIC50).", [" {\"logEC50\": [\"logEC50\"]}", {"Parameter": ["logEC50", "logIC50"]}]], [175, "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA).", [" {\"PRISM_SOFTWARE\": [\"Prism 8.0.2\"]}:", {}]], [176, "Object name is dmd.120.090860f1.jpg Fig.", [" {\"DMD gene\": [\"dmd\"], \"genetic locus\": [\"120.090860f1\"], \"image\": [\"Fig.\"]}\n\n(Note: The \"120.090860f1\" is assumed to be a genetic locus identifier, and \"Fig.\" refers to the image in the context of a scientific article.)", {}]], [177, "Mean\tS.D.", [" {\"AMOUNT\": [\"mean\", \"standard deviation\"]}", {}]], [178, "Mean\tS.D.", [" {\"AMOUNT\": [\"mean\", \"standard deviation\"]}", {}]], [179, "***P < 0.0001.", [" {\"AMOUNT\": [\"P\"]}:", {}]], [180, "; data not shown).", [" {\"PHARMACOLOGICAL_TITLES\": [\"pharmacology\"]}, {\"PHARMACEUTICAL_ENTITIES\": [\"drug\", \"medication\", \"pharmaceutical\"]}, {\"RESEARCH_ENTITIES\": [\"scientific article\"]}, {\"RESEARCH_METHODS\": [\"study\", \"research\", \"experiment\"]}, {\"RESEARCH_PARTICIPANTS\": [\"subjects\"]}, {\"RESEARCH_OUTCOMES\": [\"results\", \"findings\"]}, {\"RESEARCH_SOURCES\": [\"data\"]}, {\"RESEARCH_SOURCES\": [\"this article\"]}, {\"RESEARCH_SOURCES\": [\"this study\"]}, {\"RESEARCH_SOURCES\": [\"this research\"]}, {\"RESEARCH_SOURCES\": [\"this scientific article\"]}, {\"RESEARCH_SOURCES\": [\"this scientific article about pharmacology\"]}, {\"RESEARCH_SOURCES\": [\"this article\"]}, {\"RESEARCH_SOURCES\": [\"this\"]}, {\"RESEARCH_SOURCES\": [\"this\"]}, {\"RESEARCH_SOURCES\": [\"this\"]}, {\"RESEARCH_SOURCES\": [\"this\"]}, {\"RESEARCH_SOURCES\": [\"this\"]}, {\"RESEARCH_SOURCES\": [\"this\"]}, {\"RESEARCH_SOURCES\": [\"this\"]}, {\"RESEARCH_SOURCES\": [\"this\"]}, {\"RESEARCH_SOURCES\": [\"this\"]}, {\"RESEARCH_SOURCES\": [\"this\"]}, {\"RESEARCH_SOURCES\": [\"this\"]}, {\"RESEARCH_SOURCES\": [\"this\"]}, {\"RESEARCH_SOURCES\": [\"this\"]}, {\"RESEARCH_SOURCES\": [\"this\"]}, {\"RESEARCH_SOURCES\": [\"this\"]}, {\"RESEARCH_SOURCES\": [\"this\"]}, {\"RESEARCH_SOURCES\": [\"this\"]}, {\"RESEARCH_SOURCES\": [\"this\"]}, {\"RESEARCH_SOURCES\": [\"this\"]}, {\"RESEARCH_SOURCES\": [\"this\"]}, {\"RESEARCH_SOURCES\": [\"this\"]}, {\"RESEARCH_SOURCES", {}]], [181, "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017).", [" {\"JOURNAL_ARTICLES\": [\"Ring et al., 1996\", \"Suzuki et al., 2002\", \"Emoto et al., 2003\", \"Walsky et al., 2006\", \"VandenBrink et al., 2011\", \"Zhao et al., 2012\", \"Thu et al., 2017\"]}\n\n{\"TABLES\": [\"Table 8\"]}", {}]], [182, "The strongest reversible inhibition was against CYP2C9 (IC50 330 \u00b5g/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 \u00b5g/ml).", [" {\"CYP2C9\": [\"330 \u00b5g/ml\"]}:\n{\"CYP1A2\": [\"> 1000 \u00b5g/ml\"]}:\n{\"CYP2B6\": [\"> 1000 \u00b5g/ml\"]}:", {"Target": ["CYP2C9", "CYP1A2", "CYP2B6"], "Parameter": ["IC50", "IC50"], "Amount": ["330 \u00b5g/ml", "> 1000 \u00b5g/ml"]}]], [183, "An external file that holds a picture, illustration, etc.", [" {\"PHARMACOLOGY_ARTICLES\": [\"scientific article\", \"pharmacology article\"]},\n{\"PHARMACOLOGY_SUBJECTS\": [\"pharmacology\"]},\n{\"PHARMACEUTICAL_ENTITIES\": [\"pharmacology\", \"drugs\", \"medications\", \"pharmaceuticals\"]},\n{\"PHARMACEUTICAL_TERMS\": [\"pharmacology\", \"drug\", \"medication\", \"pharmaceutical\"]},\n{\"PHARMACEUTICAL_CONCEPTS\": [\"pharmacology\", \"drug action\", \"drug metabolism\", \"drug-receptor interaction\"]},\n{\"PHARMACEUTICAL_PRODUCTS\": [\"drugs\", \"medications\"]},\n{\"PHARMACEUTICAL_EXPERTS\": [\"pharmacologist\"]},\n{\"PHARMACEUTICAL_STUDIES\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_RESEARCH\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_METHODS\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_FINDINGS\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_CONCLUSIONS\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_APPLICATIONS\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_DEVICES\": []},\n{\"PHARMACEUTICAL_PROCEDURES\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_TREATMENTS\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_DOSAGES\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_DURATIONS\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_SIDE_EFFECTS\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_TOXICITY\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_DOSAGE_FORM\": [\"s", {}]], [184, "Object name is dmd.120.090860f3.jpg Fig.", [" {\"Drug Name\": [\"dmd\"]}\n{\"Dosage/Amount\": [\"120.090860f3\"]}\n{\"Image File Reference\": [\"dmd.120.090860f3.jpg\"]}\n{\"Figure Reference\": [\"Fig.\"]}", {}]], [185, "Data shown are the means \u00b1 S.D.", [" {\"AMOUNT\": [\"mean \u00b1 standard deviation\", \"quantities\", \"measures\", \"values\", \"results\", \"concentrations\", \"doses\", \"dosage\", \"dosages\", \"dosage amounts\", \"drug amounts\", \"drug concentrations\", \"drug doses\", \"drug dosage amounts\", \"drug dosage concentrations\"]}\n\nNote: The entities related to pharmacology in the context of a scientific article might also include specific drug names, pharmacological terms, units of measurement, and other relevant scientific terminology. However, based on the provided instruction, the above list captures the general types of quantitative entities that would be found in a pharmacological scientific article. If specific drug names or pharmacological terms were mentioned in the article, they would also be considered entities to be parsed. However, since no specific text from the article was provided, these are the general entities that would be relevant.", {}]], [186, "of triplicate determinations.", [" {\"AMOUNT\": [\"triplicate determinations\"]}\n\n(Note: In the context of pharmacology, \"triplicate determinations\" could refer to the quantity of samples or measurements taken in a study, but since it's not a specific numerical value, it's listed as a quantity related entity.)", {}]], [187, "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9.", [" {\"PHARMACOGENETIC ENZYMES\": [\"CYP2C19\", \"CYP3A4\", \"CYP2D6\", \"CYP2C9\"]}:\n{\"QUANTITIES\": [\"weak inhibitors\"]}:", {"Herb name": ["centelloids"], "Parameter": ["P450", "CYP2C19, CYP3A4, CYP2D6, and CYP2C9"]}]], [188, "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract.", [" {\"CAW-R61J\": [\"CAW-R61J\"]}\n{\"Plasma concentrations\": [\"similar plasma concentrations\"]}\n{\"Clinical studies\": [\"clinical studies\"]}\n{\"Centelloid content\": [\"centelloid content\"]}\n{\"Compounds\": [\"these compounds\"]}", {"Herb name": ["the centelloid content of CAW-R61J"], "Parameter": ["plasma concentrations for these compounds"], "Study": ["clinical studies"]}]], [189, "Ultimately, the clinical relevance of the weak P450 inhibition seen in this study will depend on the IC50 values of the as yet unknown inhibitory CAW-R61J compounds and their in vivo concentration achieved in humans.", [" {\"P450 inhibition\": [\"weak P450 inhibition\"], \"IC50 values\": [\"IC50 values\"], \"CAW-R61J compounds\": [\"CAW-R61J compounds\"], \"in vivo concentration\": [\"in vivo concentration\"]}", {"Target": ["P450"], "Parameter": ["IC50", "in vivo concentration"], "Herb name": ["CAW-R61J"]}]], [190, "It will also be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes.", [" {\"CA derivatives\": [\"CA derivatives\"], \"phase II drug-metabolizing enzymes\": [\"phase II drug-metabolizing enzymes\"]}\n{\"AMOUNT\": []}", {"Herb name": ["CA"], "Parameter": ["phase II drug-metabolizing enzymes"]}]], [191, "Therefore, the tolerability and safety of combination drugs were evaluated in the context of their DDI potential.", [" {\"Drug Interaction Potential (DDI)\": [\"DDI potential\"]}", {}]], [192, "Based on these clinical outcomes, fimasartan can be recommended for patients with hypertension and chronic kidney disease [4,14].", [" {\"PHARMACOLOGICAL AGENT\": [\"fimasartan\"]}:\n{\"CLINICAL CONDITION\": [\"hypertension\", \"chronic kidney disease\"]}:\n{\"JOURNALS AND REFERENCES\": [\"4\", \"14\"]}:", {"Drug": ["fimasartan"], "Pathology": ["hypertension", "chronic kidney disease"]}]], [193, "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA).", [" {\"PHARMACEUTICAL_COMPOUNDS\": [\"fimasartan\", \"fimasartan-amide\", \"amlodipine\", \"hydrochlorothiazide\"]}:\n\n{\"INSTUMENTATION\": [\"Agilent 6470 Triple Quadrupole LC-MS/MS system\"]}:", {"Drug": ["Fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide"]}]], [194, "Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves.", [" {\"QC sample concentrations\": [\"low\", \"medium\", \"high\"]}", {}]], [195, "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves.", [" {\"AMOUNT\": [\"150 \u03bcL\", \"1 ng/mL\"]}", {}]], [196, "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples).", [" {\"QC samples\": [\"extracted QC samples\", \"untreated QC samples\"]}:\n{\"6 \u00b0C\": [\"6 \u00b0C\"]}:\n{\"24 h\": [\"24 h\"]}:", {}]], [197, "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO.", [" {\"Drug Names\": [\"fimasartan\", \"amlodipine\", \"hydrochlorothiazide\"]}:\n{\"Dosage Units\": [\"3 mg/kg\", \"5 mg/kg\", \"5 mg/kg\"]}:\n{\"Solvents\": [\"DMSO\"]}:\n{\"Animal Model\": [\"rat\"]}:\n{\"Grouping\": [\"combination group\"]}:", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"], "Amount": ["3 mg/kg", "5 mg/kg", "5 mg/kg"]}]], [198, "The jejunal segments were then isolated and rinsed using pre-warmed saline.", [" {\"jejunal segments\": [\"jejunal segments\"], \"pre-warmed saline\": [\"pre-warmed saline\"]}\n{\"AMOUNT\": []}\n\n(Note: No specific quantities were mentioned in the text provided, hence no quantities were listed.)\n\nIf quantities were mentioned, for example, if the text included \"5 mL of pre-warmed saline,\" the output would be:\n\n{\"AMOUNT\": [\"5 mL\"]}", {}]], [199, "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS).", [" {\"AMOUNT\": [\"50 \u03bcL\", \"150 \u03bcL\", \"1 ng/mL\"]}:", {"Drug": ["amlodipine"]}]], [200, "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1).", [" {\"Authentic Standards\": [\"authentic standards\"], \"Product Ion Scan Results\": [\"product ion scan results\"], \"Figure 1\": [\"Figure 1\"]}\n{\"AMOUNT\": [\"\"]}", {}]], [201, "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide.", [" {\"Chromatograms\": [\"chromatograms of the blank matrix\", \"chromatograms of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide\"], \"Quantities\": [\"spiked at the LLOQ\", \"1 h after oral administration\"]}", {"Drug": ["fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide", "fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [202, "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37].", [" {\"QC sample\": [\"QC sample\"], \"standard curve sample\": [\"standard curve sample\"], \"response\": [\"response\"], \"analytical process\": [\"analytical process\"], \"recovery\": [\"recovery\"], \"biological sample\": [\"biological sample\"], \"analytical instrument\": [\"analytical instrument\"], \"Table 2\": [\"Table 2\"], \"inter- and intra-day accuracy\": [\"inter- and intra-day accuracy\"], \"acceptance criteria\": [\"acceptance criteria\"], \"accuracy\": [\"accuracy\"], \"Guideline of Bioanalytical method validation\": [\"Guideline of Bioanalytical method validation\"], \"FDA\": [\"FDA\"], \"EMA\": [\"EMA\"], \"ICH\": [\"ICH\"]}", {}]], [203, "These results suggest that fimasartan is an attractive candidate for the treatment of hypertension and suggest the increasing use of fimasartan monotherapy and combination therapy.", [" {\"fimasartan\": [\"fimasartan\"]}\n{\"hypertension\": [\"hypertension\"]}\n{\"fimasartan monotherapy\": [\"fimasartan monotherapy\"]}\n{\"fimasartan combination therapy\": [\"fimasartan combination therapy\"]}", {"Drug": ["fimasartan", "fimasartan"], "Pathology": ["hypertension"]}]], [204, "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1).", [" {\"PHARMACOLOGICAL_COMPUNDS\": [\"fimasartan\", \"amlodipine\", \"hydrochlorothiazide\"]}:\n\n{\"MRM_CONDITION\": [\"same MRM condition as previously published reports\"]}:\n\n{\"FIGURE_NUMBER\": [\"Figure 1\"]}:\n\n{\"QUANTITIES\": [\"\"]}:\n\n{\"STUDY_REFERENCES\": [\"[39,40]\"]}:\n\n{\"PRODUCT_ION_SPECTRA\": [\"product ion mass spectra\"]}:\n\n{\"MASS_FRAGMENTATION_PATTERNS\": [\"different mass fragmentation patterns\"]}:", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [205, "and M.P.", [" {\"AMOUNT\": [\"\"]}\n\nNote: Since the provided text does not contain any specific quantities or measurements, the \"AMOUNT\" field is left empty. However, if there were any quantities mentioned in the text, they would be listed within the brackets. For example, if the text had mentioned \"50 mg of drug X,\" then the \"AMOUNT\" field would be: {\"AMOUNT\": [\"50 mg\"]}.\n\nIn the context of pharmacology, other entities that might be found in a scientific article could include:\n\n- Drug names (e.g., \"aspirin\", \"metformin\")\n- Dosage forms (e.g., \"tablet\", \"capsule\", \"injection\")\n- Dosage amounts (e.g., \"10 mg\", \"500 mg\")\n- Biological entities (e.g., \"enzyme\", \"receptor\")\n- Study design terms (e.g., \"randomized controlled trial\", \"double-blind\")\n- Study results (e.g., \"increased efficacy\", \"reduced side effects\")\n- Researchers and institutions (e.g., \"Dr. Smith\", \"University of Pharmacology\")\n\nIf specific entities were mentioned in the text, they would be listed in the respective fields following the provided format. For example:\n\n{\"DRUG_NAMES\": [\"aspirin\", \"metformin\"]}\n{\"DOSAGE_FORMS\": [\"tablet\", \"capsule\", \"injection\"]}\n{\"DOSAGE_AMOUNTS\": [\"10 mg\", \"500 mg\"]}\n{\"BIOLOGICAL_ENTITIES\": [\"enzyme\", \"receptor\"]}\n{\"STUDY_DESIGN_TERMS\": [\"randomized controlled trial\", \"double-blind\"]}\n{\"STUDY_RESULTS\": [\"increased efficacy\", \"reduced side effects\"]}\n{\"RESEARCHERS_AND_INSTITUTIONS\": [\"Dr. Smith\", \"University of Pharmacology\"]}", {}]], [206, "Data represented as mean and CV from five or six independent experiments.", [" {\"AMOUNT\": [\"mean\", \"CV\", \"five\", \"six\", \"independent experiments\"]}", {}]], [207, "However, there are several challenges associated with the chronic nature of HAART administration.", [" {\"HAART\": [\"chronic nature of HAART administration\"]}\n{\"AMOUNT\": [\"\"]}", {"Drug": ["HAART"]}]], [208, "However, attention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].", [" {\"ART\": [\"ART\"]}\n{\"AMOUNT\": [\"\"]}\n{\"JOURNALS\": [\"1,2\"]}", {"Drug": ["ART"]}]], [209, "EFV and NVP have been associated with a number of side effects including liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia and headache [10].", [" {\"Drug Names\": [\"EFV\", \"NVP\"]}:\n{\"Side Effects\": [\"liver damage\", \"nausea\", \"vomiting\", \"fever\", \"diarrhoea\", \"dyslipidemia\", \"headache\"]}:\n{\"Journal References\": [\"[10]\"]}:", {"Drug": ["EFV", "NVP"], "Pathology": ["side effects", "liver damage", "nausea", "vomiting", "fever", "diarrhoea", "dyslipidemia", "headache"]}]], [210, "There is substantial evidence supporting the potential of medicinal plants in combating diseases, especially in developing countries [12,13,14,15].", [" {\"PHARMACEUTICAL_PLANTS\": [\"medicinal plants\"]}:\n\n{\"STUDY_REFERENCES\": [\"[12,13,14,15]\"]}:", {}]], [211, "Although effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.", [" {\"HERBAL MEDICINES\": [\"most herbal medicines\"]}\n{\"MECHANISMS OF ACTION\": [\"mechanisms of action for most herbal medicines\"]}\n{\"DISEASES\": [\"some diseases\"]}", {}]], [212, "Genetic polymorphism in CYP2B6 have been implicated in variations in the activity of the enzyme in metabolizing xenobiotics [26].", [" {\"CYP2B6\": [\"Genetic polymorphism\", \"variations\", \"metabolizing xenobiotics\"]}\n{\"xenobiotics\": [\"metabolizing xenobiotics\"]}\n{\"26\": [\"[26]\"]}\n{\"activity\": [\"activity\"]}\n{\"enzyme\": [\"enzyme\"]}\n{\"metabolizing\": [\"metabolizing\"]}\n{\"variations\": [\"variations\"]}\n{\"activity\": [\"activity\"]}\n{\"metabolizing\": [\"metabolizing\"]}\n{\"xenobiotics\": [\"metabolizing xenobiotics\"]}\n{\"CYP2B6\": [\"CYP2B6\"]}\n{\"Genetic polymorphism\": [\"Genetic polymorphism\"]}\n{\"metabolizing\": [\"metabolizing\"]}\n{\"activity\": [\"activity\"]}\n{\"enzyme\": [\"enzyme\"]}\n{\"xenobiotics\": [\"xenobiotics\"]}\n{\"variations\": [\"variations\"]}\n{\"26\": [\"26\"]}\n{\"activity\": [\"activity\"]}\n{\"metabolizing\": [\"metabolizing\"]}\n{\"xenobiotics\": [\"xenobiotics\"]}\n{\"CYP2B6\": [\"CYP2B6\"]}\n{\"Genetic polymorphism\": [\"Genetic polymorphism\"]}\n{\"metabolizing\": [\"metabolizing\"]}\n{\"activity\": [\"activity\"]}\n{\"enzyme\": [\"enzyme\"]}\n{\"xenobiotics\": [\"xenobiotics\"]}\n{\"variations\": [\"variations\"]}\n{\"26\": [\"26\"]}\n{\"activity\": [\"activity\"]}\n{\"metabolizing\": [\"metabolizing\"]}\n{\"xenobiotics\": [\"xenobiotics\"]}\n{\"CYP2B6\": [\"CYP2B6\"]}\n{\"Genetic polymorphism\": [\"Genetic polymorphism\"]}\n{\"metabolizing\": [\"metabolizing\"]}\n{\"activity\": [\"activity\"]}\n{\"enzyme\": [\"enzyme\"]}\n{\"xenobiotics\": [\"xenobiotics\"]}\n{\"variations\": [\"variations\"]}\n{\"26\": [\"26\"]}\n{\"activity\": [\"activity\"]", {"Target": ["CYP2B6"]}]], [213, "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract.", [" {\"PHARMACOLOGICAL_COMPOUNDS\": [\"test compound\"], \"BIOAVAILABILITY_MEASURES\": [\"bioavailability\"], \"BIOCHEMICAL_MEASURES\": [\"intestinal absorption\", \"plasma concentrations\"], \"HERBAL_EXTRACTS\": [\"herbal extracts\"], \"BIOCHEMICAL_MEASURES_SOURCE\": [\"bioavailability [28]\"], \"YIELD_MEASURE\": [\"% yield\"], \"BIOCHEMICAL_MEASURES_CALCULATION\": [\"estimated bioavailable concentration\"]}", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [214, "Note: values are expressed as mg\u00b7kg Structures of the phenolic compounds identified and quantified from crude herbal extracts (1) Caffeic acid; (2) Catechin; (3) Chlorogenic acid; (4) Epicatechin; (5) p-Coumaric acid.", [" {\"PHENOLIC_COMPOUNDS\": [\"Caffeic acid\", \"Catechin\", \"Chlorogenic acid\", \"Epicatechin\", \"p-Coumaric acid\"]}", {"Herb name": ["phenolic compounds", "Caffeic acid", "Catechin", "Chlorogenic acid", "Epicatechin", "p-Coumaric acid"], "Extraction process": ["crude herbal extracts"]}]], [215, "The advantage of phytochemical profiling is that similar drug interacting constituents could be identified in other related herbs that are used for therapeutic purposes and that necessary mechanistic studies are performed on them.", [" {\"PHYTOCHEMICAL PROFILE\": [\"phytochemical profiling\"], \"DRUG INTERACTING CONSTITUENTS\": [\"drug interacting constituents\"], \"HERBS\": [\"other related herbs\"], \"THERAPEUTIC PURPOSES\": [\"therapeutic purposes\"], \"MECHANISTIC STUDIES\": [\"mechanistic studies\"]}", {}]], [216, "The study showed that Launaea taraxacifolia Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6.", [" {\"Launaea taraxacifolia\": [\"Launaea taraxacifolia Hyptis suaveolens\"], \"Boerhavia diffusa\": [\"Boerhavia diffusa\"], \"Myrothamnus flabellifolius\": [\"Myrothamnus flabellifolius\"], \"CYP2B6\": [\"CYP2B6\"]}", {"Herb name": ["Launaea taraxacifolia", "Hyptis suaveolens", "Boerhavia diffusa", "Myrothamnus flabellifolius"], "Extraction process": ["extracts"], "Target": ["CYP2B6"]}]], [217, "Ethical approval was obtained from the University of Cape Town Human Research Ethics committee with number HREC REF: 826/2014.", [" {\"University of Cape Town Human Research Ethics committee\": [\"University of Cape Town Human Research Ethics committee\"]}:\n{\"HREC REF\": [\"826/2014\"]}:", {}]], [218, "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated.", [" {\"PHARMACEUTICAL_MATERIAL\": [\"material\", \"purified water\"]}:\n\n{\"EXTRACTION_TIME\": [\"72 h\"]}:\n\n{\"EXTRACTION_TEMPERATURE\": [\"room temperature\"]}:\n\n{\"EXTRACTION_INTERVAL\": [\"every 24 h\"]}:\n\n{\"SOLID_RESISTANCE_RESTORE_PROCESS\": [\"solid residue\"]}:\n\n{\"EXTRACTION_REPEAT\": [\"the extraction process to be repeated\"]}:\n\n{\"EXTRACTION_REAGENT\": [\"purified water\"]}:\n\n{\"EXTRACTION_TIME_PER_REPEAT\": [\"the same volume\"]}:", {"Duration": ["for 72 h"], "Frequency": ["every 24 h"]}]], [219, "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented.", [" {\"PHARMACISTS\": [\"Denis Chopera\", \"Kevin Dzobo\", \"Ambroise Wonkam\", \"Dee Blackhurst\", \"Michelle Skelton\"]}:\n{\"PATIENTS\": []}:\n{\"TITLE\": []}:\n{\"ARTICLE_SOURCE\": [\"scientific article\"]}:\n{\"PUBLICATION\": []}:\n{\"JOURNAL_NAME\": []}:\n{\"ARTICLE_NUMBER\": []}:\n{\"DATE\": []}:\n{\"AMOUNT\": []}:", {}]], [220, "All authors reviewed the final manuscript.", [" {\"AUTHORS\": [\"All authors\"]}:\n\n{\"MANIFEST\": [\"final manuscript\"]}:", {}]], [221, "GGT with five major ingredients also possesses chance of drug interactions when co-administering with other drugs.", [" {\"PHARMACEUTICAL_COMPOUND\": [\"GGT\"], \"INGREDIENTS\": [\"five major ingredients\"], \"DRUG_INTERACTIONS\": [\"drug interactions\"]}\n{\"DOSAGE\": [\"\"]}\n{\"DRUG_CO-ADMINISTRATION\": [\"co-administering\"]}\n{\"OTHER_DRUGS\": [\"other drugs\"]}\n{\"MEDICAL_CONDITION\": [\"\"]}", {"Herb name": ["GGT"]}]], [222, "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between.", [" {\"TREATMENT_DURATION\": [\"7 \u00b1 1-day\"]}", {}]], [223, "Therefore, we applied this dose of GGT in our study.", [" {\"GGT\": [\"GGT\"]}\n{\"Dose\": [\"this dose\"]}\n{\"Study\": [\"our study\"]}", {"Herb name": ["GGT"]}]], [224, "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23].", [" {\"AMOUNT\": [\"1000 mg\", \"1000 mg \u00d7 4 times\", \"8 tablets\"]}", {"Drug": ["AAP"], "Amount": ["1000 mg", "1000 mg"], "Frequency": ["4 times (8 tablets) per day"], "Pathology": ["common cold"]}]], [225, "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week.", [" {\"AAP dosage\": [\"1000 mg\", \"1000 mg \u00d7 4 times daily\"]}, {\"GGT dosage\": [\"7680 mg\"]}", {"Drug": ["AAP", "AAP"], "Amount": ["1000 mg", "7680 mg", "1000 mg", "7680 mg"], "Frequency": ["once daily", "once daily", "4 times daily", "once daily"], "Herb name": ["GGT", "GGT"], "Duration": ["week"]}]], [226, "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily.", [" {\"AMOUNT\": [\"1000 once a day\", \"1000 mg \u00d7 4 times a day\", \"7680 mg\"]}\n\n(Note: \"GGT\" is not quantified in this context, so it is not included in the list of quantities.)", {"Drug": ["AAP"], "Frequency": ["once a day", "4 times a day", "daily"], "Amount": ["1000 mg", "7680 mg"], "Herb name": ["GGT"]}]], [227, "and Y.C.P.", [" {\"PHARMACOLOGY TITLES\": [\"scientific article about pharmacology\"]}, {\"PHARMACOLOGY AUTHORS\": [\"Y.C.P.\"}], {\"PHARMACOLOGY PUBLICATIONS\": []}, {\"PHARMACOLOGY JOURNALS\": []}, {\"PHARMACOLOGY PUBLISHERS\": []}, {\"PHARMACOLOGY RESEARCH FACILITIES\": []}, {\"PHARMACOLOGY RESEARCH FIGURES\": []}, {\"PHARMACOLOGY RESEARCH DATES\": []}, {\"PHARMACOLOGY RESEARCH METHODS\": []}, {\"PHARMACOLOGY RESEARCH OUTCOMES\": []}, {\"PHARMACOLOGY RESEARCH PATENTS\": []}, {\"PHARMACOLOGY RESEARCH PATENT HOLDERS\": []}, {\"PHARMACOLOGY RESEARCH RESEARCHERS\": [\"Y.C.P.\"]}, {\"PHARMACOLOGY RESEARCH RESEARCH FACILITIES\": []}, {\"PHARMACOLOGY RESEARCH RESEARCH DATES\": []}, {\"PHARMACOLOGY RESEARCH RESEARCH METHODS\": []}, {\"PHARMACOLOGY RESEARCH RESEARCH OUTCOMES\": []}, {\"PHARMACOLOGY RESEARCH RESEARCH PATENTS\": []}, {\"PHARMACOLOGY RESEARCH RESEARCH PATENT HOLDERS\": []}, {\"PHARMACOLOGY RESEARCH RESEARCH AMOUNTS\": []}, {\"PHARMACOLOGY RESEARCH RESEARCH COSTS\": []}, {\"PHARMACOLOGY RESEARCH RESEARCH DURATIONS\": []}, {\"PHARMACOLOGY RESEARCH RESEARCH SCALE\": []}, {\"PHARMACOLOGY RESEARCH RESEARCH RELATED TERMS\": [\"pharmacology\"]}, {\"PHARMACOLOGY RESEARCH RESEARCH RELATED", {}]], [228, "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.", [" {\"MODELS\": [\"performing modeling\"]}:\n{\"QUANTITY\": [\"\"]}:\n{\"RESEARCHERS\": [\"Q.T.T.\", \"H.-m.B.\", \"L.T.N.\", \"J.-w.C.\", \"H.-y.Y.\"}:\n{\"PHARMACOLOGY\": [\"\"]}:", {}]], [229, "Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP.", [" {\"AAP\": [\"AAP\"]}", {"Drug": ["AAP"]}]], [230, "Single time-point, phenotypic metabolic ratios were used to determine whether long-term supplementation of St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity in elderly subjects.", [" {\"Phenotypic metabolic ratios\": [\"phenotypic metabolic ratios\"], \"CYP1A2\": [\"CYP1A2\"], \"CYP2D6\": [\"CYP2D6\"], \"CYP2E1\": [\"CYP2E1\"], \"CYP3A4\": [\"CYP3A4\"], \"St. John\u2019s wort\": [\"St. John\u2019s wort\"], \"garlic oil\": [\"garlic oil\"], \"Panax ginseng\": [\"Panax ginseng\"], \"Ginkgo biloba\": [\"Ginkgo biloba\"], \"elderly subjects\": [\"elderly subjects\"]}", {"Herb name": ["St. John\u2019s wort", "garlic oil", "Panax ginseng", "Ginkgo biloba"], "Target": ["CYP1A2", "CYP2D6", "CYP2E1", "CYP3A4"]}]], [231, "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age.", [" {\"PHARMACEUTICAL_SURVEYS\": [\"other surveys\", \"patients taking prescription medications\", \"individuals greater than 65 years of age\"]}\n{\"HERBAL_SUPPLEMENTS\": [\"herbal supplement usage\"]}\n{\"PRESCRIPTION_MEDICATIONS\": [\"prescription medications\"]}\n{\"AGE_GROUP\": [\"greater than 65 years of age\"]}", {"Study": ["surveys"], "Age": ["greater than 65 years of age"]}]], [232, "Moreover, age-related changes have been observed in the pharmacokinetics of several CYP substrates,[28\u201330] as well as certain CYP enzymes,[29,30] thus the question remains as to whether such effects may extend to botanical supplements and their effect on drug metabolism in the elderly.", [" {\"PHARMACOKINETICS\": [\"pharmacokinetics\", \"drug metabolism\"]}\n{\"CYP SUBSTRATES\": [\"CYP substrates\"]}\n{\"CYP ENZYMES\": [\"certain CYP enzymes\"]}\n{\"BOTANICAL SUPPLEMENTS\": [\"botanical supplements\"]}\n{\"ELDERLY\": [\"elderly\"]}", {"Target": ["CYP"]}]], [233, "Adherence to these restrictions was further emphasized five days before each probe drug administration.", [" {\"PRODUTES\": [\"probe drug\"], \"TIMEPOINTS\": [\"five days\"]}\n{\"AMOUNT\": []}", {}]], [234, "Peaks were assigned by a comparison of retention times and ultraviolet absorption spectra.", [" {\"REACTION_COMPARISON_ENTITIES\": [\"comparison of retention times\"], \"SPECTRAL_ENTITIES\": [\"ultraviolet absorption spectra\"]}\n{\"AMPUTATION_NUMBER\": [\"Peaks\"]}", {}]], [235, "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation.", [" {\"AMOUNT\": [\"45\"]}", {}]], [236, "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation.", [" {\"CYP\": [\"phenotypic ratio\", \"95% confidence intervals\", \"mean\", \"postsupplementation\"]}", {}]], [237, "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance.", [" {\"PHENOTYPIC_RATIO\": [\"phenotypic ratio\"]}:\n{\"MIDAZOLAM_CLEARANCE\": [\"midazolam clearance\"]}:\n{\"ST. JOHN'S WORT\": [\"St. John's wort\"]}:\n{\"AREA-UNDER-THE-CURVE\": [\"area-under-the-curve\"]}:\n{\"CONVENTIONAL_METHODS\": [\"conventional methods\"]}:\n{\"TIME_POINT_APPROACH\": [\"time-point approach\"]}:\n{\"SINGLE_TIME_POINT\": [\"single-time point\"]}:\n{\"STUDY_PARTICIPANTS\": [\"study participants\"]}:\n{\"CLEARANCE_MEASUREMENT\": [\"clearance measurement\"]}:\n{\"PHENOTYPIC_OBSERVATIONS\": [\"phenotypic observations\"]}:\n{\"CYP3A4_INHIBITOR\": [\"CYP3A4 inhibitor\"]}:\n{\"CYP3A4_INHIBITION\": [\"CYP3A4 inhibition\"]}:\n{\"ST. JOHN'S WORT_EFFECTS\": [\"St. John's wort effects\"]}:\n{\"CONVENTIONAL_METHODS_EFFECTS\": [\"conventional methods effects\"]}:\n{\"MIDAZOLAM_PHENOTYPIC_ANALYSIS\": [\"midazolam phenotypic analysis\"]}:\n{\"MIDAZOLAM_CLEARANCE_METHODS\": [\"midazolam clearance methods\"]}:\n{\"MIDAZOLAM_CLEARANCE_MEASUREMENT\": [\"midazolam clearance measurement\"]}:\n{\"MIDAZOLAM_CLEARANCE_ANALYSIS\": [\"midazolam clearance analysis\"]}:\n{\"MIDAZOLAM_CLEARANCE_METHODS_COMPARISON\": [\"midazolam clearance methods comparison\"]}:\n{\"MIDAZOLAM_CLEARANCE_MEASUREMENT_COMPARISON\": [\"midazolam clearance measurement comparison\"]}:", {"Herb name": ["St. John\u2019s wort"], "Parameter": ["area-under-the-curve", "clearance"], "Drug": ["midazolam"]}]], [238, "This finding also corroborates the results of an earlier study in young individuals.", [" {\"AMOUNT\": [\"earlier study\"]}\n\nNote: In the provided text, \"earlier study\" refers to a study with quantitative results, but it does not explicitly mention any numerical quantity. Therefore, it is not included in the \"List of quantities found in text\". However, if the context implies a comparison or a time frame, it could be considered as an implicit quantity. In this case, the information provided does not explicitly mention any numerical quantity, so the list remains empty.", {}]], [239, "[54] Thus, a potential interaction may exist between these agents and St. John\u2019s wort.", [" {\"PHARMACEUTICAL_AGENTS\": [\"St. John\u2019s wort\"]}\n{\"QUANTITIES\": [\"54\"]}\n\nNote: The quantity \"54\" is assumed to be related to a figure or statistic mentioned in the broader context of the article, which is not provided here. In the absence of additional context, it's not possible to definitively link \"54\" to a specific entity. However, it's included as per the instruction to list quantities found in the text.", {"Herb name": ["St. John\u2019s wort"]}]], [240, "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements.", [" {\"AMOUNT\": [\"42\"]}\n\n{\"AGE GROUPS\": [\"two age groups\"]}\n\n{\"CYP2E1\": [\"CYP2E1 responsivity\"]}\n\n{\"ALLYL SULFIDE\": [\"allyl sulfide content\"]}\n\n{\"GARLIC SUPPLEMENTS\": [\"garlic supplements\"]}", {"Target": ["CYP2E1"], "Herb name": ["allyl sulfide", "garlic"]}]], [241, "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy.", [" {\"AMOUNT\": [\"11\", \"12\"]}", {"Drug": ["anticoagulant therapy"]}]], [242, "This interaction appears attributable to the inhibition of platelet activating factor by various ginkgolides.", [" {\"Platelet Activating Factor\": [\"platelet activating factor\"], \"Ginkgolides\": [\"various ginkgolides\"]}\n{\"AMOUNT\": [\"\"]}", {"Target": ["platelet activating factor"], "Herb name": ["ginkgolides"]}]], [243, "[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of phytochemical-mediated effects on CYP isoforms.", [" {\"AMOUNT\": [\"18\"]}\n\n(Note: In this context, \"18\" refers to the number mentioned in the text, which is a quantity and thus falls under the category of \"AMOUNT\".)\n\nHowever, if the task requires identifying all words that refer to the described entities (in this case, \"G. biloba\" and \"CYP isoforms\"), here is an example of how that might look:\n\n- {\"HERB\": [\"G. biloba\"]}\n\n- {\"DRUG_INTERACTIONS\": [\"herb-drug interactions\"]}\n\n- {\"PHYTOCHEMICAL_EFFECTS\": [\"phytochemical-mediated effects\"]}\n\n- {\"CYP_ISOFORMS\": [\"CYP isoforms\"]}\n\n\nPlease note that the entities identified are not strictly \"words\" but phrases or concepts that are mentioned in the text. The task as described focuses on identifying specific entities, which in this case are phrases that represent the main subjects of the study.", {"Herb name": ["G. biloba"], "Target": ["CYP"]}]], [244, "Like G. biloba, Panax ginseng appears to have little effect on the activities of the specific CYP isoforms investigated in this study.", [" {\"Panax ginseng\": [\"Panax ginseng\"], \"CYP isoforms\": [\"specific CYP isoforms\"]}\n{\"G. biloba\": [\"G. biloba\"], \"cyp\": [\"CYP\"]}\n{\"study\": [\"this study\"]}", {"Herb name": ["G. biloba", "Panax ginseng"], "Target": ["CYP"]}]], [245, "[62] CYP2C9 is the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme.", [" {\"CYP2C9\": [\"the principal isoform involved in the biotransformation of warfarin\", \"the active enantiomer, S-warfarin\", \"a ginseng-mediated induction of this enzyme\"]}", {"Target": ["CYP2C9"], "Drug": ["warfarin", "warfarin"], "Study": ["reports"], "Herb name": ["ginseng"]}]], [246, "Therefore, botanical supplements, when taken concomitantly with conventional medications, can give rise to serious herb-drug interactions.", [" {\"Botanical supplements\": [\"botanical supplements\"], \"conventional medications\": [\"conventional medications\"], \"herb-drug interactions\": [\"herb-drug interactions\"]}\n{\"AMOUNT\": []}", {}]], [247, "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method.", [" {\"QUANTITY\": [\"plasma quinine\", \"3-hydroxyquinine\"]}:", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [248, "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola.", [" {\"PHYTOCHEMICAL_COMPONENTS\": [\"benxophenones\", \"xanthones\", \"alkaloids\", \"phenols\", \"tannins\", \"saponins\", \"kolaviron a biflavonoid complex\", \"metallic ions such as aluminum, magnesium, calcium and copper\"]}\n{\"STUDY_REFERENCES\": [\"6\u201311\"]}\n{\"SEED_TARGET\": \"G. kola\"}", {"Herb name": ["G. kola", "benxophenones", "xanthones", "alkaloids", "phenols", "tannins", "saponins", "kolaviron", "biflavonoid complex", "G. kola"], "Herb part": ["seeds"]}]], [249, "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study.", [" {\"QUININE\": [\"quinine\"], \"G. kola seeds\": [\"G. kola seeds\"]}\n{\"PREGNANCY\": [\"pregnancy\"], \"breastfeeding\": [\"breastfeeding\"], \"histories of hypersensitivity\": [\"histories of hypersensitivity\"], \"adverse side effects\": [\"adverse side effects\"]}\n{\"EXCLUSION CRITERIA\": [\"exclusion criteria\"]}\n{\"G. kola seeds\": [\"G. kola seeds\"]}\n{\"study\": [\"study\"]}", {"Pathology": ["Pregnancy", "breastfeeding", "hypersensitivity", "adverse side effects"], "Drug": ["quinine"], "Herb name": ["G. kola"], "Herb part": ["seeds"]}]], [250, "Participants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol.", [" {\"PHYSICIAN\": [\"certified healthy\", \"medical history\", \"clinical examination\", \"written informed consent\"]}:\n\n{\"STUDY PROTOCOL\": [\"comply with\"]}:\n\n{\"PARTICIPANTS\": [\"certified healthy\", \"written informed consent\"]}:\n\n{\"LABORATORY TESTS\": []}:\n\n{\"INFORMED CONSENT\": [\"written informed consent\"]}:", {"Pathology": ["healthy"]}]], [251, "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England).", [" {\"AMOUNT\": [\"600 mg\"]}", {"Amount": ["600 mg"], "Drug": ["quinine sulphate"]}]], [252, "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola.", [" {\"AMOUNT\": [\"5ml\"]}:", {"Drug": ["quinine sulphate", "quinine"], "Herb name": ["G. kola"]}]], [253, "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively.", [" {\"QUANTITATION_LIMIT\": [\"0.37\u00b5g/ml\", \"0.5\u00b5g/ml\"]}:", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [254, "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %.", [" {\"QUININE\": [\"quinine\"], \"AMOUNT\": [\"9%\"]}", {"Parameter": ["AUC0\u2013\u221e"], "Drug": ["quinine"]}]], [255, "Precisely, only 3 participants complained of very light dizziness.", [" {\"PARTICIPANTS\": [\"3 participants\"]}:\n{\"SYMPTOMS\": [\"very light dizziness\"]}:\n{\"DOSAGE\": []}:\n{\"MEDICATION\": []}:", {"Pathology": ["light dizziness"]}]], [256, "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination.", [" {\"QUANTITY\": [\"38\"]}:\n\n{\"TITLE\": [\"pharmacology\"]}:\n\n{\"STUDY_REFERENCES\": [\"6, 11\"]}:\n\n{\"SUBSTANCE_INTERACTION\": [\"quinine\", \"G. kola\", \"trace metals\", \"flavonoids\"]}:\n\n{\"MECHANISM_UNKNOWN\": [\"exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola\"]}:\n\n{\"REDUCTION_IN_METRICS\": [\"Cmax\", \"tmax\"]}:\n\n{\"NO_CHANGE_IN_ELIMINATION\": \"no significant change in parameters indicative of interference with elimination\"}", {"Drug": ["quinine", "quinine", "quinine"], "Herb name": ["G. kola", "flavonoids", "G. kola"], "Parameter": ["Cmax", "tmax"]}]], [257, "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola.", [" {\"QUININE\": [\"quinine\"], \"GALLOWAY KOLOA (G. kola)\": [\"Galloway Kola\", \"G. kola\"], \"T1/2\": [\"T1/2\"], \"CL/F\": [\"CL/F\"]}\n\nNote: The \"AMOUNT\" field was not explicitly mentioned in the text, so it is left empty as per the instructions. However, quantities such as \"T1/2\" and \"CL/F\" are considered as quantifiable parameters related to pharmacokinetics, which could be interpreted as a form of measurement or quantity in this context. If strictly adhering to the provided format, these would not be listed under \"AMOUNT\". Instead, they are included under the relevant pharmacokinetic parameters.", {"Parameter": ["T1/2", "CL/F"], "Drug": ["quinine"], "Herb name": ["G. kola"]}]], [258, "This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.", [" {\"AMOUNT\": [\"quantities found in text\"]}\n\n\n(Note: Since the provided text does not contain specific quantities, the \"List of quantities found in text\" is left empty as per the instructions.)", {}]], [259, "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo.", [" {\"Dosage\": [\"1,200 mg S. frutescens\"]}:", {"Amount": ["1,200 mg"], "Herb name": ["S. frutescens"]}]], [260, "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11].", [" {\"ART_initiation_facilities\": [\"public sector facilities\"]}\n{\"TCAM\": [\"TCAM\", \"similar levels of TCAM\"]}\n{\"HIV_positive_individuals\": [\"HIV positive individuals\"]}\n{\"KwaZulu-Natal\": [\"KwaZulu-Natal\"]}\n{\"scientific_article\": [\"scientific article\"]}\n{\"pharmacology\": [\"pharmacology\"]}\n{\"quantities\": [\"more than 50%\"]}\n{\"adults\": [\"adults\"]}\n{\"[10]\": [\"[10]\"]}\n{\"[11]\": [\"[11]\"]}", {"Drug": ["ART"], "Pathology": ["HIV positive"]}]], [261, "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group.", [" {\"Dosage\": [\"1200 mg\"]}", {"Amount": ["1200 mg", "1200mg"]}]], [262, "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table).", [" {\"PR interval\": [\"PR interval\"], \"QRS duration\": [\"QRS duration\"], \"corrected QT interval (QTc)\": [\"corrected QT interval (QTc)\"], \"S2 Table\": [\"S2 Table\"]}\n\n(Note: \"both arms\" is not explicitly listed as an entity but could be considered part of the context in which the measurements were taken.)\n\n(Note: \"serial electrocardiograms\" is not explicitly listed as an entity but could be considered part of the context in which the measurements were taken.)", {"Parameter": ["the PR interval", "QRS duration", "corrected QT interval (QTc)"], "Study": ["both arms"]}]], [263, "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time.", [" {\"HDL\": [\"high density lipoprotein\"], \"LDL\": [\"low density lipoprotein\"], \"P-value\": [\"P-value for interaction effect of groups over time\"]}", {"Parameter": ["HDL (high density lipoprotein)", "LDL (low density lipoprotein)"]}]], [264, "(PDF) Click here for additional data file.", [" {\"PHARMACOLOGY_ARTICLE_TITLE\": [\"This is a scientific article about pharmacology\"]},\n{\"PHARMACOLOGICAL_ENTITIES\": [\"pharmacology\", \"scientific article\", \"pharmacology article\", \"pharmacological study\", \"pharmacological entity\", \"drug\", \"medication\", \"pharmacokinetics\", \"pharmacodynamics\", \"drug action\", \"drug metabolism\", \"drug absorption\", \"drug distribution\", \"drug excretion\", \"drug-receptor interaction\", \"drug-enzyme interaction\", \"drug-protein interaction\", \"drug-lipid interaction\", \"drug-water interaction\", \"drug-solvent interaction\", \"pharmacological effect\", \"pharmacological response\", \"pharmacological dose\", \"pharmacological concentration\", \"pharmacological time\", \"pharmacological condition\", \"pharmacological outcome\", \"pharmacological endpoint\", \"pharmacological endpoint measurement\", \"pharmacological endpoint quantification\", \"pharmacological endpoint analysis\", \"pharmacological endpoint interpretation\", \"pharmacological endpoint significance\", \"pharmacological endpoint relevance\", \"pharmacological endpoint implication\", \"pharmacological endpoint impact\", \"pharmacological endpoint influence\", \"pharmacological endpoint association\", \"pharmacological endpoint correlation\", \"pharmacological endpoint causation\", \"pharmacological entity description\", \"pharmacological entity classification\", \"pharmacological entity identification\", \"pharmacological entity characterization\", \"pharmacological entity analysis\", \"pharmacological entity evaluation\", \"pharmacological entity assessment\", \"pharmacological entity measurement\", \"pharmacological entity quantification\", \"pharmacological entity determination\", \"pharmacological entity calculation\", \"pharmacological entity estimation\", \"pharmacological entity prediction\", \"pharmacological entity modeling\", \"pharmacological entity simulation\", \"pharmacological entity experimentation\", \"pharmacological entity investigation\", \"pharmacological entity research\", \"pharmacological entity study\", \"pharmacological entity review\", \"pharmacological entity critique\", \"pharm", {}]], [265, "Thabethe, D.A.", [" {\"PHARMACOLOGIST\": [\"Thabethe, D.A.\"}:\n\n{\"STUDY\": [\"scientific article\"]}:\n\n{\"SUBJECT\": [\"pharmacology\"]}:\n\n{\"PUBLICATION\": [\"scientific article\"]}:\n\n{\"RESEARCHER\": [\"Thabethe, D.A.\"}:\n\n{\"RESEARCHER_FIRST_NAME\": [\"D.A.\"}:\n\n{\"RESEARCHER_LAST_NAME\": [\"Thabethe\"]}:\n\n{\"RESEARCH_INSTITUTION\": [\"\"]}:\n\n{\"PUBLICATION_TYPE\": [\"scientific article\"]}:\n\n{\"QUANTITY_MEASURED\": [\"\"]}:\n\n{\"MEASUREMENT_UNIT\": [\"\"]}:\n\n{\"PHARMACEUTICAL_PRODUCT\": [\"\"]}:\n\n{\"MEDICAL_CONDITION\": [\"\"]}:\n\n{\"DRUG_NAME\": [\"\"]}:\n\n{\"DRUG_ACTION\": [\"\"]}:\n\n{\"DRUG_DOSAGE\": [\"\"]}:\n\n{\"DRUG_INTERACTION\": [\"\"]}:\n\n{\"DRUG_TOXICITY\": [\"\"]}:\n\n{\"DRUG_MEDICATION\": [\"\"]}:\n\n{\"DRUG_PHARMACOLOGY\": [\"\"]}:\n\n{\"DRUG_CLINICAL_TRIAL\": [\"\"]}:\n\n{\"DRUG_CLINICAL_STAGE\": [\"\"]}:\n\n{\"DRUG_CLINICAL_OUTCOME\": [\"\"]}:\n\n{\"DRUG_CLINICAL_EFFECT\": [\"\"]}:\n\n{\"DRUG_CLINICAL_EVIDENCE\": [\"\"]}:\n\n{\"DRUG_CLINICAL_EVIDENCE_TYPE\": [\"\"]}:\n\n{\"DRUG_CLINICAL_STUDY\": [\"\"]}:\n\n{\"DRUG_CLINICAL_TRIAL_STAGE\": [\"\"]}:\n\n{\"DRUG_CLINICAL_TRIAL_PHASE\": [\"\"]}:\n\n{\"DRUG_CLINICAL_TRIAL_PARTICIPANTS\": [\"\"]}:\n\n{\"DRUG_CLINICAL_TRIAL", {}]], [266, "Data were reported as prevalence (percent) of the occurrence.", [" {\"PREVALENCE\": [\"percent\"]}", {}]], [267, "Chronic kidney disease (CKD) is a global public health problem with an increasing incidence and a lot of economic burden for treatment.", [" {\"CKD\": [\"Chronic kidney disease\"], \"global public health problem\": [\"global public health problem\"], \"economic burden\": [\"economic burden\"]}\n{\"AMOUNT\": []}", {"Pathology": ["Chronic kidney disease (CKD)"]}]], [268, "However, a large number of these therapies have been shown that they are not safe and can be harmful due to their interactions with other drugs which are used contemporaneously.", [" {\"PHARMACOLOGICAL THERAPIES\": [\"therapies\"], \"DRUG INTERACTIONS\": [\"interactions\"], \"CONCURRENT DRUG USE\": [\"contemporaneously\"]}\n{\"DOSAGE\": [\"\"]}\n{\"DRUG NAMES\": [\"\"]}\n{\"STUDY FINDINGS\": [\"have been shown\"]}\n{\"DRUG SAFETY\": [\"not safe\"]}\n{\"DRUG EFFECTS\": [\"harmful\"]}\n{\"DRUG USE CONTEMPLATION\": [\"used contemporaneously\"]}", {}]], [269, "After obtaining institutional ethics committee approval (project number and ethics code: 294155) from the university research affairs, patients' demographic information (sex, age, educational status, occupational status, and marital status) were collected from patients' hospital records or by direct interviewing of patients and filled in a specially designed form for this study.", [" {\"Institutional Ethics Committee Approval\": [\"project number: 294155\", \"ethics code: 294155\"]},\n{\"Patients' Demographic Information\": [\"sex\", \"age\", \"educational status\", \"occupational status\", \"marital status\"]},\n{\"University Research Affairs\": \"institutional ethics committee approval\"}", {}]], [270, "Regarding CAM nonusers, the majority were in the age group of 20\u201360 years with the male/female ratio of 73/27 percent.", [" {\"AGE_GROUP\": [\"20\u201360 years\"]}:\n{\"MALE_FEMAL_RATIO\": [\"73/27 percent\"]}:\n{\"PHARMACOLOGY_TOPIC\": [\"CAM nonusers\"]}:\n{\"PHARMACOLOGY_TOPIC\": [\"pharmacology\"]}:\n{\"PHARMACOLOGY_TOPIC\": [\"study\"]}:\n{\"PHARMACOLOGY_TOPIC\": [\"scientific article\"]}:\n{\"PHARMACOLOGY_TOPIC\": [\"quantities\"]}:\n{\"PHARMACOLOGY_TOPIC\": [\"described entities\"]}:\n{\"PHARMACOLOGY_TOPIC\": [\"cited entities\"]}:\n{\"PHARMACOLOGY_TOPIC\": [\"words\"]}:", {"Age": ["20\u201360 years"], "Sex": ["male", "female"]}]], [271, "The others (13.23%) consisted of congenital kidney disease, polycystic kidney disease, drug-induced renal failure, and acute kidney injury.", [" {\"CONDITIONS\": [\"congenital kidney disease\", \"polycystic kidney disease\", \"drug-induced renal failure\", \"acute kidney injury\"]}:\n\n{\"DRUG_FAILURE\": [\"drug-induced renal failure\"]}:\n\n{\"PERCENTAGE\": [\"13.23%\"]}:", {"Pathology": ["congenital kidney disease", "polycystic kidney disease", "drug-induced renal failure", "acute kidney injury"]}]], [272, "The majority of the patients identified as herbal users were in the age range of 50\u201370 years, and herbal usage prevalence was high among this age range.", [" {\"AGE RANGE\": [\"50\u201370 years\"]}:\n{\"HERBAL USERS\": [\"patients identified as herbal users\"]}:\n{\"HERBAL USAGE PREVALENCE\": [\"high among this age range\"]}:", {"Age": ["50\u201370 years"]}]], [273, "'s study,[25] which reported that the trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups.", [" {\"STUDY\": [\"study\", \"this study\", \"reported\", \"50\u201364 patients\"]}:\n{\"AGE GROUP\": [\"middle-aged\", \"50\u201364\"]}:\n{\"QUANTITY\": [\"50\u201364\"]}:", {"Age": ["50\u201364"]}]], [274, "[2526] Iranian borage (E. amoenum) as unformulated and anticough syrups as formulated herbal products were the most used ones in our study population, while common cold and respiratory problems were determined to be the main indications for this trend.", [" {\"Iranian borage (E. amoenum)\": [\"Iranian borage (E. amoenum)\"], \"unciformated herbal products\": [\"unformulated herbal products\"], \"formulated herbal products\": [\"formulated herbal products\"], \"common cold\": [\"common cold\"], \"respiratory problems\": [\"respiratory problems\"]}", {"Herb name": ["Iranian borage (E. amoenum)"]}]], [275, "[27] In the study performed by Roozbeh et al.", [" {\"AMOUNT\": [\"27\"]}", {}]], [276, "The patient had a Karnofsky performance status scale of 90% after resection without neurological deficiencies and was referred to our department for further treatment with radiotherapy and temozolomide (TEM).", [" {\"Karnofsky performance status scale\": [\"90%\"]}\n{\"radiotherapy\": []}\n{\"temozolomide (TEM)\": [\"TEM\"]}", {"Pathology": ["neurological deficiencies"], "Drug": ["temozolomide"]}]], [277, "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy.", [" {\"[18 F]-fluorethylenthyrosin\": [\"[18 F]-fluorethylenthyrosin\"], \"positron emission tomography\": [\"positron emission tomography\"], \"residual tumor\": [\"residual tumor\"]}\n\nNote: \"end of radiotherapy\" is not explicitly listed as an entity in the provided format, but it is a significant term related to the context of the study. However, it is not included in the output as per the instructions.", {"Pathology": ["tumor"]}]], [278, "Therefore, we think that a comprehensive management of our patients should also include education about the risk of interactions with herbal formulas.", [" {\"Herbal Formulas\": [\"herbal formulas\"]}\n{\"Patients\": [\"our patients\"]}\n{\"Risk of Interactions\": [\"risk of interactions\"]}\n{\"Education\": [\"education\"]}\n{\"Comprehensive Management\": [\"comprehensive management\"]}\n{\"Pharmacology\": [\"pharmacology\"]}\n{\"Scientific Article\": [\"scientific article\"]}", {}]], [279, "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min.", [" {\"WHOLE BLOOD QUANTITY\": [\"0.5 mL\"]}:\n{\"NALTINAL SALINE\": [\"freshly prepared normal saline\"]}:\n{\"TEMPERATURE\": [\"37 \u00b0C\"]}:\n{\"INCUBATION DURATION\": [\"at least 6 min\"]}:", {}]], [280, "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser.", [" {\"International normalized ratio\": [\"International normalized ratio\"]}", {"Parameter": ["International normalized ratio", "International normalized ratio"], "Drug": ["warfarin"]}]], [281, "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time.", [" {\"Standard human plasma\": [\"different dilutions\", \"known factor activity\"]}:", {"Parameter": ["clotting time"]}]], [282, "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel.", [" {\"Half-life\": [\"ln 2/kel\"], \"Apparent clearance (CL/F)\": [\"dose/AUC0-\u221e\"], \"Apparent volume of distribution (V/F)\": [\"CL/kel\"]}\n{\"AMOUNT\": [\"dose\", \"AUC0-\u221e\", \"kel\"]}", {"Parameter": ["half-life", "CL/F", "AUC0\u2212\u221e", "CL/kel"]}]], [283, "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration.", [" {\"S-warfarin\": [\"S-warfarin concentration\", \"S-warfarin concentration-time data\", \"S-warfarin concentration\", \"S-warfarin\"]}\n{\"pharmacokinetic model\": [\"two-compartment pharmacokinetic model\"]}\n{\"pharmacodynamic model\": [\"indirect pharmacodynamic model\"]}\n{\"prothrombin complex activity (PCA)\": [\"percentage of prothrombin complex activity\", \"PCA\"]}\n{\"INR data\": [\"INR data\"]}\n{\"pharmacokinetic\": [\"pharmacokinetic model\"]}\n{\"pharmacodynamic\": [\"pharmacodynamic model\"]}\n{\"warfarin\": [\"S-warfarin\"]}\n{\"compartment\": [\"two-compartment pharmacokinetic model\"]}\n{\"time\": [\"concentration-time data\"]}\n{\"activity\": [\"prothrombin complex activity\"]}\n{\"derived\": [\"derived from the INR data\"]}\n{\"study\": [\"this study\"]}", {"Drug": ["S-warfarin", "S-warfarin"], "Parameter": ["prothrombin complex activity (PCA", "INR"]}]], [284, "However, this did not reach statistical significance (data not shown).", [" {\"PHARMACOLOGICAL_ARTICLES\": [\"scientific article about pharmacology\"]}:\n{\"PHARMACOLOGICAL_TERMS\": [\"pharmacology\"]}:\n{\"PHARMACEUTICAL_ENTITIES\": [\"\"]}:\n{\"PHARMACEUTICAL_STATISTICS\": [\"statistical significance\"]}:\n{\"PHARMACEUTICAL_DATA\": [\"data\"]}:\n{\"PHARMACEUTICAL_STUDY_DESCRIPTION\": [\"this is a scientific article\"]}:\n{\"PHARMACEUTICAL_FINDINGS\": [\"\"]}:\n{\"PHARMACEUTICAL_RESEARCH_FINDINGS\": [\"\"]}:\n{\"PHARMACEUTICAL_RESEARCH_STATISTICS\": [\"statistical significance\"]}:\n{\"PHARMACEUTICAL_RESEARCH_DATA\": [\"data not shown\"]}:\n{\"PHARMACEUTICAL_RESEARCH_METHODOLOGY\": [\"\"]}:\n{\"PHARMACEUTICAL_RESEARCH_CONCLUSIONS\": [\"\"]}:\n{\"PHARMACEUTICAL_RESEARCH_PUBLICATION\": [\"\"]}:\n{\"PHARMACEUTICAL_RESEARCH_ARTICLE\": [\"\"]}:\n{\"PHARMACEUTICAL_RESEARCH_ARTICLE_TITLE\": [\"\"]}:\n{\"PHARMACEUTICAL_RESEARCH_AUTHORS\": [\"\"]}:\n{\"PHARMACEUTICAL_RESEARCH_JOURNAL\": [\"\"]}:\n{\"PHARMACEUTICAL_RESEARCH_JOURNAL_NAME\": [\"\"]}:\n{\"PHARMACEUTICAL_RESEARCH_JOURNAL_ISSN\": [\"\"]}:\n{\"PHARMACEUTICAL_RESEARCH_JOURNAL_YEAR\": [\"\"]}:\n{\"PHARMACEUTICAL_RESEARCH_JOURNAL_PUBLICATION_DATE\": [\"\"]}:\n{\"PHARMACEUTICAL_RESEARCH_JOURNAL_ARTICLE_NUMBER", {}]], [285, "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax.", [" {\"Geometric mean ratio (90% CI)\": [\"1.9 (1.1\u20132.7)\"]}\n{\"Warfarin and cranberry\": \"NA\"}\n{\"Warfarin and garlic\": \"1.06 (0.77\u20131.47)\"}\n{\"Warfarin and cranberry/warfarin only\": \"0.94 (0.67\u20131.29)\"}\n{\"Warfarin and garlic/warfarin only\": \"1.06 (0.83\u20131.19)\"}\n{\"CL/F (mL\u2009h\u22121)\": [\"213 (193\u2013232)\", \"204 (183\u2013224)\", \"202 (175\u2013229)\"]}\n{\"Fraction unbound (fu)\": [\"0.010 (0.007\u20130.013)\", \"0.010 (0.007\u20130.014)\", \"1.00 (0.75\u20131.25)\", \"1.12 (0.39\u20131.84)\"]}", {"Drug": ["S-warfarin", "R-warfarin", "Warfarin", "Warfarin", "Warfarin", "Warfarin", "warfarin", "Warfarin", "warfarin", "S-warfarin", "R-warfarin"], "Herb name": ["cranberry", "garlic", "cranberry", "garlic"], "Parameter": ["tmax", "Cmax", "AUC", "CL/F", "tmax", "Cmax", "t1/2", "AUC", "CL/F", "AUC, area under the plasma concentration\u2013time curve", "CL, clearance", "CL/F, apparent clearance", "Cmax, maximum concentration", "F, bioavailability", "tmax, time to Cmax"]}]], [286, "Pharmacokinetic\u2013pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3.", [" {\"AMOUNT\": [\"population PKPD parameter estimates\"]}", {"Drug": ["warfarin"]}]], [287, "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin.", [" {\"Warfarin\": [\"S-warfarin\", \"clinically significant change in the AUC\"]}\n{\"Cranberry Juice\": [\"pretreatment with cranberry juice\"]}\n{\"2007\": [\"2007\"]}", {"Herb name": ["cranberry"], "Extraction process": ["juice"], "Duration": ["for 5 days"], "Drug": ["warfarin", "S-warfarin"], "Parameter": ["AUC"]}]], [288, "(2006b) included 7 patients with atrial fibrillation, whereas Ansell et al.", [" {\"Atrial Fibrillation\": [\"atrial fibrillation\"], \"Ansell et al.\": [\"Ansell et al.\"]}\n{\"Year\": [\"2006b\"]}\n{\"Patients\": [\"7 patients\"]}", {"Cohort": ["7 patients"], "Pathology": ["atrial fibrillation"]}]], [289, "(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10\u2009mg), which made this end point difficult to assess.", [" {\"WARFARIN_DOSAGE\": [\"10 mg\"]}", {"Drug": ["warfarin", "warfarin"], "Herb name": ["cranberry"], "Extraction process": ["juice"], "Amount": ["10\u2009mg"]}]], [290, "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking.", [" {\"CITY\": [\"Madison\"]}:\n{\"COMPANY\": [\"Covance Laboratories Inc.\"]}:\n{\"COUNTRY\": [\"USA\"]}:\n{\"LABORATORY\": [\"Covance Laboratories Inc.\"]}\n{\"LOCATION\": [\"Madison, WI, USA\"]}:\n{\"MEDICAL TREATMENT\": [\"complementary medicines\", \"warfarin\"]}:\n{\"PHARMACOLOGY AREA\": [\"Drug Metabolism and Pharmacokinetics\"]}:\n{\"PUBLICATION TYPE\": [\"scientific article\"]}:\n{\"UNIVERSITY\": [\"\"]}:\n{\"WEIGHT\": [\"\"]}:\n{\"YEAR\": [\"\"]}:", {"Drug": ["warfarin"]}]], [291, "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs.", [" {\"PHARMACOLOGICAL_COMPOUNDS\" [\"valerian\", \"anticancer drugs\"]}:\n\n{\"PUBLICATIONS\" [\"recent popular publications\"]}:\n\n{\"INFORMATION_SOURCES\" [\"information websites\"]}:\n\n{\"PATIENT_GROUP\" [\"cancer patients\"]}:\n\n{\"RESEARCHER\" [\"Igho J. Onakpoya\"]}:", {"Pathology": ["cancer patients"], "Herb name": ["valerian"], "Drug": ["anticancer drugs"]}]], [292, "However, they state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4.", [" {\"VALERIANA OFFICINALIS\": [\"Valeriana officinalis\"]}\n{\"CYP 3A4\": [\"CYP 3A4\"]}", {"Herb name": ["valerian", "Valeriana officinalis"], "Target": ["CYP 3A4"]}]], [293, "It therefore was recommended that they should be avoided in the elderly [10, 12].", [" {\"AMOUNT\": [\"10, 12\"]}", {}]], [294, "Recommended daily doses of valerian root extracts are about 600\u2009mg, usually taken as capsules or tablets.", [" {\"AMOUNT\": [\"600 mg\"]}\n\nNote: The text does not explicitly mention the units \"mg\" (milligrams) as part of the cited entities, but it is implied in the context of the recommended daily doses. Therefore, the inclusion of \"mg\" is based on the context of the dosage information provided.", {"Frequency": ["daily"], "Herb name": ["valerian"], "Herb part": ["root"], "Amount": ["600\u2009mg"]}]], [295, "A search with the search terms (valerian or valeriana) was conducted in the databases MEDLINE and TOXLIT, via DIMDI (Cologne, Germany).", [" {\"DATABASES\": [\"MEDLINE\", \"TOXLIT\", \"DIMDI\"]}:\n{\"HERBAL_NAMES\": [\"valerian\", \"valeriana\"]}:\n{\"GEOLOGICAL_REGIONS\": []}:\n{\"INSTITUTES\": [\"DIMDI\"]}:\n{\"UNITS_OF_MEASURE\": [\"\"]}:\n{\"AMOUNT\": []}:", {"Herb name": ["valerian", "valeriana"]}]], [296, "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions.", [" {\"PHARMACOLOGY_ARTICLES\": [\"studies\"],\n \"RESEARCH_ENTITIES\": [\"material and methods\", \"clinical relevance\", \"results\", \"conclusions\"],\n \"METHODS\": [\"completeness and validity\"],\n \"DATA_QUANTITIES\": [],\n \"BIOMEDICAL_ENTITIES\": [\"clinical relevance\"],\n \"BIOMEDICAL_CONCLUSIONS\": [\"potential bias in the presentation of results and conclusions\"]}\n\nNote: The \"AMOUNT\" field was not applicable in this context as there were no specific quantities mentioned in the text.", {}]], [297, "These limitations do not allow valid extrapolations with respect to a clinical relevance of the results.", [" {\"PHARMACOLOGICAL_STUDIES\": [\"scientific article about pharmacology\"]}\n{\"PHARMACOLOGICAL_CONCEPTS\": [\"pharmacology\"]}\n{\"MEDICAL_TERMS\": [\"quantities\"]}\n{\"PHARMACEUTICAL_ENTITIES\": [\"\"]}\n{\"DRUG_NAMES\": [\"\"]}\n{\"DOSAGE_MEASUREMENTS\": [\"\"]}\n{\"PHARMACEUTICAL_ACTIONS\": [\"\"]}\n{\"PHARMACOLOGICAL_RESEARCH_FINDINGS\": [\"\"]}\n{\"PHARMACOLOGICAL_STUDIES\": [\"\"]}\n{\"PHARMACOLOGICAL_CONCEPTS\": [\"\"]}\n{\"MEDICAL_TERMS\": [\"\"]}\n{\"PHARMACEUTICAL_ENTITIES\": [\"\"]}\n{\"DRUG_NAMES\": [\"\"]}\n{\"DOSAGE_MEASUREMENTS\": [\"\"]}\n{\"PHARMACEUTICAL_ACTIONS\": [\"\"]}\n{\"PHARMACOLOGICAL_RESEARCH_FINDINGS\": [\"\"]}", {}]], [298, "[36].", [" {\"PHARMACOLOGICAL_TITLES\": [\"pharmacology\"]}:\n\n{\"PHARMACEUTICAL_COMPANIES\": [\"\"]}:\n\n{\"DRUG_NAMES\": [\"\"]}:\n\n{\"DOSE_AMOUNTS\": [\"36\"]}:\n\n{\"STUDY_DETAILS\": [\"\"]}:\n\n{\"RESEARCH_SOURCES\": [\"\"]):\n\n{\"PUBLICATION_DATES\": [\"\"]):\n\n{\"JOURNAL_NAMES\": [\"\"]):\n\n{\"AUTHORS\": [\"\"]):\n\n{\"STUDY_FINDINGS\": [\"\"]):\n\n{\"METHODOLOGY\": [\"\"]):\n\n{\"STUDY_SETTING\": [\"\"]):\n\n{\"STUDY_DESIGN\": [\"\"]):\n\n{\"STUDY_PARTICIPANTS\": [\"\"]):\n\n{\"STUDY_DURATION\": [\"\"]):\n\n{\"STUDY_OUTCOMES\": [\"\"]):\n\n{\"STUDY_CONCLUSIONS\": [\"\"]):\n\n{\"STUDY_REFERENCES\": [\"\"]):", {}]], [299, "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days.", [" {\"VALERIAN EXTRACT QUANTITY\": [\"500 mg\"]}:\n{\"EXTRACTION SOLVENT CONCENTRATION\": [\"ethanol 70%\"]}:\n{\"VALERENIC ACID CONTENT\": [\"5.51 mg/tablet\"]}:\n{\"DAILY PILL TAKING DURATION\": [\"14 subsequent days\"]}:", {"Frequency": ["Daily"], "Amount": ["500\u2009mg"], "Herb name": ["valerian", "valerenic acid"], "Duration": ["14 subsequent days"]}]], [300, "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined.", [" {\"CYP 3A4/5\": [\"1-hydroxymidazolam/midazolam serum ratio\"], \"CYP 1A2\": [\"paraxanthine/caffeine serum ratio\"], \"CYP 2E1\": [\"hydroxychlorzoxazone/chlorzoxazone serum ratio\"], \"CYP 2D6\": [\"debrisoquine urinary recovery ratio\"]}", {"Drug": ["midazolam", "paraxanthine", "caffeine", "chlorzoxazone", "debrisoquine"]}]], [301, "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51].", [" {\"HALOPERIDOL\": [\"38 mg/kg bw\"]}:", {"Drug": ["Haloperidol"], "Amount": ["38\u2009mg/kg bw"], "Frequency": ["once", "every 4 weeks"], "Duration": ["12 weeks", "15 days"], "Herb name": ["valerian"]}]], [302, "The results were not presented in detail but indicated that the two drugs act independently from each other.", [" {\"Drugs\": [\"two drugs\"]}\n{\"Independence\": [\"act independently\"]}", {}]], [303, "A possible pharmacodynamic interaction of valerian preparations with other drugs is supported only by two case reports.", [" {\"PHARMACODYNAMIC_INTERACTIONS\": [\"pharmacodynamic interaction\", \"valerian preparations\", \"other drugs\", \"case reports\"]}\n{\"PHARMACOLOGICAL_AGENTS\": [\"valerian\"]}\n{\"CASE_REPORTS\": [\"two case reports\"]}\n{\"DRUG_TYPES\": [\"other drugs\"]}\n{\"QUANTITIES\": []}\n{\"PHARMACOLOGY_SUBFIELDS\": [\"pharmacodynamic interaction\"]}\n{\"PUBLICATION_TYPE\": [\"scientific article\"]}\n{\"PUBLICATION_SOURCE\": []}\n{\"PUBLICATION_DATE\": []}\n{\"PUBLICATION_AUTHORS\": []}\n{\"PUBLICATION_JOURNAL\": []}\n{\"PUBLICATION_VOLUME\": []}\n{\"PUBLICATION_PAGE_NUMBER\": []}\n{\"PUBLICATION_DOI\": []}\n{\"PUBLICATION_ABSTRACT\": []}\n{\"PUBLICATION_KEYWORDS\": [\"pharmacodynamic interaction\", \"valerian preparations\", \"other drugs\"]}\n{\"PUBLICATION_METHODOLOGY\": []}\n{\"PUBLICATION_FINDINGS\": []}\n{\"PUBLICATION_CONCLUSIONS\": []}\n{\"PUBLICATION_CLINICAL_IMPLICATIONS\": []}\n{\"PUBLICATION_RECOMMENDATIONS\": []}\n{\"PUBLICATION_FUTURE_WORK\": []}\n{\"PUBLICATION_REFERENCES\": []}\n{\"PUBLICATION_FUNDING\": []}\n{\"PUBLICATION_DESIGNATION\": []}\n{\"PUBLICATION_COMMENTS\": []}\n{\"PUBLICATION_REVIEWER\": []}\n{\"PUBLICATION_REVIEW_STATUS\": []}\n{\"PUBLICATION_REVIEWER_REMARKS\": []}\n{\"PUBLICATION_REVIEWER_RECOMMENDATIONS\": []}\n{\"PUBLICATION_REVIEWER_CONSENSUS\": []}\n{\"PUBLICATION_REVIEWER_CONCLUSIONS\": []}", {"Herb name": ["valerian"]}]], [304, "Given that none of these herbal medicines has been proven to have MAO-inhibitory properties, while induction of delirium, and a positive drug screening on opioids was reported, the assumption of an involvement of the valerian preparation does not seem to be plausible.", [" {\"HERBAL MEDICINES\": [\"herbal medicines\"], \"MAO-INHIBITORY PROPERTIES\": [\"MAO-inhibitory properties\"], \"DELIRIUM\": [\"delirium\"], \"OPIOIDS\": [\"opioids\"]}\n{\"AMOUNT\": []}", {"Target": ["MAO"], "Pathology": ["delirium"], "Drug": ["opioids"], "Herb name": ["valerian"]}]], [305, "A good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks.", [" {\"PHARMACOLOGY_TERMS\": [\"drug-drug interactions\", \"clinical risks\"]}\n{\"PHARMACEUTICAL_ENTITIES\": [\"drugs\"]}\n{\"MEASUREMENTS\": [\"\"]}\n{\"RESEARCH_SOURCES\": [\"\"]}", {}]], [306, "Especially the open questions of in vivo bioavailability and of the metabolism of extract components relevant for in vitro effects often prevent reliable extrapolations from in vitro to in vivo data.", [" {\"PHARMACOLOGICAL_COMPANIES\": [\"\"]}\n{\"PHARMACEUTICAL_COMPOUNDS\": [\"\"]}\n{\"PHARMACOLOGICAL_STUDIES\": [\"in vivo bioavailability\", \"metabolism of extract components\"]}\n{\"PHARMACOLOGICAL_METHODS\": [\"in vitro effects\"]}\n{\"PHARMACOLOGICAL_TOPICS\": [\"in vivo\", \"in vitro\"]}\n{\"PHARMACOLOGICAL_DEVICES\": [\"\"]}\n{\"PHARMACOLOGICAL_EXPERIMENTS\": [\"\"]}\n{\"PHARMACOLOGICAL_RESEARCH\": [\"\"]}\n{\"PHARMACOLOGICAL_ARTICLES\": [\"\"]}\n{\"PHARMACOLOGICAL_JOURNALS\": [\"\"]}\n{\"PHARMACOLOGICAL_PAPERS\": [\"\"]}\n{\"PHARMACOLOGICAL_PRACTICES\": [\"\"]}\n{\"PHARMACOLOGICAL_PROTOCOLS\": [\"\"]}\n{\"PHARMACOLOGICAL_PRODUCTS\": [\"\"]}\n{\"PHARMACOLOGICAL_DOSES\": [\"\"]}\n{\"PHARMACOLOGICAL_TIMESCALES\": [\"\"]}\n{\"PHARMACOLOGICAL_CONCLUSIONS\": [\"reliable extrapolations\"]}\n{\"PHARMACOLOGICAL_QUESTIONS\": [\"in vivo bioavailability\", \"metabolism of extract components\"]}\n{\"PHARMACOLOGICAL_FINDINGS\": [\"\"]}\n{\"PHARMACOLOGICAL_IMPACTS\": [\"\"]}\n{\"PHARMACOLOGICAL_IMPLICATIONS\": [\"\"]}\n{\"PHARMACOLOGICAL_IMPACTS_ON\": [\"\"]}\n{\"PHARMACOLOGICAL_STUDIES_TOPICS\": [\"in vivo bioavailability\", \"metabolism of extract components\"]}\n{\"PHARMACOLOGICAL_STUDIES_METHODS\": [\"in vitro effects\"]}\n{\"PHARMA", {"Parameter": ["bioavailability"]}]], [307, "At present therefore a relevant risk of pharmacodynamic interactions is not proven by valid clinical observations.", [" {\"PHARMACOLOGICAL_CONCEPTS\" [\"pharmacodynamic interactions\", \"clinical observations\"]}:\n\n{\"PHARMACEUTICAL_ENTITIES\" []}:\n\n{\"MEDICAL_CONDITIONS\" []}:\n\n{\"DRUG_NAMES\" []}:\n\n{\"STUDY_SOURCES\" []}:", {}]], [308, "That therapeutic safety regarding interactions is high in valerian and is mentioned in the respective monograph of the HMPC [18] and also in a fact sheet of the Office of Dietary Supplements at the NIH [32].", [" {\"HMPC Monograph\": [\"18\"]}:\n{\"Office of Dietary Supplements\": [\"32\"]}:", {"Herb name": ["valerian"]}]], [309, "In a data base for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for CYP-isoenzymes, P-gp, and UGT, based on in vitro data.", [" {\"CYP-isoenzymes\": [\"CYP-isoenzymes\"], \"P-gp\": [\"P-gp\"], \"UGT\": [\"UGT\"], \"MedIQ\": [\"MedIQ\"]}", {"Target": ["CYP-isoenzymes", "P-gp", "UGT"]}]], [310, "In summary, it can be concluded that warnings regarding a specific risk of interactions of valerian are without any recent evidence.", [" {\"Valerian\": [\"valerian\"], \"warnings\": [\"warnings\"], \"risk of interactions\": [\"specific risk of interactions\"], \"valerian\": [\"valerian\"]}\n{\"AMOUNT\": []}", {"Herb name": ["valerian"]}]], [311, "The authors declare that there is no conflict of interests regarding the publication of this paper.", [" {\"AMOUNT\": [\"\"]}\n\n(Note: Since the provided text does not contain any specific quantities, there is no list of quantities to extract. However, in a full article, quantities such as dosages, concentrations, or amounts of substances would be included and listed accordingly.)", {}]], [312, "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively.", [" {\"Rifampin\": [\"600 mg\"]}:\n{\"Clarithromycin\": [\"1000 mg\"]}:\n{\"CYP3A\": [\"positive controls for CYP3A induction and inhibition\"]}:\n{\"Time duration\": [\"7 days\"]}:", {"Drug": ["rifampin", "clarithromycin"], "Amount": ["600 mg", "1000 mg"], "Duration": ["7 days"], "Target": ["CYP3A"]}]], [313, "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant.", [" {\"Venlafaxine\": [\"Venlafaxine\"], \"serotonin-norepinephrine reuptake inhibitor\": [\"serotonin-norepinephrine reuptake inhibitor\"], \"antidepressant\": [\"antidepressant\"]}\n{\"AMOUNT\": []}", {"Drug": ["Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant"]}]], [314, "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF.", [" {\"Venlafaxine\": [\"venlafaxine\"], \"Radiological abnormalities\": [\"radiological abnormalities\"], \"LVEF\": [\"LVEF\"]}\n{\"AMOUNT\": []}", {"Drug": ["venlafaxine"], "Pathology": ["the radiological abnormalities"], "Parameter": ["LVEF"]}]], [315, "This was an important case of drug-induced cardiopulmonary toxicity.", [" {\"Drug\": [\"drug-induced cardiopulmonary toxicity\"]}:\n{\"Cardiopulmonary Toxicity\": [\"drug-induced cardiopulmonary toxicity\"]}:\n{\"Quantity\": []}:", {"Pathology": ["drug-induced cardiopulmonary toxicity"]}]], [316, "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation.", [" {\"DIP\": [\"DIP\"], \"treatment\": [\"treatment\"], \"hours\": [\"hours\"], \"months\": [\"months\"], \"reversibility\": [\"reversibility\"], \"drug discontinuation\": [\"drug discontinuation\"]}\n{\"AMOUNT\": [\"hours\", \"months\"]}", {"Pathology": ["DIP", "DIP"], "Duration": ["hours to months"]}]], [317, "The present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine.", [" {\"Venlafaxine\": [\"venlafaxine\"]}", {"Pathology": ["cardiopulmonary toxicity"], "Drug": ["venlafaxine"]}]], [318, "Uma investiga\u00e7\u00e3o ampla foi realizada, incluindo LBA, estudos de imagem, detec\u00e7\u00e3o de doen\u00e7as autoimunes, cateterismo card\u00edaco direito e bi\u00f3psia mioc\u00e1rdica.", [" {\"LBA\": [\"Liver Biopsy\"], \"studies of imaging\": [\"studies of imaging\"], \"dozen autoimmune diseases\": [\"dozen autoimmune diseases\"], \"cardiac catheterization\": [\"cardiac catheterization\"], \"biopsy of the heart muscle\": [\"biopsy of the heart muscle\"]}\n{\"AMOUNT\": [\"dozen\"]}", {}]], [319, "A administra\u00e7\u00e3o circunstancial de inibidores da isoenzima CYP2D6 e a presen\u00e7a de um fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6 podem ter resultado na acumula\u00e7\u00e3o t\u00f3xica da venlafaxina e na manifesta\u00e7\u00e3o cl\u00ednica subsequente.", [" {\"VENLAFAXIN\": [\"acumula\u00e7\u00e3o t\u00f3xica\"], \"CYP2D6\": [\"isoenzima\", \"metaboliza\u00e7\u00e3o lenta\"]}\n{\"DOSA\": [\"desconhecido\"]}:\n\nNote: In the provided text, no specific dosage amounts are mentioned, hence \"DOSA\" is left empty.", {}]], [320, "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais.", [" {\"AMOUNT\": [\"toda quantidade\"], \"PROTEINS\": [\"prote\u00ednas do complemento\"], \"ORGANS\": [\"renais\", \"hep\u00e1ticos\"], \"SPECIES\": [\"sedimento urin\u00e1rio\"]}\n\n(Note: The term \"sedimento urin\u00e1rio\" refers to the components of the urine sediment, which could be considered a collection of entities, but it's not a species in the biological sense. However, it's included here as it's a key component mentioned in the context of the study.)", {}]], [321, "A maioria dos medicamentos card\u00edacos foi, portanto, descontinuada.", [" {\"medications\": [\"maioria dos medicamentos card\u00edacos\"]}\n{\"quantities\": [\"uma maioria\"]}\n{\"units\": []}\n{\"substances\": [\"medicamentos\"]}\n{\"dosage\": []}\n{\"dosage form\": []}\n{\"route of administration\": []}\n{\"pharmacodynamics\": []}\n{\"pharmacokinetics\": []}\n{\"adverse effects\": []}\n{\"clinical trials\": []}\n{\"study design\": []}\n{\"researchers\": []}\n{\"authors\": []}\n{\"journal\": []}\n{\"year of publication\": []}", {}]], [322, "O caso ocorreu em uma paciente previamente h\u00edgida de 35 anos de idade que foi submetida a investiga\u00e7\u00e3o exaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas.", [" {\"PAINESTER\": [\"uma paciente previamente h\u00edgida de 35 anos de idade\"]}:\n\n{\"AGE\": [\"35 anos de idade\"]}:\n\n{\"INVESTIGA\u00c7\u00c3O\": [\"investiga\u00e7\u00e3o exaustiva\"]}:\n\n{\"OUTRA_CAUSAS\": [\"outras poss\u00edveis causas\"]}:", {}]], [323, "Apoio financeiro: Nenhum.", [" {\"AMOUNT\": [\"Nenhum\"]}\n\n(Note: The provided text does not explicitly mention any quantities related to pharmacology, finance, or other measurable entities. However, the phrase \"Nenhum\" translates to \"None\" in English, which can be interpreted as the absence of a specific amount or quantity in the context of financial support. If the context was strictly about pharmacological quantities, there would be no relevant entities to list in this case.)", {}]], [324, "This study aims to confirm the safety of red ginseng and herb extract complex (RHC), which are used to relieve menopausal symptoms.", [" {\"RGC\": [\"red ginseng and herb extract complex (RHC)\"]}\n{\"menopausal symptoms\": [\"menopausal symptoms\"]}", {"Herb name": ["red ginseng", "herb extract complex (RHC)"], "Pathology": ["menopausal symptoms"]}]], [325, "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.", [" {\"AMOUNT\": [\"160/100 mmHg\", \"180 mg/dL\"]}", {"Sex": ["women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "female", "women", "women", "women", "women", "women", "women"], "Pathology": ["menopausal", "surgery", "hysterectomy", "endometrial hyperplasia", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "uncontrolled diabetes mellitus", "diabetes", "uncontrolled thyroid", "severe migraines", "thromboembolism", "cerebrovascular disease", "cardiovascular disease", "uterine bleeding", "menopause", "drug or alcohol abuse", "hypersensitivity"], "Drug": ["chemotherapy", "sleep inducers", "antidepressants", "selective estrogen receptor modulators", "antihyperlipidemic drugs", "antithrombotic drugs", "Aspirin", "Warfarin", "Clopidogrel", "bisphosphonates", "calcitonin"], "Amount": ["160/100\u00a0mmHg", "180\u00a0mg/dL"], "Parameter": ["fasting blood sugar", "triglyceride", "cholesterol", "alanine aminotransferase (ALT)", "aspartate aminotransferase (AST)", "creatinine"], "Duration": ["within 3\u00a0mo", "within the last year", "after 1\u00a0yr", "within 4\u00a0wk", "within 4\u00a0wk", "within 4\u00a0wk", "within 6\u00a0mo", "more than 10\u00a0h", "within 3\u00a0mo", "women", "within 1\u00a0mo"], "Herb name": ["isoflavone", "flaxseed", "pomegranate", "horseradish", "white sorghum", "red shamrock", "red ginseng"], "Study": ["clinical trials", "clinical trial"]}]], [326, "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included.", [" {\"Drug\": [\"test substance\"]}:\n\n{\"Date of onset and disappearance\": []}:\n\n{\"Degree and result of the adverse reaction\": []}:\n\n{\"Measures taken in relation to the test substance\": []}:\n\n{\"Causal relationship with the test substance\": []}:\n\n{\"Name of the drug other than the test substance\": []}:\n\n{\"Treatment of adverse reactions\": []}:\n\n{\"Adverse reactions\": []}:\n\n{\"Pharmacology\": []}:", {"Pathology": ["adverse reactions", "adverse reaction", "adverse reactions"]}]], [327, "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups.", [" {\"PHARMACOLOGICAL STUDIES\": [\"pharmacology\"], \"RESEARCHERS\": [\"examination\"], \"PARTICIPANTS\": [\"demographic information\", \"consumption groups\"], \"MEASUREMENTS\": [\"statistically significant difference\"]}\n{\"AMOUNT\": []}", {}]], [328, "p-value by Fisher's exact test.", [" {\"Fisher's exact test\": [\"p-value\"], \"quantities\": [\"\"]}", {}]], [329, "In addition, one subject with pruritus and hot flash and another subject with headache fully recovered after discontinuation of administration in the placebo group.", [" {\"Placebo group\": [\"placebo group\"], \"headache\": [\"headache\"], \"pruritus\": [\"pruritus\"], \"hot flash\": [\"hot flash\"], \"administration\": [\"administration\"]}\n{\"Recovery\": [\"fully recovered\"]}\n{\"Subject\": [\"another subject\"]}\n{\"Dose\": [\"no quantities found\"]}\n{\"Duration\": [\"no quantities found\"]}\n{\"Treatment\": [\"discontinuation of administration\"]}\n{\"Effect\": [\"fully recovered\"]}\n{\"Placebo\": [\"placebo\"]}\n{\"Headache\": [\"headache\"]}\n{\"Pruritus\": [\"pruritus\"]}\n{\"Hot flash\": [\"hot flash\"]}", {"Pathology": ["pruritus", "hot flash", "headache"]}]], [330, "It is noteworthy that no severe adverse reactions were observed in this study.", [" {\"PHARMACOLOGICAL_STUDIES\": [\"this study\"]}\n{\"DRUG_NAMES\": []}\n{\"DRUG_ACTIONS\": []}\n{\"ADVERSE_REACTIONS\": [\"severe adverse reactions\"]}\n{\"DRUG_DOSAGES\": [\"no quantities\"]}\n{\"STUDY_PARTICIPANTS\": []}\n{\"STUDY_SETTING\": []}\n{\"STUDY_FINDINGS\": [\"no quantities\"]}\n{\"PUBLICATION_SOURCE\": [\"scientific article\"]}\n{\"PUBLICATION_TYPE\": [\"scientific article\"]}", {"Pathology": ["adverse reactions"]}]], [331, "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects.", [" {\"RHC\": [\"RHC\"], \"menopausal subjects\": [\"large-scale menopausal subjects\"]}\n{\"AMOUNT\": [\"long period\"]}\n{\"STUDY POPULATION\": [\"large-scale menopausal subjects\"]}\n{\"SAFETY ASPECT\": [\"safety of RHC intake\"]}\n{\"RESEARCH NEED\": [\"further research\"]}\n{\"SUBJECT TYPE\": [\"menopausal subjects\"]}\n{\"SUBJECT SIZE\": [\"large-scale\"]}\n{\"SUBJECT DURATION\": [\"long period\"]}\n{\"SUBJECT GENDER\": [\"menopausal\"]}\n{\"SUBJECT AGE\": [\"not specified\"]}\n{\"SUBJECT NUMBER\": [\"large-scale\"]}\n{\"SUBJECT DISTRIBUTION\": [\"not specified\"]}\n{\"SUBJECT HEALTH STATUS\": [\"not specified\"]}\n{\"SUBJECT INTAKE METHOD\": [\"RHC intake\"]}\n{\"SUBJECT OUTCOME MEASURE\": [\"not specified\"]}\n{\"SUBJECT DURATION OF STUDY\": [\"long period\"]}\n{\"SUBJECT DURATION OF INTAKE\": [\"long period\"]}\n{\"SUBJECT DURATION OF STUDY\": [\"not specified\"]}\n{\"SUBJECT DURATION OF INTAKE\": [\"not specified\"]}\n{\"SUBJECT DURATION OF INTAKE\": [\"long period\"]}\n{\"SUBJECT DURATION OF INTAKE\": [\"long period\"]}\n{\"SUBJECT DURATION OF INTAKE\": [\"long period\"]}\n{\"SUBJECT DURATION OF INTAKE\": [\"long period\"]}\n{\"SUBJECT DURATION OF INTAKE\": [\"long period\"]}\n{\"SUBJECT DURATION OF INTAKE\": [\"long period\"]}\n{\"SUBJECT DURATION OF INTAKE\": [\"long period\"]}\n{\"SUBJECT DURATION OF INTAKE\": [\"long period\"]}\n{\"SUBJECT DURATION OF INTAKE\": [\"long period\"]}\n{\"SUBJECT DURATION OF INTAKE\": [\"long period\"]}\n{\"SUBJECT DURATION OF INTAKE\": [\"long period\"]}\n{\"SUBJECT DURATION OF INTAKE\": [\"long period", {"Herb name": ["RHC"], "Pathology": ["menopausal"]}]], [332, "Furthermore, inhibition kinetic study (Dixon plot and Lineweaver-Burk plot) demonstrated that celastrol noncompetitively inhibited the UGT1A1-mediated 4-MU glucuronidation, and competitively inhibited UGT2B7-catalyzed 4-MU glucuronidation.", [" {\"UGT1A1\": [\"UGT1A1-mediated 4-MU glucuronidation\"]:\n\n{\"UGT2B7\": [\"UGT2B7-catalyzed 4-MU glucuronidation\"]:\n\n{\"Dixon plot\": []}:\n\n{\"Lineweaver-Burk plot\": []}:\n\n{\"celastrol\": [\"noncompetitively inhibited\", \"competitively inhibited\"]:\n\n{\"4-MU\": [\"4-MU glucuronidation\"]:\n\n{\"glucuronidation\": [\"4-MU glucuronidation\"]:\n\n{\"inhibition\": [\"noncompetitively inhibited\", \"competitively inhibited\"]:\n\n{\"kinetic study\": []}:\n\n{\"pharmacology\": []}", {"Study": ["inhibition kinetic study"], "Herb name": ["celastrol"], "Target": ["UGT1A1-mediated 4-MU glucuronidation", "UGT2B7-catalyzed 4-MU glucuronidation"]}]], [333, "Therefore, evaluation of inhibition of compounds towards UGT isoforms was always carried out using recombinant UGTs and nonspecific substrates [19,20,21].", [" {\"UGT isoforms\": [\"recombinant UGTs\"]}\n{\"quantities\": [\"\"]}", {"Target": ["UGT isoforms", "UGTs"]}]], [334, "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive.", [" {\"Inhibition Type\": [\"competitive\"]}\n\n{\"Intersection Location\": [\"second quadrant\"]}\n\n{\"Vertical Axis\": [\"Dixon and Lineweaver-Burk plots\"]}\n\n{\"AMOUNT\": []}", {}]], [335, "The second plot (Figure 3C) using slope (obtained from Lineweaver-Burk plot) vs. celastrol concentration showed that the inhibition kinetic parameter (Ki) was 0.49 \u03bcM.", [" {\"Kinetic Parameter (Ki)\": [\"0.49 \u03bcM\"]}:", {"Herb name": ["celastrol"]}]], [336, "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24].", [" {\"UGT1A6 expression\": [\"120-fold variability\", \"13-fold variability\"]}:\n\n{\"serotonin glucuronidation\": [\"serotonin glucuronidation\"]}:\n\n{\"human liver\": [\"human liver\"]}:\n\n{\"24\": [\"[24]\"}", {"Target": ["UGT1A6"]}]], [337, "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25].", [" {\"CLOFIBRIC ACID\": [\"clofibric acid\"], \"VALPROIC ACID\": [\"valproic acid\"]}", {"Drug": ["valproic acid"]}]], [338, "The previous study performed by Du et al.", [" {\"Du et al.\": [\"previous study\"]}\n{\"AMOUNT\": []}", {}]], [339, "Inhibition kinetic analysis of celastrol (Cela) towards UGT2B7-catalyzed 4-MU glucuronidation.", [" {\"CELASTROL\": [\"celastrol (Cela)\"], \"UGT2B7\": [\"UGT2B7-catalyzed\"], \"4-MU\": [\"4-MU glucuronidation\"]}\n{\"AMOUNT\": []}", {"Herb name": ["celastrol (Cela)"], "Target": ["UGT2B7-catalyzed 4-MU glucuronidation"]}]], [340, "The therapeutic benefits of ginseng include anti-diabetic and anti-inflammatory effect and anti-oxidative response on chronic liver disease [3,4,5,6,7,8].", [" {\"GINSENG\": [\"chronic liver disease\"]}\n{\"AMOUNT\": [\"\"]}", {"Herb name": ["ginseng"], "Pathology": ["chronic liver disease"]}]], [341, "In case of ginseng interactions, it was reported that no herb\u2013drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5\u20132.0 g/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12].", [" {\"RGE\": [\"0.5\u20132.0 g/kg\"]}", {"Herb name": ["ginseng", "red ginseng extract (RGE)"], "Ethnic group": ["Korean"], "Amount": ["0.5\u20132.0 g/kg"], "Target": ["cytochrome P450 (CYP) enzymes", "CYP1A2, 2C9, 2C19, 2D6, 3A"]}]], [342, "The results suggest that valsartan could be used as a model drug for investigating OATP (in human) or Oatp (in rats)-mediated herb\u2013drug interaction between valsartan and RGE or ginsenosides.", [" {\"VALSARTAN\": [\"valsartan\"], \"OATP\": [\"OATP\"], \"RATS\": [\"rats\"], \"HERB-DRUG INTERACTION\": [\"herb-drug interaction\"], \"GINSENOSIDES\": [\"ginsenosides\"]}", {"Drug": ["valsartan", "valsartan"], "Target": ["OATP", "Oatp"], "Herb name": ["RGE", "ginsenosides"]}]], [343, "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8).", [" {\"RGE\": [\"repeated administration of RGE\"], \"Rc\": [\"high dose of Rc\"], \"valsartan\": [\"herb\u2013drug interactions involving valsartan\"]}\n{\"Dose\": [\"high dose\"]}\n{\"Figure\": [\"Figure 5\", \"Figure 8\"]}", {"Herb name": ["RGE", "Rc"], "Drug": ["valsartan"]}]], [344, "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B).", [" {\"AMOUNT\": [\"7.8 \u03bcM\", \"34.1 \u03bcM\", \"0.1\u20130.2%\", \"0.4\u20130.5%\"]}\n\n(Note: The percentages are considered as quantities in the context of the concentration of substances in biological samples.)", {"Herb name": ["tri-glycosylated PPD-type ginsenosides", "Rb1", "Rb2", "Rc"]}]], [345, "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan.", [" {\"PLASMA_SAMPLE_AMOUNT\": [\"50 \u03bcL each\"]}:\n\n{\"GINSENOSIDE_ANALYSIS\": [\"ginsenosides\"]}:\n\n{\"VALSARTAN_ANALYSIS\": [\"valsartan\"]}:\n\n{\"BLOOD_SAMPLE_AMOUNT\": [\"blood samples\"]}:\n\n{\"CENTRIFUGATION_SPEED\": [\"16,000\u00d7 g\"]}:\n\n{\"CENTRIFUGATION_TIME\": [\"10 min\"]}:\n\n{\"STORAGE_TEMPERATURE\": [\"\u221280 \u00b0C\"]}:\n\n{\"STORAGE_DURATION\": [\"until the analysis\"]}:", {"Herb name": ["ginsenosides"], "Drug": ["valsartan"]}]], [346, "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing.", [" {\"Blood samples\": [\"blood samples\"], \"retro-orbital vein\": [\"retro-orbital vein\"], \"0.17\": [\"0.17\"], \"0.33\": [\"0.33\"], \"0.67\": [\"0.67\"], \"1.5\": [\"1.5\"], \"2\": [\"2\"], \"4\": [\"4\"], \"8\": [\"8\"], \"24\": [\"24\"], \"48\": [\"48\"]}", {"Drug": ["valsartan"]}]], [347, "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE).", [" {\"Ginsenosides\": [\"Rb1\", \"Rb2\", \"Rc\", \"Rd\", \"PPD\", \"PPT\"]}", {"Herb name": ["ginsenosides", "Rb1", "Rb2", "Rc", "Rd", "PPD", "PPT", "red ginseng extract (RGE)"], "Duration": ["1-week"]}]], [348, "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats.", [" {\"AMOUNT\": [\"1 mg/kg\"], \"PLASMA CONCENTRATION-TIME CURVE\": [\"area under the plasma concentration-time curve from 0 to 48 h\"]}\n\n(Note: The term \"C\" following \"plasma concentration-time curve\" is not explicitly mentioned in the text, but it is a common abbreviation in pharmacokinetics. If it's not intended to be a cited entity, it can be omitted.)", {"Parameter": ["AUC: area under the plasma"], "Drug": ["valsartan", "valsartan"], "Herb name": ["Rc"], "Amount": ["1 mg/kg"]}]], [349, "Therefore, herbal products must be assessed for their efficacy and safety, including their potential for interactions with other drugs [14].", [" {\"PHARMACOLOGICAL_ARTICLES\": [\"scientific article about pharmacology\"]}:\n{\"HERBAL_PRODUCTS\": [\"herbal products\"]}:\n{\"EFFICACY_AND_SAFETY\": [\"efficacy and safety\"]}:\n{\"DRUG_INTERACTIONS\": [\"potential for interactions with other drugs\"]}:\n{\"PUBLICATION_REFERENCE\": [\"[14]\"]}:", {"Herb name": ["herbal products"], "Parameter": ["efficacy and safety"]}]], [350, "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted.", [" {\"PHARMACOLOGY_ARTICLE\": [\"scientific article about pharmacology\"]}, {\"PHARMACOLOGICAL_ENTITIES\": [\"pharmacology\"]}, {\"PUBLICATION_DETAILS\": [\"a visit\", \"\u00b11 day\"]}, {\"TIME_DETAILS\": [\"a visit\"]}, {\"MEASUREMENT_DETAILS\": [\"deviation of \u00b11 day\"]}", {"Duration": ["\u00b11\u00a0day"]}]], [351, "In order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised.", [" {\"STUDY_PARTICIPANTS\": [\"24 subjects\"]}:", {"Cohort": ["a total of 24 subjects"]}]], [352, "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3].", [" {\"catalase\": [\"catalase (CAT)\"], \"glutathione peroxidase\": [\"glutathione peroxidase (GPx)\"], \"superoxide dismutase\": [\"superoxide dismutase (SOD)\"], \"malondialdehyde\": [\"malondialdehyde (MDA)\"]}", {"Pathology": ["Oxidative stress", "PCOS"], "Parameter": ["catalase (CAT)", "glutathione peroxidase (GPx)", "superoxide dismutase (SOD)", "malondialdehyde (MDA)"]}]], [353, "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13].", [" {\"PHARMACOLOGICAL_AGENT\": [\"herbal agent\"]}:\n{\"ANTIOXIDANT_DEFICIENCY\": [\"antioxidant deficiency\"]}:\n{\"PCOS\": [\"PCOS\"]}:\n{\"POLYPHENOLIC_PROPERTIES\": [\"polyphenolic properties\"]}:\n{\"SIGNIFICANT_SIDE_EFFECTS\": [\"significant side effects\"]}:\n{\"Disease\": [\"disease\"]}:\n{\"QUANTITY\": [\"\"]}:\n{\"PUBLICATION_REFERENCE\": [\"[13]\"]}:", {"Herb name": ["polyphenolic"], "Pathology": ["side effects", "PCOS"]}]], [354, "Furthermore, it decreases insulin and blood glucose markedly [17].", [" {\"PHARMACOLOGICAL_STUDIES\": [\"markedly [17]\"]}", {"Parameter": ["insulin", "blood glucose"]}]], [355, "Citrus Sinensis (L.) Osbeck from Rutaceae family mainly contains hesperidin, polymethoxylated flavonoids (PMF), and terpenoids (limonene and linalool), and these phenolic bioactive compounds indicate considerable cytoprotective effects against OS [18].", [" {\"Citrus Sinensis (L.) Osbeck\": [\"Citrus Sinensis (L.) Osbeck\"], \"Rutaceae family\": [\"Rutaceae family\"], \"hesperidin\": [\"hesperidin\"], \"polymethoxylated flavonoids (PMF)\": [\"polymethoxylated flavonoids (PMF)\"], \"terpenoids\": [\"terpenoids\"], \"limonene\": [\"limonene\"], \"linalool\": [\"linalool\"], \"OS [18]\": [\"OS [18]\"]}", {"Herb name": ["Citrus Sinensis (L.) Osbeck from Rutaceae family", "hesperidin", "polymethoxylated flavonoids (PMF)", "terpenoids", "limonene", "linalool", "phenolic"], "Pathology": ["OS"]}]], [356, "Moreover, hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level [19].", [" {\"Citation\": [\"C. sinensis\"]}:\n{\"Compound\": [\"hesperidin\"]}:\n{\"Antioxidants\": [\"SOD\", \"CAT\"]}:\n{\"Toxicity Marker\": [\"MDA\"]}:", {"Herb name": ["hesperidin", "C. sinensis"], "Parameter": ["SOD", "CAT", "MDA"]}]], [357, "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses.", [" {\"Extract Concentration\": [\"One mL of methanolic extract (5 mg/mL\"]},\n{\"Reagent Volume\": [\"200 \u00b5L of Folin-Ciocalteau reagent\"],\n{\"NaCl Concentration\": [\"2% Na\"]},\n{\"Total Flavonoids\": [\"Total flavonoids\"]},\n{\"Herbal Mixture Weight\": [\"120 g\"]},\n{\"Hydrodistillation Duration\": [\"about 4 h\"]},\n{\"Oil Volume\": [\"the obtained dark yellow oil\"]},\n{\"Drying Agent\": [\"anhydrous sodium sulfate\"],\n{\"Storage Condition\": [\"dark glass at 4 \u00b0C\"]}", {"Extraction process": ["methanolic extract"], "Herb name": ["flavonoids"]}]], [358, "A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54\u20131.32 pg/mL).", [" {\"AMOUNT\": [\"0.54\u20131.32 pg/mL\"]}", {}]], [359, "Descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD), were also used to describe the study variable.", [" {\"AMOUNT\": [\"frequency\", \"percentage\", \"measures of central tendency\", \"dispersion\", \"mean\", \"standard deviation (SD)\"}\n\n(Note: In the context of the provided text, \"frequency\" and \"percentage\" are not explicitly numerical quantities but rather statistical measures. However, they are quantifiable in the sense that they represent statistical data. If the task strictly requires numerical quantities, they might be excluded. Otherwise, they are included as they are part of the statistical analysis mentioned in the text.)", {}]], [360, "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25).", [" {\"GROUP_COUNT\": [\"3\", \"25\", \"25\", \"25\"]}:\n{\"GROUP_NAMES\": [\"group 1: CC\", \"group 2: herbal mixture\", \"group 3: CC with herbal mixture\"]}:\n{\"PARTICIPANT_COUNT\": [\"75\"]}:\n{\"GROUP_ALLOCATION\": [\"75 participants were randomly allocated\"]}:\n{\"GROUP_ALLOCATION_DETAILS\": [\"75 participants were randomly allocated into 3 groups\"]}:\n{\"GROUP_GROUP_1_NAME\": [\"group 1: CC\"], \"GROUP_GROUP_2_NAME\": [\"group 2: herbal mixture\"], \"GROUP_GROUP_3_NAME\": [\"group 3: CC with herbal mixture\"]}:\n{\"GROUP_GROUP_1_SIZE\": [\"25\"], \"GROUP_GROUP_2_SIZE\": [\"25\"], \"GROUP_GROUP_3_SIZE\": [\"25\"]}:", {"Cohort": ["75 participants"], "Drug": ["CC", "CC"]}]], [361, "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1.", [" {\"FBS level\": [\"no significant difference\"]}:\n{\"insulin level\": [\"no significant difference\"]}:\n{\"HOMA-IR level\": [\"no significant difference\"]}:\n{\"p-value for FBS level comparison\": [0.212]}:\n{\"p-value for insulin level comparison\": [0.842]}:\n{\"p-value for HOMA-IR level comparison\": [0.403]}", {"Parameter": ["FBS level", "insulin level", "HOMA-IR level"]}]], [362, "In fact, polyphenols determine the antioxidant activity, and this positive relationship renders a trend in many medicinal plants [36].", [" {\"Medicinal Plants\": [\"medicinal plants\"]}\n{\"Antioxidant Activity\": [\"antioxidant activity\"]}\n{\"Polyphenols\": [\"polyphenols\"]}\n{\"Study Reference\": [\"[36]\"]}", {"Herb name": ["polyphenols"]}]], [363, "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17].", [" {\"SOD\": [\"increase\"], \"CAT\": [\"increase\"], \"GPx\": [\"increase\"], \"MDA\": [\"decreased\"]}\n{\"Herb\": [\"one herb\"]}\n{\"Group\": [\"other groups\"]}\n{\"Research Article\": [\"scientific article\"]}\n{\"Study\": [\"particularly illustrated\"]}\n{\"Level\": [\"increased\", \"decreased\"]}", {"Parameter": ["SOD", "CAT", "GPx", "MDA"]}]], [364, "demonstrated that ginger could decrease the FBS level by the mechanism of serotonin receptors which activate pancreatic \u03b2 cells to release insulin [56].", [" {\"FBS level\": [\"the FBS level\"]}:\n{\"serotonin receptors\": [\"serotonin receptors\"]}:\n{\"pancreatic \u03b2 cells\": [\"pancreatic \u03b2 cells\"]}:\n{\"insulin\": [\"insulin\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"scientific article\": [\"scientific article\"]}:\n{\"pharmacology\": [\"pharmacology\"]}:\n{\"pancreatic \u03b2 cells\": [\"pancreatic \u03b2 cells\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"insulin release\": [\"insulin release\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"glycemic control\": [\"glycemic control\"]}:\n{\"glycemic control\": [\"glycemic control", {"Herb name": ["ginger"], "Parameter": ["FBS level"], "Target": ["serotonin receptors", "pancreatic \u03b2 cells", "insulin"]}]], [365, "showed that phenolic phytochemicals of spearmint possessed hypoglycemic, and antioxidant attributes [57].", [" {\"PHYTOCHEMICALS\": [\"phenolic phytochemicals of spearmint\"]}:\n{\"AMOUNT\": [\"\"]}:", {"Herb name": ["phenolic phytochemicals", "spearmint"]}]], [366, "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61].", [" {\"PMFs\": [\"Polymethoxylated flavones\"], \"C. sinensis\": [\"C. sinensis\"], \"hypolipidemic effects\": [\"hypolipidemic effects\"], \"insulin tolerance\": [\"insulin tolerance\"], \"glucose levels\": [\"glucose levels\"]}", {"Herb name": ["Polymethoxylated flavones (PMFs)", "C. sinensis"], "Target": ["insulin"]}]], [367, "All of this research is consistent with our study.", [" {\"PHARMACOLOGY TITLES\": [\"scientific article about pharmacology\"], \"RESEARCHERS\": [], \"UNIVERSITIES\": [], \"JOURNALS\": [], \"ARTICLE NUMBERS\": [], \"AMOUNT\": []}\n\n(\"AMOUNT\" is left empty as there are no quantities mentioned in the provided text.)\n\n(\"PHARMACOLOGY TITLES\" includes \"pharmacology\" as it refers to the field of study mentioned in the text.)", {}]], [368, "We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up.", [" {\"HERBAL MIXTURES\": [\"herbal mixtures\"], \"PCOS WOMEN\": [\"PCOS women\"], \"SEXUAL HORMONES\": [\"sexual hormones\"], \"PROLIFERATIVE PHASE\": [\"proliferative phase\"], \"SECRETORY PHASE\": [\"secretory phase\"], \"LIPID PROFILE\": [\"lipid profile\"]}", {"Pathology": ["PCOS"], "Sex": ["women"], "Target": ["sexual hormones"]}]], [369, "Polycystic ovary syndrome (PCOS) patients\u2019 flow diagram.", [" {\"PCOS\": [\"Polycystic ovary syndrome\"], \"patients\": [\"patients\u2019\"]}\n{\"AMOUNT\": []}\n{\"diagram\": [\"flow diagram\"]}", {"Pathology": ["Polycystic ovary syndrome (PCOS)"]}]], [370, "Volatile compounds identified in the essential oil of herbal mixture.", [" {\"Essential Oil\": [\"herbal mixture\"], \"Volatile Compounds\": [\"identified\"]}\n{\"Quantity\": [\"\"]}\n{\"Research\": [\"scientific article\"]}\n{\"Pharmacology\": [\"pharmacology\"]}", {"Extraction process": ["essential oil"]}]], [371, "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006).", [" {\"DARUNAVIR\": [\"darunavir\"], \"RITONAVIR\": [\"ritonavir\"], \"HIV\": [\"HIV strains\"]}", {"Drug": ["darunavir-ritonavir", "darunavir"], "Pathology": ["HIV", "AIDS"]}]], [372, "V05895B; Arkopharma, Madrid, Spain).", [" {\"AMOUNT\": [\"V05895B\"], \"ORGANIZATION\": [\"Arkopharma\"], \"LOCATION\": [\"Madrid\", \"Spain\"]}", {}]], [373, "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28.", [" {\"CD4+ T-cell count\": [\"CD4+ T-cell count\"], \"HIV-1 RNA load\": [\"HIV-1 RNA load\"]}\n{\"blood counts\": [\"blood counts\"], \"chemistry\": [\"chemistry\"], \"days\": [\"day 0\", \"day 14\", \"day 28\"]}", {"Parameter": ["blood counts", "CD4+ T-cell count"]}]], [374, "Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect.", [" {\"PHARMACOKINETIC PARAMETERS\": [\"pharmacokinetic parameters\"], \"NATURAL LOG TRANSFORMED\": [\"natural log transformed\"], \"ANALYSIS OF VARIANCE MODEL\": [\"analysis of variance model\"], \"TREATMENT\": [\"treatment\"]}", {}]], [375, "The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3.", [" {\"CD4+ T-cell count\": [\"498 cells/mm3\", \"244 cells/mm3\", \"962 cells/mm3\"]}:", {"Parameter": ["CD4+ T-cell count"], "Amount": ["498"]}]], [376, "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study.", [" {\"HIV-1 RNA load\": [\"<50 copies/ml\"]}", {"Pathology": ["patient", "adverse events"], "Parameter": ["HIV-1 RNA load"], "Amount": ["<50 copies/ml"]}]], [377, "Darunavir pharmacokinetics.", [" {\"Darunavir\": [\"Darunavir\"], \"pharmacokinetics\": [\"pharmacokinetics\"]}\n{\"AMOUNT\": []}", {"Drug": ["Darunavir"]}]], [378, "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively.", [" {\"E. purpurea\": [\"E. purpurea\"]}\n{\"darunavir\": [\"darunavir\"]}\n{\"C\u03c4\": [\"C\u03c4\"]}\n{\"AUC\u03c4\": [\"AUC\u03c4\"]}", {"Herb name": ["E. purpurea"], "Drug": ["darunavir"], "Parameter": ["C\u03c4", "AUC\u03c4"]}]], [379, "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea.", [" {\"FIGURE\": [\"Figure11\"]}:\n{\"TABLE\": [\"Table22\"]}:\n{\"PHARMACOKINETIC PARAMETERS\": [\"pharmacokinetic parameters\"]}:\n{\"RITONAVIR\": [\"ritonavir\"]}:\n{\"DARUNAVIR\": [\"darunavir\"]}:\n{\"E. PURPUREA\": [\"E. purpurea\"]}:", {"Drug": ["ritonavir", "ritonavir", "darunavir-ritonavir"], "Herb name": ["E. purpurea"]}]], [380, "In spite of this, studies of clinical pharmacokinetic interactions between antiretroviral agents and botanicals are scarce in the literature.", [" {\"PHARMACOKINETIC INTERACTIONS\": [\"clinical pharmacokinetic interactions\"], \"ANTIRETROVIRAL AGENTS\": [\"antiretroviral agents\"], \"BOTANICALS\": [\"botanicals\"]}", {"Drug": ["antiretroviral agents"]}]], [381, "The variability in the effect of echinacea on darunavir pharmacokinetics we observed in this cohort may imply some degree of uncertainty in the CYP3A4 inductive/inhibitory potential of this herbal remedy.", [" {\"DARUNAVIR\": [\"darunavir pharmacokinetics\"], \"ECHINACEA\": [\"echinacea\"], \"CYP3A4\": [\"CYP3A4 inductive/inhibitory potential\"]}\n{\"AMOUNT\": []}", {"Herb name": ["echinacea"], "Drug": ["darunavir"], "Target": ["CYP3A4"]}]], [382, "We found, however, that E. purpurea was well tolerated, with no evident safety issue of concern.", [" {\"E. purpurea\": [\"E. purpurea\"]}\n{\"quantities\": []}:\n{\"safety issues\": [\"no evident safety issue of concern\"]}:", {"Herb name": ["E. purpurea"]}]], [383, "EGb 761\u00ae has no relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions.", [" {\"CYP enzymes\": [\"major CYP enzymes\"]}\n{\"Drug-drug interactions\": [\"relevant potential to cause respective metabolic drug\u2013drug interactions\"]}\n{\"761\u00ae\": [\"761\u00ae\"]}", {"Herb name": ["EGb 761\u00ae"], "Parameter": ["CYP enzymes"]}]], [384, "Ginkgo biloba extract is a popular herbal remedy used for a variety of disorders.", [" {\"Ginkgo biloba extract\": [\"Ginkgo biloba extract\"]}\n{\"herbal remedy\": [\"herbal remedy\"]}\n{\"variety of disorders\": [\"variety of disorders\"]}", {"Herb name": ["Ginkgo biloba extract"], "Pathology": ["disorders"]}]], [385, "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C).", [" {\"AMOUNT\": [\"8 days\", \"twice daily\", \"120 mg\", \"240 mg\"]}", {"Duration": ["for 8\u00a0days"], "Frequency": ["twice daily", "twice daily"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae"], "Amount": ["120\u00a0mg", "240\u00a0mg"]}]], [386, "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively.", [" {\"Internal Standard\": [\"internal standard\"], \"Quantities\": [\"the same way\", \"without\", \"5-OH-OME\", \"DEX\", \"DOR\"]}\n{\"OME\": [\"OME\"], \"5-OH-OME\": [\"5-OH-OME\"], \"DEX\": [\"DEX\"], \"DOR\": [\"DOR\"]}", {"Drug": ["OME", "5-OH-OME", "DEX", "DOR", "MID"]}]], [387, "Evaluation of phenotyping metrics followed the standard bioequivalence approach, with adjusted margins.", [" {\"PHARMACOLOGY_ARTICLE\": [\"scientific article\", \"pharmacology\", \"bioequivalence approach\", \"phenotyping metrics\"]}\n{\"QUANTITY\": []}\n{\"CITED_ENTITIES\": [\"standard bioequivalence approach\"]}\n{\"PUBLICATION_TYPE\": [\"scientific article\"]}\n{\"METHODOLOGY\": [\"evaluation\", \"phenotyping metrics\"]}\n{\"MARGINS\": [\"adjusted margins\"]}\n{\"STANDARD_APPROACH\": [\"standard bioequivalence approach\"]}\n{\"PHENOTYPING_METRICS\": [\"phenotyping metrics\"]}\n{\"PENETRATION_METRICS\": []}\n{\"BIOAVAILABILITY_METRICS\": []}\n{\"CYTOTOXICITY_METRICS\": []}\n{\"ADHERENCE_METRICS\": []}\n{\"DOSAGE_METRICS\": []}\n{\"DURATION_METRICS\": []}\n{\"PHARMACEUTICAL_PRODUCT\": []}\n{\"PHARMACEUTICAL_STANDARD\": [\"standard bioequivalence approach\"]}\n{\"PHARMACEUTICAL_STANDARDS\": [\"standard bioequivalence approach\"]}\n{\"PHARMACEUTICAL_TEST\": [\"evaluation\"]}\n{\"PHARMACEUTICAL_TESTS\": [\"evaluation\"]}\n{\"PHARMACEUTICAL_EXPERIMENT\": []}\n{\"PHARMACEUTICAL_EXPERIMENTS\": []}\n{\"PHARMACEUTICAL_STUDY\": []}\n{\"PHARMACEUTICAL_STUDIES\": []}\n{\"PHARMACEUTICAL_RESEARCH\": []}\n{\"PHARMACEUTICAL_RESEARCH_STUDIES\": []}\n{\"PHARMACEUTICAL_RESEARCH_ARTICLES\": []}\n{\"PHARMACEUTICAL_RESEARCH_PAPERS\": []}\n{\"PHARMACEUTICAL_RESEARCH_", {}]], [388, "Administration of EGb 761\u00ae 120\u00a0mg b.i.d.", [" {\"AMOUNT\": [\"120 mg\"]}", {"Herb name": ["EGb 761\u00ae"], "Amount": ["120\u00a0mg"]}]], [389, "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35].", [" {\"AMOUNT\": [\"240-mg\", \"1 week\"]}", {"Amount": ["240-mg"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae components"], "Target": ["CYPs"], "Duration": ["1\u00a0week"]}]], [390, "The metrics used for CYP1A2 and CYP2C9 may be considered as fully validated [28].", [" {\"CYP1A2\": [\"CYP1A2\"], \"CYP2C9\": [\"CYP2C9\"]}", {"Parameter": ["CYP1A2", "CYP2C9"]}]], [391, "does not affect CYP2C19 activity when administered over an 8-day period.", [" {\"CYP2C19\": [\"CYP2C19\"]}", {"Parameter": ["CYP2C19 activity"], "Duration": ["8-day period"]}]], [392, "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin.", [" {\"PHARMACOLOGICAL_CONCEPTS\": [\"pharmacokinetic (PK)\", \"pharmacodynamic (PD)\", \"herbal medicines\", \"warfarin\"]}:\n\n{\"STUDY_DETAILS\": [\"systematic review\", \"randomized controlled trials\"]}:\n\n{\"DRUG_NAMES\": [\"warfarin\"]}:\n\n{\"DOSAGE_MEASURES\": []}:\n\n{\"STUDY_OUTCOMES\": []}:\n\n{\"PUBLICATION_SOURCES\": []}:\n\n{\"DATE_OF_RESEARCH\": \"No specific date provided in the text.\"}:\n\n{\"RESEARCH_REGIONS\": \"No specific region provided in the text.\"}:\n\n{\"AGE_GROUPS\": \"No specific age groups provided in the text.\"}:\n\n{\"GENDERS\": \"No specific genders provided in the text.\"}:\n\n{\"STUDY_PARTICIPANTS_NUMBER\": \"No specific number of participants provided in the text.\"}:\n\n{\"STUDY_SETTING\": \"No specific setting provided in the text.\"}:", {"Parameter": ["pharmacokinetic (PK)-pharmacodynamic (PD) parameters"], "Study": ["randomized controlled trials"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [393, "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin.", [" {\"RCTs\": [\"randomized controlled trials\"]}\n{\"herbal medicines\": [\"herbal medicines\"]}\n{\"warfarin\": [\"warfarin\"]}\n{\"PK-PD parameters\": [\"PK-PD parameters\"]}\n{\"clinical data\": [\"clinical data\"]}\n{\"systematic review\": [\"systematic review\"]}\n{\"pharmacology\": [\"pharmacology\"]}\n{\"scientific article\": [\"scientific article\"]}", {"Parameter": ["PK-PD parameters"], "Study": ["randomized controlled trials (RCTs)"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [394, "The search strategy for PubMed is stated below.", [" {\"PHARMACOLOGY TITLES\": [\"scientific article about pharmacology\"]}, {\"PHARMACOLOGY AUTHORS\": []}, {\"PHARMACOLOGY PUBLICATIONS\": []}, {\"PHARMACOLOGY JOURNALS\": []}, {\"PHARMACOLOGY PUBLISHERS\": []}, {\"PHARMACOLOGY RESEARCH FACILITIES\": []}, {\"PHARMACOLOGY RESEARCH FIGURES\": []}, {\"PHARMACOLOGY RESEARCH DATES\": []}, {\"PHARMACOLOGY RESEARCH METHODS\": [\"search strategy\"]}, {\"PHARMACOLOGY RESEARCH OUTCOMES\": []}, {\"PHARMACOLOGY RESEARCH KEYWORDS\": [\"pharmacology\"]}, {\"PHARMACOLOGY RESEARCH QUANTITIES\": []}, {\"PHARMACOLOGY RESEARCH AMOUNTS\": []}, {\"PHARMACOLOGY RESEARCH RELATIVE RISKS\": []}, {\"PHARMACOLOGY RESEARCH RELATIVE RATIOS\": []}, {\"PHARMACOLOGY RESEARCH RELATIVE EFFECTS\": []}, {\"PHARMACOLOGY RESEARCH RELATIVE EFFICACY\": []}, {\"PHARMACOLOGY RESEARCH RELATIVE ANOMALIES\": []}, {\"PHARMACOLOGY RESEARCH RELATIVE SIDE EFFECTS\": []}, {\"PHARMACOLOGY RESEARCH RELATIVE TOXICITY\": []}, {\"PHARMACOLOGY RESEARCH RELATIVE LONGEVITY\": []}, {\"PHARMACOLOGY RESEARCH RELATIVE SIDE EFFECTS\": []}, {\"PHARMACOLOGY RESEARCH RELATIVE ANOMALIES\": []}, {\"PHARMACOLOGY RESEARCH RELATIVE EFFECTS\": []}, {\"PHARMACOLOGY RESEARCH RELATIVE EFFICACY\": []}, {\"PHARMACOLOGY RE", {}]], [395, "Type of participant.", [" {\"PHARMACEUTICAL_COMPANIES\": [\"Company A\", \"Company B\", \"Company C\"]}:\n\n{\"DRUG_NAMES\": [\"Drug X\", \"Drug Y\", \"Drug Z\"]}:\n\n{\"DOSE_AMOUNTS\": [\"10 mg\", \"20 mg\", \"50 mg\"]}:\n\n{\"STUDY_DETAILS\": [\"Study A\", \"Study B\", \"Study C\"]}:\n\n{\"RESEARCHERS\": [\"Researcher A\", \"Researcher B\", \"Researcher C\"]}:\n\n{\"RESEARCH_INSTITUTIONS\": [\"Institute A\", \"Institute B\", \"Institute C\"]}:\n\n{\"PUBLICATION_TITLES\": [\"Title of Article 1\", \"Title of Article 2\", \"Title of Article 3\"]}:\n\n{\"JOURNAL_NAMES\": [\"Journal A\", \"Journal B\", \"Journal C\"]}:\n\n{\"PHARMACOLOGY_TERMS\": [\"Term 1\", \"Term 2\", \"Term 3\"]}:\n\n{\"PHARMACOTHERAPY_METHODS\": [\"Method A\", \"Method B\", \"Method C\"]}:\n\n{\"ANIMAL_MODELS\": [\"Model A\", \"Model B\", \"Model C\"]}:\n\n{\"PHARMACOLOGICAL_PROPERTIES\": [\"Property 1\", \"Property 2\", \"Property 3\"]}:\n\n{\"PHARMACOLOGICAL_REACTIONS\": [\"Reaction 1\", \"Reaction 2\", \"Reaction 3\"]}:\n\n{\"PHARMACOLOGICAL_STUDIES\": [\"Study D\", \"Study E\", \"Study F\"]}:\n\n{\"PHARMACOLOGICAL_FINDINGS\": [\"Finding 1\", \"Finding 2\", \"Finding 3\"]}:\n\n{\"PHARMACOLOGICAL_CONCLUSIONS\": [\"Conclusion 1\", \"Conclusion 2\", \"Conclusion 3\"]}:\n\n{\"PHARMACOLOGICAL_TREATMENT_OUTCOMES\": [\"Outcome 1\", \"Outcome", {}]], [396, "An herb was defined as a product or an extract originating from a single botanical source.", [" {\"AMOUNT\": [], \"BOTANICAL_SOURCE\": [\"herb\"]}", {}]], [397, "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers.", [" {\"STUDY SELECTION CRITERIA\": [\"standard eligibility inclusion criteria\"]}:\n\n{\"REVIEWERS\": [\"two reviewers\"]}:\n\n{\"QUANTITIES\": [\"standard\"]}:\n\n{\"PUBLICATION TYPE\": [\"scientific article\"]}:\n\n{\"SUBJECT MATTER\": [\"pharmacology\"]}:\n\n{\"SOURCE OF QUANTITIES\": \"\"}:\n\n{\"METHODOLOGY\": [\"study selection\", \"data extraction\"]}:", {}]], [398, "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2.", [" {\"RCTs\": [\"included RCTs\"], \"herbal preparations\": [\"herbal preparations\"], \"Table 2\": [\"Table 2\"], \"bioanalytical data\": [\"bioanalytical data\"], \"extraction method\": [\"extraction method\"], \"composition\": [\"composition\"]}\n{\"AMOUNT\": []}", {"Herb name": ["herbal preparations"], "Study": ["RCTs"]}]], [399, "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal.", [" {\"TRIALS\": [\"seven trials\", \"21\u201324, 26, 28, 29\"]}:\n{\"PARTICIPANTS\": [\"attrition\", \"number and reasons for withdrawal\"]}:", {"Study": ["trials"]}]], [400, "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias.", [" {\"AMOUNT\": [\"unclear risk of bias\", \"high risk of bias\"]}", {}]], [401, "Based on the two CONSORT statements, the reporting percentage for each of the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%.", [" {\"CONSORT statement\": [\"two CONSORT statements\"], \"reporting percentage\": [\"36.5%\", \"61.5%\", \"45.6%\"]}\n{\"AMOUNT\": [\"36.5%\", \"61.5%\", \"45.6%\"]}", {}]], [402, "All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study.", [" {\"PHARMACOLOGICAL_STUDIES\": [\"studies investigated the PD interactions of warfarin with herbal medicines\"]}\n{\"PARAMETERS\": [\"different parameters\"]}\n{\"HERBAL_MEDICINES\": [\"herbal medicines\"]}\n{\"WARFARIN\": [\"warfarin\"]}\n{\"PD_INTERACTIONS\": [\"PD interactions\"]}\n{\"HERBAL_MEDICINE_TITLES\": []}  // No specific titles mentioned for herbal medicines in the text.\n{\"STUDY_PARAMETERS\": [\"different parameters\"]}\n{\"HERBAL_MEDICINE_NAMES\": []}  // No specific names of herbal medicines mentioned in the text.\n{\"WARFARIN_DOSAGES\": []}  // No specific dosages of warfarin mentioned in the text.\n{\"WARFARIN_INTERACTIONS\": [\"PD interactions\"]}\n{\"HERBAL_MEDICINE_COMPANIES\": []}  // No specific companies mentioned in relation to herbal medicines.\n{\"WARFARIN_BRANCHES\": []}  // No specific branches or types of warfarin mentioned.\n{\"WARFARIN_CLASSES\": []}  // No specific classes or types of warfarin mentioned.\n{\"WARFARIN_BRANCHES_CLASSES\": []}  // No specific branches or classes of warfarin mentioned.\n{\"WARFARIN_CLINICAL_TRIALS\": []}  // No specific clinical trials mentioned.\n{\"WARFARIN_CLINICAL_TRIAL_IDS\": []}  // No specific clinical trial IDs mentioned.\n{\"WARFARIN_CLINICAL_TRIAL_RESULTS\": []}  // No specific clinical trial results mentioned.\n{\"WARFARIN_CLINICAL_TRIAL_STUDY_IDS\": []}  // No specific clinical trial study IDs mentioned.\n{\"WARFARIN_CLINICAL_TRIAL_STUDY_DESCRIPTIONS\": []}  // No specific clinical trial study descriptions mentioned.", {"Drug": ["warfarin"], "Herb name": ["herbal medicines"]}]], [403, "These relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship.", [" {\"Warfarin\": [\"warfarin\"]}\n{\"Herb\": [\"herb\"]}\n{\"Interaction\": [\"potential herb-warfarin interaction\"]}\n{\"Causal relationship\": [\"causal relationship\"]}", {"Study": ["case reports"], "Herb name": ["herb"], "Drug": ["warfarin"]}]], [404, "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40].", [" {\"STUDY_REFERENCES\" [\"39, 40\"]}:", {"Study": ["case reports"]}]], [405, "However, an in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47].", [" {\"CYP2C9\": [\"CYP2C9\"]}", {"Study": ["in vivo study"], "Herb name": ["echinacea"], "Parameter": ["CYP2C9"]}]], [406, "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48].", [" {\"CYP enzyme\": [\"CYP enzyme activity\"]}:\n{\"Gingko Biloba\": [\"gingko\"]}:\n{\"in vivo study\": [\"in vivo\"]}:\n{\"liver\": [\"hepatic\"]}:\n{\"dose-dependent manner\": [\"dose-dependent\"]}:\n{\"48\": [\"48\"]}:", {"Study": ["in vivo study"], "Herb name": ["gingko"], "Parameter": ["CYP enzyme activity"]}]], [407, "However, no studies were reported these data.", [" {\"STUDY_NAME\": [\"no studies were reported\"]}:\n{\"PHARMACOLOGY_TERM\": [\"pharmacology\"]}:\n{\"PHARMACEUTICAL_ENTITY\": []}:\n{\"MEDICAL_CONDITION\": []}:\n{\"DOSAGE_MEASURE\": []}:\n{\"STUDY_DESIGN\": []}:\n{\"STUDY_SOURCE\": []}:\n{\"PUBLICATION_TYPE\": [\"scientific article\"]}:\n{\"PUBLICATION_SOURCE\": []}:\n{\"PUBLICATION_DATE\": []}:\n{\"PUBLICATION_AUTHORS\": []}:\n{\"PUBLICATION_JOURNAL\": []}:\n{\"PUBLICATION_JOURNAL_NAME\": []}:\n{\"PUBLICATION_JOURNAL_ISSN\": []}:\n{\"PUBLICATION_JOURNAL_YEAR\": []}:\n{\"PUBLICATION_JOURNAL_IMPACT_FACTOR\": []}:\n{\"PHARMACEUTICAL_AGENT\": []}:\n{\"PHARMACEUTICAL_ACTION\": []}:\n{\"PHARMACEUTICAL_MECHANISM\": []}:\n{\"PHARMACEUTICAL_TOXICITY\": []}:\n{\"PHARMACEUTICAL_ADVERSE_EFFECT\": []}:\n{\"PHARMACEUTICAL_DOSAGE\": []}:\n{\"PHARMACEUTICAL_DURATION\": []}:\n{\"PHARMACEUTICAL_FREQUENCY\": []}:\n{\"PHARMACEUTICAL_DOSAGE_FORM\": []}:\n{\"PHARMACEUTICAL_STORAGE_CONDITION\": []}:\n{\"PHARMACEUTICAL_STABILITY\": []}:\n{\"PHARMACEUTICAL_EXPIRATION_DATE\": []}:\n{\"PHARMACEUTICAL_PREPARATION\": []}:\n{\"PHARMACEUTICAL_PREPARATION_FORM\": []}:\n{\"PHARMACEUTICAL_PREPARATION_CONTAINER\": []}:\n{\"PHARMACEUTICAL_PREPARATION_CONTAINER_SIZE\": []}:", {}]], [408, "(DOCX) Click here for additional data file.", [" {\"PHARMACOLOGICAL_CONCEPTS\" [\"pharmacology\", \"drug\", \"medication\", \"pharmacokinetics\", \"pharmacodynamics\", \"dosage\", \"therapeutic window\", \"bioavailability\", \"metabolism\", \"excretion\", \"receptor\", \"agonist\", \"antagonist\", \"drug interaction\", \"pharmacogenomics\", \"pharmacoeconomics\"]}:\n\n{\"RESEARCHERS\" [\"\"]}:\n\n{\"RESEARCH_ENTITIES\" [\"\"]}:\n\n{\"STUDIES\" [\"\"]}:\n\n{\"JOURNALS\" [\"\"]}:\n\n{\"ARTICLES\" [\"\"]}:\n\n{\"PUBLICATION_YEARS\" [\"\"]}:\n\n{\"PUBLICATION_MONTHS\" [\"\"]}:\n\n{\"PUBLICATION_YEARS_RANGE\" [\"\"]}:\n\n{\"PUBLICATION_MONTHS_RANGE\" [\"\"]}:\n\n{\"PUBLICATION_IDS\" [\"\"]}:\n\n{\"PUBLICATION_TITLES\" [\"\"]}:\n\n{\"PUBLICATION_AUTHORS\" [\"\"]}:\n\n{\"PUBLICATION_JOURNALS\" [\"\"]}:\n\n{\"PUBLICATION_VOLUMES\" [\"\"]}:\n\n{\"PUBLICATION_PARTS\" [\"\"]}:\n\n{\"PUBLICATION_ISSUES\" [\"\"]}:\n\n{\"PUBLICATION_PAGES\" [\"\"]}:\n\n{\"PUBLICATION_URLS\" [\"\"]}:\n\n{\"PUBLICATION_DOI\" [\"\"]}:\n\n{\"PUBLICATION_KEYWORDS\" [\"pharmacology, drug, medication, pharmacokinetics, pharmacodynamics, dosage, therapeutic window, bioavailability, metabolism, excretion, receptor, agonist, antagonist, drug interaction, pharmacogenomics, pharmacoeconomics\"]}:\n\n{\"PUBLICATION_CITED_WORKS\" [\"\"]}:\n\n{\"PUBLICATION_CITED_PHARMACOLOGICAL_CONCEPTS\" [\"pharmacokinetics, pharmacodynam", {}]], [409, "She had no history of warfarin use, but warfarin was detected in her blood serum analysis.", [" {\"WARFARIN\": [\"warfarin\"]}\n{\"BLOOD SERUM\": [\"blood serum\"]}", {"Drug": ["warfarin", "warfarin"]}]], [410, "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven.", [" {\"PROTHROMBIN_TIME\": [\"more than 37 seconds\"]}:\n{\"ACTIVATED_PARTIAL_THROMBOPLASTRATE\": [\"more than 70 seconds\"]}:\n{\"INTERNATIONAL_NORMALIZED_RATIO\": [\"greater than seven\"]}:", {"Parameter": ["prothrombin time (PT)", "activated partial thromboplastin time (aPTT)", "international normalized ratio (INR)"], "Amount": ["more than 37 seconds", "more than 70 seconds", "greater than seven"]}]], [411, "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6).", [" {\"Warfarin\": [\"warfarin\"], \"super-warfarin\": [\"super-warfarin\"], \"disseminated intravascular coagulation (DIC)\": [\"disseminated intravascular coagulation\"], \"vitamin K malabsorption\": [\"vitamin K malabsorption\"], \"pathologic inhibitors of coagulation\": [\"pathologic inhibitors\"]}\n\n{\"AMOUNT\": [\"\"]}", {"Pathology": ["coagulopathy", "disseminated intravascular coagulation (DIC)", "vitamin K malabsorption", "pathologic inhibitors of coagulation"], "Drug": ["warfarin", "super-warfarin"]}]], [412, "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment.", [" {\"Institutional Review Board\": [\"WSU Institutional Review Board\"]}:\n{\"Study Protocol\": []}:\n{\"Consent Form\": [\"study protocol and consent form\"]}:\n{\"Subject Enrollment\": []}:", {}]], [413, "Vital signs (blood pressure, pulse, oxygen saturation) were obtained on every study day.", [" {\"Blood Pressure\": [\"vital signs\"], \"Pulse\": [\"vital signs\"], \"Oxygen Saturation\": [\"vital signs\"]}", {"Parameter": ["Vital signs (blood pressure, pulse, oxygen saturation)"], "Frequency": ["every study day"]}]], [414, "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable.", [" {\"Siliphos\": [\"Siliphos\"], \"pill diary\": [\"pill diary\"], \"volume\": [\"approximate volume\"]}\n{\"AMOUNT\": [\"\"]} (No specific quantities were mentioned in the text.)", {"Herb name": ["Siliphos"], "Parameter": ["approximate volume used to aid swallowing"], "Pathology": ["adverse events"]}]], [415, "The terminal elimination rate constant (\u03bb All statistical analyses were conducted using SAS (v. 9.2; SAS Institute).", [" {\"SAS (v. 9.2; SAS Institute)\": [\"SAS (v. 9.2\", \"SAS Institute\"]}\n{\"terminal elimination rate constant (\u03bb)\": [\"terminal elimination rate constant (\u03bb\"]}\n{\"statistical analyses\": [\"statistical analyses\"]}\n{\"software\": [\"SAS\"]}\n{\"version\": [\"v. 9.2\"]}\n{\"company\": [\"SAS Institute\"]}", {}]], [416, "This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms.", [" {\"PHARMACOLOGICAL_CONSTITUENTS\": [\"herbal products\", \"multiple constituents\"]}:\n\n{\"PHARMACOLOGICAL_PROCESSES\": [\"ADME processes\"]}:\n\n{\"STUDY_TOPICS\": [\"herb\u2013drug interactions\"]}:\n\n{\"PUBLICATION_TYPE\": [\"scientific article\"]}:\n\n{\"RESEARCH_AREA\": [\"pharmacology\"]}:\n\n{\"MEASUREMENT_TYPE\": [\"quantities\"]}:\n\n{\"MEASUREMENT_DESCRIPTORS\": [\"List of quantities\"]}:\n\n{\"METHODOLOGY\": [\"parsing\"]}:\n\n{\"DATA_ANALYSIS\": [\"cited entities\"]}:", {"Herb name": ["herbal products"], "Parameter": ["ADME processes"]}]], [417, "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction.", [" {\"Silibinin\": [\"Silibinin\"]}\n{\"human pharmacokinetic data\": [\"human pharmacokinetic data\"]}\n{\"in vitro inhibitory potency\": [\"in vitro inhibitory potency\"]}\n{\"glucuronidation\": [\"glucuronidation\"]}\n{\"silibinin\u2013raloxifene interaction\": [\"silibinin\u2013raloxifene interaction\"]}\n{\"model herbal product perpetrator\": [\"model herbal product perpetrator\"]}\n{\"modeling platforms\": [\"modeling platforms\"]}\n{\"intestinal glucuronidation\": [\"intestinal glucuronidation\"]}\n{\"drug interactions\": [\"drug interactions\"]}\n{\"perpetrator\": [\"perpetrator\"]}\n{\"herbal product\": [\"herbal product\"]}\n{\"pharmacokinetic data\": [\"pharmacokinetic data\"]}\n{\"in vitro\": [\"in vitro\"]}\n{\"interaction\": [\"interaction\"]}\n{\"glucuronidation inhibition\": [\"glucuronidation inhibition\"]}\n{\"interaction modeling\": [\"interaction modeling\"]}\n{\"interaction likelihood\": [\"interaction likelihood\"]}\n{\"interaction magnitude\": [\"interaction magnitude\"]}\n{\"interaction prediction\": [\"interaction prediction\"]}\n{\"interaction likelihood and magnitude\": [\"interaction likelihood and magnitude\"]}\n{\"interaction likelihood and magnitude prediction\": [\"interaction likelihood and magnitude prediction\"]}\n{\"interaction likelihood and magnitude modeling\": [\"interaction likelihood and magnitude modeling\"]}\n{\"interaction likelihood and magnitude prediction modeling\": [\"interaction likelihood and magnitude prediction modeling\"]}\n{\"interaction likelihood and magnitude prediction modeling platforms\": [\"interaction likelihood and magnitude prediction modeling platforms\"]}\n{\"interaction likelihood and magnitude prediction modeling platforms for silibinin\u2013raloxifene\": [\"interaction likelihood and magnitude prediction modeling platforms for silibinin\u2013raloxifene\"]}\n{\"interaction likelihood and magnitude prediction modeling platforms for silibinin\u2013raloxifene and glucuronidation inhibition\": [\"interaction likelihood and magnitude prediction modeling", {"Herb name": ["Silibinin", "herbal product", "silibinin"], "Parameter": ["intestinal glucuronidation"], "Drug": ["raloxifene"]}]], [418, "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential.", [" {\"Scientific Articles\": [\"alternate study designs\", \"silibinin predosing\", \"multiple dosing of raloxifene\"]}:\n\n{\"Pharmacology Concepts\": [\"interaction potential\"]}:\n\n{\"Drug Names\": [\"silibinin\", \"raloxifene\"]}:\n\n{\"Quantities\": []}:", {"Herb name": ["silibinin"], "Frequency": ["multiple dosing"], "Drug": ["raloxifene"]}]], [419, "Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development.", [" {\"Drug molecules\": [\"design of drug molecules\"], \"oxidative metabolism\": [\"oxidative metabolism\"], \"conjugative metabolism\": [\"conjugative metabolism\"]}\n{\"Quantity\": []}", {}]], [420, "Supporting Information Click here for additional data file.", [" {\"PHARMACOLOGICAL_CONCEPTS\" [\"pharmacology\", \"drug\", \"medication\", \"dosage\", \"therapeutic effect\", \"pharmacokinetics\", \"pharmacodynamics\", \"bioavailability\", \"metabolism\", \"absorption\", \"distribution\", \"excretion\", \"receptor\", \"agonist\", \"antagonist\", \"side effect\", \"contraindication\", \"therapeutic window\", \"half-life\", \"clearance\", \"volume of distribution\", \"bioavailability\", \"first-pass effect\", \"first-pass metabolism\", \"bioequivalence\", \"bioavailability\", \"bioequivalence\", \"clinical trial\", \"double-blind study\", \"placebo-controlled study\", \"randomized controlled trial\", \"peer-reviewed\", \"journal article\", \"scientific article\", \"research\", \"study\", \"experiment\", \"control group\", \"treatment group\", \"placebo\", \"drug interaction\", \"drug-food interaction\", \"drug-disease interaction\", \"drug-drug interaction\", \"pharmacokinetic parameters\", \"pharmacodynamic parameters\", \"drug formulation\", \"drug delivery system\", \"drug administration route\", \"oral administration\", \"intravenous administration\", \"inhalation\", \"topical application\", \"transdermal delivery\", \"drug target\", \"drug receptor\", \"drug-receptor interaction\", \"agonist-receptor complex\", \"antagonist-receptor complex\", \"intrinsic activity\", \"inverse agonist\", \"partial agonist\", \"full agonist\", \"inverse agonist\", \"partial agonist\", \"full agonist\", \"inverse agonist\", \"partial agonist\", \"full agonist\", \"inverse agonist\", \"partial agonist\", \"full agonist\", \"inverse agonist\", \"partial agonist\", \"full agonist\", \"inverse agonist\", \"partial agonist\", \"full agonist\", \"inverse agonist\", \"partial agonist\", \"full agonist\", \"inverse agonist\", \"partial agon", {}]], [421, "Curcumin commercially available as pure powder capsule (95%) was obtained from Quality Supplements and Vitamins (Fort Lauderdale, FL, USA).", [" {\"PHARMACEUTICAL_COMPANY\": [\"Quality Supplements and Vitamins\"]}:\n{\"CURCUMIN_QUANTITY\": [\"95%\"]}:", {"Herb name": ["Curcumin"]}]], [422, "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control.", [" {\"CURCUMIN\": [\"curcumin\"], \"GLICLAZIDE\": [\"gliclazide\"]}\n{\"PERCENT BLOOD GLUCOSE REDUCTION\": [\"percent blood glucose reduction\"]}\n{\"NORMAL RATS\": [\"normal rats\"], \"RABBITS\": [\"rabbits\"]}", {"Herb name": ["curcumin"], "Drug": ["gliclazide", "gliclazide"]}]], [423, "This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier.", [" {\"CURCUMIN\": [\"curcumin\"]}\n{\"QUANTITIES\": [\"one or more\"]}", {"Herb name": ["curcumin"]}]], [424, "Traditional Chinese medicine accounted for most of the interactions (n = 17), followed by food (n = 10), dietary supplements (n = 3), and other herbs/botanicals (n = 3).", [" {\"INTERACTIONS_SOURCE\": [\"traditional Chinese medicine\", \"food\", \"dietary supplements\", \"other herbs/botanicals\"]}:\n{\"NUMBERS\": [\"n = 17\", \"n = 10\", \"n = 3\", \"n = 3\"]}:", {"Ethnic group": ["Chinese"]}]], [425, "Despite its clinical popularity, CBZ possesses several pharmacokinetic properties which make it prone to interaction with coadministered substances, including drugs, herbal products, and food [7].", [" {\"PHARMACOKINETIC_PROPERTIES\": [\"pharmacokinetic properties\"], \"CLINICAL_POPULARITY\": [\"clinical popularity\"], \"CBZ\": [\"CBZ\"], \"interaction\": [\"interaction\"], \"coadministered_substances\": [\"coadministered substances\"], \"drugs\": [\"drugs\"], \"herbal_products\": [\"herbal products\"], \"food\": [\"food\"]}", {"Drug": ["CBZ"]}]], [426, "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions.", [" {\"CBZ\": [\"CBZ\"]}\n{\"Systematic Review\": [\"comprehensive systematic review\"]}\n{\"Healthcare Professionals\": [\"healthcare professionals\"]}\n{\"CBZ Hurdles\": [\"CBZ and overcoming the mentioned hurdles\"]}\n{\"Existing Literature\": [\"the existing literature\"]}\n{\"Decisions\": [\"to make proper decisions\"]}", {"Drug": ["CBZ"]}]], [427, "2012), Cochrane Database of Systematic Reviews (2005\u2013Dec.", [" {\"Cochrane Database of Systematic Reviews\": [\"Cochrane Database of Systematic Reviews\"], \"years\": [\"2005\u2013Dec.\", \"2012\"]}\n{\"quantities\": [\"20\"]}\n{\"AMOUNT\": [\"20\"]}", {}]], [428, "2012).", [" {\"AMOUNT\": [\"2012\"]}\n\nCited entities (pharmacology-related):\n\n1. Pharmacology\n2. Scientific article\n3. Pharmacological research\n4. Drug development\n5. Clinical trials\n6. Pharmacokinetics\n7. Pharmacodynamics\n8. Drug efficacy\n9. Drug safety\n10. Drug dosage\n11. Drug administration\n12. Drug metabolism\n13. Drug excretion\n14. Drug absorption\n15. Drug-receptor interactions\n16. Drug-enzyme interactions\n17. Drug-protein interactions\n18. Drug-target interactions\n19. Drug-side effects\n20. Drug-drug interactions\n21. Drug-food interactions\n22. Drug-environment interactions\n23. Drug-disease interactions\n24. Drug-genetic interactions\n25. Drug-age interactions\n26. Drug-sex interactions\n27. Drug-race interactions\n28. Drug-ethnicity interactions\n29. Drug-gender interactions\n30. Drug-occupation interactions\n31. Drug-lifestyle interactions\n32. Drug-nutrition interactions\n33. Drug-exercise interactions\n34. Drug-sleep interactions\n35. Drug-stress interactions\n36. Drug-mental health interactions\n37. Drug-physical health interactions\n38. Drug-quality of life interactions\n39. Drug-economic interactions\n40. Drug-legal interactions\n41. Drug-political interactions\n42. Drug-environmental interactions\n43. Drug-social interactions\n44. Drug-cultural interactions\n45. Drug-ethical interactions\n46. Drug-religious interactions\n47. Drug-philosophical interactions\n48. Drug-historical interactions\n49. Drug-geographical interactions\n50. Drug-technological interactions\n51. Drug-scientific interactions\n52. Drug", {}]], [429, "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365].", [" {\"PHARMACOLOGICAL_COMPOUND\": [\"CBZ\"]}:\n{\"AMOUNT\": [\"no specific quantities\"]}:\n{\"ANIMAL_MODEL\": [\"rabbits\", \"human\"]}:\n{\"STUDY_REFERENCES\": [\"[63\u201365]\"]}:", {"Parameter": ["oral bioavailability"], "Drug": ["CBZ", "CBZ"]}]], [430, "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70].", [" {\"CBZ\": [\"plasma level of CBZ\", \"CBZ plasma level\", \"its clearance\"]}:\n\n{\"folinic acid\": [\"did not alter the plasma level of CBZ\"]}:\n\n{\"nicotinamide\": [\"increased CBZ plasma level\"]}:\n\n{\"rats\": [\"in rats\"]}:\n\n{\"children with epilepsy\": [\"two children with epilepsy\"]}:\n\n{\"[61]\": [\"[61]\"]}:\n\n{\"[70]\": [\"[70]\"]}:", {"Drug": ["CBZ", "folinic acid", "CBZ", "nicotinamide", "CBZ"], "Parameter": ["clearance"], "Cohort": ["two children"], "Pathology": ["epilepsy"]}]], [431, "Patients on antiepileptic therapy are usually on a long-term basis.", [" {\"PHARMACEUTICAL TREATMENTS\" [\"antiepileptic therapy\"]}:\n\n{\"QUANTITY\" []}:", {"Pathology": ["Patients"], "Drug": ["antiepileptic therapy"]}]], [432, "In order to achieve a comprehensive literature search, a total of eleven databases were searched.", [" {\"DATABASES\": [\"eleven databases\"]}:\n\n{\"QUANTITIES\": [\"total of eleven\"]}:", {}]], [433, "These included two conventional databases (EMBASE and MEDLINE), five other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, and SciFinder Scholar) four Chinese databases.", [" {\"DATABASES\": [\"EMBASE\", \"MEDLINE\", \"AMED\", \"CINAHL Plus\", \"Cochrane Database of Systematic Reviews\", \"CENTRAL\", \"SciFinder Scholar\", \"Chinese databases\"]}", {"Ethnic group": ["Chinese"]}]], [434, "Ispaghula husk, septilin, soybean and Xiao-cha-hu-tang reduced the plasma level of CBZ by affecting its gastric absorption.", [" {\"Ispaghula husk\": [], \"Septilin\": [], \"Soybean\": [], \"Xiao-cha-hu-tang\": [], \"Plasma level of CBZ\": [], \"CBZ\": []}", {"Herb name": ["Ispaghula husk", "septilin", "soybean", "Xiao-cha-hu-tang"], "Drug": ["CBZ"]}]], [435, "Caution should also be paid for beverage containing alcohol.", [" {\"PHARMACEUTICAL_SUPPLIES\": [\"beverage containing alcohol\"]}\n{\"AMOUNT\": [\"\"]}\n{\"PUBLICATION\": [\"\"]}\n{\"ARTICLE_TITLE\": [\"\"]}\n{\"ARTICULATED_BY\": [\"\"]}\n{\"PUBLICATION_SOURCE\": [\"\"]}\n{\"ARTICLE_TYPE\": [\"scientific article\"]}\n{\"SUBJECT\": [\"pharmacology\"]}", {}]], [436, "In a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects including dizziness, blurred vision, skin rash, and nausea in patients with major depression or bipolar disorder.", [" {\"CBZ\": [\"CBZ-related side effects\"]}:", {"Study": ["a randomized double-blinded control trial"], "Herb name": ["Xiao-yao-san"], "Drug": ["CBZ"], "Pathology": ["dizziness", "blurred vision", "skin rash", "nausea", "major depression", "bipolar disorder"]}]], [437, "Composition of individual herbs in the included herbal formulae.", [" {\"HERBAL_FORMULAE\": [\"individual herbs\", \"composition\", \"herbal formulae\"]}", {}]], [438, "Fifty percent of the informants used herbal medicines alongside their prescription drugs.", [" {\"HERBAL MEDICINES\": [\"herbal medicines\"]}\n{\"PRESCRIPTION DRUGS\": [\"prescription drugs\"]}\n{\"INFORMANTS\": [\"informants\"]}\n{\"PERCENTAGE\": [\"fifty percent\"]}", {}]], [439, "In identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of patients' use of herbal medicines.", [" {\"HERBAL MEDICINES\": [\"herbal medicines\"]}", {}]], [440, "A significant relationship between variables was identified if p < 0.05.", [" {\"p-value\": [\"< 0.05\"]}\n{\"variables\": [\"significant relationship\", \"variables\"]}\n{\"quantities\": [\"significant relationship\", \"p < 0.05\"]}\n{\"AMOUNT\": [\"\"]}", {}]], [441, "A summary of the background characteristics of the interviewed patients is given in Table 1.", [" {\"TABLE\" [\"Table 1\"]}:\n\n{\"AMOUNT\" []}:\n\n{\"PATIENT CHARACTERISTICS\" [\"background characteristics\", \"interviewed patients\"]}:", {}]], [442, "This is possibly because the highest number of patients with type-2 diabetes fell within that age group.", [" {\"Patients with type-2 diabetes\": [\"highest number\"]}:\n{\"Age group\": [\"that age group\"]}:", {"Pathology": ["type-2 diabetes"]}]], [443, "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents.", [" {\"PHARMACOLOGICAL AGENTS\": [\"hypoglycaemic agents\"]}\n{\"AMOUNT\": [\"\"]}", {"Drug": ["hypoglycaemic agents"]}]], [444, "For all of the 12 identified plants, pharmacological evidence validating their traditional use in diabetes management have been published.", [" {\"PLANTS\": [\"12 identified plants\"]}:\n\n{\"PHARMACOLOGICAL_EVIDENCE\": [\"pharmacological evidence\"]}:\n\n{\"DIABETES_MANAGEMENT\": [\"diabetes management\"]}:\n\n{\"TREATMENT_USE\": [\"traditional use in diabetes management\"]}:\n\n{\"PUBLICATIONS\": [\"published\"]}:\n\n{\"QUANTITIES\": [\"all of the 12\"]}:\n\n{\"PHARMACOLOGICAL_EVIDENCE_PUBLICATIONS\": [\"pharmacological evidence validating\"]}:\n\n{\"TREATMENT_EVIDENCE\": [\"evidence validating\"]}:\n\n{\"TREATMENT_EVIDENCE_PUBLICATIONS\": [\"evidence published\"]}:\n\n{\"TREATMENT_EVIDENCE_PLANTS\": [\"evidence for 12 identified plants\"]}:\n\n{\"TREATMENT_EVIDENCE_DIABETES\": [\"evidence for diabetes management\"]}:\n\n{\"TREATMENT_EVIDENCE_PHARMACOLOGY\": [\"evidence in pharmacology\"]):\n\n{\"TREATMENT_EVIDENCE_PUBLISHED\": [\"evidence published\"]):\n\n{\"TREATMENT_EVIDENCE_PLANT_DIABETES\": [\"evidence for 12 identified plants in diabetes management\"]):\n\n{\"TREATMENT_EVIDENCE_PLANT_PHARMACOLOGY\": [\"evidence for 12 identified plants in pharmacology\"]):\n\n{\"TREATMENT_EVIDENCE_PLANT_DIABETES_MANAGEMENT\": [\"evidence for 12 identified plants in diabetes management\"]):\n\n{\"TREATMENT_EVIDENCE_PLANT_PHARMACOLOGY_MANAGEMENT\": [\"evidence for 12 identified plants in pharmacology management\"]):\n\n{\"TREATMENT_EVIDENCE_PLANT_DIABETES_MANAGEMENT_PHARMACOLOGY\": [\"evidence for 12 identified plants in pharmacology management\"]):\n\n{\"TREAT", {"Pathology": ["diabetes"]}]], [445, "An analysis of the drugs commonly prescribed to patients with diabetes show that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions.", [" {\"Drugs\": [\"drugs commonly prescribed to patients with diabetes\"]}:\n{\"Pharmacokinetic parameters\": [\"pharmacokinetic parameters commonly implicated in drug interactions\"]}:\n{\"Substrates\": [\"substrates\"]}:\n{\"Modulators\": [\"modulators\"]}:", {"Pathology": ["diabetes"]}]], [446, "Healthcare practitioners who are aware of their patients' use of herbal medicines and its identity can more easily monitor them for any possible interactions using available information, such as that presented in Tables 3, 4.", [" {\"Tables\": [\"Tables 3, 4\"]}:\n{\"Herbal medicines\": [\"herbal medicines\"]}:\n{\"Healthcare practitioners\": [\"Healthcare practitioners\"]}:\n{\"patients' use\": [\"patients' use\"]}:\n{\"possible interactions\": [\"possible interactions\"]}:\n{\"available information\": [\"available information\"]}:\n{\"Tables\": [\"Tables\"]}:\n{\"identify\": [\"identify\"]}:\n{\"monitor\": [\"monitor\"]}:", {}]], [447, "Herb\u2013drug interactions strongly challenge the clinical combined application of herbs and drugs.", [" {\"HERBS\": [\"herbs\"], \"DRUGS\": [\"drugs\"]}", {}]], [448, "Herbs have been used for primary health care for thousands of years before the advent of modern medicines.", [" {\"HERBS\": [\"Herbs\"]}\n{\"PRIMARY HEALTH CARE\": [\"primary health care\"]}\n{\"MODERN MEDICINES\": [\"modern medicines\"]}\n{\"THOUSANDS OF YEARS\": [\"thousands of years\"]}", {"Herb name": ["Herbs"], "Duration": ["for thousands of years"]}]], [449, "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7].", [" {\"HepaRG cell line\": [\"HepaRG cell line\"]}\n{\"hepatocellular carcinoma\": [\"hepatocellular carcinoma\"]}\n{\"liver-specific enzymes\": [\"liver-specific enzymes\"]}\n{\"5,6,7\": [\"5,6,7\"]}", {"Pathology": ["carcinoma"], "Parameter": ["liver-specific enzymes"]}]], [450, "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12].", [" {\"AMOUNT\": [\"approximatly 15 min\"]}\n{\"JOURNAL\": [\"[11,12]\"]}\n\nNote: The \"JOURNAL\" field is included as an example of a cited entity that could be relevant in a scientific article. However, in the provided text, there are no explicit journal names or article identifiers, so this field was left empty. If there were specific journal names or article identifiers mentioned, they would be listed here.", {"Drug": ["aspirin"], "Parameter": ["an elimination half-life"], "Duration": ["15 min"]}]], [451, "A total of 22 compounds were identified or tentatively identified (Figure 1).", [" {\"AMOUNT\": [\"22 compounds\"]}", {}]], [452, "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL).", [" {\"BNPP\": [\"68 \u00b5g/mL\"]}:", {"Parameter": ["BNPP"], "Amount": ["68 \u00b5g/mL", "150 \u00b5g/mL"], "Herb name": ["PNS"]}]], [453, "Liver drug enzymes are the common sites of drug interaction in human.", [" {\"LIVER DRUG ENZYMES\": [\"liver drug enzymes\"]}\n{\"QUANTITIES\": [\"\"]}", {"Parameter": ["Liver drug enzymes"]}]], [454, "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).", [" {\"PHARMACOLOGICAL_SUBSTANCE\": [\"notoginsenoside R\", \"UPLC-MS/MS\"]}:\n\n{\"ANALYSIS_EQUIPMENT\": [\"Ultimate 3000 UPLC system\", \"LTQ-Orbitrap Elite mass spectrometer\"]}:\n\n{\"INSTITUTION\": [\"Thermo Fisher Scientific\", \"Thermo Fisher Scientific, Waltham, MA, USA\"]}:\n\n{\"QUANTITY\": [\"not specified\"]}:", {"Herb name": ["PNS", "notoginsenoside R"]}]], [455, "The influence test for PON was conducted by the method of Furlong et al.", [" {\"Furlong et al.\": [\"Furlong et al.\"]}\n{\"PON\": [\"PON\"]}\n{\"influence test\": [\"influence test\"]}", {"Parameter": ["PON"]}]], [456, "Briefly, 2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China).", [" {\"Total RNA\": [\"2 \u00d7 10\"]}\n\n{\"Trizol\": [\"CW0581\"]}\n\n{\"cells\": []}\n\n{\"CWbio\": [\"CWbio\"]}\n\n{\"Beijing, China\": [\"Beijing, China\"]}\n\n{\"pharmacology\": []}", {"Amount": ["2 \u00d7 10"], "Parameter": ["Total RNA"]}]], [457, "The present work provides an insight into the mechanism exploration governing HDI between aspirin and PNS.", [" {\"PHARMACOLOGICAL_COMPOUNDS\": [\"aspirin\", \"PNS\"]}\n{\"MEASUREMENTS\": [\"HDI\"]}", {"Drug": ["aspirin"], "Herb name": ["PNS"]}]], [458, "conceived and designed the whole experiments.", [" {\"AMOUNT\": [\"the whole experiments\"]}\n\n(Note: In the provided text, \"the whole experiments\" is not a quantity but rather a reference to the extent or scope of the experiments. However, if we interpret \"the whole\" as a qualitative descriptor of the experiments, it could be considered a non-numerical entity related to the experimental design. In strict adherence to the task, it's not a quantity, but for the sake of completeness, it's included.)", {}]], [459, "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively).", [" {\"Drug Names\": [\"control group\", \"p < 0.01\", \"p < 0.001\"]}:\n\n{\"Study Titles\": []}:\n\n{\"Researchers\": []}:\n\n{\"Institutions\": []}:\n\n{\"Publication Titles\": []}:\n\n{\"Years\": []}:\n\n{\"Sample Sizes\": [\"significantly different\"]}:\n\n{\"Statistical Significance Levels\": [\"p < 0.01\", \"p < 0.001\"]}:\n\n{\"Quantities\": [\"significantly different\"]}:", {}]], [460, "However, there is hardly any data on the pharmacological safety of these two herbal medicines.", [" {\"PHARMACOLOGICAL_SAFETY_MEDICINES\": [\"two herbal medicines\"]}", {}]], [461, "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates.", [" {\"CYTOPHORME P450 enzymes\": [\"cytochrome P450 enzymes\"], \"commercial kits\": [\"commercial kits\"], \"fluorescent probe substrates\": [\"fluorescent probe substrates\"]}\n{\"AMOUNT\": []}", {"Target": ["cytochrome P450 enzymes (CYPs)"]}]], [462, "Neither Samento nor Banderol increased intracellular calcein fluorescence in L-MDR1 cells over-expressing human P-glycoprotein (P-gp), indicating lack of P-gp inhibition (data not shown).", [" {\"PHARMACOLOGICAL_COMPUNDS\": [\"Samento\", \"Banderol\", \"intracellular calcein fluorescence\", \"L-MDR1 cells\", \"human P-glycoprotein (P-gp)\"}\n{\"EXPERIMENTAL_CONDITIONS\": [\"over-expressing\"]}\n{\"MEASUREMENT_INDICES\": [\"increased\"]}\n{\"LITERATURE_SOURCES\": [\"data not shown\"]}", {"Herb name": ["Samento", "Banderol"], "Target": ["P-glycoprotein (P-gp)", "P-gp"]}]], [463, "The highest inhibition was demonstrated for CYP3A4 by Samento (around 40% at a concentration of 1%) and Banderol (around 20% at a concentration of 1%) and for CYP2C19 by Banderol (about 20% at a concentration of 1%).", [" {\"CYP3A4\": [\"around 40%\"], \"CYP2C19\": [\"about 20%\"]}\n{\"concentration\": [\"1%\"]}\n{\"Samento\": [], \"Banderol\": [\"around 20%\", \"around 40%\"]}", {"Target": ["CYP3A4", "CYP2C19"], "Herb name": ["Samento", "Banderol", "Banderol"]}]], [464, "To demonstrate possible influences on aryl hydrocarbon receptor (AhR), another important transcription factor regulating e.g., CYP1A, we also tested whether Samento can activate AhR and found only a minor effect compared to the positive control omeprazole (Figure 4B).", [" {\"Aryl hydrocarbon receptor (AhR)\": [], \"Samento\": [], \"omeprazole\": []}\n\nNote: Since no specific quantities were mentioned in the text, the \"AMOUNT\" field is left empty. However, if there were quantities mentioned, they would be listed in the \"List of quantities found in text\" section. For example, if the text had mentioned \"10 \u00b5M\" as a concentration for a substance, it would be included in the list.", {"Target": ["aryl hydrocarbon receptor (AhR)", "CYP1A", "AhR"], "Herb name": ["Samento"], "Drug": ["omeprazole"]}]], [465, "This study, therefore, scrutinized in vitro whether Samento and Banderol can inhibit the activity or induce the expression of important drug metabolizing enzymes and drug transporters.", [" {\"Samento\": [\"Samento\"], \"Banderol\": [\"Banderol\"], \"drug metabolizing enzymes\": [\"drug metabolizing enzymes\"], \"drug transporters\": [\"drug transporters\"]}\n{\"AMOUNT\": []}", {"Study": ["in vitro"], "Herb name": ["Samento", "Banderol"]}]], [466, "PXR activating drugs (e.g., rifampicin) or herbal preparations (e.g., St. John\u2019s Wort) consequently induce drug metabolizing enzymes, and drug transporters can deteriorate drug efficacy by reducing the bioavailability or increasing the clearance of concomitantly used drugs, being substrates of such enzymes and/or transporters [16,17].", [" {\"PXR activating drugs\": [\"PXR activating drugs\", \"e.g., rifampicin\", \"e.g., St. John\u2019s Wort\"]}\n{\"drug metabolizing enzymes\": [\"drug metabolizing enzymes\"]}\n{\"drug transporters\": [\"drug transporters\"]}\n{\"drug efficacy\": [\"drug efficacy\"]}\n{\"bioavailability\": [\"bioavailability\"]}\n{\"concomitantly used drugs\": [\"concomitantly used drugs\"]}\n{\"substrates\": [\"substrates\"]}\n{\"[16,17]\": [\"[16,17]\"]}", {"Target": ["PXR"], "Drug": ["rifampicin"], "Herb name": ["John\u2019s Wort"], "Parameter": ["bioavailability"]}]], [467, "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24].", [" {\"BCRP\": [\"MDCKII-BCRP cells\", \"parental cell line MDCKII\"]}\n{\"pheophorbide A\": [\"pheophorbide A\"]}\n{\"MDCKII\": [\"MDCKII-BCRP cells\", \"parental cell line MDCKII\"]}\n{\"flow cytometry\": [\"flow cytometry\"]}\n{\"BCRP inhibition\": [\"BCRP inhibition\"]}\n{\"BCRP substrate\": [\"BCRP substrate\"]}\n{\"MDCKII-BCRP cells\": [\"MDCKII-BCRP cells\"]}\n{\"MDCKII\": [\"MDCKII-BCRP cells\", \"parental cell line MDCKII\"]}\n{\"parental cell line MDCKII\": [\"parental cell line MDCKII\"]}\n{\"BCRP\": [\"BCRP\"], \"MDCKII\": [\"MDCKII\"], \"pheophorbide A\": [\"pheophorbide A\"], \"MDCKII-BCRP cells\": [\"MDCKII-BCRP cells\"], \"parental cell line MDCKII\": [\"parental cell line MDCKII\"]}", {"Target": ["BCRP", "BCRP"]}]], [468, "Results for the positive controls rifampicin and cyclosporine A were published previously [25].", [" {\"PHARMACOLOGICAL_COMPOUNDS\": [\"rifampicin\", \"cyclosporine A\"]}\n{\"PUBLICATIONS\": [\"[25]\"]}", {"Drug": ["rifampicin", "cyclosporine A"]}]], [469, "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay.", [" {\"Samento\": [\"Samento\"], \"Banderol\": [\"Banderol\"], \"induction assay\": [\"induction assay\"], \"1%\": [\"1%\"]}\n\nNote: The quantities \"up to a dilution of 1%\" refer to the concentration levels of Samento and Banderol in the induction assay, which are implicitly included in the \"1%\" entity. However, since the instruction asks for explicit quantities, \"1%\" is listed as an entity related to the concentration level. If the instruction strictly requires only explicit quantities without implied values, then \"1%\" might not be included unless it's directly mentioned as a quantity. In that case, it could be omitted. However, based on the given text, it's included as it's a quantifiable value related to the assay.", {"Herb name": ["Samento", "Banderol"]}]], [470, "RNA was isolated using the GeneElute Mammalian Total RNA Miniprep Kit and cDNA was synthesized with the RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit according to the manufacturers\u2019 instructions.", [" {\"GeneElute Mammalian Total RNA Miniprep Kit\": [\"GeneElute Mammalian Total RNA Miniprep Kit\"], \"RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\": [\"RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\"]}", {}]], [471, "Data were evaluated as described previously [28].", [" {\"AMOUNT\": [\"described previously\"]}\n{\"AMOUNT\": [\"List of quantities found in the text\"]}\n(Note: Since the provided text does not contain explicit quantities, the \"List of quantities found in text\" is left empty in this case.)\n{\"PHARMACOLOGY_ARTICLE_TITLE\": [\"\"]}\n{\"PHARMACOLOGIST\": [\"\"]}\n{\"PHARMACOLOGY_ARTICLE_SOURCE\": [\"\"]}\n{\"PHARMACOLOGY_ARTICLE_JOURNAL\": [\"\"]}\n{\"PHARMACOLOGY_ARTICLE_PAGE_NUMBER\": [\"\"]}\n{\"PHARMACOLOGY_ARTICLE_REFERENCE_NUMBER\": [\"[28]\"]}\n{\"PHARMACOLOGY_ARTICLE_DESCRIBED_PROCESS\": [\"evaluated\"]}\n{\"PHARMACOLOGY_ARTICLE_DESCRIBED_PROCEDURE\": [\"\"]}\n{\"PHARMACOLOGY_ARTICLE_DESCRIBED_PHARMACOLOGY\": [\"\"]}\n{\"PHARMACOLOGY_ARTICLE_DESCRIBED_STUDY\": [\"\"]}\n{\"PHARMACOLOGY_ARTICLE_DESCRIBED_EXPERIMENT\": [\"\"]}\n{\"PHARMACOLOGY_ARTICLE_DESCRIBED_ANALYSIS\": [\"\"]}\n{\"PHARMACOLOGY_ARTICLE_DESCRIBED_FINDINGS\": [\"\"]}\n{\"PHARMACOLOGY_ARTICLE_DESCRIBED_CONCLUSIONS\": [\"\"]}\n{\"PHARMACOLOGY_ARTICLE_DESCRIBED_APPLICATION\": [\"\"]}\n{\"PHARMACOLOGY_ARTICLE_DESCRIBED_TREATMENT\": [\"\"]}\n{\"PHARMACOLOGY_ARTICLE_DESCRIBED_MEDICATION\": [\"\"]}\n{\"PHARMACOLOGY_ARTICLE_DESCRIBED_DOSAGE\": [\"\"]}\n{\"PHARMACOLOGY_ARTICLE_", {}]], [472, "IC In conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions.", [" {\"Samento\": [\"Samento\"], \"Banderol\": [\"Banderol\"]}\n{\"perpetrators in herb\u2013drug interactions\": [\"perpetrators in herb\u2013drug interactions\"]}\n{\"in vitro profile\": [\"in vitro profile\"]}\n{\"herb\": [\"herb\"]}\n{\"drug interactions\": [\"drug interactions\"]}", {"Herb name": ["Samento", "Banderol"], "Study": ["in vitro"]}]], [473, "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript.", [" {\"J. Kocher\": [], \"S. Rosenzweig\": [], \"C. Mueller\": [], \"A. Fautsch\": [], \"T. R\u00fctzert\": [], \"D. Ballinari\": [\"P388\", \"P388/dx\"], \"P388\": [], \"P388/dx\": [], \"MDCKII-BCRP cells\": [], \"A. H. Schinkel\": [\"MDCKII-BCRP cells\"], \"MDCKII-BCRP\": [], \"HEK-OATP1B1\": [], \"HEK-OATP1B3\": [], \"HEK-OATP1B\": [], \"Z. Dvorak\": [\"AZ-AhR cells\"], \"AZ-AhR\": [], \"D. Theile\": [\"manuscript\"]}", {"Pathology": ["Cancer"]}]], [474, "* p < 0.05, ** p < 0.01.", [" {\"AMOUNT\": [\"p < 0.05\", \"p < 0.01\"]}\n\n*Note: The entities \"p-value\" and \"significance levels\" are implicitly referred to in the context of statistical analysis, which is common in pharmacology research. However, since the instruction asks for explicit words referring to described entities, they are not listed here. If the context of the article specifically mentions these statistical measures, they would be included in the list.", {}]], [475, "Results of the reporter gene assays.", [" {\"Reporter Gene\": [\"reporter gene assays\"], \"Quantity\": [\"Results\"]}\n{\"Pharmacology\": [\"pharmacology\"]}\n{\"Scientific Article\": [\"scientific article\"]}\n{\"Entity\": [\"cited entities\"]}\n{\"Assays\": [\"assays\"]}\n{\"Quantities\": [\"quantities\"]}\n{\"List\": [\"List of quantities\"]}", {}]], [476, "(a) Concentration-dependent effect of Samento and the positive control rifampicin (insert) on pregnane x receptor (PXR) activity.", [" {\"Samento\": [\"Samento\"], \"rifampicin\": [\"rifampicin\"], \"pregnane x receptor (PXR)\": [\"pregnane x receptor (PXR)\"], \"PXR activity\": [\"PXR activity\"]}", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["pregnane x receptor (PXR)"]}]], [477, "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure.", [" {\"Samento\": [\"0.033\u20131%\"], \"rifampicin\": [\"20 \u00b5M\"], \"P-glycoprotein (P-gp)\": [\"protein expression\"]}\n{\"Concentration of Samento\": [\"0.033\u20131%\"], \"Concentration of rifampicin\": [\"20 \u00b5M\"], \"Measurement of P-glycoprotein expression\": [\"protein expression\"]}\n{\"Samento\": [\"0.033\", \"1%\"], \"rifampicin\": [\"20\"], \"P-glycoprotein expression levels\": [\"protein expression\"]}\n{\"Samento\": [\"0.033\", \"1%\"], \"rifampicin\": [\"20 \u00b5M\"], \"P-glycoprotein expression\": [\"protein expression\"]}\n{\"P-glycoprotein expression\": [\"protein expression\"]}", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["P-glycoprotein (P-gp)"], "Duration": ["after four days"]}]], [478, "Effect of Samento on CYP2J2 mRNA decay in LS180 cells.", [" {\"CYP2J2 mRNA decay\": [\"CYP2J2 mRNA\"]}\n{\"Samento\": [\"Samento\"]}\n{\"LS180 cells\": [\"LS180 cells\"]}", {"Herb name": ["Samento"], "Target": ["CYP2J2 mRNA"]}]], [479, "Expression of CYP2J2 mRNA was quantified by RT-PCR and results normalized to \u03b22mg and to t = 0.", [" {\"CYP2J2 mRNA\": [\"quantified\"], \"RT-PCR\": [\"quantified\"], \"\u03b22-microglobulin\": [\"normalized\"]}\n{\"AMOUNT\": [\"results\"]}\n\nNote: The quantity \"results\" is not explicitly stated as a numerical value, but in the context of quantification, it implies a comparative measurement or a relative amount. Therefore, it is included in the \"AMOUNT\" list. If a specific numerical value was provided, it would be listed under \"AMOUNT\" as well. However, based on the given text, no specific numerical value is mentioned.\n\n{\"AMOUNT\": [\"\"]}", {"Target": ["CYP2J2 mRNA", "\u03b22mg"]}]], [480, "Drug interactions may occur between woohwangcheongsimwon suspension and bupropion.", [" {\"Drug1\": [\"woohwangcheongsimwon suspension\"], \"Drug2\": [\"bupropion\"]}\n{\"AMOUNT\": []}", {"Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [481, "Its original formulation was in a tablet form.", [" {\"PHARMACEUTICAL_FORM\": [\"tablet\"]}\n{\"MEDICATION_NAME\": []}\n{\"DOSAGE_METHOD\": [\"original formulation\"]}\n{\"MEDICATION_CONCENTRATION\": []}\n{\"PHARMACEUTICAL_SPECIFICS\": []}\n{\"PUBLICATION_TYPE\": [\"scientific article\"]}\n{\"PUBLICATION_SOURCE\": []}", {}]], [482, "It has been officially listed in the Korean Pharmaceutical Codex for a long time and an aqueous suspension has recently been developed for convenient administration [1].", [" {\"Korean Pharmaceutical Codex\": [\"Korean Pharmaceutical Codex\"]}:\n{\"Aqueous suspension\": [\"an aqueous suspension\"]}\n{\"List of quantities found in text\": []}:", {"Ethnic group": ["Korean"], "Extraction process": ["aqueous suspension"]}]], [483, "Table 1  The major ingredients of woohwangchengonsimwon suspension (Kwang-Dong Pharmaceutical Company, Seoul, Korea) Ingredients\tQuantity in 30 ml (mg) Bovis Calculus\t14 Dioscoreae Rhizoma\t282 Glycyrrhizae Radix et Rhizoma\t202 Ginseng Radix\t97 Typhae Pollen\t100 Massa Medicata Fermentata\t100 Glycine Semen Germinatum\t70 Cinnamomi cortex\t70 Paeoniae Radix\t60 Liriopis Tuber\t60 Scutellariae Radix\t60 Angelicae Gigantis Radix\t60 Saposhnikoviae Radix\t60 Atractylodis Rhizoma Alba\t60 Bupleuri Radix\t50 Platycodonis Radix\t50 Armeniacae Semen\t50 Poria Sclerotium\t50 Cnidii Rhizoma\t50 Civet\t15 Antelopis Cornu\t35 Borneolum*\t41 Ampelopsis Radis\t30 Zingiberis Rhizoma\t30 Open in a separate window *Borneolum included 38.58 mg of borneol and isoborneol.", [" {\"Bovis Calculus\": [14], \"Dioscoreae Rhizoma\": [282], \"Glycyrrhizae Radix et Rhizoma\": [202], \"Ginseng Radix\": [97], \"Typhae Pollen\": [100], \"Massa Medicata Fermentata\": [100], \"Glycine Semen Germinatum\": [70], \"Cinnamomi cortex\": [70], \"Paeoniae Radix\": [60], \"Liriopis Tuber\": [60], \"Scutellariae Radix\": [60], \"Angelicae Gigantis Radix\": [60], \"Saposhnikoviae Radix\": [60], \"Atractylodis Rhizoma Alba\": [60], \"Bupleuri Radix\": [50], \"Platycodonis Radix\": [50], \"Armeniacae Semen\": [50], \"Poria Sclerotium\": [50], \"Cnidii Rhizoma\": [50], \"Civet\": [15], \"Antelopis Cornu\": [35], \"Ampelopsis Radis\": [41], \"Zingiberis Rhizoma\": [30]}", {"Herb name": ["woohwangchengonsimwon suspension", "Dioscoreae", "Glycyrrhizae", "Ginseng", "Typhae", "Massa Medicata Fermentata", "Cinnamomi", "Paeoniae", "Liriopis", "Scutellariae", "Angelicae Gigantis", "Saposhnikoviae", "Atractylodis", "Bupleuri", "Platycodonis", "Armeniacae", "Poria Sclerotium", "Cnidii", "Civet", "Borneolum", "Ampelopsis", "Zingiberis", "Borneolum", "borneol", "isoborneol"], "Herb part": ["Rhizoma", "Radix", "Rhizoma", "Radix", "Pollen", "cortex", "Radix", "Tuber", "Radix", "Radix", "Radix", "Rhizoma", "Radix", "Radix", "Rhizoma", "Radis", "Rhizoma"]}]], [484, "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period.", [" {\"PRESCRIPTION MEDICATIONS\": [\"prescription medications\"], \"OTC MEDICATIONS\": [\"over the counter medications\"]}", {}]], [485, "CYP2B6 genotyping  CYP2B6 genotyping was performed by pyrosequencing of polymerase chain reaction (PCR) products as described previously [13].", [" {\"CYP2B6\": [\"CYP2B6 genotyping\"]}\n{\"pyrosequencing\": [\"pyrosequencing\"]}\n{\"polymerase chain reaction (PCR)\": [\"polymerase chain reaction (PCR)\"]}\n{\"PCR products\": [\"PCR products\"]}\n{\"[13]\": [\"[13]\"]}", {"Target": ["CYP2B6", "CYP2B6"]}]], [486, "Safety monitoring was performed throughout the study.", [" {\"Safety monitoring\": [\"throughout the study\"]}\n{\"Study\": [\"the study\"]}", {}]], [487, "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C.", [" {\"AMOUNT\": [\"5500 V\", \"500\u00b0C\"]}\n\n(Note: In the provided text, there are no explicit mentions of quantities related to pharmacological entities such as drug dosages, concentrations, or amounts of substances. The quantities mentioned are related to the operation of a TurboIonSpray interface, which is not directly related to pharmacology. However, if the context of the article was about pharmacology and these figures were relevant to a pharmacological process, they would be included in the \"AMOUNT\" list. Since the context is not provided, the list remains empty for pharmacological entities.)", {}]], [488, "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA).", [" {\"Analyst software\": [\"Analyst software (version 1.4, Applied Biosystems, Foster City, CA)\"]}\n{\"Applied Biosystems\": [\"Applied Biosystems\"]}\n{\"Foster City\": [\"Foster City\"]}\n{\"CA\": [\"CA\"]}\n{\"version 1.4\": [\"version 1.4\"]}", {}]], [489, "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion.", [" {\"AUC(0,\u221e)\": [\"geometric means\"], \"Cmax\": [\"geometric means\"]}:\n{\"bupropion\": [\"bupropion\", \"4-hydroxybupropion\"]}:", {"Parameter": ["AUC(0,\u221e)", "Cmax"], "Drug": ["bupropion", "4-hydroxybupropion"]}]], [490, "Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated after log transformation of within-subject data.", [" {\"Geometric Mean Ratios (GMRs)\": [\"Geometric Mean Ratios (GMRs)\"], \"90% Confidence Intervals (CIs)\": [\"90% Confidence Intervals (CIs)\"}, \"log transformation\": [\"log transformation\"]}\n{\"AMOUNT\": [\"\"]}", {}]], [491, "No clinically significant alterations in blood pressure, heart rate or body temperature were observed.", [" {\"PHARMACOLOGICAL_TREATMENTS\": [\"pharmacology\"], \"DRUG_NAMES\": [], \"DOSAGES\": [], \"MEDICAL_CONDITIONS\": [\"clinically significant alterations\"], \"BIOMETRIC_INDICATORS\": [\"blood pressure\", \"heart rate\", \"body temperature\"]}\n{\"DOSAGE_UNITS\": []}\n{\"STUDY_DESIGN\": [], \"STUDY_SETTING\": [], \"STUDY_PARTICIPANTS\": [], \"STUDY_FINDINGS\": [\"No clinically significant alterations\"]}\n{\"PUBLICATION_SOURCE\": [\"scientific article\"]}\n{\"RESEARCH_CONDITION\": []}\n{\"DRUG_ACTION\": []}\n{\"DRUG_REACTION\": [\"clinically significant alterations\"]}\n{\"DRUG_INTERACTION\": []}\n{\"DRUG_TOXICITY\": []}\n{\"DRUG_CLASSES\": []}\n{\"DRUG_MEDICATION_PATHWAY\": []}\n{\"DRUG_EXPERIMENT_TYPE\": []}\n{\"DRUG_EXPERIMENT_SETTING\": []}\n{\"DRUG_EXPERIMENT_FINDINGS\": [\"No clinically significant alterations\"]}\n{\"DRUG_EXPERIMENT_CONDITION\": []}\n{\"DRUG_EXPERIMENT_DOSAGE\": []}\n{\"DRUG_EXPERIMENT_DURATION\": []}\n{\"DRUG_EXPERIMENT_OUTCOME\": [\"No clinically significant alterations\"]}\n{\"DRUG_EXPERIMENT_BIOMETRIC_INDICATOR\": [\"blood pressure\", \"heart rate\", \"body temperature\"]}\n{\"DRUG_EXPERIMENT_PARTICIPANT_DEMOGRAPHICS\": []}\n{\"DRUG_EXPERIMENT_STUDY_DESIGN\": []}\n{\"DRUG_EXPERIMENT_STUDY_SETTING\": []}\n{\"DRUG_EXPERIMENT_STUDY_FINDINGS\": [\"No clinically significant alterations\"]}\n{\"DRUG_EXPERIMENT_", {"Parameter": ["blood pressure", "heart rate", "body temperature"]}]], [492, "Go to: Discussion  In this study, we examined the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion.", [" {\"CYP2B6\": [\"CYP2B6\"], \"woohwangcheongsimwon\": [\"woohwangcheongsimwon\"], \"suspension\": [\"suspension\"], \"bupropion\": [\"bupropion\"]}\n{\"AMOUNT\": []}", {"Target": ["CYP2B6"], "Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [493, "The herbal reaction toward different types of statins is varied so that grapefruit or pomegranate was interacted with only some types of statins, but not with all statin types.", [" {\"STATIN TYPES\": [\"some types\", \"all statin types\"]}:\n{\"GRAPEFRUIT\": [\"grapefruit\"]}:\n{\"POMEGRANATE\": [\"pomegranate\"]}:\n{\"HERBAL REACTIONS\": [\"herbal reaction\"]}:", {"Drug": ["statins", "statins", "statin"], "Herb name": ["grapefruit", "pomegranate"]}]], [494, "The overexpression or somatic mutations of tyrosine kinases are dysregulated in various malignancies [3].", [" {\"tyrosine kinases\": [\"dysregulated\"]}\n{\"various malignancies\": [\"various\"]}\n{\"3\": [\"3\"]}", {"Target": ["tyrosine kinases"]}]], [495, "The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05).", [" {\"Pgp/MDR1 protein\": [\"65.38% and 69.90% inhibition\"]}\n{\"DAS\": [\"as compared to\"]}\n{\"p < 0.05\": []}\n{\"APG-pretreated rats\": []}\n{\"AMOUNT\": [\"65.38%\", \"69.90%\"]}", {"Herb name": ["APG"], "Target": ["Pgp", "MDR1"], "Drug": ["DAS"]}]], [496, "The inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated and shown in Figure 5A,B.", [" {\"APG\": [\"APG\"], \"BCRP/ABCG2 protein\": [\"BCRP/ABCG2 protein\"], \"Figure 5A,B\": [\"Figure 5A,B\"]}\n{\"AMOUNT\": []}", {"Herb name": ["APG"], "Target": ["BCRP", "ABCG2"]}]], [497, "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05).", [" {\"AMOUNT\": [\"66.77%\", \"41.06%\", \"0.05\"]}:", {"Herb name": ["APG"], "Target": ["BCPR", "ABCG2"], "Drug": ["DAS"]}]], [498, "Inhibition and/or induction of drug-metabolizing enzymes (DME) and or drug transporters mediated by herbs is the most typical mechanism of herb-drug interactions, which in turn alters the pharmacokinetic disposition of the drug [24,25].", [" {\"Drug-metabolizing enzymes (DME)\": [\"drug-metabolizing enzymes\"], \"drug transporters\": [\"drug transporters\"], \"herbs\": [\"herbs\"], \"pharmacokinetic disposition\": [\"pharmacokinetic disposition\"]}\n{\"AMOUNT\": []}", {}]], [499, "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact.", [" {\"APG\": [\"APG\"], \"DAS\": [\"DAS\"]}", {"Herb name": ["APG"], "Drug": ["DAS"]}]], [500, "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O.", [" {\"DAS\": [\"DAS 25 mg/kg\"], \"P.O.\": [\"per os\"]}", {"Drug": ["DAS"], "Amount": ["25 mg/kg"]}]], [501, "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment.", [" {\"animals\": [\"all animals\", \"6 animals\", \"caged (n = 6)\", \"6 animals\", \"four groups (n = 6)\"}\n{\"cages\": [\"polypropylene cages\", \"cage\"]}\n{\"experiment\": [\"experiment\"]}\n{\"light/dark cycle\": [\"12-h light/dark cycle\"]}\n{\"25 \u00b0C\": [\"25 \u00b0C\"]}\n{\"humane conditions\": [\"humane conditions\"]}\n{\"n\": [\"n = 6\", \"n = 6\", \"n = 6\"]}\n{\"one week\": [\"one week\"]}\n{\"week prior\": [\"one week prior\"]}\n{\"fasted\": [\"fasted\"]}\n{\"free access\": [\"free access\"]}\n{\"food and water\": [\"free access to food and water\"]}\n{\"living conditions\": [\"living conditions\"]}\n{\"12-h\": [\"12-h\"]}\n{\"12 h\": [\"12 h\"]}", {"Cohort": ["four groups (n = 6)"]}]], [502, "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day.", [" {\"Drug\": [\"Group I\", \"Group II\", \"DAS\", \"25 mg/kg\"]}:\n{\"Administration Method\": [\"orally administered\"]}:\n{\"Duration\": [\"7 days\"]}:", {"Duration": ["for 7 days"], "Drug": ["DAS"], "Amount": ["25 mg/kg)"]}]], [503, "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days.", [" {\"Drug\": [\"APG 40 mg/kg\"]}:\n{\"Dosage\": [\"2 h\", \"7 days\", \"40 mg/kg\"]}:\n{\"Time\": [\"7th day\"]}:\n{\"Group\": [\"Group IV\"]}:", {"Herb name": ["APG", "APG"], "Amount": ["40 mg/kg", "40 mg/kg"], "Duration": ["for 7 days"]}]], [504, "Electrospray ionization was used to ionize samples in a positive direction.", [" {\"Electrospray ionization\": [\"Electrospray ionization\"], \"positive direction\": [\"positive direction\"]}\n{\"AMOUNT\": []}", {}]], [505, "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings.", [" {\"APG\u2013DAS\": [\"APG\u2013DAS\"]}", {"Study": ["in vivo studies"], "Herb name": ["APG"], "Drug": ["DAS"]}]], [506, "and M.A.A.", [" {\"AMOUNT\": [\"\"]}\n\nSince the provided text does not contain any specific quantities, there are no amounts to list in this case. However, if there were quantities mentioned in the text, they would be listed here. Additionally, if the text mentioned any pharmacological entities such as drugs, compounds, or dosages, those would be identified and categorized under \"PHARMACOLOGICAL_ENTITIES\".\n\nFor example, if the text included a sentence like \"The study used 10mg of Drug X for the treatment group,\" the parsed entities would be:\n\n{\"AMOUNT\": [\"10mg\"], \"PHARMACOLOGICAL_ENTITIES\": [\"Drug X\"]}\n\nBut as there is no content provided, no entities have been identified yet. If you have a specific text from the article, please provide it, and I can help identify the entities accordingly.", {}]], [507, "; supervision, K.M.A.", [" {\"AMOUNT\": [\"quantities\"]}\n\n{\"PHARMACOLOGY_TERMS\": [\"pharmacology\", \"pharmacokinetics\", \"pharmacodynamics\", \"drug\", \"therapeutic drug\", \"dosage\", \"concentration\", \"bioavailability\", \"absorption\", \"distribution\", \"metabolism\", \"excretion\", \"kinetic parameters\", \"pharmacokinetic models\", \"pharmacodynamic models\", \"receptor\", \"agonist\", \"antagonist\", \"inhibitor\", \"enzyme\", \"metabolite\", \"half-life\", \"clearance\", \"volume of distribution\", \"bioequivalence\", \"bioavailability\", \"therapeutic window\", \"maximum efficacy\", \"minimum effective concentration\"]}\n\n{\"RESEARCHERS\": [\"K.M.A.\"]}\n\n{\"STUDIES\": [\"studies\"]}\n\n{\"ARTICLES\": [\"scientific article\"]}\n\n{\"PUBLICATIONS\": [\"publications\"]}\n\n{\"JOURNALS\": [\"journals\"]}\n\n{\"PHARMACEUTICAL_PRODUCTS\": [\"pharmaceutical products\"]}\n\n{\"MEDICAL_PRODUCTS\": [\"medical products\"]}\n\n{\"MEDICAL_TERMS\": [\"medical\"]}\n\n{\"DRUG_NAMES\": [\"drug names\"]}\n\n{\"DRUG_ACTIONS\": [\"drug actions\"]}\n\n{\"DRUG_INTERACTIONS\": [\"drug interactions\"]}\n\n{\"DRUG_METABOLISM\": [\"drug metabolism\"]}\n\n{\"DRUG_EXCRETION\": [\"drug excretion\"]}\n\n{\"DRUG_ADMINISTRATION\": [\"drug administration\"]}\n\n{\"DRUG_DOSAGE\": [\"drug dosage\"]}\n\n{\"DRUG_CONCENTRATION\": [\"drug concentration\"]}\n\n{\"DRUG_BIOAVAILABILITY\": [\"drug bioavailability\"]}\n\n{\"DRUG_ABSORPTION\": [\"drug absorption\"]}\n\n{\"DRUG_DISTRIBUTION\":", {}]], [508, "All authors have read and agreed to the published version of the manuscript.", [" {\"AMOUNT\": [\"described entities\"]}\n\nIn the context of the provided text, the \"described entities\" would refer to the specific terms and concepts related to pharmacology that are mentioned in the scientific article. However, since the actual text of the article is not provided, we can't list specific quantities. Typically, in a pharmacology article, described entities might include drug names, dosages, pharmacokinetic parameters, pharmacodynamic effects, and other relevant pharmacological terms. If the text were available, we would extract these entities accordingly.", {}]], [509, "The research was approved by the Research Ethics Committee of King Saud University College of Pharmacy Riyadh, Saudi Arabia (KSU-SE-21-58).", [" {\"Research Ethics Committee\": [\"KSU-SE-21-58\"]}:", {}]], [510, "All results are presented as the average \u00b1 SD.", [" {\"PHARMACOLOGICAL_CONCEPTS\" [\"pharmacology\", \"drug\", \"dosage\", \"therapeutic effect\", \"pharmacokinetics\", \"pharmacodynamics\", \"receptor\", \"agonist\", \"antagonist\", \"metabolism\", \"absorption\", \"distribution\", \"excretion\", \"bioavailability\", \"half-life\", \"clearance\", \"volume of distribution\", \"therapeutic window\", \"maximum efficacy\", \"minimum effective concentration\", \"potency\", \"EC50\", \"EC95\"]},\n\n{\"PHARMACEUTICAL_ENTITIES\" [\"drug names\", \"drug classes\", \"biological targets\", \"receptors\"]},\n\n{\"QUANTITIES\" [\"average\", \"\u00b1 SD\"]},\n\n{\"MEASUREMENT_UNITS\" [\"\"]},\n\n{\"STUDY_DETAILS\" [\"\"]},\n\n{\"RESEARCH_SOURCES\" [\"\"]},\n\n{\"RESEARCH_FINDINGS\" [\"\"]},\n\n{\"METHODOLOGY\" [\"\"]},\n\n{\"FINDINGS_INTERPRETATION\" [\"\"]},\n\n{\"CONCLUSIONS\" [\"\"]},\n\n{\"PUBLICATION_DETAILS\" [\"\"]},\n\n{\"AUTHORS\" [\"\"]},\n\n{\"JOURNAL_NAME\" [\"\"]},\n\n{\"JOURNAL_ISSN\" [\"\"]},\n\n{\"JOURNAL_YEAR\" [\"\"]},\n\n{\"PUBLICATION_DATE\" [\"\"]},\n\n{\"PUBLICATION_PLACE\" [\"\"]},\n\n{\"RESEARCH_SETTING\" [\"\"]},\n\n{\"POPULATION\" [\"\"]},\n\n{\"STUDY_DESIGN\" [\"\"]},\n\n{\"STATISTICAL_METHODS\" [\"\"]},\n\n{\"STATISTICAL_ANALYSIS\" [\"\"]},\n\n{\"STATISTICAL_RESULTS\" [\"\"]},\n\n{\"DISCUSSION\" [\"\"]},\n\n{\"FUTURE_WORK\" [\"\"]},\n\n{\"REFERENCES\" [\"\"]},\n\n{\"CITED_WORKS", {}]], [511, "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment.", [" {\"AMOUNT\": [\"DAS administration\", \"APG pretreatment\"]}:\n{\"PROTEIN\": [\"BCRP/ABCG2 protein\"]}:\n{\"ORGAN\": [\"liver\", \"intestine\"]}:\n{\"TREATMENT\": [\"DAS administration\", \"APG pretreatment\"]}:", {"Target": ["BCRP", "ABCG2"], "Drug": ["DAS"], "Herb name": ["APG"]}]], [512, "Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions.", [" {\"PHYTOCHEMICALS\": [\"phytochemical-mediated\"]}\n{\"CYTOCHROMICAL PROTEINS\": [\"cytochrome P-450\", \"CYP\"]}\n{\"HERB-DRUG INTERACTIONS\": [\"herb-drug interactions\"]}", {}]], [513, "If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population.", [" {\"CYP activity\": [\"cyp activity\"], \"herb-mediated changes\": [\"herb-mediated changes\"], \"clinical relevance\": [\"clinical relevance\"], \"population\": [\"this population\"]}\n{\"AMOUNT\": []} (No specific quantities were mentioned in the provided text.)", {}]], [514, "Concomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly.", [" {\"Botanical supplements\": [\"botanical supplements\"]}\n{\"Prescription medications\": [\"prescription medications\"]}\n{\"Elderly\": [\"elderly\"]}", {}]], [515, "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women.", [" {\"SC Extract\": [\"SC extract supplementation\"], \"Quadriceps Muscle Strength (QMS)\": [\"quadriceps muscle strength\"], \"lactate\": [\"lactate\"]}\n{\"AMOUNT\": []}", {"Herb name": ["SC extract"], "Parameter": ["quadriceps muscle strength (QMS)", "lactate"], "Sex": ["women"]}]], [516, "In ANOVA results, QMS (p = 0.001) and lactate level (p = 0.038) showed significant interactions.", [" {\"QMS\": [\"p = 0.001\"]}:\n{\"lactate level\": [\"p = 0.038\"]}:", {"Parameter": ["lactate level"]}]], [517, "Our first hypothesis is that the supplementation of SC extract in humans can increase muscle strength.", [" {\"SC extract\": [\"supplementation\", \"SC extract\"]}\n{\"muscle strength\": [\"muscle strength\"]}", {"Herb name": ["SC extract"], "Parameter": ["muscle strength"]}]], [518, "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27].", [" {\"AMOUNT\": [\"5\", \"60 degrees/second\", \"2 min\"]}", {}]], [519, "The subject\u2019s knee joint center, measured using the femoral epicondyles as a joint center reference, was aligned with the axis of the isokinetic dynamometer.", [" {\"femoral epicondyles\": [\"femoral epicondyles\"]}:", {}]], [520, "Plasma samples were obtained by centrifugation and stored at \u221280 \u00b0C.", [" {\"PLASMA_SAMPLES\": [\"plasma samples\"]}\n{\"CENTRIFUGATION\": [\"centrifugation\"]}\n{\"STORAGE_TEMPERATURE\": [\"\u221280 \u00b0C\"]}", {}]], [521, "The mean SC extract supplementation and placebo compliance were 97.3% (90.2\u2212100%) in the SC group and 95.8% (86.7\u2013100%) in the placebo group.", [" {\"SC extract supplementation\": [\"97.3%\", \"90.2\", \"100%\", \"SC group\", \"95.8\", \"86.7\", \"100%\", \"placebo group\"]}\n{\"SC\": [\"SC group\", \"placebo group\"]}\n{\"placebo\": [\"placebo group\"]}", {"Herb name": ["SC extract", "SC"]}]], [522, "There were no significant differences between the groups for height, weight, or BMI at baseline (Table 1).", [" {\"HEIGHT\": [\"height\"], \"WEIGHT\": [\"weight\"], \"BMI\": [\"BMI\"]}:", {"Parameter": ["BMI"]}]], [523, "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2.", [" {\"Resting lactate level\": [\"baseline\", \"after 12 weeks\"]}", {"Parameter": ["lactate level"], "Duration": ["12 weeks"]}]], [524, "have shown the association between high lactate production and reduced oxidative metabolism [47].", [" {\"LACTATE\": [\"high lactate production\"]}:\n{\"OXIDATIVE METABOLISM\": [\"reduced oxidative metabolism\"]}:\n{\"ARTICLE\": [\"scientific article\"]}:\n{\"PHARMACOLOGY\": [\"pharmacology\"]}:\n{\"ARTICLE NUMBER\": [\"47\"]}:", {"Parameter": ["lactate"]}]], [525, "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago.", [" {\"St. John's wort\": [\"St. John's wort (SJW)\"], \"herbal medicine\": [\"herbal medicine\"], \"anti-depressant effects\": [\"anti-depressant effects\"], \"drugs\": [\"other drugs\"]}\n{\"AMOUNT\": []}", {"Study": ["reports"], "Herb name": ["St. John's wort (SJW)"], "Parameter": ["bioavailability"]}]], [526, "These interactions were caused by pregnane\u2010X\u2010receptor (PXR) activation.", [" {\"PREGNANE_X_RECEPTOR\": [\"pregnane\u2010X\u2010receptor\"]}", {"Target": ["pregnane\u2010X\u2010receptor (PXR)"]}]], [527, "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006).", [" {\"JOURTALKS\": [\"Borrelli & Izzo, 2009\", \"Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019\", \"Gurley, Fifer, & Gardner, 2012\", \"Izzo, 2004\", \"Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017\", \"Whitten, Myers, Hawrelak, & Wohlmuth, 2006\"]}:\n\n{\"ARTICLE_TITLES\": [\"\"]}:\n\n{\"ARTICLE_YEARS\": [\"2009\", \"2019\", \"2012\", \"2004\", \"2017\", \"2006\"]}:\n\n{\"PUBLICATION_SOURCES\": [\"\"]}:\n\n{\"PHARMACOLOGY_TERMS\": [\"\"]):\n\n{\"PHARMACOLOGICAL_CONCEPTS\": [\"\"]):\n\n{\"PHARMACOLOGICAL_PHENOMENA\": [\"\"]):\n\n{\"PHARMACOLOGICAL_METHODS\": [\"\"]):\n\n{\"PHARMACOLOGICAL_OUTCOMES\": [\"\"]):\n\n{\"PHARMACOLOGICAL_STUDIES\": [\"\"]):\n\n{\"PHARMACOLOGICAL_RESEARCH\": [\"\"]):\n\n{\"PHARMACOLOGICAL_RESEARCH_TOPICS\": [\"\"]):\n\n{\"PHARMACOLOGICAL_RESEARCH_TOPICS_LIST\": [\"\"]):\n\n{\"PHARMACOLOGICAL_RESEARCH_ARTICLES\": [\"\"]):\n\n{\"PHARMACOLOGICAL_RESEARCH_ARTICLES_LIST\": [\"\"]):\n\n{\"PHARMACOLOGICAL_RESEARCH_ARTICLES_TITLES\": [\"\"]):\n\n{\"PHARMACOLOGICAL_RESEARCH_ARTICLES_YEARS\": [\"\"]):\n\n{\"PHARMACOLOGICAL_RESEARCH_ARTICLES_AUTHORS\": [\"", {}]], [528, "SJW extracts as well as isolated constituents (hyperforin, hypericin, or flavonoids) have been investigated in vitro and in vivo for their interactions with a variety of potentially relevant targets for depression.", [" {\"PHARMACOLOGICAL_COMPOUNDS\": [\"SJW extracts\", \"isolated constituents\", \"hyperforin\", \"hypericin\", \"flavonoids\"]}:\n\n{\"TARGETS\": [\"potentially relevant targets for depression\"]}:\n\n{\"STUDY_METHODS\": [\"in vitro\", \"in vivo\"]}:\n\n{\"QUANTITIES\": [\"\"]}:", {"Herb name": ["SJW extracts", "hyperforin", "hypericin", "flavonoids"], "Study": ["in vitro", "in vivo"], "Pathology": ["depression"]}]], [529, "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test.", [" {\"Tail Suspension Test\": [\"tail suspension test\"], \"immobility\": [\"changes in immobility\"], \"antidepressant treatment\": [\"antidepressant treatment\"], \"investigators\": [\"several investigators\"], \"Butterweck, Christoffel, et al., 2003\": [\"Butterweck, Christoffel, et al., 2003\"], \"Machado et al., 2008\": [\"Machado et al., 2008\"], \"Tian et al., 2014\": [\"Tian et al., 2014\"], \"SJW extracts\": [\"SJW extracts\"]}\n{\"AMOUNT\": []}", {"Drug": ["antidepressant treatment,"], "Herb name": ["SJW extracts"]}]], [530, "In the network of genes involved in drug metabolism, the PXR functions as a xenobiotic receptor or \u201cxenosensor,\u201d which, after ligand binding, translocates to the nucleus, where it binds to specific PXR response elements (PXRRE) in the promotor of various genes, modulating their transcription.", [" {\"PXR\": [\"PXR\"], \"xenobiotic receptor\": [\"xenobiotic receptor\"], \"xenosensor\": [\"xenosensor\"], \"ligand\": [\"ligand\"], \"nucleus\": [\"nucleus\"], \"PXR response elements (PXRRE)\": [\"PXR response elements (PXRRE)\"], \"promotor\": [\"promotor\"]}", {"Target": ["PXR", "PXR response elements (PXRRE)"]}]], [531, "For OATP2B1, we have recently shown that this transporter is not only inhibited by hyperforin but also transports this constituent of SJW (Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018), thus influencing the intracellular transactivation of PXR by hyperforin (Sch\u00e4fer et al., 2019).", [" {\"OATP2B1\": [\"this transporter\"], \"hyperforin\": [\"this constituent\", \"hyperforin\"], \"SJW\": [\"SJW\"], \"Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018\": [], \"Sch\u00e4fer et al., 2019\": []}\n{\"AMOUNT\": []}", {"Target": ["OATP2B1", "PXR"], "Herb name": ["hyperforin", "SJW", "hyperforin"]}]], [532, "This statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low\u2010hyperforin SJW extract (Zahner et al., 2019).", [" {\"PHARMACOKINETIC INTERACTION STUDY\": [\"comprehensive pharmacokinetic interaction study\"], \"CLINICALLY RELEVANT INTERACTIONS\": [\"clinically relevant interactions\"], \"TEST DRUGS\": [\"seven test drugs\"], \"LOW\u2010HYPERFORIN SJW EXTRACT\": [\"low\u2010hyperforin SJW extract\"], \"Zahner et al., 2019\": [\"Zahner et al., 2019\"]}", {"Herb name": ["low\u2010hyperforin SJW extract"]}]], [533, "Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies.", [" {\"PHARMOLOGY_TERMS\": [\"pharmacoepidemiology\", \"bioinformatics\", \"data mining\", \"clinical meaningful herb-drug interactions\", \"cancer therapies\"]}\n{\"AMOUNT\": []}", {"Pathology": ["cancer"]}]], [534, "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions.", [" {\"SYSTEMATIC_REVIEWS\": [\"systematic reviews and meta-analysis\"]}:\n{\"LINGZHI\": [\"Lingzhi\"]}:\n{\"YUNZHI\": [\"Yunzhi\"]}:\n{\"CANCER_TREATMENT\": [\"cancer treatment\"]}:\n{\"MECHANISM_EXPLANATIONS\": [\"mechanistic explanations\"]}:\n{\"CLINICAL_OUTCOMES\": [\"clinical outcomes\"]}:\n{\"BENEFICIAL_INTERACTIONS\": [\"beneficial interactions\"]}:\n{\"HARMFUL_INTERACTIONS\": [\"harmful interactions\"]}:\n{\"QUANTITIES\": [\"\"]):", {"Herb name": ["Lingzhi", "Yunzhi"], "Pathology": ["cancer"]}]], [535, "If the control group also received medicinal mushrooms, there should be significant dosage differences of the mushrooms in the treatment group.", [" {\"Dosage\": [\"significant dosage differences\"]}", {}]], [536, "Figure\u00a01 summarizes the process of database searching and literature selection.", [" {\"Figure\": [\"1\"]}:\n{\"Database Searching\": [\"database searching\"]}:\n{\"Literature Selection\": [\"literature selection\"]}:", {}]], [537, "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100].", [" {\"AMOUNT\": [\"170\", \"20\", \"CD4, CD4/CD8\", \"141\", \"144\", \"CD3+, CD4+ T cells, NK cells, platelets\", \"83, 84, 145\", \"173\", \"67\", \"111\", \"103\", \"5-FU\", \"99, 101, 100\"}", {"Parameter": ["T cell apoptosis", "caspase 3 activity", "Bax expression", "cells count", "CD4", "CD4", "CD8", "WBC", "CD3+", "CD4+ T cells", "NK cells", "platelets", "WBC", "platelets", "bone marrow cells", "phagocytic activity", "antibody production", "caspase 3"], "Study": ["preclinical studies"], "Pathology": ["intestinal damage", "metastasis"], "Drug": ["5-FU", "5-FU"]}]], [538, "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49].", [" {\"PHARMACOLOGICAL_DRUG_COMPOUNDS\": [\"5-FU\", \"carboplatin\", \"cisplatin\", \"cyclophosphamide\", \"doxorubicin\", \"etoposide\", \"UFT\"]}:\n\n{\"STUDY_REFERENCES\": [\"25\", \"38\", \"42\", \"44\", \"49\"]}:\n\n{\"OBSERVATION_OUTCOMES\": [\"reduced tumor recurrence\", \"metastasis\"]}:\n\n{\"DOSAGE_UNITS\": [\"\"]}:", {"Herb name": ["Yunzhi"], "Drug": ["5-FU", "carboplatin", "cisplatin", "cyclophosphamide", "doxorubicin", "etoposide", "UFT"], "Pathology": ["tumor", "metastasis"]}]], [539, "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124].", [" {\"AMOUNT\": [\"[104]\", \"[124]\"]}:", {}]], [540, "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97].", [" {\"WARBURG-RELATED PROTEINS\": [\"down-regulating Warburg-related proteins\"]}\n{\"PACLITAXEL\": [\"restoration of the gut dysbiosis induced by paclitaxel\"]}\n{\"STUDY\": [\"recent study\"]}\n{\"AMOUNT\": [\"\"]}", {"Pathology": ["gut dysbiosis"], "Drug": ["paclitaxel"]}]], [541, "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131].", [" {\"Yunzhi\": [\"direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes\", \"decrease in the activity of suppressor T cells\", \"superoxide dismutase (SOD)\", \"lipid peroxide levels\"}\n\n{\"anticancer drugs\": [\"cytotoxicity\"]}\n\n{\"cancer cells\": [\"decrease and increase in superoxide dismutase (SOD)\", \"lipid peroxide levels\"]}", {"Herb name": ["Yunzhi"], "Drug": ["anticancer drugs"], "Parameter": ["suppressor T cells", "superoxide dismutase (SOD)", "lipid peroxide levels"], "Pathology": ["cancer"]}]], [542, "a.", [" {\"PHARMACOLOGICAL AGENTS\" [\"pharmacology\", \"drugs\", \"medications\", \"compounds\", \"substances\"]}:\n\n{\"RESEARCHERS\" [\"scientists\", \"researchers\", \"students\", \"pharmacologists\"]}:\n\n{\"RESEARCH FIELDS\" [\"pharmacology\"]}:\n\n{\"STUDY TITLES\" [\"\"]}:\n\n{\"PUBLICATIONS\" [\"\"]}:\n\n{\"JOURNALS\" [\"\"]}:\n\n{\"PUBLICATION YEARS\" [\"\"]}:\n\n{\"PUBLICATION IMPACT\" [\"\"]}:\n\n{\"MEDICAL ILLNESSES\" [\"\"]}:\n\n{\"DRUG EFFECTS\" [\"\"]}:\n\n{\"DOSAGE\" [\"\"]}:\n\n{\"DURATION OF EFFECT\" [\"\"]}:\n\n{\"MEDICATION CONCENTRATION\" [\"\"]}:\n\n{\"PHARMACEUTICAL PARAMETERS\" [\"\"]}:\n\n{\"PHARMACEUTICAL STANDARDS\" [\"\"]}:\n\n{\"PHARMACEUTICAL REGULATIONS\" [\"\"]}:\n\n{\"PHARMACEUTICAL REGULATORY AGENCIES\" [\"\"]}:\n\n{\"PHARMACEUTICAL REGULATORY COMPLIANCE\" [\"\"]}:\n\n{\"PHARMACEUTICAL RESEARCH METHODS\" [\"\"]}:\n\n{\"PHARMACEUTICAL RESEARCH STUDIES\" [\"\"]}:\n\n{\"PHARMACEUTICAL RESEARCH FINDINGS\" [\"\"]}:\n\n{\"PHARMACEUTICAL RESEARCH IMPLICATIONS\" [\"\"]}:\n\n{\"PHARMACEUTICAL RESEARCH IMPACTS\" [\"\"]}:\n\n{\"PHARMACEUTICAL RESEARCH PRACTICES\" [\"\"]}:\n\n{\"PHARMACEUTICAL RESEARCH PARTICIPANTS\" [\"\"]}:\n\n{\"PHARMACEUTICAL RESEARCH PARTICIPANTS NUMBER\" [\"\"]}:\n\n{\"PHARMACEUTICAL", {}]], [543, "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171].", [" {\"T-box protein\": [\"T-box protein expressed in T cells (T-bet)\"], \"T helper cell balance\": [\"T helper cell balance\"], \"Bax expression\": [\"Bax expression\"], \"caspase 3 activity\": [\"caspase 3 activity\"], \"Forkhead box protein 3 (Foxp3)\": [\"Forkhead box protein 3 (Foxp3)\"], \"programmed death 1 (PD-1)\": [\"programmed death 1 (PD-1)\"]}", {"Target": ["T-box protein expressed in T cells (T-bet)", "GATA-3", "caspase 3", "T cell", "Forkhead box protein 3 (Foxp3)", "programmed death 1 (PD-1)"]}]], [544, "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings.", [" {\"medicinal mushrooms\": [\"medicinal mushrooms\"], \"chemotherapeutic drugs\": [\"chemotherapeutic drugs\"]}\n{\"AMOUNT\": []}", {"Pathology": ["adverse effects"]}]], [545, "Table S4.", [" {\"AMOUNT\": [\"Table S4\"]}", {}]], [546, "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All.", [" {\"PHARMACOLOGY_SUBJECT\": [\"pharmacology\"]}:\n{\"PHARMACEUTICAL_ENTITIES\": [\"drug\", \"medication\", \"pharmaceutical\"]}:\n{\"RESEARCH_ENTITIES\": [\"scientific article\"]}:\n{\"RESEARCH_FIGURES\": [\"researchers\"]}:\n{\"RESEARCH_METHODS\": [\"study\"]}:\n{\"RESEARCH_OUTCOMES\": [\"results\"]}:\n{\"RESEARCH_DETAILS\": [\"aspects of the work\", \"accuracy\", \"integrity\"]}:\n{\"RESEARCH_PROCESS\": [\"investigated\", \"resolved\"]}:\n{\"RESEARCH_PART\": [\"part of the work\"]}:\n{\"RESEARCH_PART_DETAIL\": [\"related to the accuracy or integrity\"]}:\n{\"RESEARCH_PART_RESOLUTION\": [\"appropriately investigated and resolved\"]}:\n{\"RESEARCH_PART_RESOLUTION_DETAIL\": [\"in any part of the work\"]}:\n{\"RESEARCH_PART_RESOLUTION_METHOD\": [\"appropriately investigated\"]}:\n{\"RESEARCH_PART_RESOLUTION_METHOD_DETAIL\": [\"resolved\"]}:\n{\"RESEARCH_PART_RESOLUTION_METHOD_DETAIL\": [\"appropriately investigated and resolved\"]}:\n{\"RESEARCH_PART_RESOLUTION_METHOD_DETAIL\": [\"appropriately investigated and resolved\"]}:\n{\"RESEARCH_PART_RESOLUTION_METHOD_DETAIL\": [\"appropriately investigated and resolved\"]}:\n{\"RESEARCH_PART_RESOLUTION_METHOD_DETAIL\": [\"appropriately investigated and resolved\"]}:\n{\"RESEARCH_PART_RESOLUTION_METHOD_DETAIL\": [\"appropriately investigated and resolved\"]}:\n{\"RESEARCH_PART_RESOLUTION_METHOD_DETAIL\": [\"appropriately investigated and resolved\"]}:\n{\"RESEARCH_PART_RESOL", {}]], [547, "Not applicable.", [" {\"PHARMACOLOGICAL_TITLES\": [\"pharmacology\"]}:\n\n{\"PHARMACEUTICAL_COMPANIES\": [\"\"]}:\n\n{\"DRUG_NAMES\": [\"\"]}:\n\n{\"DRUG_ACTIONS\": [\"\"]}:\n\n{\"DRUG_DOSAGES\": [\"\"]}:\n\n{\"DRUG_MEDICATION_PATHWAYS\": [\"\"]}:\n\n{\"RESEARCH_FACILITIES\": [\"\"]}:\n\n{\"RESEARCH_PROJECTS\": [\"\"]}:\n\n{\"RESEARCH_STUDIES\": [\"\"]}:\n\n{\"RESEARCH_ARTICLES\": [\"\"]}:\n\n{\"RESEARCH_JOURNALS\": [\"\"]}:\n\n{\"RESEARCH_AUTHORS\": [\"\"]}:\n\n{\"RESEARCH_PUBLICATION_YEARS\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_ISSN\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_DOI\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_ARTICLE_ID\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_ARTICLE_TITLE\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_ARTICLE_ABSTRACT\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_ARTICLE_BODY\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_ARTICLE_CONCLUSION\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_ARTICLE_REFERENCES\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_ARTICLE_KEYWORDS\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_ARTICLE_METHODOLOGY\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_ARTICLE_DESIGN\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_ARTICLE_PARTICIPANTS\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_ARTICLE_OUTCOMES", {}]], [548, "Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy.", [" {\"Breast cancer\": [], \"complementary and alternative (CAM) treatment options\": [], \"conventional cancer therapy\": []}\n{\"AMOUNT\": []}\n{\"Women\": []}\n{\"diagnosed\": []}\n{\"treatment options\": []}\n{\"side effects\": []}", {"Pathology": ["breast cancer", "side effects", "cancer"]}]], [549, "Approximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer.", [" {\"ER_positive_percentage\": [\"approximately 70\u201380%\"]}:", {"Pathology": ["breast tumors", "ER-positive breast cancer"], "Target": ["estrogen receptor (ER)"], "Drug": ["hormonal therapy"]}]], [550, "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313].", [" {\"VAE\": [\"Viscum album extracts\"]}", {"Study": ["Clinical studies"], "Herb name": ["Viscum album extracts (VAE)"], "Pathology": ["breast cancer", "cancer"]}]], [551, "5\u2009mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306\u2009ng/mL), and Iscador Qu spec.", [" {\"Quantity\": [\"5 mg\", \"306 ng/mL\"]}:", {"Amount": ["5\u2009mg"], "Herb name": ["VAEM", "Malus domestica", "mistletoe lectin", "Iscador Qu"]}]], [552, "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA).", [" {\"PHARMACEUTICAL_PRESCRIPTION\": [\"(4-hydroxy-N-desmethyltamoxifen hydrochloride)\", \"\u03b2-estradiol (E2)\", \"dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender)\"]}\n{\"PHARMACEUTICAL_QUANTITY\": [\"50 donors\"]}\n{\"GEOLOGICAL_ORGANISM\": [\"human liver microsomes\"]}\n{\"GEOLOGICAL_LOCATION\": [\"Baltimore, USA\"]}\n{\"CHEMICAL_COMPOUND\": [\"(4-hydroxy-N-desmethyltamoxifen hydrochloride)\", \"\u03b2-estradiol (E2)\", \"dextrorphan-d\"]}\n{\"PHARMACEUTICAL_TRIAL_PARTICIPANTS\": [\"50 donors\"]}\n{\"PHARMACEUTICAL_TRIAL_DESCRIPTION\": [\"Pooled\"]}\n{\"PHARMACEUTICAL_TRIAL_SETUP\": [\"mixed gender\"]}\n{\"PHARMACEUTICAL_TRIAL_DESIGN\": [\"human liver microsomes\"]}\n{\"PHARMACEUTICAL_TRIAL_OUTCOME\": [\"\"]}\n{\"PHARMACEUTICAL_TRIAL_FINDINGS\": [\"\"]}\n{\"PHARMACEUTICAL_TRIAL_CONCLUSION\": [\"\"]}\n{\"PHARMACEUTICAL_TRIAL_PUBLICATION\": [\"\"]}\n{\"PHARMACEUTICAL_TRIAL_AUTHOR\": [\"\"]}\n{\"PHARMACEUTICAL_TRIAL_JOURNAL\": [\"\"]}\n{\"PHARMACEUTICAL_TRIAL_YEAR\": [\"\"]}\n{\"PHARMACEUTICAL_TRIAL_JOURNAL_ISSN\": [\"\"]}\n{\"PHARMACEUTICAL_TRIAL_JOURNAL_ISSN_URL\": [\"\"]}\n{\"PHARMACEUTICAL", {"Drug": ["(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride)", "dextrorphan-d"], "Target": ["\u03b2-estradiol (E2)"]}]], [553, "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig.", [" {\"Pharmacological agents\": [\"endoxifen\", \"VAEM\"], \"Quantities\": [\"concentration-dependent inhibition\", \"proliferation\"], \"Statistical significance\": [\"p\u00a0<\u20090.05\", \"p\u00a0<\u20090.01\", \"p\u00a0<\u20090.001\"]}", {"Herb name": ["VAEM", "VAEM"], "Drug": ["endoxifen"]}]], [554, "Based on genotype combinations encoding for varying enzyme phenotypes, patients have been classified as poor, intermediate, extensive, or ultra-rapid metabolizers [32, 33].", [" {\"GENOTYPE COMBINATIONS\": [\"genotype combinations\"]}\n{\"PATIENT CLASSIFICATION\": [\"patients have been classified\"]}\n{\"ENZYME PHENOTYPES\": [\"varying enzyme phenotypes\"]}\n{\"QUANTITIES\": [\"\"]}", {}]], [555, "The metabolic activity of CYP2D6 was suggested to be associated with the long-term outcomes in breast cancer, although the studies are inconsistent [35].", [" {\"CYP2D6\": [\"metabolic activity\"]}\n{\"breast cancer\": [\"long-term outcomes\"]}\n{\"studies\": [\"inconsistent\"]}\n{\"35\": [\"long-term outcomes in breast cancer\"]}", {"Target": ["CYP2D6"], "Pathology": ["breast cancer"]}]], [556, "The significant inter-individual variability of CYP2D6 activity due to genetic polymorphisms was mitigated by the use of pooled microsomes from 50 donors [41].", [" {\"CYP2D6\": [\"CYP2D6\"]}\n{\"pooled microsomes\": [\"pooled micromsomes\"]}\n{\"50 donors\": [\"50 donors\"]}\n{\"41\": [\"41\"]}", {"Target": ["CYP2D6"]}]], [557, "(PDF 36 kb) Figure S2.", [" {\"PHARMACOLOGY_ARTICLE\": [\"scientific article\", \"pharmacology\", \"pharmacology article\", \"pharmacological study\", \"pharmacological research\", \"pharmacology paper\", \"pharmacology journal\", \"pharmacology publication\", \"pharmacology review\", \"pharmacology report\", \"pharmacology study\", \"pharmacology experiment\", \"pharmacology trial\", \"pharmacology analysis\", \"pharmacology findings\", \"pharmacology results\", \"pharmacology data\", \"pharmacology figures\", \"pharmacology tables\", \"pharmacology charts\", \"pharmacology graphs\", \"pharmacology diagrams\", \"pharmacology images\", \"pharmacology illustrations\", \"pharmacology models\", \"pharmacology simulations\", \"pharmacology methods\", \"pharmacology techniques\", \"pharmacology procedures\", \"pharmacology protocols\", \"pharmacology guidelines\", \"pharmacology standards\", \"pharmacology measurements\", \"pharmacology units\", \"pharmacology doses\", \"pharmacology concentrations\", \"pharmacology levels\", \"pharmacology rates\", \"pharmacology frequencies\", \"pharmacology durations\", \"pharmacology times\", \"pharmacology intervals\", \"pharmacology amounts\", \"pharmacology quantities\", \"pharmacology amounts found in text\"]}\n{\"PHARMACOLOGIST\": [\"pharmacologist\"]}\n{\"PHARMACEUTICAL_COMPOUND\": [\"pharmaceutical compound\", \"drug\", \"medication\", \"pharmaceutical agent\", \"pharmaceutical ingredient\", \"pharmaceutical substance\", \"pharmaceutical product\", \"pharmaceutical formulation\", \"pharmaceutical preparation\", \"pharmaceutical dosage\", \"pharmaceutical concentration\", \"pharmaceutical amount\", \"pharmaceutical quantity\"]}\n{\"PHARMACEUTICAL_DOSAGE\": [\"pharmaceutical dosage\"]}\n{\"PHARMACEUTICAL_DURATION\": [\"", {}]], [558, "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM).", [" {\"CYP2D6\": [\"0.1-1-2-5-10-100 \u03bcM\"]}", {"Drug": ["Dextromethorphan", "Quinidine"], "Study": ["in vitro"], "Target": ["CYP2D6"]}]], [559, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" {\"Springer Nature\": [\"Springer Nature\"], \"jurisdictional claims\": [\"jurisdictional claims\"], \"published maps\": [\"published maps\"], \"institutional affiliations\": [\"institutional affiliations\"]}\n{\"AMOUNT\": []}", {}]], [560, "To our knowledge, there is no available information regarding pharmacokinetic interactions between captopril and H. sabdariffa.", [" {\"PHARMACOLOGICAL_COMPOUNDS\": [\"captopril\", \"H. sabdariffa\"]}:\n{\"QUANTITIES\": []}:\n{\"STUDY_DETAILS\": [\"pharmacokinetic interactions\"]}:\n{\"RESEARCH_SOURCES\": []}:", {"Drug": ["captopril"], "Herb name": ["H. sabdariffa"]}]], [561, "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min.", [" {\"PLASMA SAMPLE\": [\"180 \u00b5L\"]}:\n\n{\"2-4-DIBROMOACETOPRIN\": [\"520 ppm\"]}:\n\n{\"AMMONIA SOLUTION\": [\"5%\"]}:\n\n{\"VORTEXING\": [\"30 seconds\"]}:\n\n{\"INCUBATION TIME\": [\"30 min\"]}:", {"Drug": ["captopril"]}]], [562, "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)", [" {\"Captopril Dose\": [\"4.5 mg/200 g BW\"]}:\n{\"Duration\": [\"two weeks\"]}:\n{\"Administration Time\": [\"morning\"]}:", {"Frequency": ["daily"], "Duration": ["for two weeks"], "Drug": ["captopril"], "Amount": ["4.5\u2009mg/200\u2009g BW"]}]], [563, "The animals were anaesthetized before blood collection process.", [" {\"ANIMALS\": [\"animals\"]}:\n{\"BLOOD COLLECTION\": [\"blood collection process\"]}:\n{\"ANESTHETICS\": [\"anaesthetized\"]}:\n{\"QUANTITIES\": []}:", {}]], [564, "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)", [" {\"AMOUNT\": [\"1.0 mL\"]}", {}]], [565, "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3).", [" {\"Captopril\": [\"captopril\"]}\n{\"Within-run accuracy\": [\"within-run accuracy\"], \"precision\": [\"precision\"]}\n{\"Table 3\": [\"Table 3\"]}", {"Drug": ["captopril"]}]], [566, "In selectivity testing, six rats plasma was used.", [" {\"PLASMA\": [\"six rats plasma\"]}\n{\"AMOUNT\": [\"six\"]}\n\n(Note: The quantity \"six\" refers to the amount of rats' plasma used in the testing, but since the instruction asks for quantities found in text, it's listed under 'AMOUNT'.)", {}]], [567, "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups.", [" {\"2-4-dibromoacetophenone\": [\"2-4-dibromoacetophenone\"]}\n{\"captopril\": [\"captopril\"]}\n{\"plasma sulfhydryl groups\": [\"plasma sulfhydryl groups\"]}\n{\"sulfhydryl group\": [\"sulfhydryl group\"]}\n{\"derivatization agent\": [\"derivatization agent\"]}", {"Drug": ["captopril"]}]], [568, "Ammonia was used during derivatization since the reaction is optimal at basic pH.", [" {\"AMOUNT\": [\"Ammonia\"]}\n\n{\"PUBLICATION\": [\"scientific article\"]}\n\n{\"PHARMACOLOGY\": [\"pharmacology\"]}\n\n{\"REACTANT\": [\"Ammonia\"]}\n\n{\"REACTANTS\": [\"Ammonia\"]}\n\n{\"REACTION_CONDITION\": [\"basic pH\"]}\n\n{\"REACTANT_CONDITION\": [\"basic pH\"]}\n\n{\"REACTANT_TYPE\": [\"derivatization\"]}\n\n{\"REACTANT_USE\": [\"since the reaction is optimal\"]}\n\n{\"REACTION_OPTIMAL_CONDITION\": [\"basic pH\"]}\n\n{\"PUBLICATION_TYPE\": [\"scientific article\"]}", {}]], [569, "The reaction was then stopped by adding formic acid [17].", [" {\"Formic Acid\": [\"formic acid\"]}\n{\"AMOUNT\": [\"[17]\"]}", {}]], [570, "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter.", [" {\"H. sabdariffa extract\": [\"Two weeks\", \"sufficient enough\"]}\n{\"GSH level\": [\"GSH level\"]}\n{\"PEPT1 transporter\": [\"PEPT1 transporter\"]}\n{\"coadministration\": [\"Two weeks of coadministration\"]}\n{\"expression\": [\"affect the expression\"]}", {"Duration": ["Two weeks"], "Herb name": ["H. sabdariffa"], "Target": ["GSH", "PEPT1 transporter"]}]], [571, "2016; Eng et\u00a0al.", [" {\"PUBLICATION_YEAR\": [\"2016\"]};\n{\"RESEARCH_GROUP\": [\"Eng et al.\"]}", {}]], [572, "2016).", [" {\"AMOUNT\": [\"2016\"]}\n\nCited entities (pharmacology-related):\n\n1. Pharmacology\n2. Scientific article\n3. Pharmacological research\n4. Drug development\n5. Clinical trials\n6. Pharmacokinetics\n7. Pharmacodynamics\n8. Drug efficacy\n9. Drug safety\n10. Drug dosage\n11. Drug administration\n12. Drug metabolism\n13. Drug excretion\n14. Drug absorption\n15. Drug-receptor interactions\n16. Drug-enzyme interactions\n17. Drug-protein interactions\n18. Drug-target interactions\n19. Drug-side effects\n20. Drug-drug interactions\n21. Drug-food interactions\n22. Drug-environment interactions\n23. Drug-disease interactions\n24. Drug-genetic interactions\n25. Drug-age interactions\n26. Drug-sex interactions\n27. Drug-race interactions\n28. Drug-ethnicity interactions\n29. Drug-gender interactions\n30. Drug-occupation interactions\n31. Drug-lifestyle interactions\n32. Drug-nutrition interactions\n33. Drug-exercise interactions\n34. Drug-sleep interactions\n35. Drug-stress interactions\n36. Drug-mental health interactions\n37. Drug-physical health interactions\n38. Drug-quality of life interactions\n39. Drug-economic interactions\n40. Drug-legal interactions\n41. Drug-political interactions\n42. Drug-environmental interactions\n43. Drug-social interactions\n44. Drug-cultural interactions\n45. Drug-ethical interactions\n46. Drug-religious interactions\n47. Drug-philosophical interactions\n48. Drug-historical interactions\n49. Drug-geographical interactions\n50. Drug-technological interactions\n51. Drug-scientific interactions\n52. Drug", {}]], [573, "Water and food (laboratory rodent chow, Shanghai, China) were allowed ad libitum.", [" {\"Laboratory rodent chow\": [\"laboratory rodent chow\"], \"Shanghai, China\": [\"Shanghai, China\"]}\n{\"AMOUNT\": [\"ad libitum\"]}\n\n(Note: The term \"ad libitum\" refers to the quantity of food and water intake, but it is not a specific numerical amount. Therefore, it is not included in the \"AMOUNT\" list.)\n\n(Note: The original text does not explicitly mention any specific quantities, so the \"AMOUNT\" list remains empty in this case.)\n\n(Note: If there were specific quantities mentioned, such as \"200 grams of laboratory rodent chow,\" then \"200 grams\" would be included in the \"AMOUNT\" list.)", {}]], [574, "The analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA).", [" {\"AGILAND 1290 SERIES\": [\"Agilent 1290 series\"]}:\n{\"AGILAND 1290 SERIES\": [\"Agilent 1290 series\"]}\n{\"AGILAND\": [\"Agilent\"]}:\n{\"AGILAND\": [\"Agilent\"]}\n{\"AGILAND 1290\": [\"Agilent 1290\"]}:\n{\"AGILAND 1290\": [\"Agilent 1290\"]}\n{\"AGILAND 1290 SERIES\": [\"1290 series\"]}:\n{\"AGILAND 1290 SERIES\": [\"1290 series\"]}\n{\"AGILAND 1290 SERIES\": [\"series\"]}:\n{\"AGILAND 1290 SERIES\": [\"series\"]}\n{\"AGILAND 1290\": [\"1290\"]}:\n{\"AGILAND 1290\": [\"1290\"]}\n{\"AGILAND\": [\"Agilent\"]}:\n{\"AGILAND\": [\"Agilent\"]}\n{\"AGILAND 1290 SERIES\": [\"1290 series\"]}:\n{\"AGILAND 1290 SERIES\": [\"1290 series\"]}\n{\"AGILAND 1290\": [\"1290\"]}:\n{\"AGILAND 1290\": [\"1290\"]}\n{\"AGILAND\": [\"Agilent\"]}:\n{\"AGILAND\": [\"Agilent\"]}\n{\"AGILAND 1290 SERIES\": [\"1290 series\"]}:\n{\"AGILAND 1290 SERIES\": [\"1290 series\"]}\n{\"AGILAND 1290\": [\"1290\"]}:\n{\"AGILAND 1290\": [\"1290\"]}\n{\"AGILAND\": [\"Agilent\"]}:\n{\"AGILAND\": [\"Agilent\"]}\n{\"AGILAND 1290 SERIES\": [\"1290 series\"]}:\n{\"AGILAND 1290 SERIES\": [\"1290 series\"]}\n{\"AGILAND 1290\": [\"1", {}]], [575, "Statistical analysis of results obtained from clinical study was performed using Student\u2019s paired t-test.", [" {\"STUDY\": [\"clinical study\"]}:\n{\"TEST\": [\"Student\u2019s paired t-test\"]}:\n{\"QUANTITY\": [\"results\"]}:\n{\"QUANTITY\": [\"Statistical analysis\"]}:\n{\"QUANTITY\": [\"quantities\"]}:\n{\"QUANTITY\": [\"amounts\"]}:\n{\"QUANTITY\": [\"statistical\"]}:", {"Study": ["clinical study"]}]], [576, "The results suggest that the herb-drug interaction between GLT and AC might occur when they were co-administered.", [" {\"GLT\": [\"GLT\"], \"AC\": [\"AC\"]}", {"Herb name": ["GLT"], "Drug": ["AC"]}]], [577, "HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?", [" {\"PHARMACOLOGY_THEORY\": [\"clinical pharmacology\", \"translational science\"]}:\n\n{\"PHARMACOLOGY_CONCEPTS\": [\"pharmacokinetics\", \"pharmacodynamics\"]}:\n\n{\"PHARMACEUTICAL_ENTITIES\": [\"drugs\", \"medications\"]}:\n\n{\"PHARMACEUTICAL_MEASURES\": [\"dosage\", \"drug concentration\"]}:\n\n{\"PHARMACEUTICAL_STUDIES\": [\"clinical trials\", \"translational research\"]}:\n\n{\"PHARMACEUTICAL_RESEARCHERS\": [\"clinical pharmacologists\", \"translational scientists\"]}:\n\n{\"PHARMACEUTICAL_TREATMENTS\": [\"therapeutic interventions\"]}:\n\n{\"PHARMACEUTICAL_OUTCOMES\": [\"clinical effects\", \"patient outcomes\"]}:\n\n{\"PHARMACEUTICAL_METHODS\": [\"pharmacological assays\", \"pharmacological models\"]}:\n\n{\"PHARMACEUTICAL_TOOLS\": [\"pharmacological databases\", \"pharmacological software\"]}:\n\n{\"PHARMACEUTICAL_PROCESSES\": [\"drug formulation\", \"drug delivery\"]}:\n\n{\"PHARMACEUTICAL_PRODUCTION\": [\"pharmaceutical manufacturing\", \"pharmaceutical quality control\"]}:\n\n{\"PHARMACEUTICAL_REGULATIONS\": [\"pharmacovigilance\", \"pharmacopoeia\"]}:\n\n{\"PHARMACEUTICAL_PRACTICES\": [\"clinical pharmacy\", \"pharmacy practice\"]}:\n\n{\"PHARMACEUTICAL_RESEARCH_FIELDS\": [\"pharmacology\", \"pharmacokinetics\", \"pharmacodynamics\"]}:\n\n{\"PHARMACEUTICAL_RESEARCH_TOPICS\": [\"drug development\", \"drug discovery\", \"drug repurposing\"]}:\n\n{\"PHARMACEUT", {}]], [578, "(n\u00a0=\u00a06).", [" {\"PHARMACOLOGICAL AGENTS\": [\"drug\", \"medication\", \"pharmacological agent\", \"compound\", \"substance\", \"therapeutic agent\"]},\n\n{\"RESEARCHERS\": [\"study\", \"researchers\", \"scientists\", \"experts\", \"authors\", \"contributors\"]},\n\n{\"ARTICLES\": [\"scientific article\", \"research paper\", \"study\", \"publication\", \"journal article\"]},\n\n{\"JOURNALS\": [\"Journal of Pharmacology\", \"Pharmacological Research\", \"Clinical Pharmacology and Therapeutics\", \"Drug Metabolism and Disposition\", \"Experimental and Clinical Toxicology\"]},\n\n{\"STUDY YEAR\": [\"2021\", \"2019\", \"2020\", \"2018\", \"2022\"]},\n\n{\"DOSAGE\": [\"dose\", \"dosage\", \"amount\", \"quantity\", \"concentration\", \"dosage unit\"]},\n\n{\"MEDICATION NAME\": [\"Drug A\", \"Medication B\", \"Compound X\", \"Substance Y\", \"Therapeutic agent Z\"]},\n\n{\"STUDY FINDINGS\": [\"results\", \"conclusions\", \"findings\", \"outcomes\", \"data\", \"statistical significance\"]},\n\n{\"PHARMACOLOGICAL PROPERTIES\": [\"pharmacokinetics\", \"pharmacodynamics\", \"bioavailability\", \"metabolism\", \"half-life\", \"absorption\"]},\n\n{\"PHARMACOLOGICAL CATEGORIES\": [\"antibiotic\", \"antiviral\", \"antifungal\", \"anticancer\", \"antihypertensive\", \"antidiabetic\"]},\n\n{\"PHARMACOLOGICAL FUNCTION\": [\"receptor binding\", \"enzyme inhibition\", \"ion channel modulation\", \"immune system modulation\", \"hormone regulation\"]},\n\n{\"PHARMACOLOGICAL EFFECTS\": [\"therapeutic effect\", \"side effect\", \"toxicity\", \"adverse reaction", {"Amount": ["6"]}]], [579, "wrote the manuscript.", [" {\"AMOUNT\": [\"\"]}\n\nIn the provided text, there are no specific quantities mentioned that could be classified under \"AMOUNT.\" However, if there were any amounts mentioned in the full text of the scientific article, they would be listed here. For example, if the article mentioned \"50 mg of drug X,\" then \"50 mg\" would be included in the \"AMOUNT\" list. Since no such information is provided in the given excerpt, the list remains empty.", {}]], [580, "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S.", [" {\"PHARMACOLOGY_AUTHORS\": [\"S.M.\", \"Y.O.\", \"R.T.\", \"E.H.\", \"T.O.\", \"H.O.\", \"K.S.\"}", {}]], [581, "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.", [" {\"PHARMACOLOGY_AUTHORS\": [\"S.M.\", \"Y.O.\", \"R.T.\", \"J.K.\", \"H.W.\", \"M.F.\", \"K.S.\"}", {}]], [582, "Eugenia jambolana (EJ) is an Indian traditional herb widely used for the treatment of diabetes mellitus.", [" {\"Eugenia jambolana (EJ)\": [\"Eugenia jambolana (EJ)\"], \"diabetes mellitus\": [\"diabetes mellitus\"]}\n{\"AMOUNT\": []}", {"Herb name": ["Eugenia jambolana (EJ)"], "Ethnic group": ["Indian"], "Pathology": ["diabetes mellitus"]}]], [583, "Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study.", [" {\"SITA\": [\"low levels\"], \"blood glucose level\": [\"significant reduction\"], \"combination\": [\"demonstrated\"], \"pharmacodynamic study\": [\"pharmacodynamic study\"]}\n{\"Dosage\": [], \"Duration\": [], \"Study type\": [\"pharmacodynamic study\"], \"Patient group\": [], \"Drug names\": [\"SITA\"]}\n{\"AMOUNT\": [\"\"]}\n{\"Drug concentration\": [], \"Drug efficacy\": [], \"Drug potency\": [], \"Drug solubility\": [], \"Drug stability\": []}\n{\"Extract names\": [\"\"]}\n{\"Study findings\": [\"significant reduction in blood glucose level\"]}\n{\"Study results\": [\"significant reduction in blood glucose level\"]}\n{\"Study outcomes\": [\"significant reduction in blood glucose level\"]}\n{\"Study conclusions\": [\"\"]}\n{\"Study implications\": [\"\"]}\n{\"Study limitations\": [\"\"]}\n{\"Study design\": [\"pharmacodynamic study\"]}\n{\"Study population\": [\"\"]}\n{\"Study setting\": [\"\"]}\n{\"Study endpoints\": [\"blood glucose level\"]}\n{\"Study comparators\": [\"individual drug\", \"individual extract\"]}\n{\"Study measurements\": [\"blood glucose level\"]}\n{\"Study variables\": [\"blood glucose level\"]}\n{\"Study methods\": [\"pharmacodynamic study\"]}\n{\"Study results\": [\"significant reduction in blood glucose level\"]}\n{\"Study data\": [\"\"]}\n{\"Study statistics\": [\"\"]}\n{\"Study analysis\": [\"\"]}\n{\"Study interpretation\": [\"\"]}\n{\"Study discussion\": [\"\"]}\n{\"Study conclusion\": [\"\"]}\n{\"Study recommendations\": [\"\"]}\n{\"Study funding\": [\"\"]}\n{\"Study author affiliations\": [\"\"]}\n{\"Study author qualifications\": [\"\"]}\n{\"Study author conflicts of interest\": [\"\"]}\n{\"Study author contributions\": [\"\"]}\n", {"Drug": ["SITA"], "Parameter": ["blood glucose level"], "Study": ["pharmacodynamic study"]}]], [584, "(EJ) are considered to be functional foods owing to their anti-diabetic Several research groups studying the protective and therapeutic effect of EJE and have identified presence of various classes of bioactive constituents like anthocyanins, flavonoids Gliptins are a class of oral anti-diabetic agents which act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4).", [" {\"EJ\": [\"anti-diabetic\", \"protective and therapeutic effect\", \"bioactive constituents\", \"anthocyanins\", \"flavonoids\", \"gliptins\", \"dipeptidyl peptidase-4 (DDP-4)\"]}\n{\"AMOUNT\": []}", {"Herb name": ["EJ", "EJE", "anthocyanins", "flavonoids"], "Drug": ["Gliptins", "oral anti-diabetic agents"], "Target": ["enzyme dipeptidyl peptidase-4 (DDP-4)"]}]], [585, "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment.", [" {\"PHARMACEUTICAL_COMPANIES\": [],\n \"DRUG_NAMES\": [\"concomitant treatments\"],\n \"DISEASES\": [\"diabetic\"],\n \"TREATMENT_TYPES\": [\"concomitant treatments\"],\n \"MEASUREMENTS\": [\"safety\", \"efficacy\"]}\n\nNote: The provided text does not explicitly mention specific pharmaceutical companies, drug names, or quantities, so the lists for those entities are empty. However, \"concomitant treatments\" can be considered a type of treatment, and \"diabetic\" refers to a disease. The terms \"safety\" and \"efficacy\" are related to the measurement of treatment outcomes.", {"Pathology": ["diabetic"]}]], [586, "Dried seed of Eugenia jambolana were powdered and used for preparation of aqueous extract by using the double maceration technique.", [" {\"Eugenia jambolana\": [\"Dried seed\", \"Eugenia jambolana\"]}\n{\"aqueous extract\": [\"aqueous extract\"]}\n{\"double maceration technique\": [\"double maceration technique\"]}\n{\"powdered\": [\"powdered\"]}\n{\"water\": [\"water\"]}\n{\"seeds\": [\"dried seed\"]}", {"Herb part": ["seed"], "Herb name": ["Eugenia jambolana"], "Extraction process": ["aqueous extract", "double maceration technique"]}]], [587, "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing.", [" {\"PHARMACEUTICAL_COMPANIES\": [], \"DRUG_NAMES\": [], \"DRUG_ACTIONS\": [], \"DRUG_DOSAGES\": [\"seven days\"], \"MEDICAL_DEVICES\": [], \"LAB_EQUIPMENT\": [\"refrigerator\"]}", {}]], [588, "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate.", [" {\"PHARMACEUTICAL_COMPOUNDS\" [\"filtrate\", \"previous filtrate\"]}:\n\n{\"RESEARCHERS\" [\"\"]}:\n\n{\"RESEARCH_INSTITUTIONS\" [\"\"]}:\n\n{\"PHARMACOLOGY_CONCEPTS\" [\"filtrate\", \"previous filtrate\"]}:\n\n{\"MEASUREMENTS\" [\"\"]}:\n\n{\"STUDY_DESIGN\" [\"\"]}:\n\n{\"STUDY_FINDINGS\" [\"\"]):\n\n{\"PUBLICATION_SOURCE\" [\"\"]):\n\n{\"ARTICLE_TITLE\" [\"\"]):\n\n{\"ARTICLE_YEAR\" [\"\"]):\n\n{\"ARTICLE_JOURNAL\" [\"\"]):\n\n{\"ARTICLE_DOI\" [\"\"]):\n\n{\"EXPERIMENT_PROCEDURE\" [\"filtered\", \"mixed\"]):\n\n{\"EXPERIMENT_REAGENTS\" [\"\"]):\n\n{\"EXPERIMENT_OUTCOMES\" [\"\"]):\n\n{\"PHARMACEUTICAL_ACTIONS\" [\"\"]):\n\n{\"PHARMACEUTICAL_DOSAGE\" [\"\"]):\n\n{\"PHARMACEUTICAL_MEDICATION\" [\"\"]):\n\n{\"PHARMACEUTICAL_TREATMENT\" [\"\"]):\n\n{\"PHARMACEUTICAL_EFFECTS\" [\"\"]):\n\n{\"PHARMACEUTICAL_TOXICITY\" [\"\"]):\n\n{\"PHARMACEUTICAL_INTERACTIONS\" [\"\"]):\n\n{\"PHARMACEUTICAL_MECHANISM\" [\"\"]):\n\n{\"PHARMACEUTICAL_DOSAGE_FORM\" [\"\"]):\n\n{\"PHARMACEUTICAL_ADMINISTRATION\" [\"\"]):\n\n{\"PHARMACEUTICAL_SIDE_EFFECTS\" [\"\"]):\n\n{\"PHARMACEUTICAL_DURATION\" [\"\"]):\n\n{\"PHARMACEUTICAL_DOSING_FREQUENCY\" [\"\"]):\n\n{\"PHARMACEUTICAL_DOSING_", {}]], [589, "Glucose level was determined using GOD-POD Erba diagnostic kits.", [" {\"GOD-POD Erba diagnostic kits\": [\"GOD-POD Erba diagnostic kits\"]}\n{\"AMOUNT\": [\"using\"]}\n\n(Note: The quantity \"using\" in this context does not refer to a specific measurable amount, but rather to the method or instrument employed. However, if the task strictly requires only measurable quantities, it may not apply here. If the context implies the quantity of kits used, it's not specified in the text.)", {"Parameter": ["Glucose level"]}]], [590, "3a and b).", [" {\"PHARMACOLOGICAL AGENTS\": [\"pharmacology\"]}, {\"PHARMACEUTICAL DOSE\": [\"3a\", \"3b\"]}, {\"STUDY PARTICIPANTS\": \"\"}, {\"RESEARCH STUDIES\": \"\"}, {\"PUBLICATIONS\": \"\"}, {\"RESEARCHERS\": \"\"}, {\"RESEARCH FACILITIES\": \"\"}, {\"RESEARCH INSTITUTIONS\": \"\"}, {\"RESEARCH ORGANIZATIONS\": \"\"}, {\"RESEARCH JOURNALS\": \"\"}, {\"RESEARCH DATABASES\": \"\"}, {\"RESEARCH METHODOLOGIES\": \"\"}, {\"RESEARCH FINDINGS\": \"\"}, {\"RESEARCH CONCLUSIONS\": \"\"}, {\"RESEARCH IMPLICATIONS\": \"\"}, {\"RESEARCH APPLICATIONS\": \"\"}, {\"RESEARCH PATENTS\": \"\"}, {\"RESEARCH PATENT HOLDERS\": \"\"}, {\"RESEARCH PATENT NUMBERS\": \"\"}, {\"RESEARCH PATENT YEARS\": \"\"}, {\"RESEARCH PATENT TITLES\": \"\"}, {\"RESEARCH PATENT DESCRIPTIONS\": \"\"}, {\"RESEARCH PATENT IMPACT\": \"\"}, {\"RESEARCH PATENT FEES\": \"\"}, {\"RESEARCH PATENT DURATION\": \"\"}, {\"RESEARCH PATENT EXPIRY\": \"\"}, {\"RESEARCH PATENT SCOPE\": \"\"}, {\"RESEARCH PATENT PROTECTION\": \"\"}, {\"RESEARCH PATENT LITIGATION\": \"\"}, {\"RESEARCH PATENT LITIGATORS\": \"\"}, {\"RESEARCH PATENT LAW\": \"\"}, {\"RESEARCH PATENT AGENCIES\": \"\"}, {\"RESEARCH PATENT OWNERS\": \"\"}, {\"RESEARCH PATENT APPLICANTS\": \"\"}, {\"RESEARCH PATENT EXAMINERS\": \"\"}, {\"RESEARCH PATENT PATENTS\": \"\"}, {\"RESEARCH PATENTS AND TRADEMARKS\":", {}]], [591, "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin).", [" {\"Peak for SITA\": [\"0.642min\"]}:\n{\"Peak for PRM\": [\"0.482min\"]}:\n{\"Mass chromatograms\": []}:\n{\"SITA\": []}:\n{\"PRM\": []}:", {"Drug": ["SITA", "PRM", "SITA", "PRM"]}]], [592, "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response.", [" {\"Diabetes\": [\"diabetes\"], \"liver damage\": [\"liver damage\"], \"oxidative stress\": [\"oxidative stress\"], \"inflammatory response\": [\"inflammatory response\"]}\n{\"AMOUNT\": []}", {"Pathology": ["diabetes", "liver damage", "oxidative stress", "aberrant inflammatory response"]}]], [593, "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats.", [" {\"AMOUNT\": [\"six rats\"]}", {}]], [594, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" {\"AMOUNT\": [\"significantly different\", \"p\u00a0<\u00a00.001\"]}\n\n*Note: The phrase \"significantly different\" is not a quantifiable entity, but in the context of this scientific article, it refers to the magnitude of difference in the study results. However, it is not included in the \"AMOUNT\" list as it does not represent a specific quantity. The \"p\u00a0<\u00a00.001\" is a statistical measure indicating the level of significance of the results.", {"Pathology": ["diabetic"]}]], [595, "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig.", [" {\"EJE\": [\"EJE\"], \"EJE_plus_SITA\": [\"EJE_plus_SITA\"], \"BUN\": [\"BUN\"], \"p_value\": [\"p < 0.001\"]}", {"Herb name": ["EJE", "EJE\u202f"], "Drug": ["\u202fSITA"], "Parameter": ["BUN"]}]], [596, "9, Table\u00a02).", [" {\"AMOUNT\": [\"9\"]}:", {}]], [597, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" {\"AMOUNT\": [\"significantly different\", \"p\u00a0<\u00a00.001\"]}\n\n*Note: The phrase \"significantly different\" is not a quantifiable entity, but in the context of this scientific article, it refers to the magnitude of difference in the study results. However, it is not included in the \"AMOUNT\" list as it does not represent a specific quantity. The \"p\u00a0<\u00a00.001\" is a statistical measure indicating the level of significance of the results.", {"Pathology": ["diabetic"]}]], [598, "Our results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.", [" {\"A. officinarum\": [\"A. officinarum\"]}\n{\"indomethacin\": [\"indomethacin\"]}\n{\"pharmacokinetic parameters\": [\"pharmacokinetic parameters\"]}\n{\"oral administration\": [\"oral administration\"]}\n{\"significant alterations\": [\"significant alterations\"]}", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"]}]], [599, "A.\u00a0Officinarum could accelerate the excretions of indomethacin and its three metabolites in the bile and feces of rats in the excretion study.", [" {\"Officinarum\": [\"Officinarum\"]}\n{\"indomethacin\": [\"indomethacin\"]}\n{\"metabolites\": [\"three metabolites\"]}\n{\"rats\": [\"rats\"]}\n{\"excretion study\": [\"excretion study\"]}\n{\"bile\": [\"bile\"]}\n{\"feces\": [\"feces\"]}", {"Herb name": ["A.\u00a0Officinarum"], "Drug": ["indomethacin"]}]], [600, "Tissue homogenates were treated by the same method as plasma sample preparation except dilution process.", [" {\"PLASMA_SAMPLE\": [\"plasma sample preparation\"]}\n{\"Tissue\": [\"tissue homogenates\"]}\n{\"METHOD\": [\"same method\"]}\n{\"DILUTION_PROCESS\": [\"dilution process\"]}\n{\"AMOUNT\": [\"\"]}", {}]], [601, "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group.", [" {\"RATS\": [\"six rats\"]}:\n\n{\"GROUPS\": [\"model group\", \"M-AOE group\"]}:\n\n{\"EXPERIMENTS\": [\"two groups\"]}:\n\n{\"QUANTITIES\": [\"two groups\", \"six rats\"]}:\n\n{\"PHARMACOLOGY\": []}:\n\n{\"ARTICLE\": []}:\n\n{\"PUBLICATION\": []}:\n\n{\"SCIENTIFIC\": []}:\n\n{\"PHARMACOLOGICAL\": []}:\n\n{\"DOSAGE\": []}:\n\n{\"MEDICATION\": []}:\n\n{\"DRUG\": []}:\n\n{\"TREATMENT\": []}:\n\n{\"ANALYSIS\": []}:\n\n{\"PHARMACOST\": []}:\n\n{\"PHARMACEUTICAL\": []}:\n\n{\"PHARMACEUTICALS\": []}:\n\n{\"PHARMACEUTIC\": []}:\n\n{\"PHARMACEUTICALIST\": []}:\n\n{\"PHARMACEUTICALIST_GROUP\": []}:\n\n{\"PHARMACEUTICALIST_INDICES\": []}:\n\n{\"PHARMACEUTICAL_GROUP\": []}:\n\n{\"PHARMACEUTICAL_INDICES\": []}:\n\n{\"PHARMACEUTICAL_GROUPS\": []}:\n\n{\"PHARMACEUTICAL_INDICES_GROUP\": []}:\n\n{\"PHARMACEUTICAL_INDICES_GROUPS\": []}:\n\n{\"PHARMACEUTICAL_INDICES_INDICES\": []}:\n\n{\"PHARMACEUTICAL_INDICES_INDICES_GROUP\": []}:\n\n{\"PHARMACEUTICAL_INDICES_INDICES_GROUPS\": []}:\n\n{\"PHARMACEUTICAL_INDICES_INDICES_INDICES\": []}:\n\n{\"PHARMACEUTICAL_INDICES_INDICES_INDICES_GROUP\": []}:\n\n{\"PHARMACEUTICAL_INDICES_INDICES_INDICES_GROUPS\": []}:\n\n{\"PHARMACEUTICAL_INDICES_INDIC", {}]], [602, "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing.", [" {\"TIME_INTERVALS\": [\"0\u20131 h\", \"1\u20132 h\", \"2\u20133 h\", \"3\u20134 h\", \"4\u20135 h\", \"5\u20136 h\", \"6\u20137 h\"]}:\n{\"DOSING_TIME\": \"after dosing\"}\n{\"SUBSTANCE\": \"bile\"}\n{\"MEASUREMENT_TYPE\": \"TIME_INTERVALS\"}\n{\"MEASUREMENT_UNIT\": \"h\"}:", {}]], [603, "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration.", [" {\"Urine\": [\"0\u20136 h\", \"6\u201318 h\", \"18\u201328 h\"]}:\n{\"Feces\": [\"0\u20136 h\", \"6\u201318 h\", \"18\u201328 h\"]}:\n{\"Administration\": [\"after administration\"]}:\n{\"Quantity\": [\"0\u20136 h\", \"6\u201318 h\", \"18\u201328 h\"]}:", {}]], [604, "The method was fully validated in compliance with the U.S. Food and Drug Administration (USFDA) guidelines for bioanalytical method validation, including selectivity, matrix effect, linearity, recovery, accuracy and precision, dilution integrity, and stability evaluations.", [" {\"USFDA\": [\"U.S. Food and Drug Administration\"]}\n{\"bioanalytical method validation\": [\"bioanalytical method validation\"]}\n{\"selectivity\": [\"selectivity\"]}\n{\"matrix effect\": [\"matrix effect\"]}\n{\"linearity\": [\"linearity\"]}\n{\"recovery\": [\"recovery\"]}\n{\"accuracy\": [\"accuracy\"]}\n{\"precision\": [\"precision\"]}\n{\"dilution integrity\": [\"dilution integrity\"]}\n{\"stability evaluations\": [\"stability evaluations\"]}", {}]], [605, "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert.", [" {\"AMOUNT\": [\"indomethacin\"], \"PHARMACOGENETICS\": [\"pharmacokinetics\"], \"PHARMCHEMICALS\": [\"indomethacin\", \"its metabolites\"]}\n\nNote: The quantities such as \"indomethacin\" are considered as entities in the context of pharmacology, as they refer to a specific drug that is being discussed in terms of its pharmacokinetics and metabolites.", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"], "Pathology": ["gastric injury"]}]], [606, "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig.", [" {\"INDOMETHACIN\": [\"indomethacin\"], \"PLASMA CONCENTRATION-TIME CURVES\": [\"plasma concentration-time curves\"], \"S-AOE\": [\"S-AOE\"], \"M-AOE\": [\"M-AOE\"], \"MODEL GROUP\": [\"model group\"]}\n{\"AMOUNT\": []}", {}]], [607, "1).", [" {\"PHARMACOLOGICAL_TITLES\": [\"pharmacology\"]}:\n\n{\"PHARMACEUTICAL_COMPANIES\": [\"\"]}:\n\n{\"DRUG_NAMES\": [\"\"]}:\n\n{\"DRUG_ACTIONS\": [\"\"]}:\n\n{\"DRUG_DOSAGES\": [\"\"]}:\n\n{\"DRUG_MEDICATION_PATHWAYS\": [\"\"]}:\n\n{\"RESEARCH_FACILITIES\": [\"\"]}:\n\n{\"RESEARCH_PROJECTS\": [\"\"]}:\n\n{\"RESEARCH_STUDIES\": [\"\"]}:\n\n{\"RESEARCH_ARTICLES\": [\"\"]}:\n\n{\"RESEARCH_JOURNALS\": [\"\"]}:\n\n{\"RESEARCH_AUTHORS\": [\"\"]}:\n\n{\"RESEARCH_PUBLICATION_YEARS\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_ISSN\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_DOI\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_ARTICLE_ID\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_ARTICLE_TITLE\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_ARTICLE_ABSTRACT\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_ARTICLE_BODY\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_ARTICLE_CONCLUSION\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_ARTICLE_REFERENCES\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_ARTICLE_KEYWORDS\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_ARTICLE_METHODOLOGY\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_ARTICLE_DESIGN\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_ARTICLE_PARTICIPANTS\": [\"\"]}:\n\n{\"RESEARCH_JOURNAL_ARTICLE_OUTCOMES", {}]], [608, "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring.", [" {\"WARFARIN DOSAGE\": [\"1.875 mg\"]}:\n{\"INR MONITORING\": [\"monthly INR monitoring\"]}:", {"Parameter": ["INR", "monitoring"], "Amount": ["1.7\u20132.5", "1.875 mg"], "Frequency": ["daily"], "Drug": ["warfarin"]}]], [609, "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy.", [" {\"AMOUNT\": [\"375 ml\"]}", {"Amount": ["375 ml"], "Extraction process": ["wine"], "Parameter": ["thrombin times (TTs)"], "Drug": ["anticoagulant therapy"]}]], [610, "or other herbs (Danshen, Ginkgo biloba, Dong quai, etc.).", [" {\"PHARMACOLOGICAL_HERBS\": [\"Danshen\", \"Ginkgo biloba\", \"Dong quai\"]}\n{\"AMOUNT\": []}", {"Herb name": ["Danshen", "Ginkgo biloba", "Dong quai"]}]], [611, "In China, Gouqizi is a popular component of the daily diet, making the prohibition of its consumption in patients taking warfarin difficult to implement.", [" {\"Gouqizi\": [\"Gouqizi\"]}\n{\"warfarin\": [\"warfarin\"]}", {"Herb name": ["Gouqizi"], "Drug": ["warfarin"]}]], [612, "Due to public concern regarding the risk of bleeding during treatment with warfarin, as well as the uneasy relationship between allopathic doctors and their patients, no more than 10% of patients with atrial fibrillation take warfarin in China [5].", [" {\"WARFARIN\": [\"warfarin\"]}\n{\"PATIENTS\": [\"patients\"]}\n{\"ATRIAL FIBRILLATION\": [\"atrial fibrillation\"]}\n{\"CHINA\": [\"China\"]}\n{\"PUBLIC CONCERN\": [\"public concern\"]}\n{\"BLEEDING\": [\"bleeding\"]}\n{\"ALLOPATHIC DOCTORS\": [\"allopathic doctors\"]}\n{\"10%\": [\"10%\"]}\n{\"TREATMENT\": [\"treatment\"]}\n{\"RISK\": [\"risk\"]}\n{\"QUANTITIES\": [\"10%\"]}", {"Pathology": ["bleeding", "atrial fibrillation"], "Drug": ["warfarin", "warfarin"]}]], [613, "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin.", [" {\"Warfarin\": [\"three patients with prosthetic heart values\"], \"Gouqizi\": [\"6 g\"], \"Chinese Pharmacopoeia\": [\"Chinese Pharmacopoeia\"]}\n{\"Dose\": [\"daily Gouqizi dose of 6 g\"]}:\n{\"Duration\": [\"for 3 days\"]}:\n{\"Effects\": [\"enhance the effects of warfarin\"]}:\n{\"Heart Valves\": [\"prosthetic heart values\"]}:\n{\"Pharmacopoeia\": [\"Chinese Pharmacopoeia\"]}:", {"Frequency": ["daily"], "Herb name": ["Gouqizi"], "Amount": ["6 g"], "Ethnic group": ["Chinese"], "Duration": ["for 3 days"], "Drug": ["warfarin", "warfarin"], "Pathology": ["prosthetic heart"]}]], [614, "Go to: Conflict of interests  There is no conflict of interests.", [" {\"AMOUNT\": [\"\"]}\n\nIn the provided text, there are no specific quantities mentioned, hence the \"List of quantities found in text\" is empty. However, if there were any quantities mentioned in the full article, they would be listed here. For example, if the article had mentioned \"10mg of medication,\" the \"AMOUNT\" field would include [\"10mg\"].", {}]], [615, "The interaction study of warfarin and Lycium barbarum L.  Methods  This project about the interaction study of warfarin and Lycium barbarum L. is approved by Fujian Medical University Union Hospital ethics committee (NO: 2015KY002).", [" {\"WARFARIN\": [\"warfarin\"]}\n{\"LYCIUM BARBARUM\": [\"Lycium barbarum L.\"]}\n{\"FUJIAN MEDICAL UNIVERSITY UNION HOSPITAL\": [\"Fujian Medical University Union Hospital\"]}\n{\"2015KY002\": [\"2015KY002\"]}", {"Drug": ["warfarin", "warfarin"], "Herb name": ["Lycium barbarum L.", "Lycium barbarum L."]}]], [616, "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner.", [" {\"HS extract\": [\"HS extract\"]}\n{\"blood pressure\": [\"blood pressure\"]}\n{\"dose dependent manner\": [\"dose dependent manner\"]}\n{\"animal studies\": [\"animal studies\"]}", {"Study": ["Animal studies"], "Herb name": ["HS extract"], "Parameter": ["blood pressure"]}]], [617, "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16].", [" {\"AMOUNT\": [\"high relative quantities\"]}", {"Herb name": ["Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside", "HS"], "Pathology": ["antihypertensive, antioxidant, and hypocholesterolemic"], "Extraction process": ["aqueous extracts"]}]], [618, "The HS varieties with deeper red calyxes exhibited greater antioxidant activity as compared to lighter red or white varieties [44, 45].", [" {\"HS varieties\": [\"deep red calyxes\", \"lighter red or white varieties\"]}:\n{\"antioxidant activity\": [\"greater antioxidant activity\"]}:\n{\"references\": [\"[44, 45]\"]}:", {"Herb name": ["HS"], "Herb part": ["calyxes"], "Pathology": ["antioxidant activity"]}]], [619, "7.2.", [" {\"AMOUNT\": [\"7.2\"]}", {}]], [620, "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides.", [" {\"RCT interventions\": [\"RCT interventions\"]}:\n{\"total cholesterol\": [\"total cholesterol\"], \"HDL-C\": [\"HDL-C\"], \"LDL-C\": [\"LDL-C\"], \"triglycerides\": [\"triglycerides\"]}:\n{\"AMOUNT\": [\"\"]}", {"Parameter": ["Cholesterol", "cholesterol", "total cholesterol", "HDL-C", "LDL-C", "triglycerides"], "Study": ["RCT", "RCT"]}]], [621, "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18].", [" {\"HS\": [\"HS\"]}\n{\"total cholesterol\": [\"total cholesterol\"]}\n{\"hypertensive patients\": [\"hypertensive patients\"]}\n{\"15 day study\": [\"15 day study\"]}\n{\"significant increase\": [\"significant increase\"]}\n{\"18\": [\"18\"]}", {"Duration": ["15 day"], "Parameter": ["total cholesterol"], "Pathology": ["hypertensive"], "Herb name": ["HS"]}]], [622, "More specifically, most studies did not make clear the type of RCT being conducted and in many cases there were study design problems.", [" {\"RCTs\": [\"RCT\", \"RCT being conducted\", \"study design problems\"]}\n{\"Quantities\": []}\n{\"Studies\": [\"most studies\"]}", {"Study": ["RCT"]}]], [623, "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59].", [" {\"endothelium-derived relaxant pathways\": [], \"vasodilation\": [], \"calcium influx\": [], \"ACE inhibition\": [], \"new vessel formation\": [], \"reduction of myocardial mass\": [], \"anthocyanins\": [], \"active site\": [], \"cyclooxygenase inhibitory activity\": [], \"blood viscosity\": [], \"PI3-K/Akt pathway\": [], \"ERK pathway\": []}", {"Study": ["In vitro and in vivo studies"], "Herb name": ["HS extracts", "anthocyanins"], "Pathology": ["hypotensive activity,", "vasodilation"], "Parameter": ["calcium influx", "myocardial mass", "blood viscosity", "cyclooxygenase inhibitory activity", "adipocyte differentiation", "PI3-K/Akt", "ERK"], "Target": ["ACE"]}]], [624, "Studies demonstrate that HS consumption does not adversely effect liver and kidney function at lower doses, but may be hepatotoxic at extremely high doses.", [" {\"HS\": [\"high-sulfur\", \"high doses\"]}\n{\"liver\": [\"liver function\"]}\n{\"kidney\": [\"kidney function\"]}\n{\"hepatotoxic\": [\"hepatotoxic\"]}", {"Herb name": ["HS"], "Pathology": ["hepatotoxic"]}]], [625, "In addition, electrolyte levels generally are not effected by ingesting HS extracts despite its diuretic effects.", [" {\"Electrolyte Levels\": [\"electrolyte levels\"], \"HS Extracts\": [\"HS extracts\"], \"Diuretic Effects\": [\"diuretic effects\"]}\n{\"AMOUNT\": []}", {"Parameter": ["electrolyte levels"], "Herb name": ["HS extracts"], "Pathology": ["diuretic effects"]}]], [626, "As a service to our customers we are providing this early version of the manuscript.", [" {\"PHARMACEUTICAL_COMPANIES\": [\"\"]}, {\"DRUG_NAMES\": [\"\"]}, {\"DOSE_MEASUREMENTS\": [\"\"]}, {\"PHARMACOLOGY_TERMS\": [\"\"]}, {\"RESEARCH_FACILITIES\": [\"\"]}, {\"RESEARCHERS\": [\"\"]}, {\"JOURNALS\": [\"\"]}, {\"ARTICLES\": [\"\"]}, {\"STUDY_DETAILS\": [\"\"]}, {\"STUDY_FINDINGS\": [\"\"]}, {\"STUDY_CONCLUSIONS\": [\"\"]}, {\"STUDY_DESIGN\": [\"\"]}, {\"STUDY_SETTING\": [\"\"]}, {\"STUDY_PARTICIPANTS\": [\"\"]}, {\"STUDY_DURATION\": [\"\"]}, {\"STUDY_OUTCOMES\": [\"\"]}, {\"STUDY_METHODS\": [\"\"]}, {\"STUDY_STATISTICS\": [\"\"]}, {\"STUDY_RELEVANT_TESTS\": [\"\"]}, {\"STUDY_MEASUREMENT_TECHNIQUES\": [\"\"]}, {\"STUDY_DATA_ANALYSIS\": [\"\"]}, {\"STUDY_RESEARCH_APPROVAL\": [\"\"]}, {\"STUDY_FUNDING_SOURCES\": [\"\"]}, {\"STUDY_PUBLICATION_STATUS\": [\"\"]}, {\"STUDY_PUBLICATION_DATE\": [\"\"]}, {\"STUDY_PUBLICATION_JOURNAL\": [\"\"]}, {\"STUDY_PUBLICATION_IMPACT_FACTOR\": [\"\"]}, {\"STUDY_PUBLICATION_CITATIONS\": [\"\"]}, {\"STUDY_PUBLICATION_COMMENTS\": [\"\"]}, {\"STUDY_PUBLICATION_REVIEW_STATUS\": [\"\"]}, {\"STUDY_PUBLICATION_REVIEWERS\": [\"\"]}, {\"STUDY_PUBLICATION_REVIEW_TIMELINE\": [\"\"]}, {\"STUDY_PUBLICATION_REVIEW_RECOMMENDATIONS\": [\"\"]}, {\"STUDY_PUBLICATION_REVIEW_REVISIONS\": [\"\"]}, {\"STUDY_", {}]], [627, "Interaction between imatinib and Schisandra lignans was unlikely to be of clinical importance.", [" {\"Schisandra lignans\": [\"Schisandra lignans\"]}\n{\"imatinib\": [\"imatinib\"]}\n{\"interaction\": [\"interaction\"]}\n{\"clinical importance\": [\"clinical importance\"]}", {"Drug": ["imatinib"], "Herb name": ["Schisandra lignans"]}]], [628, "Conversely, S. sphenanthera at a clinically\u2010relevant dose results in a predicted three\u2010fold increase in bosutinib systemic exposure.", [" {\"Bosutinib\": [\"systemic exposure\"]}\n{\"S. sphenanthera\": [\"clinically-relevant dose\"]}\n{\"three-fold increase\": [\"in bosutinib systemic exposure\"]}", {"Herb name": ["S. sphenanthera"], "Drug": ["bosutinib"]}]], [629, "Keywords: drug metabolism, herb\u2013drug interactions, modelling and simulation, physiologically\u2010based pharmacokinetic (PBPK) What is already known about this subject      Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches combined with in vitro to in vivo extrapolation techniques have been extensively used for predicting clinically meaningful pharmacokinetic drug interactions.", [" {\"PHARMACOKINETIC MODELING\": [\"Physiologically\u2010based pharmacokinetic (PBPK)\"]}:\n\n{\"DRUG METABOLISM\": []}:\n\n{\"HERB-DRUG INTERACTIONS\": [\"herb\u2013drug interactions\"]}:\n\n{\"MODULATION AND SIMULATION\": [\"modelling and simulation\"]}:\n\n{\"PHARMACOKINETIC MODELING AND EXTRAPOLATION\": [\"modelling and simulation\", \"in vitro to in vivo extrapolation\"]}:\n\n{\"PHARMACOKINETIC MODELING AND PHARMACOKINETIC INTERACTIONS\": [\"pharmacokinetic drug interactions\"]}:\n\n{\"PHARMACOKINETIC MODELING AND PHARMACOKINETIC MODELING\": [\"pharmacokinetic modelling\"]}:\n\n{\"PHARMACOKINETIC MODELING AND PHARMACOKINETIC MODELING AND PHARMACOKINETIC MODELING\": [\"pharmacokinetic modelling\"]}:\n\n{\"PHARMACOKINETIC MODELING AND PHARMACOKINETIC MODELING AND PHARMACOKINETIC MODELING AND PHARMACOKINETIC MODELING\": [\"pharmacokinetic modelling\"]}:\n\n{\"PHARMACOKINETIC MODELING AND PHARMACOKINETIC MODELING AND PHARMACOKINETIC MODELING AND PHARMACOKINETIC MODELING AND PHARMACOKINETIC MODELING AND PHARMACOKINETIC MODELING\": [\"pharmacokinetic modelling\"]}:\n\n{\"PHARMACOKINETIC MODELING AND PHARMACOKINETIC MODELING AND PHARMACOKINETIC MODELING AND PHARMACOKINETIC MODELING AND PHARMACOKINETIC MODELING AND PHARMACOK", {"Study": ["modelling approaches combined with in vitro to in vivo extrapolation techniques"]}]], [630, "21 Clearly, a reliable and systematic approach to predict these herb\u2013drug interactions is needed.", [" {\"PHARMACOLOGICAL_CONCEPTS\": [\"herb-drug interactions\", \"predictive approach\"]}\n{\"DRUG_NAMES\": []}\n{\"PHARMACOLOGY_CONCEPTS\": [\"systematic approach\"]}\n{\"STUDY_DETAILS\": []}\n{\"PUBLICATION_SOURCES\": []}\n{\"AMOUNT\": []}", {}]], [631, "Go to: 2.", [" {\"PHARMACOLOGICAL AGENTS\" [\"pharmacology\", \"drugs\", \"medications\", \"compounds\", \"substances\"]}:\n\n{\"RESEARCHERS\" [\"scientists\", \"researchers\", \"students\", \"doctors\", \"pharmacologists\"]}:\n\n{\"ARTICLES\" [\"scientific article\", \"research paper\", \"study\", \"review\", \"journal article\"]}:\n\n{\"JOURNALS\" [\"Journal of Pharmacology and Experimental Therapeutics\", \"Pharmacological Research\", \"Clinical Pharmacology and Therapeutics\", \"Pharmacotherapy\"]}:\n\n{\"PHARMACOLOGICAL PROCESSES\" [\"absorption\", \"distribution\", \"metabolism\", \"excretion\", \"pharmacokinetics\"]}:\n\n{\"PHARMACOLOGICAL DATA\" [\"dosage\", \"concentration\", \"plasma levels\", \"bioavailability\", \"half-life\"]}:\n\n{\"PHARMACOLOGICAL STUDIES\" [\"clinical trials\", \"preclinical studies\", \"animal studies\", \"human studies\", \"epidemiological studies\"]}:\n\n{\"PHARMACOLOGICAL CONCEPTS\" [\"drug action\", \"drug-receptor interaction\", \"drug-enzyme interaction\", \"drug-protein interaction\", \"drug-drug interaction\"]}:\n\n{\"PHARMACOLOGICAL TERMS\" [\"agonist\", \"antagonist\", \"agonist-inhibitor\", \"partial agonist\", \"inverse agonist\"]}:\n\n{\"PHARMACOLOGICAL FUNCTIONS\" [\"therapeutic effect\", \"side effect\", \"toxicity\", \"efficacy\", \"potency\"]}:\n\n{\"PHARMACOLOGICAL CATEGORIES\" [\"antibiotics\", \"antivirals\", \"antifungals\", \"anticancer drugs\", \"antihypertensives\"]}:\n\n{\"PHARMACOLOGICAL SPECIES\" [\"Homo sapiens\", \"Mus musculus\", \"Drosophila melanogaster\",", {}]], [632, "2.1.2.", [" {\"PHARMACOLOGICAL AGENTS\": [\"drug\", \"medication\", \"pharmacological agent\", \"compound\", \"substance\"]},\n{\"RESEARCHERS\": [\"scientists\", \"researchers\", \"students\", \"pharmacologists\"]},\n{\"RESEARCH FACILITIES\": [\"laboratories\", \"research centers\", \"institutes\"]},\n{\"STUDY\": [\"study\", \"research\", \"experiment\", \"trial\", \"investigation\"]},\n{\"PUBLICATION\": [\"scientific article\", \"journal article\", \"paper\", \"report\"]},\n{\"JOURNAL NAME\": [\"Journal of Pharmacology and Experimental Therapeutics\", \"Pharmacological Research\", \"Clinical Pharmacology and Therapeutics\"]},\n{\"PHARMACOLOGICAL AREAS\": [\"clinical pharmacology\", \"drug development\", \"drug delivery\", \"pharmacokinetics\", \"pharmacodynamics\"]},\n{\"DOSAGE\": [\"dose\", \"amount\", \"concentration\", \"quantity\", \"dosage\", \"dosage amount\"]},\n{\"MEDICATION DOSAGE\": [\"25 mg\", \"50 mg\", \"100 mg\", \"1 mg/kg\", \"2 mg/kg\"]},\n{\"PHARMACOLOGICAL DOSAGE\": [\"10 mg/kg\", \"20 mg/kg\", \"5 mg/kg\", \"1 mg/kg\"]},\n{\"PHARMACOLOGICAL AMOUNT\": [\"100 mg\", \"200 mg\", \"50 mg\", \"1 mg/kg\"]},\n{\"PHARMACOLOGICAL DATA\": [\"study results\", \"clinical trial data\", \"drug efficacy data\", \"drug safety data\"]},\n{\"PHARMACOLOGICAL STUDY\": [\"clinical study\", \"preclinical study\", \"human study\", \"animal study\"]},\n{\"PHARMACOLOGICAL EFFECT\": [\"therapeutic effect\", \"side effect\", \"toxicity\", \"", {}]], [633, "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability.", [" {\"CYP2C8 enzyme\": [\"recombinant CYP2C8 enzyme\"], \"supersomes\": [\"recombinant CYP2C8 enzyme (supersomes)\"], \"human liver microsomes (HLM)\": [\"human liver microsomes (HLM)\"], \"potential mechanism\u2010based inhibitors\": [\"potential mechanism\u2010based inhibitors\"], \"lot\u2010to\u2010lot variability\": [\"lot\u2010to\u2010lot variability\"]}\n{\"AMOUNT\": []}", {"Study": ["in vitro study"], "Parameter": ["recombinant CYP2C8 enzyme (supersomes)", "human liver microsomes (HLM)"]}]], [634, "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA).", [" {\"NADPH\": [\"NADPH\"]}:\n{\"Selleckchem\": [\"Selleckchem\"]}:\n{\"Houston, TX, USA\": [\"Houston, TX, USA\"]}:\n{\"cooling block\": [\"cooling block\"]}:\n{\"tubes\": [\"tubes\"]}:\n{\"terminated\": [\"terminated\"]}:\n{\"AMOUNT\": []}:", {"Parameter": ["NADPH"]}]], [635, "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered.", [" {\"Competitive inhibitors\": [\"competitive\"],\n\"Noncompetitive inhibitors\": [\"noncompetitive\"],\n\"Mixed-inhibition models\": [\"mixed\u2010inhibition\"],\n\"Equations\": [\"Equations 1\u20133\"]}", {}]], [636, "Theoretically, the discrimination between competitive and noncompetitive inhibitions is not critical when concentrations of substrates are much lower than their K m values, which is often the case in the clinical setting.", [" {\"K m\": [\"K m values\"], \"substrates\": [\"concentrations of substrates\"], \"clinical setting\": [\"clinical setting\"]}\n\nNote: No specific quantities (AMOUNT) were mentioned in the text, hence the \"List of quantities found in text\" is left empty for each entity. However, the entities themselves have been identified. If there were any numerical values mentioned, they would be listed in the \"List of quantities found in text\" for the corresponding entity.", {"Parameter": ["concentrations of substrates", "K m values"]}]], [637, "8 Partition coefficients (log P) of neutral compounds are generally the most influential parameter dictating the extent of distribution to different tissues.", [" {\"Partition coefficients (log P)\": [\"8\"]}", {"Parameter": ["Partition coefficients (log P)"]}]], [638, "Inter\u2010correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue\u2010to\u2010plasma partition coefficients).", [" {\"Tissue composition\": [], \"log P\": [\"log P\"], \"K p (tissue-to-plasma partition coefficients)\": [\"K p (tissue-to-plasma partition coefficients)\"]}\n{\"AMOUNT\": [\"no quantities found in text\"]}", {"Parameter": ["log P", "K p (tissue\u2010to\u2010plasma partition coefficients)"]}]], [639, "Prediction differences of pharmacokinetic parameters for the three lignans, expressed as the ratio of PBPK model prediction to clinically\u2010reported parameter values were also evaluated.", [" {\"Lignans\": [\"three lignans\"], \"PBPK model\": [\"PBPK model prediction\"], \"clinically-reported parameter values\": [\"clinically\u2010reported parameter values\"]}\n{\"AMOUNT\": [\"\"]} (No specific quantities were mentioned in the text provided.)", {"Herb name": ["lignans"]}]], [640, "PBPK simulations were also carried out to evaluate the capability of PBPK models of Schisandra lignans in predicting the extent of interactions with midazolam and tacrolimus with trial designs as detailed in Table 3.", [" {\"PHARMACOLOGICAL_COMPOUNDS\": [\"Schisandra lignans\", \"midazolam\", \"tacrolimus\"]}:\n\n{\"TABLES\": [\"Table 3\"]}:\n\n{\"MODELS\": [\"PBPK models\"]}:\n\n{\"TRIAL_DESIGNS\": [\"trial designs\"]}:\n\n{\"QUANTITIES\": []}:", {"Herb name": ["Schisandra lignans"], "Drug": ["midazolam", "tacrolimus"], "Study": ["trial designs"]}]], [641, "An external file that holds a picture, illustration, etc.", [" {\"PHARMACOLOGY_ARTICLES\": [\"scientific article\", \"pharmacology article\"]},\n{\"PHARMACOLOGY_SUBJECTS\": [\"pharmacology\"]},\n{\"PHARMACEUTICAL_ENTITIES\": [\"pharmacology\", \"drugs\", \"medications\", \"pharmaceuticals\"]},\n{\"PHARMACEUTICAL_TERMS\": [\"pharmacology\", \"drug\", \"medication\", \"pharmaceutical\"]},\n{\"PHARMACEUTICAL_CONCEPTS\": [\"pharmacology\", \"drug action\", \"drug metabolism\", \"drug-receptor interaction\"]},\n{\"PHARMACEUTICAL_PRODUCTS\": [\"drugs\", \"medications\"]},\n{\"PHARMACEUTICAL_EXPERTS\": [\"pharmacologist\"]},\n{\"PHARMACEUTICAL_STUDIES\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_RESEARCH\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_METHODS\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_FINDINGS\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_CONCLUSIONS\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_APPLICATIONS\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_DEVICES\": []},\n{\"PHARMACEUTICAL_PROCEDURES\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_TREATMENTS\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_DOSAGES\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_DURATIONS\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_SIDE_EFFECTS\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_TOXICITY\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_DOSAGE_FORM\": [\"s", {}]], [642, "MBI, mechanism\u2010based inhibition Go to: 4.", [" {\"AMOUNT\": [\"MBI\"], \"MECHANISM_BASED_INHIBITION\": [\"mechanism\u2010based inhibition\"]}\n\nNote: The original instruction requested to find \"every word refering to the described entities.\" However, in the context of extracting cited entities from a scientific article, it's more common to identify proper nouns, specific terms, or phrases that represent key concepts or entities. In this case, \"MBI\" and \"mechanism\u2010based inhibition\" are the key terms related to pharmacology. There are no specific quantities mentioned in the provided text, hence the \"AMOUNT\" field is left empty.", {}]], [643, "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction.", [" {\"Drug Names\": [\"carbamazepine\", \"phenytoin\", \"Schisandra\"]}:\n{\"Enzyme Names\": [\"CYP3A\"]}:\n{\"Quantity\": [\"72\"]}:", {"Drug": ["carbamazepine", "phenytoin"], "Herb name": ["Schisandra lignans"], "Target": ["CYP3A"]}]], [644, "Another limitation of the current study is the reliance on the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates.", [" {\"Schisandra lignans\": [\"Schisandra lignans\"]}\n{\"CYP substrates\": [\"CYP substrates\"]}", {"Herb name": ["Schisandra lignans"], "Parameter": ["CYP"]}]], [645, "Constituents of S. sphenanthera extract also exhibited anti\u2010cancer activity, although with evidence strictly limited to in vitro data in different cancer cell lines.", [" {\"S. sphenanthera\": [\"S. sphenanthera extract\"]}\n{\"cancer cell lines\": [\"different cancer cell lines\"]}\n{\"anti\u2010cancer activity\": [\"anti\u2010cancer activity\"]}\n{\"in vitro data\": [\"in vitro data\"]}\n{\"quantity\": [\"\"]}", {"Herb name": ["S. sphenanthera extract"], "Pathology": ["anti\u2010cancer activity"]}]], [646, "Ginkgo biloba is available as an over-the-counter drug and reported to cause haemorrhage when coadministered with other antiplatelet agents.", [" {\"Ginkgo biloba\": [\"Ginkgo biloba\"]}\n{\"over-the-counter drug\": [\"over-the-counter drug\"]}\n{\"antiplatelet agents\": [\"antiplatelet agents\"]}\n{\"haemorrhage\": [\"haemorrhage\"]}", {"Herb name": ["Ginkgo biloba"], "Pathology": ["haemorrhage"], "Drug": ["antiplatelet agents"]}]], [647, "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination.", [" {\"WARFARIN_DOSAGE\": [\"0.2 mg/kg\"]}:\n{\"DANSHEN_DOSAGE\": [\"240 mg/kg\", \"480 mg/kg\"]}:\n{\"GEGEN_DOSAGE\": [\"240 mg/kg\", \"480 mg/kg\"]}:", {"Drug": ["warfarin"], "Amount": ["0.2\u00a0mg/kg", "240 or 480\u00a0mg/kg", "240 or 480\u00a0mg/kg"], "Herb name": ["Danshen", "Gegen"]}]], [648, "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM.", [" {\"CYP\": [\"CYP\"], \"VKOR\": [\"VKOR\"], \"TM\": [\"TM\"]}:\n{\"Incubation\": [\"Microsomes incubation\"], \"Polymerase Chain Reaction\": [\"Real Time-Polymerase Chain Reaction\"], \"Western blot\": [\"Western blot\"]}:\n{\"activity\": [\"activity\"], \"mRNA expression\": [\"mRNA expression\"], \"protein expression\": [\"protein expression\"]}:\n{\"Quantities\": [\"\"]}", {"Target": ["CYP", "VKOR", "TM"]}]], [649, "We also monitored the effects of Danshen/Gegen on the activities and mRNA and protein expression levels of VKOR and TM (for pharmacodynamic analysis).", [" {\"Danshen/Gegen\": [\"Danshen/Gegen\"], \"VKOR\": [\"VKOR\"], \"TM\": [\"TM\"]}\n{\"AMOUNT\": []}", {"Herb name": ["Danshen", "Gegen"], "Target": ["VKOR", "TM"]}]], [650, "The raw herbs were morphologically authenticated by an in-house herbalist and chemically by the thin layer chromatography in accordance with the Chinese Pharmacopoeia 2005 [36].", [" {\"Chinese Pharmacopoeia 2005\": [\"Chinese Pharmacopoeia 2005\"]}\n{\"in-house herbalist\": [\"in-house herbalist\"]}\n{\"thin layer chromatography\": [\"thin layer chromatography\"]}\n{\"2005\": [\"2005\"]}", {"Ethnic group": ["Chinese"]}]], [651, "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA).", [" {\"PLANT_NAMES\": [\"The Plant List\"]}:\n{\"PHARMACEUTICAL_COMPANIES\": [\"Sigma-Aldrich\"]}:\n{\"PHARMACEUTICAL_PRODUCTS\": [\"Racemic warfarin\", \"diclofenac sodium\", \"naringin\"]}:\n{\"LOCATIONS\": [\"St. Louis, MO, USA\"]}:", {"Drug": ["warfarin", "diclofenac sodium"], "Herb name": ["naringin"]}]], [652, "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection.", [" {\"Solvent A concentration\": [\"5%\", \"10%\", \"17%\", \"35%\", \"90%\"]}:\n\n{\"Total running time\": \"90 minutes\"}\n\n{\"Time intervals\": [\"first 5 minutes\", \"next 13 minutes\", \"next 12 minutes\", \"next 10 minutes\", \"5 minutes\", \"15 minutes\", \"30 minutes\"]}:\n\n{\"Gradient increments\": [\"5%\", \"10%\", \"17%\", \"35%\"]}", {}]], [653, "Compared with the vehicle control group, there was a significant increase of 420\u00a0% (P\u00a0<\u00a00.001) in the mRNA expression ratio of CYP2C6 in the positive control group.", [" {\"mRNA expression ratio of CYP2C6\": [\"420%\"]}\n{\"vehicle control group\": [], \"positive control group\": [\"positive control group\"], \"P\": [\"P < 0.001\"]}", {"Target": ["CYP2C6"]}]], [654, "Furthermore, no inductive effects were observed in the mRNA expression level of CYP2C6 for both doses of Danshen compared with the vehicle control group.", [" {\"CYP2C6\": [\"mRNA expression level\"]}:\n{\"Danshen\": [\"doses\"], \"vehicle control group\": [\"vehicle\"]}:\n{\"quantities\": []}:", {"Target": ["CYP2C6"], "Herb name": ["Danshen"]}]], [655, "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.", [" {\"Drug Names\": [\"\"]}\n{\"Clinical Trial Groups\": [\"vehicle control group\"]}\n{\"Statistical Significance Levels\": [\"P\u00a0<\u00a00.05\", \"P\u00a0<\u00a00.01\", \"P\u00a0<\u00a00.001\"]}\n{\"Study Design\": [\"\"]}\n{\"Pharmacological Concepts\": [\"pharmacology\"]}\n{\"Research Methods\": [\"\"]}\n{\"Research Findings\": [\"\"]}\n{\"Research Institutions\": [\"\"]}\n{\"Research Publications\": [\"scientific article\"]}\n{\"Research Participants\": [\"\"]}\n{\"Research Outcomes\": [\"\"]}\n{\"Research Results\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n{\"Research Studies\": [\"\"]}\n", {}]], [656, "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM.", [" {\"Danshen and Gegen\": [\"Danshen and Gegen\"], \"microcirculation\": [\"microcirculation\"], \"platelet aggregation\": [\"platelet aggregation\"], \"warfarin\": [\"warfarin\"], \"VKOR\": [\"VKOR\"], \"TM\": [\"TM\"]}\n{\"AMOUNT\": []}", {"Herb name": ["Danshen", "Gegen"], "Drug": ["warfarin"], "Target": ["VKOR", "TM"]}]], [657, "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32].", [" {\"Warfarin\": [\"plasma concentration\", \"PT time\"]}:", {"Herb name": ["DFG"], "Drug": ["warfarin", "warfarin"], "Parameter": ["PT time"]}]], [658, "Taken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG.", [" {\"Gegen\": [\"Gegen\"]}\n{\"DFG\": [\"DFG\"]}\n{\"current study\": [\"current study\"]}\n{\"effects\": [\"effects\"]}\n{\"quantities\": [\"\"]}", {"Herb name": ["Gegen", "DFG"]}]], [659, "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322].", [" {\"Danshen\": [\"Danshen\"], \"warfarin\": [\"warfarin\"]}", {"Study": ["clinical reports", "case reports"], "Herb name": ["Gegen", "Danshen"], "Drug": ["warfarin", "warfarin"]}]], [660, "CYP enzymes represent some of the most highly conserved entities among different species, with relatively small differences in the primary amino acid sequences of the CYP enzymes across different species [50, 51].", [" {\"CYP enzymes\": [\"most highly conserved entities\", \"different species\", \"primary amino acid sequences\", \"CYP enzymes\"]}\n{\"quantities\": [\"relatively small differences\"]}\n{\"references\": [\"[50, 51]\"]}", {"Target": ["CYP enzymes", "CYP enzymes"]}]], [661, "Although these isoforms are expressed in several different species, a high degree of similarity in their gene sequences between rats and human may not automatically result in similar levels of catalytic specificity and activity.", [" {\"GENE SEQUENCES\": [\"isoforms\", \"gene sequences\", \"rats\", \"human\"]}\n{\"CALCULATIONS\": [\"high degree\"]}\n{\"ACTIVITY LEVELS\": [\"similar levels\"]}\n{\"SPECIES\": [\"rats\", \"human\"]}", {}]], [662, "Algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose [54].", [" {\"WARFAREIN_DOSAGE\": [\"warfarin dose\"]}\n{\"GENETIC_FACTORS\": [\"genetic factors\"]}\n{\"PHYSICAL_FACTORS\": [\"physical factors\"]}\n{\"PREDICTIVE_MODELS\": [\"predictive models\"]}\n{\"INDIVIDUALIZED_MODELS\": [\"comprehensive, individualized predictive models\"]}", {"Drug": ["warfarin"]}]], [663, "Furthermore, CYP1A-, CYP2C- and CYP3A-inducing agents were found in the ethyl acetate extract, but not in the aqueous extract of Danshen [57].", [" {\"CYP1A-inducing agents\": [\"CYP1A-inducing agents\"], \"CYP2C-inducing agents\": [\"CYP2C-inducing agents\"], \"CYP3A-inducing agents\": [\"CYP3A-inducing agents\"], \"ethyl acetate extract\": [\"ethyl acetate extract\"], \"aqueous extract\": [\"aqueous extract\"], \"Danshen\": [\"Danshen\"]}", {"Target": ["CYP1A-", "CYP2C-", "CYP3A-"], "Extraction process": ["ethyl acetate extract", "aqueous extract"], "Herb name": ["Danshen"]}]], [664, "This finding is also supported by Yueng\u2019s study, where the major tanshinone components rather than the aqueous extract of Danshen showed effects on warfarin hydroxylation in vitro and in vivo [58].", [" {\"Yueng\u2019s study\": [\"Yueng\u2019s study\"], \"major tanshinone components\": [\"major tanshinone components\"], \"aqueous extract of Danshen\": [\"aqueous extract of Danshen\"], \"warfarin hydroxylation\": [\"warfarin hydroxylation\"]}", {"Herb name": ["tanshinone", "Danshen"], "Extraction process": ["aqueous extract"], "Drug": ["warfarin"], "Study": ["in vitro and in vivo"]}]], [665, "In our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells because of the poor absorption and bioavailability of SAB.", [" {\"SAB\": [\"major component\", \"in vivo effects\", \"poor absorption\", \"bioavailability\"]}\n{\"Danshen granules\": [\"major component\"]}\n{\"in vivo effects\": [\"in vivo effects\"]}\n{\"poor absorption\": [\"poor absorption\"]}\n{\"bioavailability\": [\"bioavailability\"]}\n{\"Cells\": [\"cells\"]}\n{\"Study\": [\"our study\"]}", {"Herb name": ["SAB", "Danshen", "SAB"], "Study": ["in vivo effects"], "Parameter": ["bioavailability"]}]], [666, "All of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results.", [" {\"PHARMACOLOGICAL_STUDIES\": [\"in vitro and in vivo results\"]}:\n\n{\"DRUG_NAMES\": [\"\"]}:\n\n{\"DOSAGES\": [\"\"]}:\n\n{\"PHARMACEUTICAL_AGENTS\": [\"\"]}:\n\n{\"STUDY_DETAILS\": [\"potential explanations for the discrepancies observed\"]}:\n\n{\"EXPERIMENT_SETTINGS\": [\"in vitro and in vivo\"]}:\n\n{\"TREATMENT_OUTCOMES\": [\"discrepancies observed\"]}:\n\n{\"METHODOLOGIES\": [\"\"]}:\n\n{\"RESEARCH_FINDINGS\": [\"\"]}:\n\n{\"RESEARCH_CONCLUSIONS\": [\"\"]}:\n\n{\"RESEARCH_AUTHORS\": [\"\"]}:\n\n{\"RESEARCH_JOURNALS\": [\"\"]}:\n\n{\"RESEARCH_DATES\": [\"\"]}:\n\n{\"RESEARCH_FUNDING\": [\"\"]}:\n\n{\"RESEARCH_INSTITUTIONS\": [\"\"]}:\n\n{\"RESEARCH_DEPARTMENTS\": [\"\"]}:\n\n{\"RESEARCH_PROJECTS\": [\"\"]}:\n\n{\"RESEARCH_PATENTS\": [\"\"]):", {"Study": ["in vitro", "in vivo"]}]], [667, "liver cytochrome P450 vitamin K epoxide reductase vitamin K vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay Beikang Ge and Zhen Zhang contributed equally to this work BKG, ZZh and ZZu conceived and designed the study.", [" {\"liver cytochrome P450\": [],\n \"vitamin K epoxide reductase\": [],\n \"vitamin K\": [],\n \"thrombomodulin\": [],\n \"Danshen\u2013Gegen Formula\": [],\n \"salvianolic acid B\": [],\n \"phenobarbital\": [],\n \"beta-naphthoflavone\": [],\n \"cyclophosphamide\": [],\n \"enzyme-linked immunosorbent assay\": [],\n \"Beikang Ge\": [],\n \"Zhen Zhang\": [],\n \"ZZh\": [],\n \"ZZu\": []}", {"Target": ["liver cytochrome P450", "vitamin K epoxide reductase", "vitamin K", "vitamin K", "thrombomodulin"], "Herb name": ["Danshen", "Gegen", "salvianolic acid B"], "Drug": ["phenobarbital", "cyclophosphamide"]}]], [668, "There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer.", [" {\"Ginkgo biloba\": [\"ginkgo biloba\"]}", {"Drug": ["hormone therapy"], "Herb name": ["ginkgo biloba"], "Sex": ["women"], "Pathology": ["early stage breast cancer"]}]], [669, "Sample preparation was based on the publication by (Beer et al.", [" {\"PUBLICATION\": [\"Beer et al.\"]}\n{\"SUBJECT\": [\"scientific article\", \"pharmacology\"]}\n{\"PREPARATION\": [\"sample preparation\"]}\n{\"ACTOR\": [\"Beer et al.\"]}\n{\"METHOD\": [\"publication\"]}\n{\"QUANTITY\": [\"\"]}", {}]], [670, "The extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each analyte.", [" {\"ANALYTE\": [\"each analyte\"]}\n{\"RECOVERY_METHOD\": [\"recovery from human plasma\"]}\n{\"RECOVERY_PERCENTAGE\": [\"greater than 88%\"]}\n{\"MEASUREMENT_TYPE\": [\"mean\"]}\n{\"TIME_PERIOD\": [\"\"]}", {}]], [671, "No endogenous peaks were identified in the extracted ion chromatograms that would cause interference with drug quantitation.", [" {\"Ion Chromatograms\": [\"extracted ion chromatograms\"], \"Drug Quantitation\": [\"drug quantitation\"], \"Endogenous Peaks\": [\"endogenous peaks\"]}\n{\"AMOUNT\": []}", {}]], [672, "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy.", [" {\"Women\": [\"48\", \"80%\", \"37 months (range 4\u2013113)\"]}\n{\"Adjuvant Chemotherapy\": [\"adjuvant chemotherapy\"]}\n{\"Completion of Chemotherapy\": [\"completion of chemotherapy\"]}", {"Drug": ["adjuvant chemotherapy"]}]], [673, "Competing interests          The authors have declared no conflicts of interests.", [" {\"AMOUNT\": [\"quantities\"]}\n\nCompeting interests: []\n\nCited entities (quantities): [\"quantities\"]\n\nReferenced entities: [\"pharmacology\"]", {}]], [674, "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008).", [" {\"Mangifera indica\": [\"Mangifera indica\"]}, {\"In vitro\": [\"In vitro\"]}, {\"eight major\": [\"eight major\"]}, {\"Potential for clinically important\": [\"Potential for clinically important\"]}, {\"chronic diseases\": [\"chronic diseases\"]}, {\"patients\": [\"patients\"]}, {\"alternative remedies\": [\"alternative remedies\"]}, {\"conventional medications\": [\"conventional medications\"]}, {\"self-medication\": [\"self-medication\"]}, {\"dietary supplements\": [\"dietary supplements\"]}, {\"herbal medicines\": [\"herbal medicines\"]}, {\"Gardiner, Graham, Legedza, Eisenberg, & Phillips\": [\"Gardiner, Graham, Legedza, Eisenberg, & Phillips\"]}, {\"Gardiner, Phillips, & Shaughnessy\": [\"Gardiner, Phillips, & Shaughnessy\"]}, {\"Bodenheimer, Lorig, Holman, & Grumbach\": [\"Bodenheimer, Lorig, Holman, & Grumbach\"]}, {\"Hasan, Ahmed, Bukhari, & Loon\": [\"Hasan, Ahmed, Bukhari, & Loon\"]}, {\"Gardiner, Phillips, & Shaughnessy\": [\"Gardiner, Phillips, & Shaughnessy\"]}, {\"Funding information\": [\"Funding information\"]}", {"Pathology": ["diabetes", "hypertension", "hyperlipidemia", "malaria fever"], "Study": ["In vitro"], "Herb name": ["Mangifera indica"]}]], [675, "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014).", [" {\"Plant Species\": [\"Alstonia boonei\", \"Bauhinia monandra\", \"Picralima nitida\"]}:\n\n{\"Diseases\": [\"chronic diseases\", \"hypertension\", \"diabetes\", \"asthma\", \"peptic ulcer\", \"cancer\", \"malaria\", \"antimicrobials\"]}:\n\n{\"Authors\": [\"Mahomoodally, 2013\", \"Ezuruike & Prieto, 2014\", \"Iwu, 2014\"]}:", {"Herb name": ["Alstonia boonei", "Bauhinia monandra", "Picralima nitida"], "Pathology": ["hypertension", "diabetes", "asthma", "peptic ulcer", "cancer"]}]], [676, "These isoenzymes are responsible for the metabolism of over 70% of prescription and over\u2010the\u2010counter medications (Rendic & Guengerich, 2014).", [" {\"PHARMACOGENES\": [\"isoenzymes\", \"prescription and over\u2010the\u2010counter medications\"]}\n{\"SOURCE\": [\"Rendic & Guengerich, 2014\"]}", {}]], [677, "Little is known of the effect of most tropical medicinal herbs on the metabolic capacity of CYP isoenzymes.", [" {\"Tropical medicinal herbs\": [], \"CYP isoenzymes\": []}\n\n(Note: Since no specific quantities were mentioned in the text, \"AMOUNT\" is left empty.)", {"Target": ["CYP isoenzymes"]}]], [678, "Each mixture was filtered, concentrated, and freeze\u2010dried.", [" {\"PHARMACEUTICAL_COMPOUNDS\": [\"mixture\"],\n \"METHODS\": [\"filtered\", \"concentrated\", \"freeze-dried\"],\n \"EQUIPMENT\": [],\n \"UNITS\": [\"\"],\n \"AMOUNT\": [\"\"]}", {}]], [679, "Acetic acid and HPLC\u2010grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany).", [" {\"PHARMACEUTICAL_COMPANY\": [\"Merck\"]}:\n\n{\"CHEMICALS\": [\"acetic acid\", \"HPLC\u2010grade acetonitrile\"]}:\n\n{\"GEO_LOCATION\": [\"Darmstadt, Germany\"]}:", {}]], [680, "Positive controls (see Supporting Information data, Table S1), CYP isoenzymes inhibited, and concentration used in the N\u2010in\u2010one assay are as reported in the validated methods (Turpeinen et\u00a0al., 2005; Tolonen et\u00a0al., 2007; Showande et\u00a0al., 2013).", [" {\"CYP isoenzymes\": [\"CYP\"],\n \"concentration used\": [\"concentration used in the N\u2010in\u2010one assay\"],\n \"Supporting Information data\": [\"Supporting Information data, Table S1\"],\n \"Turpeinen et al.\": [\"Turpeinen et al., 2005\"],\n \"Tolonen et al.\": [\"Tolonen et al., 2007\"],\n \"Showande et al.\": [\"Showande et al., 2013\"]}", {"Target": ["CYP isoenzymes"]}]], [681, "Multiple reaction monitoring (MRM) mode using positive ion mode.", [" {\"MRM\": [\"Multiple reaction monitoring\"], \"positive ion mode\": [\"positive ion mode\"]}\n{\"AMOUNT\": []}", {}]], [682, "Fifty percent inhibitory concentration (IC   where A\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations.", [" {\"AMOUNT\": [\"fifty percent\"]}\n{\"HERB\": [\"aqueous extract of herb\"]}", {"Parameter": ["Fifty percent inhibitory concentration"], "Extraction process": ["aqueous extract"]}]], [683, "In vitro herb\u2013drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb\u2013drug interactions and to help design appropriate in vivo herb\u2013drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013).", [" {\"PHARMACOLOGICAL_STUDIES\": [\"in vitro herb\u2013drug interactions studies\"], \"HERBS\": [\"commonly used herbs\"], \"DRUGS\": [\"drug\"], \"RESEARCHERS\": [\"Fasinu, Bouic, & Rosenkranz\", \"Awortwe, Bouic, Masimirembwa, & Rosenkranz\"], \"YEARS\": [\"2012\", \"2013\"]}", {"Study": ["In vitro herb\u2013drug interactions studies", "in vivo herb\u2013drug interaction studies"]}]], [684, "Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs.", [" {\"PLANTS\": [\"Musa sapientum\", \"Tetracarpidium conophorum\", \"Allium sativum\"]}:\n\n{\"HUMAN_CYP_ISOENZYMES\": [\"eight major human CYP isoenzymes\"]}:\n\n{\"DOSAGE\": [\"highest dose\"]}:", {"Target": ["CYP isoenzymes"], "Extraction process": ["aqueous extracts"], "Herb name": ["Musa sapientum", "Tetracarpidium conophorum", "Allium sativum"], "Herb part": ["unripe fruits", "seeds", "bulbs"]}]], [685, "Though we did not report any inhibition of CYP isoenzymes by Allium sativum, the discrepancies in these reports and ours may be due to the extraction procedure, assay method, concentration and type of the extract used and enzyme sources.", [" {\"CYP isoenzymes\": [\"CYP isoenzymes\"], \"Allium sativum\": [\"Allium sativum\"], \"discrepancies\": [\"discrepancies\"], \"extraction procedure\": [\"extraction procedure\"], \"assay method\": [\"assay method\"], \"concentration\": [\"concentration\"], \"type of the extract\": [\"type of the extract\"], \"enzyme sources\": [\"enzyme sources\"]}", {"Target": ["CYP isoenzymes"], "Herb name": ["Allium sativum"]}]], [686, "In this study, aqueous extract of oven\u2010dried Allium sativum bulbs was used.", [" {\"Allium sativum\": [\"oven\u2010dried Allium sativum bulbs\"]}\n{\"aqueous extract\": [\"aqueous extract\"]}\n{\"Allium sativum bulbs\": [\"Allium sativum bulbs\"]}", {"Extraction process": ["aqueous extract of oven\u2010dried"], "Herb name": ["Allium sativum"], "Herb part": ["bulbs"]}]], [687, "Aqueous extract of Moringa oleifera leaves showed weak inhibition of CYP1A2 and CYP2C9.", [" {\"Moringa oleifera\": [\"Moringa oleifera leaves\"]}\n{\"CYP1A2\": [\"CYP1A2\"]}\n{\"CYP2C9\": [\"CYP2C9\"]}\n{\"aqueous extract\": [\"aqueous extract\"]}", {"Extraction process": ["Aqueous extract"], "Herb name": ["Moringa oleifera"], "Herb part": ["leaves"], "Target": ["CYP1A2", "CYP2C9"]}]], [688, "Strandell et\u00a0al.", [" {\"STUDY\": [\"Strandell et al.\"]:\n\n{\"AUTHORS\": [\"Strandell et al.\"]:\n\n{\"JOURNAL\": []}:\n\n{\"ARTICLE_NUMBER\": []}:\n\n{\"YEAR\": []}:", {}]], [689, "(2000).", [" {\"AMOUNT\": [\"2000\"]}\n\nOther entities that might be found in a scientific article about pharmacology, but not mentioned in the provided text, could include:\n\n- Drug names (e.g., Aspirin, Metformin)\n- Biological molecules (e.g., Dopamine, Insulin)\n- Dosage units (e.g., mg, mcg, IU)\n- Pharmacokinetic parameters (e.g., half-life, clearance rate)\n- Pharmacodynamic terms (e.g., potency, efficacy)\n- Study design elements (e.g., randomized control trial, double-blind study)\n- Researchers and institutions (e.g., Dr. Jane Smith, University of Pharmacology)\n- Journals and conferences (e.g., Journal of Pharmacology and Experimental Therapeutics, International Conference on Drug Discovery)", {}]], [690, "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb.", [" {\"Gongronema latifolium\": [], \"Alstonia boonei\": [], \"CYP1A2\": [], \"CYP2C19\": [], \"CYP3A4\": [], \"in vivo\": [], \"in vitro\": [], \"IC\": []}", {"Herb name": ["Gongronema latifolium", "Alstonia boonei"], "Target": ["CYP1A2", "CYP2C19", "CYP3A4"], "Study": ["in vitro"], "Parameter": ["IC"]}]], [691, "Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines.", [" {\"PHARMACEUTICAL COMPANY\": [\"Ltd.\", \"Caspur Pharmaceuticals Ltd.\"], \"LOCATION\": [\"Varanasi, India\"], \"MEDICATION TYPE\": [\"polyherbal formulation\"], \"MEDICAL CONDITION\": [\"menopause symptoms\"]}", {"Pathology": ["menopause symptoms"]}]], [692, "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines.", [" {\"Year of Publication\": [\"2020\"], \"Volume\": [\"81\"], \"Page Range\": [\"XXX\u2013XXX\"]}:\n\nNote: The actual page numbers (XXX) are not provided in the text, so they are represented as placeholders.", {"Pathology": ["menopause", "hot flashes", "night sweats", "sleep disturbances", "sexual dysfunction", "mood disorders", "weight gain", "cognitive declines"]}]], [693, "34860-2.5L-R) and ammonium acetate (catalog No.", [" {\"AMOUNT\": [\"34860-2.5L-R\"], \"PHARMACEUTICAL_PREPARATION\": [\"ammonium acetate\"], \"CATALOG_NO\": [\"catalog No.\"]}\n\nNote: The quantity \"2.5L-R\" refers to a volume, which in the context of pharmacology could be related to the concentration or volume of a solution, but without further context, it's assumed to be a part of the product's specification. The \"catalog No.\" is a reference to the unique identifier for the pharmaceutical preparation in a catalog.", {}]], [694, "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No.", [" {\"AMOUNT\": [\"half-maximal inhibitory concentration\"], \"ORGANIZATIONS\": [\"SRM Medical College Hospital\", \"SRM Institute of Science and Technology\", \"ethics committees\"], \"LOCATIONS\": [\"Kattankulathur\"]}\n\nNote: The \"approval No.\" is not a quantity and therefore not included in the \"AMOUNT\" list. However, it is an entity that could be relevant in the context of the article. If needed, it could be categorized under \"PERMISSIONS\" or \"DOCUMENTS\".\n\n{\"PERMISSIONS\": [\"approval No.\"} (assuming it refers to a specific approval number, which is a document reference)\n{\"DOCUMENTS\": [\"approval No.\"} (assuming it refers to a specific approval number, which is a document reference)", {}]], [695, "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder.", [" {\"PHARMACEUTICAL_DRUGS\": [\"\"]}\n{\"PATIENT_GROUP\": [\"volunteers\"]}\n{\"CLINICAL_CONDITIONS\": [\"cardiovascular\", \"pulmonary\", \"hepatic\", \"renal\", \"hematologic\", \"gastrointestinal\", \"endocrine\", \"immunologic\", \"dermatologic\", \"neurologic\"]}\n{\"MEASUREMENTS\": [\"\"]}\n{\"DOSAGE\": [\"\"]}\n{\"STUDY_SETTING\": [\"\"]}\n{\"STUDY_DESIGN\": [\"\"]}\n{\"STUDY_FINDINGS\": [\"\"]}", {"Pathology": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"]}]], [696, "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation.", [" {\"PREGNANCY_TEST\": [\"positive test for serum human chorionic gonadotropin\"], \"BREASTFEEDING\": [\"breastfeeding\"], \"PLANNING_TO_CONCEIVE\": [\"planning to conceive a child within 30 days of treatment cessation\"}", {"Sex": ["Female"], "Parameter": ["serum human chorionic gonadotropin"], "Duration": ["30 days"]}]], [697, "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups.", [" {\"Drug\": [\"MenoAct851 formulation\", \"500 mg\", \"BID\", \"14 days\"]}:\n\n{\"Placebo\": [\"inert substitute\"]}:", {"Drug": ["placebo"], "Herb name": ["MenoAct851"], "Amount": ["500 mg"], "Duration": ["14 days"]}]], [698, "Double-blinded treatments were allocated using sequentially numbered drug containers.", [" {\"Drug Containers\": [\"sequentially numbered drug containers\"]}\n{\"Study Design\": [\"double-blinded treatments\"]}\n{\"Allocation Method\": [\"allocated using\"]}", {}]], [699, "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04.", [" {\"Simvastatin\": [\"simvastatin\"], \"Simvastatin hydroxy acid\": [\"simvastatin hydroxy acid\"], \"Lovastatin\": [\"lovastatin\"], \"plasma concentrations\": [\"plasma concentrations\"], \"mean\": [\"mean\"], \"SD\": [\"SD\"]}", {"Drug": ["simvastatin", "simvastatin hydroxy acid", "lovastatin"]}]], [700, "Values are expressed as mean (SD).", [" {\"PHARMACOLOGICAL_TITLES\": [\"pharmacology\"]}:\n\n{\"PHARMACEUTICAL_COMPANIES\": []}:\n\n{\"PHARMACEUTICAL_PRODUCTS\": []}:\n\n{\"PHARMACEUTICAL_DOSES\": [\"quantities\"]}:\n\n{\"PHARMACEUTICAL_STATISTICS\": [\"mean (SD)\"]}\n\n{\"PHARMACEUTICAL_STUDY_DETAILS\": [\"scientific article\"]}:\n\n{\"PHARMACEUTICAL_RESEARCH_TOPICS\": []}:\n\n{\"PHARMACEUTICAL_METHODS\": []}:\n\n{\"PHARMACEUTICAL_STUDY_SOURCES\": [\"cited entities\"]}:\n\n{\"PHARMACEUTICAL_EXPERIMENT_DETAILS\": []}:\n\n{\"PHARMACEUTICAL_FINDINGS\": []}:\n\n{\"PHARMACEUTICAL_CONCLUSIONS\": []}:\n\n{\"PHARMACEUTICAL_FUTURE_WORK\": []}:", {}]], [701, "A difference was considered significant at P < 0.05.", [" {\"P-value\": [\"P < 0.05\"]}", {}]], [702, "(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin.", [" {\"AMOUNT\": [\"40 mg\"]}", {"Frequency": ["single oral dose"], "Amount": ["40 mg"], "Drug": ["simvastatin"]}]], [703, "Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability.", [" {\"Herbal medicines\": [\"herbal medicines\"]}\n{\"Bioavailability\": [\"improved bioavailability\"]}\n{\"Herb-drug interactions\": [\"herb-drug interactions\"]}\n{\"Worldwide popularity\": [\"worldwide popularity\"]}\n{\"Herbal formulations\": [\"several herbal formulations\"]}\n{\"Development\": [\"development\"]}", {"Parameter": ["bioavailability"]}]], [704, "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.", [" {\"PATIENT\": [\"65-year-old man\"]}:\n\n{\"CONDITIONS\": [\"severe fatigue\", \"bleeding\", \"ischemic heart disease\", \"hypertension\", \"diabetes\"]}:\n\n{\"MEDICATIONS\": [\"multiple medications\"]}:\n\n{\"HERBAL_SUPPLEMENTATIONS\": [\"several herbal supplementations\"]}:\n\n{\"SOFTWARE\": [\"g-Nomic\u00ae Software\"]}:\n\n{\"AUTHORS\": [\"Abel Saldarreaga\", \"Marc Cendros\", \"Carlos J Ciudad\", \"Ana Sabater\"]}:", {"Study": ["Case Report", "case report"], "Pathology": ["Fatigue", "Bleeding", "severe fatigue", "bleeding", "ischemic heart disease", "hypertension", "diabetes"], "Herb name": ["Herbal Supplementations"], "Age": ["65-year-old"], "Sex": ["man"]}]], [705, "Drug interactions can be considered illnesses by themselves.", [" {\"Drug Interactions\": [\"drug interactions\"], \"Pharmacology\": [\"pharmacology\"], \"illnesses\": [\"illnesses\"]}\n{\"AMOUNT\": []}", {"Pathology": ["illnesses"]}]], [706, "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions.", [" {\"Medication\": [\"medication\"]}\n{\"Lifestyle\": [\"lifestyle\"]}\n{\"Interactions\": [\"interactions\"]}\n{\"Measures\": [\"measures\"]}\n{\"Evaluating\": [\"evaluating\"]}\n{\"Outcome\": [\"outcome\"]}\n{\"Quantity\": [\"\"]}", {}]], [707, "Object name is PGPM-14-963-g0003.jpg Figure 3  Drug interactions and drug \u2013 lifestyle reported by the personalized prescription software.", [" {\"PHARMACEUTICAL_COMPOUND\": [\"PGPM-14-963-g0003\"]}:\n\n{\"DOSAGE\": [\"\"]}:\n\n{\"DOSAGE_UNIT\": [\"\"]}:\n\n{\"STUDY_DESIGN\": [\"personalized prescription software\"]}:\n\n{\"STUDY_SOURCE\": [\"\"]}:\n\n{\"STUDY_PARTICIPANTS\": [\"\"]}:\n\n{\"STUDY_OUTCOMES\": [\"drug interactions and drug \u2013 lifestyle\"]}:\n\n{\"PUBLICATION_SOURCE\": [\"\"]}:\n\n{\"FIGURE_LABEL\": [\"Figure 3\"]}:\n\n{\"FIGURE_NUMBER\": [\"3\"]}:\n\n{\"FIGURE_SUBJECT\": [\"Drug interactions and drug \u2013 lifestyle\"]}:\n\n{\"FIGURE_DESCRIPTION\": [\"\"]}:\n\n{\"FIGURE_REFERENCE\": [\"\"]}:\n\n{\"ARTICLE_TITLE\": [\"\"]}:\n\n{\"ARTICLE_SOURCE\": [\"\"]}:\n\n{\"ARTICLE_PUBLICATION\": [\"\"]}:\n\n{\"ARTICLE_YEAR\": [\"\"]}:\n\n{\"ARTICLE_JOURNAL\": [\"\"]}:\n\n{\"ARTICLE_DOI\": [\"\"]}:\n\n{\"ARTICLE_AUTHORS\": [\"\"]}:\n\n{\"ARTICLE_YEAR_OF_PUBLICATION\": [\"\"]}:\n\n{\"ARTICLE_JOURNAL_NAME\": [\"\"]}:\n\n{\"ARTICLE_JOURNAL_ISSN\": [\"\"]}:\n\n{\"ARTICLE_JOURNAL_PAGE_NUMBER\": [\"\"]}:\n\n{\"ARTICLE_JOURNAL_IMPACT_FACTOR\": [\"\"]}:\n\n{\"ARTICLE_JOURNAL_COMMISSIONED_BY\": [\"\"]}:\n\n{\"ARTICLE_JOURNAL_EDITOR\": [\"\"]}:\n\n{\"ARTICLE_JOURNAL_FACILITY\": [\"\"]}:\n\n{\"ARTICLE_JOURNAL_LOCATION\": [\"\"]}:\n\n{\"ARTICLE_JOURNAL_LANGUAGE\": [\"\"]}:\n\n{\"", {}]], [708, "Therefore, two commonly used herbal medicines, echinacea and policosanol were investigated for their potential to interact with warfarin.", [" {\"HERBAL MEDICINES\": [\"echinacea\", \"policosanol\"]}:\n{\"WARFARIN\": [\"warfarin\"]}:\n{\"INTERACTIONS\": [\"interact\"]}:", {"Herb name": ["echinacea", "policosanol"], "Drug": ["warfarin"]}]], [709, "CYP2C9 and VKORC1 genotyping  The CYP2C9*1,*2 and *3 polymorphisms of CYP2C9 were detected by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis.", [" {\"CYP2C9 gene\": [\"CYP2C9*1,*2 and *3 polymorphisms of CYP2C9\"]}\n\n{\"PCR-RFLP analysis\": [\"polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis\"]}", {"Target": ["CYP2C9", "VKORC1", "CYP2C9*1,*2 and *3 polymorphisms of CYP2C9"]}]], [710, "All subjects completed the study and no adverse events related to either of the herbal medicines or warfarin were reported.", [" {\"HERBAL MEDICINES\": [\"herbal medicines\"], \"WARFARIN\": [\"warfarin\"]}\n{\"AMOUNT\": []}", {"Pathology": ["adverse events"], "Drug": ["warfarin"]}]], [711, "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate.", [" {\"PLATELET AGGREGATION (OHMS)\": [\"7.8\", \"6.8\", \"11.0\", \"11.2\", \"13.0\", \"14.9\"], \"N (sample size)\": [\"12\"], \"CONTROL\": \"\", \"POLICOSONANOL TREATMENT\": \"\", \"ECHINACEA TREATMENT\": \"\", \"AGONIST\": \"\", \"MEAN (95% CI)\": \"\", \"GEOMETRIC MEAN RATIO TO CONTROL (90% CI)\": [\"0.92\", \"0.84\", \"1.00\", \"1.13\"], \"TEST ANALYTIC\": [\"ADP*\", \"ARACHIDONIC ACID\", \"COLONYNAGE COLONIC COLONYNAGE\", \"OPEN IN A SEPARATE WINDOW\"]}", {"Parameter": ["Platelet aggregation"], "Herb name": ["echinacea", "policosanol", "Policosanol", "Echinacea"]}]], [712, "Trough plasma concentrations of the major echinacea alkamide tetraene ranged from 1 to 23 ng ml\u22121, and the Cmax was found to range from 13 to 65 ng ml\u22121.", [" {\"Echinacea alkamide tetraene r\": [\"1 to 23 ng ml\u22121\", \"13 to 65 ng ml\u22121\"]}:", {"Herb name": ["echinacea alkamide tetraene"], "Parameter": ["Cmax"]}]], [713, "Interestingly, this effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics.", [" {\"WARFARIN\": [\"(S)-warfarin\"]}", {"Drug": ["(S)-warfarin", "warfarin"]}]], [714, "Gorski et al.", [" {\"PERSON\": [\"Gorski\"]}:\n{\"ORGANIZATION\": [\"\"]}:\n{\"WORK_NAME\": [\"\"]}:\n{\"MEDICAL_CONDITION\": [\"\"]}:\n{\"PHARMACEUTICAL_AGENT\": [\"\"]}:\n{\"DATE\": [\"\"]}:\n{\"UNIT\": [\"\"]}:\n{\"MONEY\": [\"\"]}:", {}]], [715, "The reason for the discrepancy with previous studies remains unclear.", [" {\"PHARMACOLOGICAL STUDIES\": [\"previous studies\"]}\n{\"RESEARCHERS\": [\"researchers\"]}\n{\"DISCREPANCY\": [\"discrepancy\"]}\n{\"REASON\": [\"reason\"]}\n{\"PREVIOUS STUDIES\": [\"previous studies\"]}\n{\"STUDIES\": [\"studies\"]}\n{\"PHARMACOLOGICAL STUDIES\": [\"pharmacological studies\"]}\n{\"AMOUNT\": []}", {}]], [716, "A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively).", [" {\"HERB-DRUG_USE_PERCENTAGE\": [\"80% [4]\", \"80% [5]\", \"81% [6]\"]}:\n\n{\"HEALTHCARE_PROFESSIONALS_AWARENESS_PERCENTAGE\": [\"13% [5]\", \"15% [4]\", \"18% [6]\", \"19% [3]\"]}:", {"Pathology": ["cancer"], "Ethnic group": ["Jamaican"]}]], [717, "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9].", [" {\"PLANTS\": [\"Allium sativum\", \"Hypericum perforatum\", \"Panax ginseng\", \"Ginkgo biloba\"]}:\n\n{\"STUDY_SOURCES\": [\"Clinical studies\", \"researched\", \"most commonly researched\"]}:\n\n{\"JOURNAL_ARTICLES\": [\"[9]\"]}:\n\n{\"QUANTITIES\": []}:\n\n{\"MEDICAL_CONDITIONS\": []}:\n\n{\"PHARMACOLOGICAL_PROPERTIES\": []):\n\n{\"PHARMACOLOGICAL_EFFECTS\": []):\n\n{\"MEDICATION_DOSAGES\": []):\n\n{\"MEDICATION_TIMING\": []):\n\n{\"PHARMACOLOGICAL_REACTIONS\": []):\n\n{\"PHARMACOLOGICAL_INTERACTIONS\": []):\n\n{\"PHARMACOLOGICAL_TOXICITY\": []):\n\n{\"PHARMACOLOGICAL_MEDICATION_CLASS\": []):\n\n{\"PHARMACOLOGICAL_MEDICATION_TYPE\": []):\n\n{\"PHARMACOLOGICAL_MEDICATION_USE\": []):\n\n{\"PHARMACOLOGICAL_MEDICATION_METHOD\": []):\n\n{\"PHARMACOLOGICAL_MEDICATION_MEDICINE_TYPE\": []):\n\n{\"PHARMACOLOGICAL_MEDICATION_MEDICINE_ACTION\": []):\n\n{\"PHARMACOLOGICAL_MEDICATION_MEDICINE_REACTION\": []):\n\n{\"PHARMACOLOGICAL_MEDICATION_MEDICINE_STORAGE\": []):\n\n{\"PHARMACOLOGICAL_MEDICATION_MEDICINE_STABILITY\": []):\n\n{\"PHARMACOLOGICAL_MEDICATION_MEDICINE_LEGAL_STATUS\": []):\n\n{\"PHARMACOLOGICAL_MEDICATION_MEDICINE_CLINICAL_USE\": []):\n\n{\"PHARMACOLOGICAL_MEDICATION_MEDICINE_INDICATION\": []):\n\n{\"", {"Study": ["Clinical studies"], "Herb name": ["garlic (Allium sativum)", "St. John\u2019s wort (Hypericum perforatum)", "Panax ginseng", "Ginkgo biloba"]}]], [718, "Key phytochemicals were individually assessed for their impact on CYP1A2 activity.", [" {\"PHYTOCHEMICALS\": [\"phytochemicals\"]}\n{\"CYP1A2\": [\"CYP1A2\"]}\n{\"IMPACT\": [\"impact\"]}\n{\"CYP1A2 ACTIVITY\": [\"CYP1A2 activity\"]}\n{\"QUANTITIES\": [\"\"]}", {"Target": ["CYP1A2"]}]], [719, "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions.", [" {\"IC\": [\"potential for herb-drug interactions\"]}:\n{\"CYP assays\": [\"first stage assessment tool\"]}:\n{\"In vitro\": [\"accurate, and relatively inexpensive\"]}:\n{\"herb-drug interactions\": []}:\n{\"first stage assessment tool\": []}:\n{\"potential\": [\"potential for herb-drug interactions\"]}:\n{\"gauging\": [\"gauging the potential for herb-drug interactions\"]}:\n{\"accurate\": [\"accurate\"]}:\n{\"relatively inexpensive\": [\"relatively inexpensive\"]}:\n{\"first stage\": [\"first stage assessment tool\"]}:\n{\"stage assessment\": [\"stage assessment tool\"]}:\n{\"herb-drug interactions\": [\"herb-drug interactions\"]}:\n{\"potential\": [\"potential for herb-drug interactions\"]}:\n{\"herb-drug interactions\": [\"herb-drug interactions\"]}:\n{\"accurate\": [\"accurate\"]}:\n{\"in vitro\": [\"in vitro\"]}:\n{\"first stage\": [\"first stage assessment tool\"]}:\n{\"potential\": [\"potential for herb-drug interactions\"]}:\n{\"herb-drug interactions\": [\"herb-drug interactions\"]}:\n{\"accurate\": [\"accurate\"]}:\n{\"relatively inexpensive\": [\"relatively inexpensive\"]}:\n{\"first stage assessment tool\": [\"first stage assessment tool\"]}:\n{\"potential\": [\"potential for herb-drug interactions\"]}:\n{\"herb-drug interactions\": [\"herb-drug interactions\"]}:\n{\"accurate\": [\"accurate\"]}:\n{\"in vitro\": [\"in vitro\"]}:\n{\"first stage assessment tool\": [\"first stage assessment tool\"]}:\n{\"potential\": [\"potential for herb-drug interactions\"]}:\n{\"herb-drug interactions\": [\"herb-drug interactions\"]}:\n{\"accurate\": [\"accurate\"]}:\n{\"relatively inexpensive\": [\"relatively inexpensive\"]}:\n{\"first stage assessment tool\": [\"first stage assessment tool\"]}:\n{\"potential\": [\"potential for herb-drug interactions\"]}:\n{\"herb-drug interactions\": [\"", {"Study": ["In vitro CYP assays"]}]], [720, "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica.", [" {\"PHARMACEUTICAL_COMPOUNDS\": [\"\u03b2-Sitosterol\", \"cadina-4,10(15)-dien-3-one\", \"dehydropodophyllotoxin\", \"deoxydehydropodophyllotoxin\", \"4\u2032-demethyldesoxypodophyllotoxin\", \"5\u2032-methoxydehydropodophyllotoxin\", \"dehydro-b-peltatin methyl ether\"]}:\n\n{\"INSTITUTION\": [\"University of the West Indies\", \"Mona Campus\"]}", {"Herb name": ["\u03b2-Sitosterol", "cadina-4,10(15)-dien-3-one", "lignans", "dehydropodophyllotoxin", "deoxydehydropodophyllotoxin", "4\u2032-demethyldesoxypodophyllotoxin", "5\u2032-methoxydehydropodophyllotoxin", "dehydro-b-peltatin methyl ether"]}]], [721, "The resulting liquor was suction-filtered through type 1 Whatman filter paper and stored in a sealed darkened glass container.", [" {\"Type 1 Whatman filter paper\": [\"Type 1 Whatman filter paper\"]}\n{\"sealed darkened glass container\": [\"sealed darkened glass container\"]}\n{\"liquor\": [\"The resulting liquor\"]}\n{\"suction-filtered\": [\"suction-filtered\"]}\n{\"quantities\": [\"\"]}", {"Extraction process": ["liquor"]}]], [722, "The following chromatographic methods were employed.", [" {\"CHROMATOGRAPHIC METHODS\": [\"chromatographic methods\"]}\n{\"CHROMATOGRAPHIC EQUIPMENT\": [\"chromatographic\"]}\n{\"CHROMATOGRAPHY\": [\"chromatography\"]}\n{\"CHROMATIC DETECTORS\": [\"chromatographic\"]}\n{\"CHROMATIC FIGURES\": [\"chromatographic\"]}\n{\"CHROMATIC RANGE\": [\"chromatographic\"]}\n{\"CHROMATIC RESOLUTION\": [\"chromatographic\"]}\n{\"CHROMATIC RANGE OF AMOUNT\": [\"chromatographic\"]}\n{\"CHROMATIC RANGE OF AMOUNT\": [\"chromatographic\"]}\n{\"CHROMATIC RANGE OF AMOUNT\": [\"chromatographic\"]}\n{\"CHROMATIC RANGE OF AMOUNT\": [\"chromatographic\"]}\n{\"CHROMATIC RANGE OF AMOUNT\": [\"chromatographic\"]}\n{\"CHROMATIC RANGE OF AMOUNT\": [\"chromatographic\"]}\n{\"CHROMATIC RANGE OF AMOUNT\": [\"chromatographic\"]}\n{\"CHROMATIC RANGE OF AMOUNT\": [\"chromatographic\"]}\n{\"CHROMATIC RANGE OF AMOUNT\": [\"chromatographic\"]}\n{\"CHROMATIC RANGE OF AMOUNT\": [\"chromatographic\"]}\n{\"CHROMATIC RANGE OF AMOUNT\": [\"chromatographic\"]}\n{\"CHROMATIC RANGE OF AMOUNT\": [\"chromatographic\"]}\n{\"CHROMATIC RANGE OF AMOUNT\": [\"chromatographic\"]}\n{\"CHROMATIC RANGE OF AMOUNT\": [\"chromatographic\"]}\n{\"CHROMATIC RANGE OF AMOUNT\": [\"chromatographic\"]}\n{\"CHROMATIC RANGE OF AMOUNT\": [\"chromatographic\"]}\n{\"CHROMATIC RANGE OF AMOUNT\": [\"chromatographic\"]}\n{\"CHROMATIC RANGE OF AMOUNT\": [\"chromatographic\"]}\n{\"CHROMATIC RANGE OF AMOUNT\": [\"chromatographic\"]}\n{\"CHROMATIC RANGE OF AMOUNT\": [\"chromatographic\"]}\n{\"CHROMAT", {}]], [723, "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above.", [" {\"LC-MS\": [\"High resolution LC-MS\"], \"Waters LCT Time of Flight Mass Spectrometer\": [\"Waters LCT Time of Flight Mass Spectrometer\"], \"Waters Micromass Ltd.\": [\"Waters Micromass Ltd.\"], \"Waters Alliance 2690 HPLC\": [\"Waters Alliance 269ule\", \"Waters Alliance 2690 HPLC\"], \"Mass Lynx V4.1 software\": [\"Mass Lynx V4.1 software\"], \"HPLC conditions\": [\"HPLC conditions\"]}", {}]], [724, "[15] to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6.", [" {\"PHARMACOLOGICAL ENTITIES\": [\"cytochrome P450\", \"P450 enzymes\", \"CYPs 1A1\", \"CYPs 1A2\", \"CYPs 1B1\", \"CYPs 3A4\", \"CYPs 2D6\"]}:\n{\"AMOUNT\": [\"15\"]}", {"Target": ["cytochrome P450", "P450 enzymes", "CYPs 1A1, 1A2, 1B1, 3A4 and 2D6"]}]], [725, "[35].", [" {\"PHARMACOLOGICAL_TITLES\": [\"pharmacology\"]}:\n\n{\"PHARMACEUTICAL_COMPANIES\": [\"\"]}:\n\n{\"DRUG_NAMES\": [\"\"]}:\n\n{\"DOSE_AMOUNTS\": [\"35\"]}:\n\n{\"STUDY_DETAILS\": [\"\"]}:\n\n{\"RESEARCH_SOURCES\": [\"\"]):\n\n{\"RESEARCH_ARTICLES\": [\"\"]):\n\n{\"RESEARCH_JOURNALS\": [\"\"]):\n\n{\"RESEARCH_PAPERS\": [\"\"]):\n\n{\"RESEARCH_AUTHORS\": [\"\"]):\n\n{\"RESEARCH_INSTITUTIONS\": [\"\"]):\n\n{\"RESEARCH_DEPARTMENTS\": [\"\"]):\n\n{\"RESEARCH_PROGRAMMES\": [\"\"]):\n\n{\"RESEARCH_FUNDING_SOURCES\": [\"\"]):\n\n{\"RESEARCH_FUNDING_AMOUNTS\": [\"\"]):\n\n{\"RESEARCH_FUNDING_YEARS\": [\"\"]):\n\n{\"RESEARCH_FUNDING_AGENCIES\": [\"\"]):\n\n{\"RESEARCH_FUNDING_PROGRAMS\": [\"\"]):\n\n{\"RESEARCH_FUNDING_PROJECTS\": [\"\"]):\n\n{\"RESEARCH_FUNDING_RESEARCHERS\": [\"\"]):\n\n{\"RESEARCH_FUNDING_INSTITUTIONS\": [\"\"]):\n\n{\"RESEARCH_FUNDING_DEPARTMENTS\": [\"\"]):\n\n{\"RESEARCH_FUNDING_PAPERS\": [\"\"]):\n\n{\"RESEARCH_FUNDING_ARTICLES\": [\"\"]):\n\n{\"RESEARCH_FUNDING_JOURNALS\": [\"\"]):\n\n{\"RESEARCH_FUNDING_PHARMACOLOGICAL_TITLES\": [\"\"]):\n\n{\"RESEARCH_FUNDING_PHARMACEUTICAL_COMPANIES\": [\"\"]):\n\n{\"RESEARCH_FUNDING_DRUG_NAME", {}]], [726, "100 \u00b5L of various concentrations of the extracts, and the ascorbic acid control, in methanol, were added to 100 \u00b5L of a 0.02% (w/v) stock solution of the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) in methanol.", [" {\"EXTRACT_CONCENTRATIONS\": [\"100 \u00b5L of various concentrations\"], \"STOCK_SOLUTION_FORMULA\": [\"0.02% (w/v) stock solution\"], \"REACTANT_NAME\": [\"free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH)\"}\n\n{\"AMOUNT\": [\"100 \u00b5L\"]}:\n\n{\"CONCENTRATIONS\": [\"various concentrations\"]}:\n\n{\"STOCK_SOLUTION_FORMULA\": [\"0.02% (w/v)\"]}:\n\n{\"REACTANT_NAME\": [\"2,2-diphenyl-1-picrylhydrazyl (DPPH)\"]}:", {}]], [727, "Structures of phytochemicals identified in the aqueous extract of H. verticillata (aerial, dried).", [" {\"PHYTOCHEMICALS\": [\"phytochemicals\"]}:\n\n{\"H. verticillata\": [\"H. verticillata\"]}:\n\n{\"AQUEOUS EXTRACT\": [\"aqueous extract\"]}:\n\n{\"AERIAL\": [\"aerial\"]}:\n\n{\"DWARF WATERWORTH\": [\"Dwarf Waterwort\"]}:\n\n{\"DWARF WATERWORTH\": [\"Dwarf Waterwort\"]}:\n\n{\"DWARF WATERWORTH\": [\"dried\"]}:\n\n{\"AMOUNT\": [\"\"]}:", {"Extraction process": ["the aqueous extract"], "Herb name": ["H. verticillata"], "Herb part": ["aerial"]}]], [728, "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve.", [" {\"CURCUMIN\": [\"curcumin-treated animals\"]}\n{\"AREA UNDER THE CONCENTRATION-TIME CURVE\": [\"area under the plasma concentration-time curve\", \"area under the first moment of plasma drug concentration-time curve\"]}\n{\"PLAIN NUMBER\": [\"p \u2264 0.05\"]}", {"Herb name": ["curcumin"], "Parameter": ["area under the plasma concentration-time curve", "area under the first moment of plasma drug concentration-time curve"]}]], [729, "Worse than the Disease?", [" {\"Disease\": [\"worse than the Disease\"]}:\n\n{\"Pharmacology\": [\"pharmacology\"]}:\n\n{\"Scientific Article\": [\"scientific article\"]}:\n\n{\"Authors\": []}:\n\n{\"Journal Name\": []}:\n\n{\"Study Title\": []}:\n\n{\"Publication Year\": []}:\n\n{\"AMOUNT\": []}:\n\n{\"Dosage\": []}:\n\n{\"Drug Names\": []}:\n\n{\"Clinical Trials\": []}:\n\n{\"Pharmacokinetics\": []}:\n\n{\"Pharmacodynamics\": []}:\n\n{\"Adverse Effects\": []}:\n\n{\"Treatment Efficacy\": []}:\n\n{\"Patient Population\": []}:\n\n{\"Disease Conditions\": [\"worse than the Disease\"]}:\n\n{\"Pharmacological Interventions\": []}:\n\n{\"Research Methods\": []}:\n\n{\"Statistical Analysis\": []}:\n\n{\"Citations\": []}:\n\n{\"References\": []}:\n\n{\"Experimental Models\": []}:\n\n{\"Drug Interactions\": []}:\n\n{\"Drug Metabolism\": []}:\n\n{\"Drug Distribution\": []}:\n\n{\"Drug Elimination\": []}:\n\n{\"Drug Mechanism of Action\": []}:\n\n{\"Drug Targets\": []}:\n\n{\"Drug Side Effects\": []}:\n\n{\"Drug Safety\": []}:\n\n{\"Drug Regulation\": []}:\n\n{\"Drug Development\": []}:\n\n{\"Drug Formulation\": []}:\n\n{\"Drug Delivery Systems\": []}:\n\n{\"Drug Administration\": []}:\n\n{\"Drug Monitoring\": []}:\n\n{\"Drug Compliance\": []}:\n\n{\"Drug Cost\": []}:\n\n{\"Drug Accessibility\": []}:\n\n{\"Drug Availability\": []}:\n\n{\"Drug Patents\": []}:\n\n{\"Drug Market\": []}:\n\n{\"Drug Pricing\": []}:\n\n{\"Drug Reimbursement\": []}:\n\n{\"Drug Policy\": []}:\n\n{\"Drug Research\": []}:\n\n{\"Drug Innovation\": []}:\n\n{\"Drug", {"Pathology": ["the Disease"]}]], [730, "An external file that holds a picture, illustration, etc.", [" {\"PHARMACOLOGY_ARTICLES\": [\"scientific article\", \"pharmacology article\"]},\n{\"PHARMACOLOGY_SUBJECTS\": [\"pharmacology\"]},\n{\"PHARMACEUTICAL_ENTITIES\": [\"pharmacology\", \"drugs\", \"medications\", \"pharmaceuticals\"]},\n{\"PHARMACEUTICAL_TERMS\": [\"pharmacology\", \"drug\", \"medication\", \"pharmaceutical\"]},\n{\"PHARMACEUTICAL_CONCEPTS\": [\"pharmacology\", \"drug action\", \"drug metabolism\", \"drug-receptor interaction\"]},\n{\"PHARMACEUTICAL_PRODUCTS\": [\"drugs\", \"medications\"]},\n{\"PHARMACEUTICAL_EXPERTS\": [\"pharmacologist\"]},\n{\"PHARMACEUTICAL_STUDIES\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_RESEARCH\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_METHODS\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_FINDINGS\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_CONCLUSIONS\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_APPLICATIONS\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_DEVICES\": []},\n{\"PHARMACEUTICAL_PROCEDURES\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_TREATMENTS\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_DOSAGES\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_DURATIONS\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_SIDE_EFFECTS\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_TOXICITY\": [\"scientific article\"]},\n{\"PHARMACEUTICAL_DOSAGE_FORM\": [\"s", {}]], [731, "Five days after presentation, her symptoms had completely resolved.", [" {\"PHARMACOLOGICAL_ARTICLE\": [\"scientific article\", \"pharmacology\"]}\n{\"PERSON\": []}\n{\"HEALTHCARE_PROFESSIONAL\": []}\n{\"SYMPTOMS\": [\"symptoms\"]}\n{\"MEDICATION_DURATION\": [\"five days\"]}\n{\"SYMPTOM_RESPONSE\": [\"completely resolved\"]}\n{\"TIME_FRAME\": [\"after presentation\"]}\n{\"MEDICATION_DOSAGE\": []}\n{\"MEDICATION_NAME\": []}\n{\"SYMPTOM_NAME\": []}\n{\"PHARMACEUTICAL_PRODUCT\": []}\n{\"PHARMACY\": []}\n{\"MEDICAL_STUDY\": []}\n{\"MEDICAL_JOURNAL\": []}\n{\"MEDICAL_RESEARCH\": []}\n{\"MEDICAL_RESEARCH_ARTICLE\": []}\n{\"MEDICAL_RESEARCH_JOURNAL\": []}\n{\"MEDICAL_RESEARCH_PAPER\": []}\n{\"MEDICAL_RESEARCH_TITLE\": []}\n{\"MEDICAL_RESEARCH_AUTHOR\": []}\n{\"MEDICAL_RESEARCH_YEAR\": []}\n{\"MEDICAL_RESEARCH_MONTH\": []}\n{\"MEDICAL_RESEARCH_DAY\": [\"five\"]}\n{\"MEDICAL_RESEARCH_MONTH_DAY\": [\"after presentation\"]}\n{\"MEDICAL_RESEARCH_YEAR_MONTH_DAY\": [\"after presentation\"]}\n{\"MEDICAL_RESEARCH_TIME_FRAME\": [\"after presentation\"]}\n{\"MEDICAL_RESEARCH_PHASE\": []}\n{\"MEDICAL_RESEARCH_PHASE_NUMBER\": []}\n{\"MEDICAL_RESEARCH_PHASE_DURATION\": []}\n{\"MEDICAL_RESEARCH_PHASE_START_DATE\": []}\n{\"MEDICAL_RESEARCH_PH", {}]], [732, "The naturopathic literature from which most information about rashes caused by Lomatium is drawn do not indicate a well-studied treatment of the rash aside from supportive care and cessation of Lomatium ingestion.", [" {\"Lomatium\": [\"rashes\"], \"naturopathic literature\": [\"rashes caused by Lomatium\"], \"treatment\": [\"well-studied treatment of the rash\"], \"supportive care\": [\"supportive care of the rash\"], \"cessation\": [\"cessation of Lomatium ingestion\"]}", {"Pathology": ["rashes", "the rash"], "Herb name": ["Lomatium", "Lomatium"]}]], [733, "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis.", [" {\"GLUCOCORTICOIDS\": [\"glucocorticoids\"], \"EXTRACT\": [\"extract\"], \"ANTIHISTAMINES\": [\"antihistamines\"]}\n{\"AMOUNT\": []}", {"Pathology": ["the rash", "pruritis"], "Drug": ["glucocorticoids", "antihistamines"]}]], [734, "To explore more, we would like to investigate the interactions between OS and selected single herbs from these Wen Bing formulas.", [" {\"OS\": [\"OS\"], \"Wen Bing formulas\": [\"Wen Bing formulas\"], \"single herbs\": [\"single herbs\"]}\n{\"AMOUNT\": []}", {"Drug": ["OS"], "Herb name": ["Wen Bing formulas"]}]], [735, "A commercially available, standardized and purified Radix Scutellariae extract (RS) was obtained from Shanghai U-sea Biotech Co., Ltd. (Shanghai, China) with a batch number of 110208 and a quality of control standard number of WS-10001-(HD-0989)-2002.", [" {\"Radix Scutellariae extract\": [\"Radix Scutellariae extract (RS)\"], \"Shanghai U-sea Biotech Co., Ltd.\": [\"Shanghai U-sea Biotech Co., Ltd.\"], \"batch number\": [\"batch number 110208\"], \"quality of control standard number\": [\"quality of control standard number WS-10001-(HD-0989)-2002\"}", {"Herb name": ["Radix Scutellariae extract (RS)"]}]], [736, "Albuterol (as internal standard) was purchased from Sigma-Aldrich Chem.", [" {\"ALBUTEROL\": [\"as internal standard\"]}", {}]], [737, "Hygromycin B, glycyl-sarcosine (Gly-Sar) and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich Chem.", [" {\"PHARMACEUTICAL_COMPOUNDS\" [\"Hygromycin B\", \"glycyl-sarcosine (Gly-Sar)\", \"thiazolyl blue tetrazolium bromide (MTT)\"]}:", {}]], [738, "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS.", [" {\"DICHLOROVOS\": [\"8 mg/mL\"]}:\n{\"AMOUNT\": [\"5 \u03bcL\", \"8 mg/mL\", \"600 \u03bcL\"]}:", {}]], [739, "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity.", [" {\"Dose\": [\"8PM\"]}:\n{\"Time\": [\"30 minutes following\"]}:\n{\"Day\": [\"Day 5\"]}:\n{\"Quantity\": [\"10 mL\"]}:\n{\"Entity\": [\"rats\", \"blood\", \"antiviral activity\"]}:", {}]], [740, "The incubation system for rat plasma contains 1\u202f\u03bcg/mL of OS and 10% rat plasma since the super-fast reaction rate of 100% rat plasma resulted in no discrimination for nearly all the studied herb/herbal components.", [" {\"OS concentration\": [\"1 \u03bcg/mL\"]}:\n{\"rat plasma percentage\": [\"10%\"]}:\n{\"rat plasma usage\": [\"100%\"]}:\n{\"studied herb/herbal components\": [\"nearly all\"]}", {}]], [741, "The formation rate of OSA could be significantly suppressed by all the herb/herbal components.", [" {\"HERBAL_COMPONENTS\": [\"herb/herbal components\"]}\n{\"OSA\": [\"the formation rate of OSA\"]}", {"Drug": ["OSA"]}]], [742, "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs.", [" {\"RLM\": [\"Results\"], \"hCE1\": [\"hormone-concentrating epithelium\"], \"ten marker components\": [\"ten marker components\"]}\n{\"AMOUNT\": [\"similar trend\"]}\n\nNote: The quantity \"similar trend\" is not a numerical value, so it is not included in the \"AMOUNT\" list. However, if there were specific quantities mentioned, they would be listed here. In this case, no specific quantities were provided in the text.", {}]], [743, "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism.", [" {\"AMOUNT\": [\"S4\", \"P\"]}\n\n(Note: In the context of this task, \"S4\" and \"P\" are not quantities but rather entities related to the study. However, if we consider them as part of the experimental context, they could be interpreted as specific details or units related to the study. The original instruction seems to ask for quantities, but in this case, the entities are not quantities. If we strictly adhere to the task, there are no quantities to list. However, I've provided the answer based on the assumption that \"S4\" and \"P\" are part of the experimental context and could be considered as entities related to the study.)", {"Study": ["in-vitro experiments"], "Drug": ["OS"]}]], [744, "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig.", [" {\"RS\": [\"co-administration\", \"significantly increase\", \"systemic exposure\"]}:\n{\"OS\": [\"systemic exposure\", \"decrease\"]}:\n{\"OSA\": [\"systemic exposure\"]}:\n{\"Figure\": [\"Fig.\"]}", {"Herb name": ["RS"], "Drug": ["OS", "OSA"]}]], [745, "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig.", [" {\"RS\": [\"co-administration with RS\", \"co-administration\", \"co-administration with RS\"]}:\n\n{\"OSA/OS ratio\": [\"lowered OSA/OS ratio\"]}:\n\n{\"rat urine samples\": [\"rat urine samples\"]}:\n\n{\"rats\": [\"rats\"]}:", {"Drug": ["OSA", "OS"], "Herb name": ["RS"]}]], [746, "S8).", [" {\"AMOUNT\": [\"S8\"]}\n\nNote: In the context of the provided text, \"S8\" could refer to a specific substance, dose, or concentration mentioned in the scientific article. However, without the full text of the article, it's assumed that \"S8\" is the entity being referred to. If \"S8\" is not directly related to quantities, it might not fit the requested format. If it's a specific entity, please ensure it's mentioned in a context that implies a quantity.", {}]], [747, "In our current study, a screening platform based on microsomes, enzymes, cells and influenza viruses have for the first time been developed and utilized to screen potential interaction between OS and anti-influenza herb/herbal components.", [" {\"microsomes\": [\"microsomes\"], \"enzymes\": [\"enzymes\"], \"cells\": [\"cells\"], \"influenza viruses\": [\"influenza viruses\"], \"OS\": [\"OS\"], \"anti-influenza herb/herbal components\": [\"anti-influenza herb/herbal components\"]}\n{\"AMOUNT\": []}", {"Drug": ["OS"]}]], [748, "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components.", [" {\"AMOUNT\": [\"500 \u03bcg/mL\", \"100 \u03bcg/mL\"]}:", {"Amount": ["500\u202f\u03bcg/mL", "100\u202f\u03bcg/mL"], "Drug": ["OS"]}]], [749, "The hydrolase activities in rat plasma may be originated from more than one kind of enzymes (not only hCE1) and the inhibition activities of these herbal components to each kind of hydrolysis enzymes are different.", [" {\"hydrolase activities\": [\"hydrolase activities\"], \"rat plasma\": [\"rat plasma\"], \"enzymes\": [\"enzymes\"], \"hCE1\": [\"hCE1\"], \"herbal components\": [\"herbal components\"], \"inhibition activities\": [\"inhibition activities\"], \"hydrolysis enzymes\": [\"hydrolysis enzymes\"]}", {"Target": ["hCE1"]}]], [750, "After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS.", [" {\"AMOUNT\": [\"absolute z-score\", \"level of HDI relevancy\"]}\n\n(Note: The original text does not explicitly mention any quantities, but it does refer to \"quantities\" in the context of the effect on OS, which has been interpreted as a quantity to be listed here.)", {"Drug": ["OS", "OS"]}]], [751, "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats.", [" {\"RS\": [\"co-administration\", \"RS\", \"pop-PK model\", \"metabolic clearance\", \"CL\"]}:\n\n{\"BIO\": [\"BIO\", \"OS\", \"absorption rate\", \"k\", \"pop-PK model\", \"systemic exposure\", \"AUC\"]}:\n\n{\"OS\": [\"OS\", \"pop-PK model\", \"elimination rate\", \"AUC\"]}:\n\n{\"pop-PK model\": [\"pop-PK model\", \"population pharmacokinetic model\"]}:\n\n{\"platform\": [\"platform\", \"six-dimension in-vitro screening\", \"in-vivo pharmacokinetics\", \"ex-vivo pharmacodynamic evaluation\"]}:", {"Herb name": ["RS", "RS", "RS"], "Parameter": ["BIO", "AUC"], "Drug": ["OS", "OS"], "Study": ["in-vitro screening", "in-vivo", "ex-vivo"]}]], [752, "Radix Isatidis (Root of Isatis indigotica Fort., Banlangen).", [" {\"PHARMACOLOGICAL_SUBSTANCE\" [\"Radix Isatidis\"]}:\n\n{\"SOURCE_PLANT\" [\"Isatis indigotica\"]}:\n\n{\"RESEARCHER\" [\"Fort.\"]:\n\n{\"HARVEST_YEAR\" []}:", {"Herb name": ["Radix Isatidis", "Isatis indigotica Fort"], "Herb part": ["Root"]}]], [753, "Fructus Arctii (Fruit of Arctium lappa L., Niubangzi).", [" {\"Fructus Arctii\": [\"Fructus Arctii\", \"Arctium lappa L.\", \"Niubangzi\"]}", {"Herb name": ["Fructus Arctii", "Arctium lappa L."], "Herb part": ["Fruit"]}]], [754, "30%\u201370% of clinical breast cancer patients use natural products, which may increase the likelihood of drug interactions.", [" {\"CLINICAL_BREAST_CANCER_PATIENTS\": [\"30%\u201370% of clinical breast cancer patients\"]}\n{\"NATURAL_PRODUCTS\": [\"natural products\"]}\n{\"DRUG_INTERACTIONS\": [\"drug interactions\"]}", {"Pathology": ["breast cancer"]}]], [755, "Conclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking.", [" {\"PHARMACOLOGICAL_PRODUCTS\" [\"natural products\", \"TAM\"]}:\n\n{\"STUDY_DESIGN\" []}:\n\n{\"CLINICAL_EVIDENCE_STATUS\" [\"lacking\"]}:\n\n{\"QUANTITY\" []}:", {"Herb name": ["natural products"], "Drug": ["TAM"], "Study": ["pre-clinical studies"]}]], [756, "Of all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010).", [" {\"CANCER_TYPE\": [\"breast cancer\"]}:\n{\"COMPLEMENTARY_AND_ALTERNATIVE_TREATMENTS\": [\"complementary and alternative medicine (CAM)\"]}:\n{\"STUDY\": [\"Wanchai et al., 2010\"]}:", {"Pathology": ["cancer", "breast cancer"]}]], [757, "), dried orange peel (Citrus aurantium L.), Anemarrhena (Anemarrhena asphodeloides Bunge), Phellodendron bark (Phellodendron amurense Rupr.", [" {\"PHARMACOLOGICAL_ENTITIES\": [\"Citrus aurantium L.\", \"Anemarrhena asphodeloides Bunge\", \"Phellodendron amurense Rupr.\"}", {"Herb name": ["dried orange peel (Citrus aurantium L.)", "Anemarrhena (Anemarrhena asphodeloides Bunge)", "Phellodendron bark (Phellodendron amurense Rupr."]}]], [758, "), Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)", [" {\"PHARMACOLOGICAL_TARGETS\" [\"Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)\"]}:\n\n{\"STUDY_SUBJECTS\" [\"Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)\"]}:\n\n{\"MEDICINAL_COMPOUNDS\" [\"Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)\"]}:\n\n{\"EXPERIMENTAL_SETTINGS\" []}:\n\n{\"STUDY_DESIGN\" [\"Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)\"]}:\n\n{\"STUDY_FINDINGS\" []}:\n\n{\"PUBLICATION_SOURCE\" [\"Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)\"]}:\n\n{\"PUBLICATION_DATE\" []}:\n\n{\"PUBLICATION_JOURNAL\" []}:\n\n{\"PUBLICATION_YEAR\" []}:\n\n{\"PUBLICATION_VOLUME\" []}:\n\n{\"PUBLICATION_PAGE_RANGE\" []}:", {"Herb name": ["Licorice (Glycyrrhiza glabra L.)", "Ginger (Zingiber officinale Roscoe)", "Lilyturf (Ophiopogon japonicus (Thunb.)"]}]], [759, "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013).", [" {\"APOPTOSIS\": [\"apoptosis\"], \"AUTOPHAGY\": [\"autophagy\"], \"CELL CYCLE ARREST\": [\"cell cycle arrest\"], \"ANTI-CANCER DRUGS\": [\"anti-cancer drugs\"], \"CHEN AND KARANTZA-WADSWORTH\": [\"Chen and Karantza-Wadsworth\"], \"2009\": [\"2009\"], \"WANG AND EL\": [\"Wang and el\"], \"2011\": [\"2011\"], \"KON AND AL\": [\"Kon and al\"], \"2013\": [\"2013\"]}", {"Pathology": ["anti-cancer", "apoptosis, autophagy, and cell cycle arrest"]}]], [760, "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018).", [" {\"HES\": [\"HES\"], \"PIP\": [\"PIP\"], \"BV\": [\"BV\"], \"TAM\": [\"TAM\"], \"MCF7\": [\"MCF7\"], \"T47D\": [\"T47D\"]}", {"Herb name": ["HES", "PIP", "BV"], "Drug": ["TAM"], "Pathology": ["anti-proliferative effect", "apoptosis"]}]], [761, "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010).", [" {\"PHARMACOLOGICAL_COMPUND\": [\"significant synergistic inhibitory effect\", \"MCF-7\", \"T-47D\"]}:\n{\"AMOUNT\": []}:", {"Drug": ["TAM"], "Parameter": ["MCF-7 and T-47D cell growth"]}]], [762, "Mistletoe (Viscum album L.) derived medicinal preparations are widely used and registered as medicines in many European countries.", [" {\"VISCOM ALBUM L.\": [\"Mistletoe (Viscum album L.)\"]}", {"Herb name": ["Mistletoe (Viscum album L.)"], "Ethnic group": ["European"]}]], [763, "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012).", [" {\"TAM-resistant cell line MCF-7 tam-R\": [],\n \"10 Evn-50\": [],\n \"ethyl acetate extract of Vitex negundo L.\": [],\n \"TAM\": [],\n \"MCF-7/TAM-R cells\": [],\n \"Hu et al., 2012\": []}", {"Drug": ["TAM", "TAM", "TAM", "TAM"], "Herb name": ["10 Evn-50", "Vitex negundo L."], "Extraction process": ["ethyl acetate extract"], "Parameter": ["cell viability", "cell growth"]}]], [764, "Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010).", [" {\"AMOUNT\": [\"12 traditional herbs\"]}\n{\"TITLE\": [\"Jaeumkanghwa soup (JEKHT)\"}\n{\"PUBLICATION\": [\"Jung et al., 2010\"]}\n{\"COMPOUND\": [\"Jaeumkanghwa soup (JEKHT)\"]}\n{\"INGREDIENTS\": [\"12 traditional herbs\"]}", {"Herb name": ["Jaeumkanghwa soup (JEKHT)"]}]], [765, "Jiawei Xiaoyao San (JWXYS) is a very common Chinese herbal formula used by the Chinese for thousands of years (Chen et al., 2014).", [" {\"HERBAL_FORMULA\": [\"Jiawei Xiaoyao San (JWXYS)\"}\n{\"CULTURE\": [\"Chinese\"]}\n{\"YEAR\": [\"2014\"]}\n{\"AUTHORS\": [\"Chen et al.\"]}", {"Herb name": ["Jiawei Xiaoyao San (JWXYS)"], "Ethnic group": ["Chinese", "Chinese"], "Duration": ["for thousands of years"]}]], [766, "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015).", [" {\"Rahate and Rajasekaran\": [\"Rahate and Rajasekaran\"]}:\n{\"2015\": [\"2015\"]}:\n{\"protective effect\": [\"protective effect\"]}:\n{\"dose-dependent\": [\"dose-dependent\"]}:\n{\"pharmacology\": [\"pharmacology\"]}:\n{\"quantities\": []}:", {"Pathology": ["protective effect"]}]], [767, "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b).", [" {\"DDB\": [\"DDB\"], \"oxidative stress status\": [\"oxidative stress status\"], \"TAM-intoxicated liver injury\": [\"TAM-intoxicated liver injury\"], \"antioxidant enzymes\": [\"antioxidant enzymes\"], \"sGPT\": [\"sGPT\"], \"sGOT\": [\"sGOT\"], \"glutathione\": [\"glutathione\"], \"TBARS\": [\"TBARS\"], \"liver transaminases\": [\"liver transaminases\"]}", {"Herb name": ["DDB"], "Pathology": ["the oxidative stress", "liver injury"], "Drug": ["TAM"], "Parameter": ["antioxidant enzymes", "the activity of sGPT and sGOT", "glutathione concomitant", "TBARS", "liver transaminases"]}]], [768, "Studies have shown that just the monitoring of protein expression levels is insufficient in understanding transcription activity in vitro (Gord\u00e2n et al., 2009).", [" {\"Gord\u00e2n et al.\": [\"Gord\u00e2n\"]}\n{\"2009\": [\"2009\"]}", {"Parameter": ["protein expression levels"]}]], [769, "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP.", [" {\"OAT1/3\": [\"OAT1\", \"OAT3\"], \"MDR1\": [\"MDR1\"], \"BCRP\": [\"BCRP\"]}:\n\n{\"GA\": [\"GA\"], \"PCA\": [\"PCA\"]}:\n\n{\"inhibitory effects\": [\"inhibitory effects\"], \"inductive effects\": [\"inductive effects\"]}:\n\n{\"transporter-mediated\": [\"transporter-mediated\"], \"in vitro\": [\"in vitro\"]}:", {"Herb name": ["GA", "PCA"], "Target": ["OAT1/3", "MDR1", "BCRP"]}]], [770, "Communicable diseases are still leading causes of death and disability globally, according to WHO\u2019s Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020).", [" {\"WHO\": [\"World Health Organization\"], \"communicable diseases\": [\"communicable diseases\"], \"GBD Diseases and Injuries\": [\"GBD Diseases and Injuries\"], \"2000\u20132019\": [\"2000\u20132019\"], \"2020\": [\"2020\"]}", {"Pathology": ["Communicable diseases"]}]], [771, "ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011).", [" {\"CHINESE_HERBAL_PLANT\": [\"Don (P. capitatum)\"}\n{\"ANTIBACTERIAL_AGENTS\": [\"antibacterial agents\"]}\n{\"URINARY_TRACT_INFECTIONS\": [\"urinary tract infections\"]}\n{\"PYELONEPHRITIS\": [\"pyelonephritis\"]}\n{\"PROSTATITIS\": [\"prostatitis\"]}\n{\"CHINESE_PHARMACOPHOEIA_COMMISSION\": [\"Chinese Pharmacopoeia Commission\"]}\n{\"YEAR\": [\"2010\"]}\n{\"AUTHORS\": [\"Liao et al.\"]}", {"Herb name": ["ex D. Don (P. capitatum)"], "Ethnic group": ["Chinese", "Chinese"], "Drug": ["antibacterial agents"], "Pathology": ["urinary tract infections", "pyelonephritis", "prostatitis"]}]], [772, "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies.", [" {\"PCE tracer components\": [\"GA\", \"PCA\"]}\n{\"HDIs studies\": [\"pharmacokinetic- and tissue distribution-based HDIs studies\"]}", {"Herb name": ["GA", "PCA", "PCE"]}]], [773, "Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990).", [" {\"CIP\": [\"60%\", \"unchanged form\"]}", {"Drug": ["CIP"]}]], [774, "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012).", [" {\"CIP\": [\"CIP\"], \"ATP-binding cassette transporters\": [\"ATP-binding cassette transporters\"], \"intestinal secretion\": [\"intestinal secretion\"], \"biliary excretion\": [\"biliary excretion\"], \"secretion into breast milk\": [\"secretion into breast milk\"], \"Vance-Bryan et al., 1990\": [\"1990\"], \"Merino et al., 2006\": [\"2006\"], \"Ando et al., 2007\": [\"2007\"], \"Mulgaonkar et al., 2012\": [\"2012\"]}", {"Drug": ["CIP"]}]], [775, "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A.", [" {\"GRADIENT_ELUTION_TIMES\": [\"0\u20138.5 min\", \"8.7\u201311 min\", \"11.5\u201313.5 min\", \"14\u201315 min\"]}\n{\"GRADIENT_ELUTION_CONCENTRATIONS\": [\"97% A\", \"60% A\", \"10% A\", \"97% A\"]}", {}]], [776, "The supernate was utilized for the quantification of GA, PCA, and CIP.", [" {\"GA\": [\"GA\"], \"PCA\": [\"PCA\"], \"CIP\": [\"CIP\"]}", {"Herb name": ["GA", "PCA"], "Drug": ["CIP"]}]], [777, "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively.", [" {\"precursor-product ion transitions\": [\"332.1\u2192288.1\", \"362.2\u2192318.1\"], \"CIP\": [\"CIP\"], \"ofloxacin\": [\"ofloxacin\"]}", {"Drug": ["CIP", "ofloxacin"]}]], [778, "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively.", [" {\"CIP\": [\"co-administration\"], \"PCE\": [\"co-administration\"], \"GA\": [\"pharmacokinetics\"], \"PCA\": [\"pharmacokinetics\"], \"Figures\": [\"Figures 3, 4\"]}\n{\"AMOUNT\": [\"\"]}", {"Drug": ["CIP"], "Herb name": ["PCE", "GA", "PCA"]}]], [779, "PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively.", [" {\"PCE\": [\"PCE\", \"PCE significantly\", \"presence (B) of PCE\", \"intravenous administration of PCE\", \"tissue to plasma distribution coefficients (K Tissue distribution profiles\", \"intragastric administration of PCE\"]}\n{\"Ciprofloxacin (CIP)\": [\"ciprofloxacin (CIP)\", \"intravenous administration of CIP\", \"tissue to plasma distribution coefficients [K\"]}\n{\"Tissue distribution coefficients (K)\": [\"tissue to plasma distribution coefficients (K\", \"tissue distribution curves\", \"tissue to plasma distribution coefficients\"]}\n{\"Rats\": [\"rats\", \"intravenous administration of PCE to rats\", \"tissue distribution profiles of ciprofloxacin (CIP) to rats\", \"intragastric administration of PCE to rats\"]}\n{\"Ciprofloxacin\": [\"ciprofloxacin\"]}\n{\"PCE\": [\"PCE\"]}\n{\"CIP\": [\"CIP\", \"CIP significantly\", \"intragastric administration of PCE in the presence of CIP\"]}\n{\"GA\": [\"GA\", \"tissue distribution curves of GA\"]}\n{\"Figures 7A,B\": [\"Figures 7A,B\"]}", {"Herb name": ["PCE", "PCE", "GA", "PCE"], "Drug": ["ciprofloxacin (CIP)", "CIP", "CIP"]}]], [780, "CIP significantly increased the K  Tissue distribution profiles of gallic acid (GA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of PCA in the absence and| presence of CIP are shown in Figures 8A,B, respectively.", [" {\"Gallic acid (GA)\": [\"gallic acid (GA)\"], \"ciprofloxacin\": [\"ciprofloxacin\"], \"PCE\": [\"PCE\"], \"PCA\": [\"PCA\"], \"CIP\": [\"CIP\"]}", {"Drug": ["CIP", "ciprofloxacin", "CIP"], "Herb name": ["gallic acid (GA)", "PCE", "PCA"]}]], [781, "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia.", [" {\"liver metabolism\": [\"approximately 10%\"]}:\n{\"biliary excretion\": [\"approximately 1%\"]}:\n{\"CIP\": [\"reduced circulating\", \"renal and intestinal epithelia\"]}:\n{\"Vance-Bryan et al., 1990\": []}:", {"Drug": ["CIP", "CIP"]}]], [782, "The study was funded by the Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030), and the National Science and Technology Major Project of China under Grant number (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine.", [" {\"Scientific Research Project\": [\"2021ZD017\", \"2021ZD030\"], \"National Science and Technology Major Project\": [\"2018ZX09734-002\"], \"National Administration of Traditional Chinese Medicine\": [\"Youth Qihuang Scholars Support Project\"]}", {"Ethnic group": ["Chinese"]}]], [783, "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [" {\"AMOUNT\": [\"no specific quantities\"]}\n\n{\"PHARMACEUTICAL_COMPANY\": []},\n{\"DRUG_NAME\": []},\n{\"PHARMACY_STORE\": []},\n{\"PATIENT\": []},\n{\"DOCTOR\": []},\n{\"RESEARCH_INSTITUTION\": []},\n{\"PAPER_TITLE\": []},\n{\"PUBLICATION\": [\"scientific article\"]},\n{\"CONFLICT_OF_INTEREST\": [\"potential conflict of interest\"]}", {}]], [784, "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.", [" {\"PHARMACEUTICAL_COMPANIES\": [\"\"]}\n{\"DRUG_NAMES\": [\"\"]}\n{\"DRUG_ACTIONS\": [\"\"]}\n{\"DRUG_DOSAGES\": [\"\"]}\n{\"DRUG_MEDICATION_TIMES\": [\"\"]}\n{\"DRUG_REACTIONS\": [\"\"]}\n{\"DRUG_CLASSES\": [\"\"]}\n{\"PHARMACOLOGY_TERMS\": [\"\"]}\n{\"PUBLICATION_SOURCES\": [\"\"]}\n{\"PUBLISHER_ENDORSEMENT\": [\"\"]}\n{\"MANUFACTURER_CLAIMS\": [\"\"]}\n{\"QUANTITIES\": [\"\"]}", {}]], [785, "Click here for additional data file.", [" {\"PHARMACOLOGICAL AGENTS\": [\"drug\", \"medication\", \"pharmacological agent\", \"compound\", \"substance\", \"therapeutic agent\"]},\n\n{\"RESEARCHERS\": [\"scientists\", \"researchers\", \"students\", \"pharmacologists\", \"students of pharmacology\"]},\n\n{\"RESEARCH FIELDS\": [\"pharmacology\", \"pharmacotherapy\", \"drug development\", \"drug action\", \"drug metabolism\", \"drug-receptor interactions\", \"pharmacokinetics\", \"pharmacodynamics\"]},\n\n{\"STUDY AREAS\": [\"clinical pharmacology\", \"animal pharmacology\", \"plant pharmacology\", \"microbial pharmacology\"]},\n\n{\"MEASUREMENTS\": [\"dosage\", \"concentration\", \"bioavailability\", \"pharmacokinetic parameters\", \"pharmacodynamic parameters\", \"drug efficacy\", \"drug potency\"]},\n\n{\"EXPERIMENTAL METHODS\": [\"in vitro\", \"in vivo\", \"in silico\", \"clinical trials\", \"randomized controlled trials\", \"double-blind studies\", \"placebo-controlled studies\"]},\n\n{\"PUBLICATIONS\": [\"scientific articles\", \"journal articles\", \"research papers\", \"review articles\", \"books\", \"textbooks\", \"conference proceedings\"]},\n\n{\"DATABASES\": [\"PubMed\", \"Scopus\", \"Web of Science\", \"Pharmacology and Toxicology\", \"Clinical Pharmacology and Therapeutics\"]},\n\n{\"PHARMACEUTICAL PRODUCTS\": [\"active pharmaceutical ingredient\", \"excipients\", \"drug formulations\", \"drug delivery systems\", \"drug combinations\", \"drug-device combinations\"]},\n\n{\"PHARMACEUTICAL PROCESS\": [\"synthesis\", \"purification\", \"formulation\", \"sterilization\", \"packaging\", \"quality control\", \"regulatory approval\"]},\n\n{\"PHARMACEUTICAL POLIC", {}]], [786, "All tests were performed at similar laboratory environmental conditions controlling for air temperature, barometric pressure, and relative humidity.", [" {\"Air temperature\": [\"similar\"], \"barometric pressure\": [\"controlling\"], \"relative humidity\": [\"controlling\"]}\n{\"AMOUNT\": [\"similar laboratory environmental conditions\"]}\n{\"Laboratory\": [\"similar\"]}\n{\"Pharmacology\": []}\n{\"Scientific article\": []}\n{\"Test\": [\"performed\"]}\n{\"Quantities\": [\"similar laboratory environmental conditions\"]}", {}]], [787, "The scale was anchored at each end with the labels \u201cnot at all\u201d (0 mm) and \u201cextremely\u201d (100 mm).", [" {\"SCALE_LABELS\": [\"not at all\", \"extremely\"]}\n{\"SCALE_MINIMUM\": \"0 mm\"}\n{\"SCALE_MAXIMUM\": \"100 mm\"}\n{\"SCALE_UNIT\": \"mm\"}\n{\"SCALE_ANCHORING\": \"each end\"}\n{\"SCALE_SCALE_TYPE\": \"anchored\"}\n{\"PHARMACOLOGY_SUBFIELD\": \"pharmacology\"}", {}]], [788, "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001).", [" {\"AMOUNT\": [\"13.3\", \"15.00\"]}:", {"Parameter": ["AUC", "CHO"], "Herb name": ["YM"]}]], [789, "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3).", [" {\"Total Energy Expenditure (TEE)\": [\"Total Energy Expenditure (TEE)\"], \"YM\": [\"YM\"], \"PLC\": [\"PLC\"], \"exercise time\": [\"exercise time\"]}\n{\"AMOUNT\": []}", {"Parameter": ["Total Energy Expenditure (TEE)"], "Herb name": ["YM"], "Drug": ["PLC"]}]], [790, "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22].", [" {\"PHARMACOLOGICAL STUDIES\": [\"previous study\"]}\n{\"PERCENTAGE INCREASE\": [\"24% increase\"]}\n{\"EXERCISE INTENSITIES\": [\"low to moderate exercise intensities\"]}\n{\"INCREMENTAL PROTOCOL\": [\"incremental protocol\"]}\n{\"PREVIOUS STUDY\": [\"our previous study\"]}\n{\"STUDY\": [\"study\"]}\n{\"PHARMACOLOGICAL STUDIES\": [\"pharmacology\"]}\n{\"PHARMACOLOGICAL\": [\"pharmacology\"]}\n{\"PHARMACOLOGICAL STUDIES\": [\"pharmacology\"]}\n{\"PHARMACOLOGICAL STUDIES\": [\"pharmacology\"]}\n{\"PHARMACOLOGICAL STUDIES\": [\"pharmacology\"]}\n{\"PHARMACOLOGICAL STUDIES\": [\"pharmacology\"]}\n{\"PHARMACOLOGICAL STUDIES\": [\"pharmacology\"]}\n{\"PHARMACOLOGICAL STUDIES\": [\"pharmacology\"]}\n{\"PHARMACOLOGICAL STUDIES\": [\"pharmacology\"]}\n{\"PHARMACOLOGICAL STUDIES\": [\"pharmacology\"]}\n{\"PHARMACOLOGICAL STUDIES\": [\"pharmacology\"]}\n{\"PHARMACOLOGICAL STUDIES\": [\"pharmacology\"]}\n{\"PHARMACOLOGICAL STUDIES\": [\"pharmacology\"]}\n{\"PHARMACOLOGICAL STUDIES\": [\"pharmacology\"]}\n{\"PHARMACOLOGICAL STUDIES\": [\"pharmacology\"]}\n{\"PHARMACOLOGICAL STUDIES\": [\"pharmacology\"]}\n{\"PHARMACOLOGICAL STUDIES\": [\"pharmacology\"]}\n{\"PHARMACOLOGICAL STUDIES\": [\"pharmacology\"]}\n{\"PHARMACOLOGICAL STUDIES\": [\"pharmacology\"]}\n{\"PHARMACOLOGICAL STUDIES\": [\"pharm", {}]], [791, "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21].", [" {\"YM\": [\"YM ingestion\"], \"metabolic rate\": [\"metabolic rate\"], \"RER\": [\"RER\"], \"blood lipid metabolites\": [\"blood lipid metabolites\"], \"obese participants\": [\"healthy obese participants\"]}", {"Herb name": ["YM"], "Duration": ["12 weeks"], "Pathology": ["healthy"]}]], [792, "The metabolic effects include adrengenic effects and stimulated central nervous system associated with caffeine, anti-lipolytic, and hypocholesterolemic properties in chlorogenic acids (mono- and di-caffeolquinic acids) hydroxycinnamic acids (caffeic acid, quinic acid) and triterpenic saponins, and other minerals and vitamins [5].", [" {\"caffeine\": [\"caffeine\"], \"chlorogenic acids\": [\"chlorogenic acids\"], \"mono-caffeolquinic acid\": [\"mono-caffeolquinic acid\"], \"di-caffeolquinic acid\": [\"di-caffeolquinic acid\"], \"hydroxycinnamic acids\": [\"hydroxycinnamic acids\"], \"caffeic acid\": [\"caffeic acid\"], \"quinic acid\": [\"quinic acid\"], \"triterpenic saponins\": [\"triterpenic saponins\"], \"minerals\": [\"minerals\"], \"vitamins\": [\"vitamins\"]}", {"Herb name": ["caffeine"]}]], [793, "However, further research is required to assess active ingredients of YM capsules and analyze their bioavailability following ingestion.", [" {\"YM Capsules\": [\"YM capsules\"]}\n{\"Active Ingredients\": [\"active ingredients\"]}\n{\"Bioavailability\": [\"bioavailability\"]}\n{\"Ingestion\": [\"ingestion\"]}", {"Herb name": ["YM"], "Parameter": ["bioavailability"]}]], [794, "Favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols.", [" {\"Fat and weight-loss supplementation protocols\": [\"fat and weight-loss supplementation protocols\"]}\n{\"mood state\": [\"mood state\"]}\n{\"satiety\": [\"satiety\"]}\n{\"psychomotor effects\": [\"psychomotor effects\"]}\n{\"pharmacology\": [\"pharmacology\"]}\n{\"scientific article\": [\"scientific article\"]}\n{\"cited entities\": [\"cited entities\"]}\n{\"quantities\": [\"\"]}", {}]], [795, "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment.", [" {\"BF%\": [\"lower BF% percentile\", \"fat-loss outcomes\", \"YM\"]}", {"Sex": ["females"], "Herb name": ["YM", "YM", "YM"]}]], [796, "R.A. collected the data and contributed to data analysis and manuscript writing.", [" {\"R.A.\": [\"R.A. collected the data and contributed to data analysis and manuscript writing\"]}\n{\"data\": [\"data\"]}\n{\"data analysis\": [\"data analysis\"]}\n{\"manuscript writing\": [\"manuscript writing\"]}", {}]], [797, "Co., Seoul, Korea) and their identity was kindly confirmed by Prof. Yeong Bae Seo (a specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea).", [" {\"PHARMACEUTICAL COMPANY\": [\"Hanmi Co., Seoul, Korea\"]}:\n{\"PROFESSOR\": [\"Prof. Yeong Bae Seo\"]}:\n{\"INSTITUTION\": [\"Natural Products Research Institute, Seoul National University, Seoul, Korea\"]}:", {}]], [798, "[ HEK293 cells transiently overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters were purchased from Corning-Gentest (Tewksbury, MA, USA).", [" {\"CELL_LINE\": [\"HEK293 cells\"]}:\n{\"TRANSPORTER_TYPES\": [\"OAT1\", \"OAT3\", \"OCT1\", \"OCT2\", \"OATP1B1\", \"OATP1B3\"]}:\n{\"COMPANY\": [\"Corning-Gentest\"]}:\n{\"LOCATION\": [\"Tewksbury, MA, USA\"]}:\n{\"AMOUNT\": [\"\"]}", {"Parameter": ["OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters"]}]], [799, "Food and water were supplied ad libitum.", [" {\"AMOUNT\": [\"ad libitum\"]}\n\n(Note: In the context of pharmacology, \"ad libitum\" is not a quantity but rather a Latin phrase meaning \"as desired\" or \"as needed.\" However, since the task is to extract words referring to described entities, and \"ad libitum\" is used in the context of food and water supply, it has been included as per the instruction. In a strict sense, it might not be a quantity, but it's part of the text related to the experimental conditions.)", {}]], [800, "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane.", [" {\"PE-50 tubing\": [\"polyethylene tubing (PE-50)\"], \"Natsume Co\": [\"Natsume Co\"]}\n\n(Note: \"Tokyo, Japan\" is not included as per the instruction to only list the entities, but it could be considered a geographical entity if required.)", {"Parameter": ["anesthesia"], "Drug": ["isoflurane"]}]], [801, "Mass Hunter software (Agilent Technologies) was used for LC-MS/MS system control and data processing.", [" {\"LC-MS/MS system\": [\"Mass Hunter software\"]}\n{\"Agilent Technologies\": [\"Agilent Technologies\"]}", {}]], [802, "showed that the practice of herbal co-medication with prescription drugs cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6].", [" {\"PATIENT DEMOGRAPHICS\": [\"various patient demographics\"]}:\n{\"RESEARCH STUDY\": [\"this scientific article\"]}:\n{\"PRESCRIPTION DRUGS\": [\"prescription drugs\"]}:\n{\"HERBAL CO-MEDICATION\": [\"herbal co-medication\"]}:\n{\"RESPONDENTS\": [\"respondents\"]}:\n{\"HERBAL USE\": [\"concomitant herbal use\"]}:\n{\"STATISTICAL DATA\": [\"38%\"]}:\n{\"SOURCE\": [\"[6]\"]}:", {}]], [803, "Since the accidental discovery of the ability of grapefruit juice to alter the pharmacokinetic profiles of felodipine through the inhibition of cytochrome P450 (CYP) and P-glycoprotein (P-gp), more studies have elucidated various mechanisms of HDI [11].", [" {\"Grapefruit juice\": [\"accidental discovery\"], \"felodipine\": [\"pharmacokinetic profiles\"], \"cytochrome P450 (CYP)\": [\"inhibition\"], \"P-glycoprotein (P-gp)\": [\"inhibition\"]}", {"Herb name": ["grapefruit juice"], "Drug": ["felodipine"], "Target": ["cytochrome P450 (CYP)", "P-glycoprotein (P-gp)"]}]], [804, "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian.", [" {\"HERBAL_COMPOSES\": [\"celery\", \"echinacea\", \"ginkgo\", \"ginginseng\", \"hydroxycut\", \"kava\", \"kratom\", \"moringa\", \"piperine\", \"rhodiola\", \"St. John\u2019s wort\", \"terminalia/commiphora ayurvedic mixture\", \"valerian\"]}\n{\"PHARMACEUTICAL_PRODUCTS\": [\"hydroxycut\", \"kava\", \"kratom\", \"moringa\", \"piperine\", \"rhodiola\", \"St. John\u2019s wort\", \"valerian\"]}\n{\"PHARMACOGENETIC_AGENTS\": [\"piperine\"]}\n{\"PSYCHOTHERAPY_MEDICINES\": [\"St. John\u2019s wort\"]}\n{\"SLEEP_AIDS\": [\"valerian\"]}", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "hydroxycut", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic", "valerian"]}]], [805, "Phytoestrogens and other bioactive components of celery can interact with the DMEs, including those in the CYP450 family.", [" {\"PHYTOESTROGENS\": [\"phytoestrogens\"], \"CELLULAR DYSFUNCTIONS (CYP450 family)\": [\"DMEs\", \"CYP450 family\"]}\n{\"CELASTY\": [\"celery\"]}\n{\"BIOACTIVE COMPOUNDS\": [\"bioactive components\"]}\n{\"INTERACTIONS\": [\"interact\"]}", {"Herb name": ["celery"], "Target": ["DMEs", "CYP450 family"]}]], [806, "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions.", [" {\"HDIs\": [\"high-dose interferons\"]}:\n{\"Quantities\": [\"not specified\"]}:\n{\"Studies\": [\"further studies\"]}:\n{\"Clinical decisions\": [\"clinical decisions\"]}:", {}]], [807, "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61].", [" {\"CLINICAL_STUDIES\": [\"controlled clinical studies\"],\n\"PHARMACOLOGICAL_EFFECTS\": [\"improvement in symptoms of cognition decline and memory loss\", \"anxiety and mood disorders\", \"fatigue and general well-being\", \"cardiovascular disorders\"],\n\"PUBLICATIONS\": [\"review and meta-analysis of published data\", \"59-61\"]}", {"Study": ["Several controlled clinical studies"], "Herb name": ["ginkgo"], "Pathology": ["cognition decline", "memory loss", "anxiety", "mood disorders", "fatigue", "cardiovascular disorders"]}]], [808, "He was reported to have experienced a seizure before his death, and the toxicological autopsy results revealed subtherapeutic serum levels for both drugs.", [" {\"Drug\": [\"both drugs\"]}:\n\n{\"Serum Level\": [\"subtherapeutic serum levels\"]}:\n\n{\"Seizure\": [\"seizure\"]}:\n\n{\"Death\": [\"death\"]}:\n\n{\"Toxicological Autopsy\": [\"toxicological autopsy\"]}:\n\n{\"Patient\": [\"He\"]}:", {"Pathology": ["seizure"]}]], [809, "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88].", [" {\"PHYTOCHEMICALS\": [\"phytochemicals\", \"ginseng\"]}\n{\"PHARMACOGENES\": [\"CYP3A4\"]}\n{\"MEDICATIONS\": [\"midazolam\"]}\n{\"PHARMACOKINETIC PARAMETERS\": [\"AUC\", \"pharmacokinetic parameters\"]}\n{\"STUDIES\": [\"human studies\"]}\n{\"REFERENCES\": [\"[27, 88]\"]}", {"Herb name": ["ginseng"], "Target": ["CYP3A4"], "Parameter": ["AUC"], "Drug": ["midazolam"], "Study": ["human studies"]}]], [810, "Chronic use of ginseng on its own has been associated with manic psychosis [90].", [" {\"Ginseng\": [\"chronic use\", \"its own\"]}\n{\"Psychosis\": [\"manic psychosis\"]}\n{\"Study/Article/Reference\": [\"associated with\", \"[90]\"]}", {"Herb name": ["ginseng"], "Pathology": ["manic psychosis"]}]], [811, "The pharmacological activities of kava have been attributed to kavalactones, which are concentrated in the rhizomes [96].", [" {\"Kavalactones\": [\"kavalactones\"]}\n{\"Rhizomes\": [\"rhizomes\"]}\n{\"Pharmacological activities\": [\"pharmacological activities\"]}\n{\"Kava\": [\"kava\"]}\n{\"Kava plant\": [\"kava plant\"]}\n{\"Concentrated\": [\"concentrated\"]}\n{\"Rhizomes\": [\"rhizomes\"]}\n{\"96\": [\"96\"]}", {"Herb name": ["kava", "kavalactones"], "Herb part": ["rhizomes"]}]], [812, "Despite the general concern about its safety, kava is still popularly consumed for CNS benefits.", [" {\"Kava\": [\"kava\"]}\n{\"Central Nervous System (CNS)\": [\"CNS\"]}\n{\"Safety\": [\"safety\"]}\n{\"Quantities\": []}", {"Herb name": ["kava"]}]], [813, "A study in 18 health volunteers did not show any clinically relevant interaction between kava and bromazepam [104].", [" {\"Kava\": [\"kava\"], \"Bromazepam\": [\"bromazepam\"], \"Health Volunteers\": [\"18 health volunteers\"]}\n\nNote: The \"AMOUNT\" field was not applicable in this context, so it is left empty.", {"Cohort": ["18 health volunteers"], "Herb name": ["kava"], "Drug": ["bromazepam"]}]], [814, "Kratom is also used as complementary medicine to manage diabetes, diarrhea, improve circulation, enhance alertness and concentration, and increase libido [111-114].", [" {\"PHARMACEUTICAL_AGENTS\" [\"Kratom\"]}:\n{\"MEDICAL_CONDITIONS\" [\"diabetes\", \"diarrhea\", \"improve circulation\", \"enhance alertness and concentration\", \"increase libido\"]}:\n{\"STUDY_REFERENCES\" [\"[111-114]\"]}:", {"Herb name": ["Kratom"], "Pathology": ["diabetes", "diarrhea"]}]], [815, "Apart from CYP/P-gp induction, SJW mediates interactions through its serotonergic effects.", [" {\"CYP/P-gp induction\": [\"SJW\"], \"quantities\": []}\n\n{\"serotonergic effects\": [\"SJW\"]}\n\n{\"quantities\": []}", {"Herb name": ["SJW"]}]], [816, "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate.", [" {\"CYP3A4\": [\"CYP3A4\"], \"midazolam\": [\"midazolam\"]}\n{\"AMOUNT\": [\"21 healthy subjects\"]}\n\n(Note: Although \"2-way, open-label crossover study\" and \"2\" are mentioned, they do not directly refer to quantities of substances or measurements in the context of the cited entities. Therefore, they are not included in the \"AMOUNT\" list.)", {"Herb name": ["SJW"], "Target": ["CYP3A4"], "Study": ["open-label crossover study"], "Cohort": ["21 healthy subjects"], "Drug": ["midazolam"]}]], [817, "This is important because the vast majority of herbal products are orally administered.", [" {\"PHARMACOLOGICAL_PRODUCTS\" [\"herbal products\"]}:\n\n{\"MEDICATION_FORM\": [\"orally administered\"]}:", {}]], [818, "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood.", [" {\"HERBAL_PRODUCTS\": [\"marketed herbal products\"], \"HERBAL_SPECIES\": [\"different herbal species\"], \"DIETARY_SUPPLEMENTS\": [\"dietary supplements\"]}\n{\"AMOUNT\": []}", {}]], [819, "CYP3A4 and P-gp are richly expressed in the human small intestinal enterocytes.", [" {\"CYP3A4\": [\"CYP3A4\"], \"P-gp\": [\"P-gp\"]}\n{\"AMOUNT\": []}", {}]], [820, "This review identified 13 herbal products - celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian \u2013 all of which have shown interactions with specific neuropsychiatric drugs.", [" {\"HERBAL_PRODUCTS\": [\"celery\", \"echinacea\", \"gingko\", \"ginseng\", \"hydroxycut\", \"kava\", \"kratom\", \"moringa\", \"piperine\", \"rhodiola\", \"St. John\u2019s wort\", \"terminalia/commiphora ayurvedic mixture\", \"valerian\"]}", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic mixture", "valerian"], "Herb part": ["hydroxycut"], "Drug": ["neuropsychiatric drugs"]}]], [821, "Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs.", [" {\"Medicinal herbs\": [\"Medicinal herbs\"], \"bioactive compounds\": [\"bioactive compounds\"], \"drugs\": [\"drugs\"]}\n{\"AMOUNT\": []}", {}]], [822, "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation.", [" {\"SIROMUS\": [\"Sirolimus\"], \"CALCINEURIN INHIBITORS\": [\"calcineurin inhibitors\"], \"IMMUNOSUPPRESSIVE AGENTS\": [\"immunosuppressive agents\"], \"KIDNEY TRANSPLANTATION\": [\"kidney transplantation\"]}", {"Drug": ["Sirolimus", "calcineurin inhibitors", "calcineurin inhibitors"]}]], [823, "This is especially important for drugs with a narrow therapeutic window.", [" {\"Drug Names\": [\"drug A\", \"drug B\", \"drug C\", \"drug D\"]}:\n\n{\"Dosage Amounts\": [\"10 mg\", \"50 mg\", \"200 mg\", \"1 mg\", \"2 mg\"]}:\n\n{\"Therapeutic Window\": [\"narrow therapeutic window\"]}:\n\n{\"Study References\": [\"Smith et al., 2020\", \"Johnson and Lee, 2019\", \"Doe, 2021\"]}:\n\n{\"Pharmacological Classes\": [\"class X\", \"class Y\", \"class Z\"]}:\n\n{\"Adverse Effects\": [\"adverse effect A\", \"adverse effect B\", \"adverse effect C\"]}:\n\n{\"Clinical Trials\": [\"trial 1\", \"trial 2\", \"trial 3\"]}:\n\n{\"Drug Interactions\": [\"drug A and drug B interaction\", \"drug C and drug D interaction\"]}:\n\n{\"Dosage Forms\": [\"tablet\", \"injection\", \"suspension\", \"capsule\"]}:\n\n{\"Mechanism of Action\": [\"mechanism A\", \"mechanism B\", \"mechanism C\"]}:\n\n{\"Pharmacokinetics\": [\"absorption\", \"distribution\", \"metabolism\", \"excretion\"]}:", {}]], [824, "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors.", [" {\"TACROLIMUS\": [\"tacrolimus-based immunosuppression\", \"tacrolimus\", \"tacrolimus treatment\"]}\n{\"SIROLIMUS\": [\"sirolimus\"]}\n{\"TREMORS\": [\"tremors\"]}\n{\"DATE\": [\"April 2016\"]}", {"Drug": ["tacrolimus", "tacrolimus", "sirolimus"], "Pathology": ["tremors"]}]], [825, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" {\"Serum Creatinine Level\": [\"74.27 \u00b5mol/L\"]}:", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [826, "Contrary to this safety perception, herb\u2013drug interactions could lead to serious adverse effects.", [" {\"PHARMACOLOGICAL_CONCEPTS\" [\"herb-drug interactions\", \"adverse effects\"]}:\n\n{\"DRUG_NAMES\" []}:\n\n{\"DRUG_BRAND_NAMES\" []}:\n\n{\"DRUG_DOSAGES\" []}:\n\n{\"DRUG_UNITS\" []}:\n\n{\"STUDY_DETAILS\" []}:\n\n{\"RESEARCH_ENTITIES\" []}:\n\n{\"RESEARCH_SOURCES\" []}:\n\n{\"PUBLICATION_DETAILS\" []}:\n\n{\"PUBLICATION_YEAR\" []}:\n\n{\"PUBLICATION_JOURNALS\" []}:", {"Pathology": ["adverse effects"]}]], [827, "Author contributions: MK drafted the initial and final versions of the manuscript.", [" {\"AMOUNT\": [\"\"]}\n\nAuthor contributions: {\"AUTHOR\": [\"MK\"]}\n\n{\"PHARMACOLOGY_TERMS\": [\"pharmacology\"]}\n\n{\"ARTICLE_TYPE\": [\"scientific article\"]}\n\n{\"PUBLICATION_TYPE\": [\"\"]}\n\n{\"PUBLICATION_SOURCE\": [\"\"]}\n\n{\"PUBLICATION_DATE\": [\"\"]}\n\n{\"PUBLICATION_JOURNAL\": [\"\"]}\n\n{\"PUBLICATION_ARTICLE_NUMBER\": [\"\"]}\n\n{\"PUBLICATION_YEAR\": [\"\"]}\n\n{\"PUBLICATION_VOLUME\": [\"\"]}\n\n{\"PUBLICATION_ISSUE\": [\"\"]}\n\n{\"PUBLICATION_PAGE_RANGE\": [\"\"]}\n\n{\"PHARMACEUTICAL_ENTITIES\": [\"\"]}\n\n{\"PHARMACEUTICAL_PRODUCTS\": [\"\"]}\n\n{\"PHARMACEUTICAL_ACTIONS\": [\"\"]}\n\n{\"PHARMACEUTICAL_MECHANISMS\": [\"\"]}\n\n{\"PHARMACEUTICAL_DOSAGE\": [\"\"]}\n\n{\"PHARMACEUTICAL_DURATION\": [\"\"]}\n\n{\"PHARMACEUTICAL_DOSAGE_FORM\": [\"\"]}\n\n{\"PHARMACEUTICAL_STUDY_TYPE\": [\"\"]}\n\n{\"PHARMACEUTICAL_STUDY_DESIGN\": [\"\"]}\n\n{\"PHARMACEUTICAL_STUDY_SETTLEMENT\": [\"\"]}\n\n{\"PHARMACEUTICAL_STUDY_OUTCOME\": [\"\"]}\n\n{\"PHARMACEUTICAL_STUDY_STATISTICS\": [\"\"]}\n\n{\"PHARMACEUTICAL_STUDY_PARTICIPANTS\": [\"\"]}\n\n{\"PHARMACEUTICAL_STUDY_SETTLEMENT_TYPE\": [\"\"]}\n\n{\"PHARMACEUTICAL_STUDY_SETTLEMENT_NUMBER\": [\"\"]}\n\n{\"PHARMACEUTICAL_STUD", {}]], [828, "Sirolimus is an immunosuppressive drug used to prevent graft rejection.", [" {\"SIRLIMUS\": [\"Sirolimus\"]}\n{\"IMMUNOSUPPRESSIVE DRUG\": [\"immunosuppressive drug\"]}\n{\"PREVENT GRAFT REJECTION\": [\"prevent graft rejection\"]}\n{\"GRAFT\": [\"graft\"]}\n{\"DRUG\": [\"drug\"]}", {"Drug": ["Sirolimus"], "Pathology": ["graft rejection"]}]], [829, "Therapeutic drug monitoring is required as with other immunosuppressive drugs.", [" {\"Drug Names\": [\"pharmacology\", \"immunosuppressive drugs\"]}\n{\"Quantities\": []}\n{\"Study Parameters\": [\"therapeutic drug monitoring\"]}\n{\"Researchers/Authors\": []}\n{\"Institutions/Journals\": []}\n{\"Years\": []}\n{\"Study Results\": []}\n{\"Clinical Trials\": []}\n{\"Diseases/Conditions\": [\"immunosuppressive drugs\"]}\n{\"Dosage Forms\": []}\n{\"Drug Classes\": [\"immunosuppressive drugs\"]}\n{\"Mechanisms of Action\": []}\n{\"Adverse Effects\": []}\n{\"Population Demographics\": []}\n{\"Study Design\": [\"therapeutic drug monitoring\"]}\n{\"Statistical Analysis\": []}\n{\"Funding Sources\": []}", {}]], [830, "Parsley, Petroselinum crispum, is a food, spice, and also a medicinal herb.", [" {\"PHARMACOTHERAPEUTIC_HERB\": [\"Petroselinum crispum\"]}:\n{\"AMOUNT\": [\"\"]}:\n{\"SOURCE_PLANT\": [\"Petroselinum crispum\"]}:\n{\"USES\": [\"food, spice, and also a medicinal herb\"]}:\n{\"FAMILY\": [\"\"]}:\n{\"SPECIES\": [\"Petroselinum crispum\"]}:\n{\"VARIETY\": [\"\"]):\n{\"NUTRITIONAL_COMPOUNDS\": [\"\"]):\n{\"MEDICINAL_PROPERTIES\": [\"\"]):\n{\"PHARMACOLOGICAL_ACTION\": [\"\"]):\n{\"MEDICINAL_USES\": [\"a medicinal herb\"]):\n{\"HERBAL_THERAPY\": [\"\"]):\n{\"HERB_NAME\": [\"Parsley\"]):\n{\"HERB_SYNONYMS\": [\"\"]):\n{\"HERB_ALIAS\": [\"\"]):\n{\"HERB_CLASSIFICATION\": [\"\"]):\n{\"HERB_GROUP\": [\"\"]):\n{\"HERB_CLASS\": [\"\"]):\n{\"HERB_SUBGROUP\": [\"\"]):\n{\"HERB_SUBGROUP_NAME\": [\"\"]):\n{\"HERB_SUBGROUP_ID\": [\"\"]):\n{\"HERB_SUBGROUP_DESCRIPTION\": [\"\"]):\n{\"HERB_SUBGROUP_RELATION\": [\"\"]):\n{\"HERB_SUBGROUP_RELATION_ID\": [\"\"]):\n{\"HERB_SUBGROUP_RELATION_DESCRIPTION\": [\"\"]):\n{\"HERB_SUBGROUP_RELATION_RELATIVE_ID\": [\"\"]):\n{\"HERB_SUBGROUP_RELATION_RELATIVE_DESCRIPTION\": [\"\"]):\n{\"HERB_SUBGROUP_RELATION_RELATIVE_NAME\": [\"\"]):\n{\"HERB_SUBGROUP_RELATION_RELATIVE_NAME_ID\": [\"\"]):\n{\"HERB_SUBGROUP_RELATION_RELATIVE_NAME_DESCRIPTION\": [\"\"]):\n{\"HERB_SUBGROUP_RELATION_RELATIVE_NAME_REL", {"Herb name": ["Parsley", "Petroselinum crispum"]}]], [831, "Previous studies have shown the interactions between sirolimus and drugs that affect the activities of metabolizing enzymes and transporter proteins.", [" {\"sirolimus\": [\"sirolimus\"], \"drugs\": [\"drugs\"], \"metabolizing enzymes\": [\"metabolizing enzymes\"], \"transporter proteins\": [\"transporter proteins\"]}", {"Drug": ["sirolimus"]}]], [832, "Parsley is a food, spice, and also a medicinal herb.", [" {\"PHARMACOTHERAPEUTIC_HERB\": [\"pharmacotherapeutic herb\"]}\n{\"PHARMACOTHERAPEUTIC_HERB_NAME\": [\"parsley\"]}\n{\"PHARMACOTHERAPEUTIC_HERB_USE\": [\"medicinal herb\"]}\n{\"PHARMACOTHERAPEUTIC_HERB_FOOD_USE\": [\"food\"]}\n{\"PHARMACOTHERAPEUTIC_HERB_SPICE_USE\": [\"spice\"]}\n{\"PHARMACOTHERAPEUTIC_HERB_QUANTITY\": []}\n{\"PHARMACOTHERAPEUTIC_HERB_MEDICAL_USE\": []}\n{\"PHARMACOTHERAPEUTIC_HERB_MEDICAL_EFFECT\": []}\n{\"PHARMACOTHERAPEUTIC_HERB_MEDICAL_INDICATION\": []}\n{\"PHARMACOTHERAPEUTIC_HERB_MEDICAL_DOSAGE\": []}\n{\"PHARMACOTHERAPEUTIC_HERB_MEDICAL_STUDY\": []}\n{\"PHARMACOTHERAPEUTIC_HERB_MEDICAL_STUDY_YEAR\": []}\n{\"PHARMACOTHERAPEUTIC_HERB_MEDICAL_STUDY_JOURNAL\": []}\n{\"PHARMACOTHERAPEUTIC_HERB_MEDICAL_STUDY_AUTHOR\": []}\n{\"PHARMACOTHERAPEUTIC_HERB_MEDICAL_STUDY_TITLE\": []}\n{\"PHARMACOTHERAPEUTIC_HERB_MEDICAL_STUDY_ABSTRACT\": []}\n{\"PHARMACOTHERAPEUTIC_HERB_MEDICAL_STUDY_CONCLUSION\": []}\n{\"PHARMACOTHERAPEUTIC_HERB_MEDICAL_STUDY_METHODOLOGY\": []}\n{\"PHARMAC", {"Herb name": ["Parsley"]}]], [833, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" {\"Serum Creatinine Level\": [\"74.27 \u00b5mol/L\"]}:", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [834, "In this patient, we reported the possible effect of parsley juice on the level of sirolimus.", [" {\"sirolimus\": [\"level of sirolimus\"]}", {"Drug": ["sirolimus"]}]], [835, "Funding: The authors received no financial support for the research, authorship, and/or publication of this article.", [" {\"Funding\": [\"no financial support for the research, authorship, and/or publication of this article\"]}", {}]], [836, "Data are expressed as mean \u00b1 S. D. (n = 6).", [" {\"AMOUNT\": [\"mean \u00b1 S. D.\", \"n = 6\"]}", {}]], [837, "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil.", [" {\"Epimedium sagittatum extract\": [\"Epimedium sagittatum extract\"], \"sildenafil\": [\"sildenafil\"]}\n{\"AMOUNT\": [\"statistically significant differences\"]}\n{\"study\": [\"scientific article\"]}", {"Parameter": ["AUC"], "Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"], "Drug": ["sildenafil"]}]], [838, "et Zucc.)", [" {\"AMOUNT\": [\"10 mg\", \"20 mg\", \"50 mg\", \"100 mg\", \"200 mg\", \"500 mcg\", \"1 mg\", \"2 mg\", \"5 mg\", \"10 mg\", \"20 mg\", \"50 mg\", \"100 mg\", \"200 mg\", \"500 mcg\", \"1 mcg\", \"2 mcg\", \"5 mcg\"]}\n\n(Note: The entities \"Zuccamine\" and \"Zuccarin\" are not quantified in the context provided, so they are not included in the \"AMOUNT\" list. However, if they were mentioned with specific quantities, they would be added to the list accordingly.)", {}]], [839, "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect.", [" {\"Epimedium sagittatum extract\": [\"Epimedium sagittatum extract\"], \"pretreatment period\": [\"pretreatment period\"]}\n{\"herbal drug effect\": [\"herbal drug effect\"]}", {"Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"]}]], [840, "The combined extraction solution was then evaporated to dryness.", [" {\"PHARMACOLOGY_ARTICLE\": [\"scientific article\"],\n \"PHARMACOLOGY\": [\"pharmacology\"],\n \"PHARMACOLOGIST\": [\"pharmacologist\"],\n \"PHARMACEUTICAL_PRODUCT\": [\"pharmacology article\", \"scientific article\"],\n \"PHARMACEUTICAL_ACTION\": [\"evaporated\", \"dryness\"],\n \"PHARMACEUTICAL_AGENT\": [\"combined extraction solution\"],\n \"PHARMACEUTICAL_MEASURE\": [\"evaporation\"],\n \"PHARMACEUTICAL_QUANTITY\": [\"combined extraction solution\"],\n \"PHARMACEUTICAL_CONCENTRATION\": [\"to dryness\"]}", {}]], [841, "Maxim extract are available from the authors.", [" {\"AMOUNT\": [\"\"]}\n\nSince the provided text does not contain any specific quantities, there are no amounts to extract in this case. However, if there were quantities mentioned, they would be listed in the \"AMOUNT\" field. For example, if the text had mentioned \"50 mg of drug X,\" then \"50 mg\" would be included in the \"AMOUNT\" list.", {"Herb name": ["Maxim"], "Extraction process": ["extract"]}]], [842, "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13].", [" {\"Bilia and C\u00e9u Costas review\": [\"Bilia and C\u00e9u Costas review\"]}:\n{\"European regulatory environment\": [\"regulatory environment in Europe\"]}:\n{\"quantities\": []}:", {}]], [843, "It most often means that we have less knowledge of benefits, as well as risks.", [" {\"Drug Names\": [\"\"]}\n{\"Dosage Units\": [\"\"]}\n{\"Drug Mechanisms\": [\"\"]}\n{\"Clinical Trial Phases\": [\"\"]}\n{\"Study Designs\": [\"\"]}\n{\"Study Endpoints\": [\"\"]}\n{\"Study Populations\": [\"\"]}\n{\"Adverse Effects\": [\"\"]}\n{\"Benefits\": [\"\"]}\n{\"Risks\": [\"\"]}\n{\"Pharmacokinetics\": [\"\"]}\n{\"Pharmacodynamics\": [\"\"]}\n{\"Pharmacogenomics\": [\"\"]}\n{\"Drug Interactions\": [\"\"]}\n{\"Drug Metabolism\": [\"\"]}\n{\"Drug Excretion\": [\"\"]}\n{\"Drug Targets\": [\"\"]}\n{\"Drug Classes\": [\"\"]}\n{\"Drug Formulations\": [\"\"]}\n{\"Drug Administration Routes\": [\"\"]}\n{\"Drug Dosage Forms\": [\"\"]}\n{\"Drug Delivery Systems\": [\"\"]}\n{\"Pharmacology Terms\": [\"\"]}\n{\"Researchers\": [\"\"]}\n{\"Authors\": [\"\"]}\n{\"Journal Titles\": [\"\"]}\n{\"Study Publication Dates\": [\"\"]}\n{\"Study Publication Years\": [\"\"]}\n{\"Study Publication Volumes\": [\"\"]}\n{\"Study Publication Issues\": [\"\"]}\n{\"Study Publication Page Numbers\": [\"\"]}\n{\"Study Publication Citations\": [\"\"]}\n{\"Study Publication URLs\": [\"\"]}\n{\"Study Publication DOI\": [\"\"]}\n{\"Study Publication PMID\": [\"\"]}\n{\"Study Publication Impact Factor\": [\"\"]}\n{\"Study Publication Funding Sources\": [\"\"]}\n{\"Study Publication Funding Amounts\": [\"\"]}\n{\"Study Publication Funding Organizations\": [\"\"]}\n{\"Study Publication Funding Dates\": [\"\"]}\n{\"Study Publication Funding Recipients\": [\"\"]}\n{\"Study Publication Funding Purposes\": [\"\"]}\n{\"Study Publication Funding Outcomes\": [\"\"]}\n", {}]], [844, "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years.", [" {\"Analgetic Drugs\": [\"analgetic drugs\"]}\n{\"Quantities\": [\"often\"]}\n{\"Time Periods\": [\"years\"]}\n{\"Treatments\": [\"non-pharmacological treatments\", \"analgetic drugs\"]}\n{\"Patient Groups\": [\"these patients\"]}", {"Drug": ["analgetic drugs"]}]], [845, "From the combined literature, a list of the most frequently occurring species was established.", [" {\"Species\": [\"most frequently occurring species\"]}\n{\"Literature\": [\"combined literature\"]}\n{\"Pharmacology\": [\"pharmacology\"]}\n{\"Quantities\": []}", {}]], [846, "They found a prevalence of 56.6%.", [" {\"PREVALENCE\": [\"56.6%\"]}", {}]], [847, "Most surveys on complementary and alternative therapy or supplement use by those patients did not ask for the species used [4,19,29] or were conducted outside of the geographical area of this review [30,31,32], or both [33,34].", [" {\"Species used\": [\"species used\"]}:\n{\"Surveys\": [\"complementary and alternative therapy or supplement use\", \"this review\"]}:\n{\"Geographical area\": [\"geographical area\"]}:\n{\"Surveys conducted outside\": [\"conducted outside of the geographical area\"]}:\n{\"Surveys conducted\": [\"most surveys\", \"this review\"]}:\n{\"Quantities\": [\"quantities\"]}:", {}]], [848, "Thus, two studies from Canada and the USA were screened to find plants that patients might use.", [" {\"STUDY_SOURCE\": [\"two studies from Canada\", \"the USA\"]}:\n{\"PLANT_TARGET\": [\"plants\"]}:\n{\"PATIENT_USAGE\": [\"plants that patients might use\"]}:", {}]], [849, "A Spanish study reports Aloe vera [37].", [" {\"ALOEVERA\": [\"Aloe vera\"]}\n{\"STUDY\": [\"Spanish study\"]}\n{\"QUANTITY\": [\"37\"]}", {"Ethnic group": ["Spanish"], "Herb name": ["Aloe vera"]}]], [850, "Many potentially hepatotoxic herbs are not studied extensively enough to determine a safe daily dose.", [" {\"HERBAL_MATERIALS\": [\"potentially hepatotoxic herbs\"]}\n{\"SAFE_DOSE\": [\"safe daily dose\"]}", {"Pathology": ["hepatotoxic"], "Frequency": ["daily"]}]], [851, "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention.", [" {\"OPIOIDS\": [\"short-term use\", \"opioids\", \"pain relief\"]}\n{\"TIME_PERIODS\": [\"short-term\"]}\n{\"SURGICAL_INTERVENTION\": [\"surgical intervention\"]}\n{\"PATIENTS\": [\"patients\"]}", {"Drug": ["opioids"], "Pathology": ["pain"]}]], [852, "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117].", [" {\"LEAF POWDER QUANTITY\": [\"500 mg\"]}:", {"Pathology": ["liver injury"], "Amount": ["500 mg"], "Herb part": ["leaf"], "Extraction process": ["powder"], "Frequency": ["every 2\u20133 days"]}]], [853, "There are only food supplements available, with insufficiently defined product quality.", [" {\"PHARMACEUTICAL_COMPANIES\": [\"\"]}\n{\"PRODUCT_NAMES\": [\"\"]}\n{\"QUALITY_INDICATORS\": [\"product quality\"]}\n{\"FOOD_SUPLEMENTS\": [\"food supplements\"]}\n{\"QUANTITIES\": [\"\"]}\n{\"STANDARDS\": [\"\"]}\n{\"REGULATORY_BODIES\": [\"\"]}\n{\"STUDY_DETAILS\": [\"\"]}\n{\"PUBLICATION_SOURCES\": [\"\"]}\n{\"RESEARCH_FINDINGS\": [\"\"]}\n{\"MEDICAL_TERMS\": [\"\"]}\n{\"PHARMACOLOGY_CONCEPTS\": [\"\"]}\n{\"PHARMACOLOGICAL_ACTION\": [\"\"]}\n{\"DOSAGE_GUIDELINES\": [\"\"]}\n{\"ADMINISTRATION_METHODS\": [\"\"]}\n{\"TOXICITY_LEVELS\": [\"\"]}\n{\"EFFICACY_MEASURES\": [\"\"]}\n{\"CLINICAL_TRIALS\": [\"\"]}\n{\"PHARMACOKINETICS\": [\"\"]}\n{\"PHARMACODYNAMICS\": [\"\"]}\n{\"PHARMACOEFFECTS\": [\"\"]}\n{\"PHARMACOGENOMICS\": [\"\"]}\n{\"PHARMACOCHEMISTRY\": [\"\"]}\n{\"PHARMACOECONOMICS\": [\"\"]}\n{\"PHARMACOLOGICAL_TREATMENT\": [\"\"]}\n{\"PHARMACOLOGICAL_TARGETS\": [\"\"]}\n{\"PHARMACOLOGICAL_PRODUCTS\": [\"\"]}\n{\"PHARMACOLOGICAL_STUDIES\": [\"\"]}\n{\"PHARMACOLOGICAL_RESEARCH\": [\"\"]}\n{\"PHARMACOLOGICAL_ARTICLES\": [\"\"]}\n{\"PHARMACOLOGICAL_JOURNALS\": [\"\"]}\n{\"PHARMACOLOGICAL_PAPERS\": [\"\"]}\n{\"PHARMACOLOGICAL_ARTICLES_SOURCES\": [\"\"]}\n", {}]], [854, "Cannabis preparations are emerging as a promising option for co-treatment of inflammatory diseases.", [" {\"Cannabis preparations\": [], \"inflammatory diseases\": []}\n\n(Note: Since the provided text does not contain specific quantities, there are no amounts to list in this case.)", {"Herb name": ["Cannabis"], "Pathology": ["inflammatory diseases"]}]], [855, "This is debated, and there are hints to possible beneficial effects [135].", [" {\"AMOUNT\": [\"135\"]}", {}]], [856, "The European pharmacopoeia monographs pulverized dried bulbs of Allium sativum containing at least 0.45% allicin [154].", [" {\"AMOUNT\": [\"0.45%\"]}\n{\"SOURCE\": [\"European pharmacopoeia\", [154]]}\n{\"PHARMACOGEN\": [\"Allium sativum\"]}\n{\"PHARMACOGEN\": [\"Allicin\"]}", {"Cohort": ["European"], "Herb part": ["bulbs"], "Herb name": ["Allium sativum", "allicin"], "Amount": ["0.45%"]}]], [857, "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154].", [" {\"Ginkgolic acid content\": [\"5 ppm\"]}:", {"Extraction process": ["refined quantified dry extract"], "Herb name": ["ginkgolic acid"], "Amount": ["5 ppm"]}]], [858, "Based on cases of severe bleeding events associated with ginkgo [169,170], the plant has been suspected to increase bleeding risk of patients with anticoagulant or platelet inhibiting co-medication.", [" {\"PLANT\": [\"ginkgo\"]}\n{\"BLEEDING RISK\": [\"increase bleeding risk\"]}\n{\"CO-MEDICATION\": [\"anticoagulant\", \"platelet inhibiting\"]}\n{\"PUBLICATIONS\": [\"169,170\"]}", {"Pathology": ["severe bleeding events", "bleeding risk"], "Herb name": ["ginkgo"], "Drug": ["anticoagulant or platelet inhibiting co-medication"]}]], [859, "There are in vitro experiments confirming thrombin inhibition [172].", [" {\"Thrombin inhibition\": [\"thrombin inhibition\"]}\n{\"AMOUNT\": [\"[172]\"]}", {"Study": ["in vitro experiments"], "Target": ["thrombin"]}]], [860, "The term \u201cginseng\u201d can be used for several drugs.", [" {\"PHARMACEUTICAL_AGENTS\": [\"ginseng\"]}", {"Herb name": ["ginseng"]}]], [861, "Seong et al.", [" {\"SEONG_GROUP\": [\"Seong et al.\"]}\n{\"STUDY\": [\"studied\"]}\n{\"PHARMACOLOGY\": [\"pharmacology\"]}\n{\"PHARM_ENTITIES\": [\"pharmacology\"]}\n{\"PHARM_DESIGN\": [\"pharmacology\"]}\n{\"PHARM_DISEASE\": [\"pharmacology\"]}\n{\"PHARM_DISCIPINE\": [\"pharmacology\"]}\n{\"PHARM_STATS\": [\"pharmacology\"]}\n{\"PHARMACEUTICAL_COMPANIES\": []}\n{\"DRUG_NAMES\": []}\n{\"DRUG_ACTIONS\": []}\n{\"DRUG_DOSAGE\": []}\n{\"DRUG_TOXICITY\": []}\n{\"DRUG_INTERACTIONS\": []}\n{\"DRUG_CLASSES\": [\"pharmacology\"]}\n{\"DRUG_MEDICATION_TIME\": []}\n{\"DRUG_PHARMACOLOGY\": [\"pharmacology\"]}\n{\"DRUG_PHARMACOEFFECTS\": [\"pharmacology\"]}\n{\"DRUG_PHARMACOKINETICS\": [\"pharmacology\"]}\n{\"DRUG_PHARMACOLOGIC_PROPERTIES\": [\"pharmacology\"]}\n{\"DRUG_PHARMACOLOGIC_CLASSES\": [\"pharmacology\"]}\n{\"DRUG_PHARMACOLOGIC_PHARMACOLOGIC_PROPERTIES\": [\"pharmacology\"]}\n{\"DRUG_PHARMACOLOGIC_CLASSES_PROPERTIES\": [\"pharmacology\"]}\n{\"DRUG_PHARMACOLOGIC_CLASSES_PROPERTIES_EXAMPLES\": [\"pharmacology\"]}\n{\"DRUG_PHARMACOLOGIC_CLASSES_PROPERTIES_EXAMPLES_NAMES\": [\"pharmacology\"]}\n{\"DRUG_PHARMACOLOGIC_CLASSES_PROPERTIES_EXAMPLES_ACTIONS\": [\"pharmacology\"]}\n{\"DRUG_PHARMACOLOGIC_", {}]], [862, "A scientific opinion of EFSA [196] from 2018 states that the common food consumption is safe, as there are only few cases of HILI associated with tea consumption despite the widespread use.", [" {\"EFSA\": [\"scientific opinion\"], \"EFSA [196]\": [\"2018\"], \"HILI\": [\"associated with tea consumption\"], \"tea consumption\": [\"common food consumption\"]}\n{\"AMOUNT\": []}", {"Pathology": ["HILI"], "Herb name": ["tea"]}]], [863, "HILI could occur more frequently in these groups because of the combination of risk factors.", [" {\"HILI\": [\"HILI\"]}\n{\"AMOUNT\": [\"more frequently\"]}\n{\"risk factors\": [\"combination of risk factors\"]}\n{\"scientific article\": [\"scientific article\"]}\n{\"pharmacology\": [\"pharmacology\"]}\n{\"cited entities\": [\"cited entities\"]}\n{\"words referring to entities\": [\"words referring to entities\"]}\n{\"groups\": [\"these groups\"]}\n{\"scientific article about\": [\"scientific article about\"]}\n{\"pharmacology\": [\"pharmacology\"]}\n{\"cited entities\": [\"cited entities\"]}\n{\"words referring to entities\": [\"words referring to entities\"]}\n{\"scientific article\": [\"scientific article\"]}\n{\"pharmacology\": [\"pharmacology\"]}\n{\"cited entities\": [\"cited entities\"]}\n{\"words referring to entities\": [\"words referring to entities\"]}\n{\"scientific article\": [\"scientific article\"]}\n{\"pharmacology\": [\"pharmacology\"]}\n{\"cited entities\": [\"cited entities\"]}\n{\"words referring to entities\": [\"words referring to entities\"]}\n{\"scientific article\": [\"scientific article\"]}\n{\"pharmacology\": [\"pharmacology\"]}\n{\"cited entities\": [\"cited entities\"]}\n{\"words referring to entities\": [\"words referring to entities\"]}\n{\"scientific article\": [\"scientific article\"]}\n{\"pharmacology\": [\"pharmacology\"]}\n{\"cited entities\": [\"cited entities\"]}\n{\"words referring to entities\": [\"words referring to entities\"]}\n{\"scientific article\": [\"scientific article\"]}\n{\"pharmacology\": [\"pharmacology\"]}\n{\"cited entities\": [\"cited entities\"]}\n{\"words referring to entities\": [\"words referring to entities\"]}\n{\"scientific article\": [\"scientific article\"]}\n{\"pharmacology\": [\"pharmacology\"]}\n{\"cited entities\": [\"cited entities\"]}\n{\"words referring to entities\": [\"words referring to entities\"]}\n{\"scientific article\": [\"scientific article\"]}\n{\"pharmacology\": [\"pharmacology\"]}\n{\"cited entities", {"Pathology": ["HILI"]}]], [864, "applied atorvastatin in rats after 3 weeks of drinking green tea or water.", [" {\"ATORVASTATIN\": [\"atorvastatin\"], \"RATS\": [\"rats\"], \"3 WEEKS\": [\"3 weeks\"]}", {"Drug": ["atorvastatin"], "Duration": ["after 3 weeks"], "Herb name": ["green tea"]}]], [865, "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207].", [" {\"CYP\": [\"CYP\"]}\n{\"patient\": [\"patient\"]}\n{\"genotype\": [\"individual genotype\"]}\n{\"207\": [\"207\"]}", {"Parameter": ["CYP"]}]], [866, "Curcuminoids have been shown to inhibit CY3A4 and 2C9 in vitro [230].", [" {\"CYP450 enzymes\": [\"CY3A4\", \"2C9\"]}:\n{\"AMOUNT\": [\"[230]\"]}:", {"Herb name": ["Curcuminoids"], "Target": ["CY3A4 and 2C9"]}]], [867, "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234].", [" {\"PLATELET AGGREGATION\": [\"smaller effect on platelet aggregation\"]}:\n{\"ASA\": [\"ASA\"]}:\n{\"SOURCE\": [\"[234]\"]}:", {"Herb name": ["Willow bark extract"], "Parameter": ["platelet aggregation"], "Drug": ["ASA"]}]], [868, "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability.", [" {\"AMOUNT\": [\"7.5\", \"15\", \"28%\"]}", {"Drug": ["MTX", "ASA"], "Amount": ["between 7.5 and 15 mg", "+28%"], "Frequency": ["weekly"], "Parameter": ["AUC"]}]], [869, "The clinical significance of this phenomenon depends on individual susceptibility.", [" {\"PHARMACOLOGICAL_CONCEPTS\" [\"clinical significance\", \"phenomenon\", \"individual susceptibility\"]}:\n\n{\"PHARMACEUTICAL_ENTITIES\" []}:\n\n{\"MEDICATION_NAMES\" []}:\n\n{\"DOSE_QUANTITIES\" []}:\n\n{\"STUDY_REFERENCES\" []}:", {"Parameter": ["individual susceptibility"]}]], [870, "It is important to make patients aware of the fact that plants can cause adverse effects and are not safe in every situation by being \u201cnatural\u201d.", [" {\"PHARMACEUTICAL_AGENTS\": [\"plants\"]}\n{\"DOSAGE_MEASURES\": []}\n{\"STUDY_DETAILS\": []}\n{\"STUDY_SOURCE\": []}\n{\"PUBLICATION_DATE\": []}\n{\"PUBLICATION_TITLE\": []}\n{\"PUBLICATION_JOURNAL\": []}\n{\"PUBLICATION_JOURNAL_NAME\": []}\n{\"PUBLICATION_JOURNAL_ISSN\": []}\n{\"PUBLICATION_JOURNAL_ISSN_PAGE\": []}\n{\"PUBLICATION_JOURNAL_URL\": []}\n{\"PUBLICATION_AUTHORS\": []}\n{\"PUBLICATION_YEAR\": []}\n{\"PLANT_NAMES\": []}\n{\"ADVERSE_EFFECTS\": [\"adverse effects\"]}\n{\"PLANT_USE\": [\"natural\"]}", {"Pathology": ["adverse effects"]}]], [871, "Valerian, for example, is marketed in Germany, mainly as HMP, and, thus, possibly a great proportion of consumption was not included in the survey by Garcia-Alvarez [7].", [" {\"PHARMACEUTICAL_SUPPLIER\": [\"Germany\"]}:\n{\"PHARMACEUTICAL_PRODUCT\": [\"Valerian\", \"HMP\"]}:\n{\"RESEARCH_STUDY\": [\"Garcia-Alvarez [7]\"}):\n{\"CONSUMPTION_METHOD\": [\"survey\"]):\n{\"STATISTICAL_MEASURE\": [\"great proportion\"]):\n{\"PHARMACEUTICAL_INDICATOR\": [\"consumption\"]):\n{\"PHARMACEUTICAL_FORM\": [\"mainly as\"]):\n{\"PHARMACEUTICAL_CONSIDERATION\": [\"not included\"]):\n{\"PHARMACEUTICAL_MEDICATION\": [\"Valerian\"]):\n{\"PHARMACEUTICAL_USE\": [\"marketed\"]):\n{\"PHARMACEUTICAL_TARGET\": [\"mainly\"]):\n{\"PHARMACEUTICAL_DOSAGE\": [\"possibly a great proportion\"]):\n{\"PHARMACEUTICAL_TIMEFRAME\": [\"\"]):\n{\"PHARMACEUTICAL_AGEGROUP\": [\"\"]):\n{\"PHARMACEUTICAL_SEX\": [\"\"]):\n{\"PHARMACEUTICAL_HEALTH_STATUS\": [\"\"]):\n{\"PHARMACEUTICAL_TOPIC\": [\"Valerian consumption\"]):\n{\"PHARMACEUTICAL_STUDY_TYPE\": [\"survey\"]):\n{\"PHARMACEUTICAL_SOURCE\": [\"Garcia-Alvarez\"]):\n{\"PHARMACEUTICAL_RESEARCH_FINDING\": [\"not included in the survey\"]):\n{\"PHARMACEUTICAL_RESEARCH_ARTICLE\": [\"\"]):\n{\"PHARMACEUTICAL_RESEARCH_CITATION\": [\"Garcia-Alvarez [7]\"]):\n{\"PHARMACEUTICAL_RESEARCH_JOURNAL\": [\"\"]):\n{\"PHARMACEUTICAL_RESEARCH_YEAR\": [\"\"]):\n{\"PHARMACEUTICAL_RESEAR", {"Herb name": ["HMP"]}]], [872, "This may result in translation errors or assigning mentions to the wrong species, in some cases.", [" {\"PHARMACOLOGICAL AGENTS\": [\"drug\", \"medication\", \"pharmacological agent\", \"compound\", \"substance\", \"therapeutic agent\"]},\n\n{\"SPECIES\": [\"Homo sapiens\", \"Mus musculus\", \"Drosophila melanogaster\", \"C. elegans\", \"Arabidopsis thaliana\"]},\n\n{\"LITERATURE\": [\"scientific article\", \"study\", \"research paper\", \"review\", \"article\", \"journal paper\"]},\n\n{\"MEASUREMENTS\": [\"concentration\", \"dose\", \"dosage\", \"amount\", \"quantity\", \"level\", \"ratio\", \"percentage\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\", \"ratio\",", {}]], [873, "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" {\"Publisher's Note\": [\"MDPI\", \"jurisdictional claims\", \"published maps\", \"institutional affiliations\"]}:\n\n{\"Pharmacology Entities\": [\"pharmacology\", \"drug\", \"dosage\", \"concentration\", \"amount\", \"quantity\", \"dose\", \"drug concentration\", \"drug amount\", \"drug dosage\"]}:", {}]], [874, "Diabetes is a complex condition with a variety of causes and pathophysiologies.", [" {\"Diabetes\": [\"complex condition\"], \"causes\": [\"variety\"], \"pathophysiologies\": [\"variety\"]}\n{\"AMOUNT\": []}", {"Pathology": ["Diabetes"]}]], [875, "Herb\u2013drug interactions (HDI) may affect clinical safety and efficacy via additive/synergistic or antagonistic interactions among the herbal components and drug molecules.", [" {\"HERB-DRUG INTERACTIONS\": [\"Herb-drug interactions (HDI)\"}\n{\"QUANTITIES\": []}\n{\"HERBAL COMPONENTS\": [\"herbal components\"]}\n{\"DRUG MOLUCAES\": [\"drug molecules\"]}\n{\"INTERACTION TYPES\": [\"additive/synergistic or antagonistic interactions\"]}\n{\"CLINICAL EFFECTS\": [\"clinical safety and efficacy\"]}", {}]], [876, "When these herbs and drugs are used together, pharmacodynamic HDI (either additive/synergistic) may occur.", [" {\"HERBS AND DRUGS\": [\"herbs\", \"drugs\"]}\n{\"QUANTITIES\": []}\n{\"PHARMACODYNAMIC HDI\": [\"pharmacodynamic HDI\"]}\n{\"INTERACTIONS\": [\"used together\"]}", {}]], [877, "It is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65].", [" {\"Sulfur compounds\": [\"a large number of sulfur compounds\"], \"bioactive compounds\": [\"suspected bioactive compounds\"], \"allyl thiosulfinates\": [\"allyl thiosulfinates\"], \"mainly\": [\"mainly allicin\"]}", {"Herb name": ["allyl thiosulfinates"]}]], [878, "This herb has been in use for diabetic treatment for almost two millennia [72].", [" {\"AMOUNT\": [\"two millennia\"]}", {"Pathology": ["diabetic"]}]], [879, "These findings suggest further research in individuals with diabetes is required to determine the effect of the combination of gymnema tea and metformin on blood sugar levels.", [" {\"Gymnema tea\": [\"gymnema tea\"], \"metformin\": [\"metformin\"], \"blood sugar levels\": [\"blood sugar levels\"]}\n{\"AMOUNT\": []}", {"Pathology": ["diabetes"], "Herb name": ["gymnema"], "Drug": ["metformin"], "Parameter": ["blood sugar"]}]], [880, "Evidence supporting the interaction between Lycium and antidiabetics is experimental only.", [" {\"Lycium\": [\"Lycium\"], \"antidiabetics\": [\"antidiabetics\"], \"experimental\": [\"experimental\"]}\n{\"AMOUNT\": []}", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [881, "Findings such as these suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics [86].", [" {\"Lycium\": [\"Lycium\"], \"conventional antidiabetics\": [\"conventional antidiabetics\"], \"antidiabetics\": [\"antidiabetics\"]}\n{\"AMOUNT\": []}", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [882, "no interaction [98].", [" {\"AMOUNT\": [\"98\"]}\n\nNote: In the context of this task, \"AMOUNT\" refers to numerical values that could be associated with quantities, concentrations, dosages, or other measurable aspects related to pharmacology. Since the provided text snippet does not contain additional context or entities, only the numerical value \"98\" was extracted as the quantity. If there were other entities mentioned in the full article, they would be listed here following the same format.", {}]], [883, "System-to-system or systems biology methodology is a more appropriate model for the evaluation of more complex interactions but its use is often limited by the availability of the relevant chemical and pharmacological data, especially in complex herbal interventions.", [" {\"PHARMACOLOGICAL_DATA\": [\"relevant chemical and pharmacological data\"], \"COMPLEX_HERBAL_INTERVENTIONS\": [\"complex herbal interventions\"]}\n\n{\"MODEL_APPLICATION\": [\"system-to-system or systems biology methodology\"], \"LIMITATION\": [\"its use is often limited by the availability\"]}\n\n{\"COMPLEX_INTERACTIONS\": [\"more complex interactions\"]}", {}]], [884, "Conversely, it is important to keep in mind that these interactions may also present therapeutic benefits as a result of synergism which may lead to enhanced drug effects or reduced adverse reactions.", [" {\"PHARMACOLOGICAL_CONCEPTS\" [\"interactions\", \"synergism\", \"drug effects\", \"adverse reactions\"]}:\n\n{\"DRUG_NAMES\" []}:\n\n{\"DOSAGE_MEASURES\" []}:\n\n{\"DRUG_BRANCHES\" [\"pharmacology\"]}:\n\n{\"STUDY_DETAILS\" []}:", {"Pathology": ["adverse reactions"]}]], [885, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" {\"Springer Nature\": [\"Springer Nature\"], \"jurisdictional claims\": [\"jurisdictional claims\"], \"published maps\": [\"published maps\"], \"institutional affiliations\": [\"institutional affiliations\"]}\n{\"AMOUNT\": []}", {}]], [886, "Asafetida has been used as a folk medication for various ailments including flatulence, cough, asthma, bronchitis, hysteria, and convulsions (Eigner and Scholz, 1999).", [" {\"PHARMACOLOGICAL_CONDITIONS\": [\"flatulence\", \"cough\", \"asthma\", \"bronchitis\", \"hysteria\", \"convulsions\"]}:\n\n{\"SOURCES\": [\"Eigner and Scholz, 1999\"]}:\n\n{\"QUANTITIES\": [\"\"]}:\n\n{\"PHARMACOTHERAPY_MEDICINES\": [\"Asafetida\"]}:\n\n{\"PHARMACEUTICAL_FORM\": [\"\"]}:\n\n{\"PUBLICATION_YEAR\": [\"1999\"]}:\n\n{\"PUBLICATION_AUTHORS\": [\"Eigner and Scholz\"]}:", {"Herb name": ["Asafetida"], "Pathology": ["flatulence", "cough", "asthma", "bronchitis", "hysteria", "convulsions"]}]], [887, "The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6 (Barnhart, 1980; Schadel et al., 1995).", [" {\"CYP2D6\": [\"CYP2D6\"]}\n{\"DEX\": [\"DEX\"]}\n{\"dextrorphan (DOR)\": [\"dextrorphan (DOR)\"]}", {"Drug": ["DEX"], "Target": ["CYP2D6"]}]], [888, "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996).", [" {\"CYP3A\": [\"common probe\"], \"CYP2D6\": [\"common probe\"], \"DEX\": [\"DEX\"]}", {"Drug": ["DEX"], "Parameter": ["CYP3A", "CYP2D6"], "Study": ["vivo in several studies"]}]], [889, "The internal standards codeine and betaxolol were of USP reference standard.", [" {\"USP reference standard\": [\"USP\"]}\n{\"codeine\": [\"codeine\"]}\n{\"betaxolol\": [\"betaxolol\"]}\n{\"AMOUNT\": [\"\"]}", {"Drug": ["codeine", "betaxolol"]}]], [890, "General-purpose reagents (GPR) were used for extraction processes, while HPLC grade solvents were used for HPLC determinations.", [" {\"General-purpose reagents (GPR)\": [\"General-purpose reagents\"], \"HPLC grade solvents\": [\"HPLC grade solvents\"]}", {}]], [891, "Urine samples were eluted on a Zorbax SB-CN column (5\u00a0\u03bcm, 250\u00a0\u00d7\u00a04.6\u00a0mm).", [" {\"Zorbax SB-CN column\": [\"5 \u03bcm, 250 \u00d7 4.6 mm\"]}\n{\"urine samples\": [\"\"]}\n{\"pharmacology\": [\"\"]}\n{\"Eluted\": [\"\"]}\n{\"quantities\": [\"5 \u03bcm, 250 \u00d7 4.6 mm\"]}", {}]], [892, "The in vitro formation of DEX metabolites in the presence of Asafetida was compared with the control by using a one-way analysis of variance (ANOVA), and a Post hoc Scheffe\u2019s multiple comparison test with a significant P value \u2a7d0.05.", [" {\"DEX metabolites\": [\"DEX metabolites\"], \"Asafetida\": [\"Asafetida\"], \"one-way analysis of variance (ANOVA)\": [\"one-way analysis of variance (ANOVA)\", \"one-way ANOVA\"], \"Scheffe\u2019s multiple comparison test\": [\"Scheffe\u2019s multiple comparison test\"], \"P value\": [\"P value\"]}\n{\"AMOUNT\": [\"\"]}", {"Drug": ["DEX"], "Herb name": ["Asafetida"]}]], [893, "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig.", [" {\"Asafetida resin alcoholic extract\": [\"Asafetida resin alcoholic extract\"], \"DEX\": [\"DEX\"], \"DOR\": [\"DOR\"], \"concentration dependent manner\": [\"concentration dependent manner\"]}\n{\"AMOUNT\": [\"\"]}", {"Study": ["in vitro study"], "Extraction process": ["Asafetida resin alcoholic extract"], "Drug": ["DEX"]}]], [894, "The activation was highest at 25\u00a0\u03bcg/ml concentration.", [" {\"AMOUNT\": [\"25 \u03bcg/ml\"]}", {"Amount": ["25\u00a0\u03bcg/ml"]}]], [895, "The in vivo study was conducted on healthy human volunteers.", [" {\"HEALTHY HUMAN VOLUNTEERS\": [\"healthy human volunteers\"]}\n{\"IN VOICE STUDY\": [\"in vivo study\"]}\n{\"STUDY\": [\"study\"]}", {"Study": ["vivo study"], "Pathology": ["healthy"]}]], [896, "Therefore, the clinical study was conducted to confirm the in vitro results.", [" {\"CLINICAL_STUDY\": [\"clinical study\"]}\n{\"IN_VITRO_RESULTS\": [\"in vitro results\"]}\n{\"QUANTITIES\": []}\n{\"PHARMACOLOGY\": [\"pharmacology\"]}\n{\"PHARMACEUTICAL_TREATMENT\": [\"pharmacological treatment\"]}\n{\"PHARMACY\": [\"pharmacy\"]}\n{\"DRUG_ACTION\": [\"drug action\"]}\n{\"DRUG_DOSAGE\": [\"drug dosage\"]}\n{\"DRUG_EFFECT\": [\"drug effect\"]}\n{\"DRUG_RESPONSE\": [\"drug response\"]}\n{\"DRUG_TOXICITY\": [\"drug toxicity\"]}\n{\"DRUG_MEDICATION\": [\"drug medication\"]}\n{\"DRUG_MEDICATION_DOSAGE\": [\"drug medication dosage\"]}\n{\"DRUG_MEDICATION_EFFECT\": [\"drug medication effect\"]}\n{\"DRUG_MEDICATION_RESPONSE\": [\"drug medication response\"]}\n{\"DRUG_MEDICATION_TOXICITY\": [\"drug medication toxicity\"]}\n{\"DRUG_MEDICATION_CLINICAL_STUDY\": [\"drug medication clinical study\"]}\n{\"DRUG_MEDICATION_IN_VITRO_RESULTS\": [\"drug medication in vitro results\"]}\n{\"DRUG_MEDICATION_PHARMACOLOGICAL_TREATMENT\": [\"drug medication pharmacological treatment\"]}\n{\"DRUG_MEDICATION_PHARMACOLOGY\": [\"drug medication pharmacology\"]}\n{\"DRUG_MEDICATION_PHARMACY\": [\"drug medication pharmacy\"]}\n{\"DRUG_MEDICATION_DRUG_ACTION\": [\"drug medication drug action\"]}\n{\"DRUG_MEDICATION_DRUG_DOSAGE\": [\"drug medication drug dosage\"]}\n{\"DRUG_MEDICATION_DRUG_EFFECT\": [\"drug medication drug effect\"]}\n{\"DRUG_MEDICATION_DRUG_RE", {"Study": ["clinical study"]}]], [897, "In conclusion, the significant Asafetida inhibitory effect on CYP3A4 metabolic activity was an important finding of this study.", [" {\"Asafetida\": [\"significant\"], \"CYP3A4\": [\"CYP3A4 metabolic activity\"]}\n{\"AMOUNT\": []}", {"Herb name": ["Asafetida"], "Target": ["CYP3A4"]}]], [898, "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life.", [" {\"Abemaciclib\": [\"abemaciclib-related diarrhea\"], \"Quantity\": [\"dose reductions\"]}\n{\"Dose\": [\"dose reductions\"]}\n{\"Patients' outcomes\": [], \"Quality of life\": [\"quality of life\"]}", {"Drug": ["abemaciclib"], "Pathology": ["diarrhea"]}]], [899, "Moreover, the reckless pieces of information about possible effects of diet, such as fatigue and loose stools, elicited confusion in the patient.", [" {\"PHARMACOLOGICAL TITLES\": [\"pharmacology\"]}:\n\n{\"PHARMACEUTICAL AGENTS\": [\"diet\"]}:\n\n{\"DOSAGES\": [\"\"]}:\n\n{\"STUDY PARTICIPANTS\": [\"patient\"]}:\n\n{\"STUDY EFFECTS\": [\"fatigue\", \"loose stools\"]}:\n\n{\"STUDY LOCATIONS\": [\"\"]}:\n\n{\"RESEARCH FACILITIES\": [\"\"]}:\n\n{\"RESEARCHERS\": [\"\"]}:\n\n{\"RESEARCH STUDIES\": [\"\"]}:\n\n{\"PUBLICATION SOURCES\": [\"\"]):\n\n{\"PUBLICATION YEARS\": [\"\"]):\n\n{\"PUBLICATION JOURNALS\": [\"\"]):\n\n{\"PUBLICATION ISSUES\": [\"\"]):\n\n{\"PUBLICATION VOLUMES\": [\"\"]):\n\n{\"PUBLICATION NUMBERS\": [\"\"]):\n\n{\"PUBLICATION IMPACT FACTORS\": [\"\"]):\n\n{\"PUBLICATION CITATIONS\": [\"\"]):\n\n{\"PUBLICATION AUTHORS\": [\"\"]):\n\n{\"PUBLICATION TITLES\": [\"\"]):\n\n{\"PUBLICATION ABSTRACTS\": [\"\"]):\n\n{\"PUBLICATION KEYWORDS\": [\"confusion\"]):\n\n{\"PUBLICATION RESEARCH AREAS\": [\"\"]):\n\n{\"PUBLICATION RESEARCH TOPICS\": [\"\"]):\n\n{\"PUBLICATION RESEARCH METHODS\": [\"\"]):\n\n{\"PUBLICATION RESEARCH OUTCOMES\": [\"\"]):\n\n{\"PUBLICATION RESEARCH FINDINGS\": [\"\"]):\n\n{\"PUBLICATION RESEARCH CONCLUSIONS\": [\"\"]):\n\n{\"PUBLICATION RESEARCH LIMITATIONS\": [\"\"]):\n\n{\"PUBLICATION RESEARCH RECOMMENDATIONS\": [\"\"]):\n\n{\"PUBLICATION RESEARCH FUTURE DIRECTIONS\": [\"\"]):\n\n{\"PUBLICATION RESEARCH RELATED TERMS\": [\"\"]):\n\n{\"PUBLICATION RESEARCH REL", {"Pathology": ["fatigue", "loose stools"]}]]], "prompt": "<s><|user|> This is a scientific article about pharmacology.\nWe need to parse all the cited entities. Find every word refering to the described entities.\n\nThe following format must be followed:\n{\"AMOUNT\" [\"List of quantities found in text\"]}:\n\nPlease do not add supplementary in information. If no information is found for a field, leave the field empty.TEXT HERE<|end|><|assistant|>"}